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The misfolding and aggregation of protein is a characteristic hallmark of 
neurodegenerative disorders, most notably of amyloid beta and tau in 
Alzheimer’s disease and alpha synuclein in Parkinson’s disease. There is 
gathering evidence that early soluble aggregates of these proteins are the 
most toxic species. In this thesis I have used whole-cell patch clamp recording 
to quantitively analyse the cellular and sub-cellular effects of introducing tau or 
alpha synuclein aggregates on neuronal or synaptic function in single neurons.  
I have demonstrated that full-length tau oligomers (oTau) induce marked 
changes to action potential dynamics, synaptic transmission and plasticity that 
were not observed with monomeric tau. Consistent with these 
electrophysiological changes, oTau could diffuse from the injection site (soma) 
to synaptic sites within 30 minutes of recording. This study had provided 
valuable new insight into the actions of tau oligomers within single neurons. I 
then looked to define the mechanisms underlying these changes using tau 
truncations. CFRAG (aa124-444) oTau caused a shift in the spike-initiation 
threshold, mediating the increase in excitability. While NFRAG (aa1-123) tau 
aggregates and monomers both resulted in comparable changes to AP 
waveform as full length-oTau. Recording isolated voltage-gated sodium 
channels highlighted a tau-mediated reduction in both the half-activation and 
maximal sodium channel conductance.   
Using the same method, I have demonstrated that introduction of aggregated 
αSyn into dopaminergic neurons in the substantia nigra significantly increased 
conductance and decreased excitability, an effect which could be partially 
prevented by pre-incubation of the slices with Glibenclamide. While evaluating 
these neurons, I discovered that they have an unexpected connexin 
hemichannel-mediated CO2-sensitivity phenotype. These cells are located in 
regions of the brain that are involved in movement, reward, and arousal 
behaviour. Physiological changes in PCO2 markedly altered whole-cell 
conductance and excitability. This work suggests a mechanism by which CO2, 
could alter complex goal-directed behaviours. 
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1. Introduction 
1. Introduction  
Neurodegenerative disorders such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) are both characterised pathologically by the 
misfolding and aggregation of native proteins. In AD, amyloid beta aggregates 
to form plaques and tau aggregates to form neurofibrillary tangles. In PD, alpha 
synuclein aggregates and accumulates within Lewy Body inclusions. While the 
presence of these large inclusions is well documented, there is gathering 
evidence that early soluble aggregates of these proteins are the most toxic 
species in pathology. There is relatively little understanding of the mechanisms 
of action of these small, soluble aggregates on neuronal function early in 
disease. In this thesis I have used whole-cell patch clamp recording to 
quantitively analyse the cellular and sub-cellular effects of introducing tau into 
cortical neurons (Chapter 3 and 4) or alpha synuclein aggregates into 
dopaminergic neurons (Chapter 5) on neuronal or synaptic function. While 
evaluating these dopaminergic neurons, I discovered that they, along with a 
neighbouring population of GABAergic neurons are unexpectedly sensitive to 
physiological changes in the level of CO2. I have therefore gone on to 
characterise this phenotype and explored the underlying mechanisms 
(Chapter 6).  
Parts of this chapter have been published previously: (Hill et al, 2020, Review) 
1.1 Tau and associated tauopathies 
1.1.1 Tau - physiology and pathology 
Tau is a native human protein that is encoded by the microtubule associated 
protein tau (MAPT) gene. There are six isoforms in the human brain which are 
differentially expressed during development (Goedert et al., 1989, 1988; 
Goedert and Jakes, 2005). The N-terminal region can have 0, 1 or 2 inserts 
between amino acids 45 and 103, which results in 0N, 1N or 2N tau (Fig 1.1). 
The mid-region of tau is rich in prolines, as well as serine and threonine 
residues, which are strong targets for phosphorylation and have been linked 
to many physiological and pathophysiological cellular processes (Hampel et 
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al., 2010; Hanger et al., 2007; Stoothoff and Johnson, 2005; Wang et al., 
2013). At the C-terminus of tau there are four pseudo-repeat domains, often 
referred to as R1-R4 (Fig 1.1), which form the microtubule binding domain. In 
its monomeric form, full length (2N4R) tau is intrinsically disordered with little 
to no secondary structure (Barghorn et al., 2004; Cleveland et al., 1977; 
Mirbaha et al., 2018; Mukrasch et al., 2009). 
Figure 1.1: The six isoforms of tau protein in the human brain.  
Alternative splicing produces six different isoforms of tau which differ by their 
composition of N and C terminal inserts (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R). 
2N4R tau represents the full-length protein, also referred to as htau40 or tau441, and 
is the most commonly found isoform in the human brain. Figure adapted from 
(Karikari, 2017).  
1.1.2 Physiological functions of tau 
Primarily tau associates with the labile domain of microtubules, modulating 
their stability (Tracy and Gan, 2018; Fig 1.2) with a reduction in binding leading 
to enhanced rigidity, poorer flexibility and control (Qiang et al., 2018). Tau also 
regulates axonal transport (Fig 1.2), both from the axon to the soma 
(retrograde; Dixit et al, 2008) and from the soma to the axon (anterograde; 
Stamer et al., 2002). It can either act as a competitor for the binding sites of 
kinesin or dynein on the microtubules or it can bind directly to dynein (Magnani 
et al., 2007) or to the N-terminus of kinesin and modulate their activity directly 
(Kanaan et al., 2011). Tau can also be found in the nucleus and in the 
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dendrites. In dendrites it can assist with the spine remodelling that occurs 
during synaptic plasticity (Frandemiche et al., 2014; Regan et al., 2015; Fig 
1.2). In the nucleus of human neuroblastoma cells, tau has been shown to 
contribute to the regulation of the integrity of genomic DNA (Loomis et al., 
1990; Fig 1.2). 
Figure 1.2: Tau in neuronal physiology. 
The most prominent function is its modulation of microtubule stability (i). (ii) Tau 
regulates the integrity of genomic DNA in the nucleus by binding to different 
chromosomal regions. (iii) It also regulates axonal transport between the axon and 
soma by interfering with the binding of motor proteins kinesin and dynein to 
microtubules (iv) Finally, tau plays important roles in the regulation of synaptic 
plasticity at both pre- and postsynapses, for example by its contribution to the process 
of spine remodeling. Design concept from Wang and Mandelkow (2016). 
1.1.3 Pathological cascade leading to tangles. 
Physiologically, tau can undergo different post-translational modifications 
including phosphorylation, acetylation, and ubiquitination (Alonso et al., 2016; 
Beharry et al., 2014). The targeted binding and un-binding of tau to 
microtubules is mediated by the level of phosphorylation and must be finely 
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balanced in order to regulate its function (Fig 1.3). This balance is maintained 
by the counter-activity of kinases and phosphatases on specific residues of the 
tau protein and a number of these phosphorylation residues have been linked 
to tau functionality (Stoothoff and Johnson, 2005). 
In disease states, the balance between phosphorylation and de-
phosphorylation becomes dysregulated, leading to increased abnormal ‘hyper’ 
phosphorylated tau (Köpke et al., 1993). This hyperphosphorylated tau 
dissociates from microtubules and can sequester other monomeric tau 
molecules away from tubulin, disrupting microtubule function (Qiang et al., 
2018). This disassociated monomeric tau is initially aggregation incompetent 
(Mirbaha et al., 2018) and has to undergo monomer-monomer interactions 
either via disulphide bonding or via its hexapeptide motifs to drive a 
conformational change from an unfolded, disordered structure to a new 
structured conformation that is rich in beta-sheets and aggregation-competent 
(Congdon et al., 2008; Friedhoff et al., 1998). This marks the beginning of the 
conventional pathological cascade starting with the aggregation to small 
soluble oligomeric structures, through to fibrils and then on to neurofibrillary 
tangles (NFTs; Avila et al., 2006; Maeda et al., 2006; Fig 1.3). This pathological 
cascade for tau is common to several disorders, collectively termed 
tauopathies. Until relatively recently, NFTs were thought to be the major toxic 
species, as their presence correlates well with disease progression and they 
are the most well characterised form of brain tau pathology (Braak and Braak, 
1991). However the initial soluble tau oligomers (oTau), which are formed 
much earlier in the aggregation process, have been highlighted as more potent 
drivers of toxicity (Andorfer et al., 2003; Cowan et al., 2010; Lee et al., 2001; 
Spires et al., 2006; Tanemura et al., 2002; Tatebayashi et al., 2002; Wittmann 
et al., 2001; Yoshiyama et al., 2007). This theory is supported by the discovery 
of certain forms of tau that can form pathological (soluble) oligomers with 
functional implications but cannot aggregate any further into fibrils and NFTs 
(Karikari et al., 2019; Lasagna-Reeves et al., 2014, 2010). 
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Figure 1.3: Tau in physiology and pathophysiology. 
Under physiological conditions, tau is bound to microtubules and the stability is maintained by the balanced activities of kinases and phosphatases 
acting to regulate the binding of tau to the microtubules. If the balance is altered in favour of increased kinase activity, then tau can become 
hyperphosphorylated and detach from the microtubules. Initially, monomers are aggregation incompetent and have to undergo a conformational 
change using interactions via their hexapeptide motif or by disulphide bonding. Tau can then form aggregates, firstly small soluble oligomers 
which are β-sheet-rich and are thought to be the smallest toxic species. Subsequently, these species aggregate further into protofibrils, fibrils and 
finally into neurofibrillary tangles (NFTs). 
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1.1.4 Pathological actions of tau 
Pathologically tau can cause cellular disruption by a host of mechanisms, 
depending on its cellular location. Tau can undergo a range of post-
translational modifications including ubiquitination, acetylation or truncation. 
All of which can enhance detachment from microtubules and impairment of 
function. Once detached the pathological tau can mislocalise around the cell.  
Tau can disrupt long term plasticity (both long-term potentiation and long-term 
depression) by its actions at postsynaptic sites. Hoover et al., (2010) 
demonstrated that this synaptic dysfunction precedes any visible 
neurodegeneration and that these are amongst the earliest detectable 
changes in many tauopathies. Post-synaptic mislocalisation of tau aggregates 
occurs much earlier than the loss of spines. In the P301L (human tau) mutant 
mouse, tau mislocalisation could be observed at post synaptic compartments 
and at pre-synapses by as early as 3-months, it was only at 18 months that 
synaptic loss begins. Pickett et al., (2017) further demonstrated that there is 
spread of the human tau between neurons of the middle molecular layer (MML) 
of the dentate gyrus at this stage – highlighting that this mislocalisation, and 
synaptic spread will occur in the early stages of the disease. Tau-mediated 
postsynaptic dysfunction has been confirmed both in in vitro and in vivo studies 
(Hill et al., 2019; Hoover et al., 2010; Lasagna-Reeves et al., 2012; 
Mondragón-Rodríguez et al., 2018; Ondrejcak et al., 2018; Puzzo et al., 2017; 
Rocher et al., 2010; Tai et al., 2014; Tamagnini et al., 2017; Thies and 
Mandelkow, 2007).  
Although the postsynaptic roles of tau are more established, emerging 
evidence has also highlighted its roles in the disruption of presynaptic function. 
Tau accumulates in presynaptic terminals and can lead to a reduction in the 
number of vesicles available for release, inducing synaptic dysfunction and 
eventually leading to the loss of synapses (Decker et al., 2015). Tau can bind 
by its N-terminus to vesicles and by its C-terminus to actin filaments, cross-
linking them and slowing down their movement. This leads to a reduction in 
presynaptic vesicle release (Fig 1.4). This could be reversed by removing the 
N-terminal region or by targeting with a peptide to bind and block the binding 
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site on the vesicles (McInnes et al., 2018; Zhou et al., 2017). Although 
phosphorylated tau cannot enter the nucleus, it can interact directly with the 
nuclear pore complex and disrupt nuclear transport (Eftekharzadeh et al., 
2018; Fig 1.4). The sequestration of physiological tau into pathological 
aggregates will also limit the availability of normal tau to enter the nucleus and 
fulfil its roles in maintaining DNA integrity (Sultan et al., 2011). In cell culture 
experiments, it has been shown that small soluble tau oligomers are applied 
onto stem cell-derived cortical neurons or human neuroblastoma cells, some 
oligomers can be taken up into the nuclei so they may also have inter-nuclear 
effects (Evans et al., 2018; Karikari et al., 2019b, 2019a; Puangmalai et al., 
2020; Usenovic et al., 2015; Wegmann et al., 2016).  
1.1.5 Tau in co-operation with other proteins 
Amyloid beta (Aβ) is produced by the proteolytic cleavage of amyloid precursor 
protein (APP), which is synthesised in the cell body and then conveyed by 
vesicular axonal transport to presynaptic terminals. APP is normally inserted 
into the presynaptic membrane and removed by endocytosis; in the endosome 
it is cleaved to make Aβ by secretases. There are two main forms of Aβ which 
differ depending on the patten of secretase activity that cleave the APP to 
produce them. Gamma secretase will always cleave APP first. If this is followed 
by alpha secretase, the non-amyloidogenic form of Aβ (Aβ40) will be produced. 
However it is followed by beta secretase, then the amlyoidogenic form of Aβ 
(Aβ42) will be produced instead (Cai et al., 1993; Citron et al., 1992; Suzuki et 
al., 1994). Both forms of Aβ (Aβ40/ Aβ42) are found in AD patients and healthy 
controls, but the ratio of Aβ42 to Aβ40 can be used as a maker of disease 
progression. (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992). In 
healthy individuals, CSF has soluble Aβ of which 90% is Aβ40 and the 
remaining 10% is Aβ42 (more hydrophobic and more prone to aggregation). 
As plaques are formed, soluble Aβ42 levels drop in the CSF can be used as a 
biomarker for AD. Aβ will aggregate through a similar cascade to tau, through 
fibrils to large insoluble aggregates called plaques (Masters et al., 1985) which 
are largely not expected to be toxic due to their folded nature rendering the 
reactive surfaces inaccessible. An early intermediary to this aggregation 
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process is oligomers, which like tau, are soluble and highly toxic (Walsh et al., 
2002).  
Aβ can accelerate the phosphorylation of tau in the early stages, causing its 
dissociation and aggregation (Lewis et al., 2001). However, in the later stages 
of tau pathology (NFTs) this is independent of Aβ pathology and in fact NFT 
pathology tracks with disease progression much better than Aβ pathology (Lue 
et al., 1999; McLean et al., 1999; Näslund et al., 2000; Wang et al., 1999).  
Tau can act together with amyloid beta (Aβ) oligomers to disrupt synaptic 
function. Co-treatment with Aβ oligomers and tau aggregates leads to tau mis-
sorting to dendrites which triggers the translocation of tubulin tyrosine ligase-
like enzyme 6 (TTLL6) into dendrites, which subsequently leads to the 
degradation of microtubules by Spastin, further damaging their integrity 
(Zempel et al., 2013). Dendritic aggregated tau can also act as a scaffold for 
the non-receptor-associated tyrosine kinase FYN. FYN is responsible for 
phosphorylating subunit 2 of the NMDA receptor (NMDAR), which leads to the 
stabilisation of the interaction between PSD95 and the NMDAR. By binding, it 
will enhance signalling and could contribute to the excitotoxicity that is reported 
with Aβ oligomers. Thus, the excitotoxicity caused by Aβ oligomers could 
depend on the co-presence of tau oligomers (Ittner et al., 2010; Roberson et 
al., 2007; Fig 1.4) 
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Figure 1.4: Functions of tau in pathology. 
Tau can cause disruption to a wide range of cellular processes, depending on its 
localisation within the affected cell. If it reaches the dendrites, it can induce the loss 
of dendritic spines leading to postsynaptic dysfunction (i). Although phospho-tau 
cannot enter the nucleus, it can bind and disrupt the function of the nuclear pore 
complex (ii). The most prominent and well described consequence of aggregated tau 
is the disassembly of microtubules (iii) and the consequent alterations in their stability, 
function, and ability to assist in trafficking and cell transport. (iv) Pathological tau can 
also mislocalise to presynaptic terminals, whereby it binds to vesicles and slows down 
their rate of release and restock, thus limiting output. Finally, pathological tau in one 
neuron can act as a seed to transmit the pathology to neighbouring neurons (v), thus 
enabling the progression of the disease.  
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1.1.6 Tau propagation
Tau pathology originates in a single region and then spreads methodically 
through defined pathways that are individual to the tauopathy of interest (Braak 
and Braak, 1991). Tau can seed the spread of pathology between neurons, 
enabling transfer between different brain regions. Over time tau oligomers 
(oTau), both brain-derived and recombinantly sourced, can be internalised into 
neurons following extracellular application. Once inside, oTau can interact with 
endogenous tau and induce it to misfold and aggregate (Gibbons et al., 2019; 
Walsh and Selkoe, 2016). Some of this newly misfolded tau complex is then 
secreted to initiate a new cycle of propagation and associated toxicity in 
healthy neurons (Gibbons et al., 2019; Walsh and Selkoe, 2016). This initiates 
the cascade of intracellular toxicity that then transmits throughout the network. 
This cycle of propagation is often referred to as the transneuronal spread 
model (Fig 1.5a) and has been demonstrated in animal studies using both 
transgenic and wild type animals as well as basic cell models (Boluda et al., 
2015; Clavaguera et al., 2009; Evans et al., 2018; Guo and Lee, 2011; He et 
al., 2020; Iba et al., 2013; Karikari et al., 2019a; Narasimhan et al., 2017; 
Puangmalai et al., 2020; Usenovic et al., 2015; Wegmann et al., 2016) 
A second model for propagation is that of selective vulnerability, whereby 
some neurons are more susceptible to pathology than others, perhaps due to 
the presence of misfolded tau protein. In response to neuronal stress, a 
presynaptic ‘affected’ neuron will release diffusible metabolic factors which can 
then target these ‘vulnerable neurons’, transducing the stress and inducing the 
process of protein aggregation in the postsynaptic target cell. In the early 
stages of disease, only the ‘vulnerable’ neurons will be affected, but as disease 
progresses, aggregates are also able to transfer from cell to cell via a direct 
internalisation and release mechanism (Walsh and Selkoe, 2016; Fig 1.5b).  
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Figure 1.5: Methods of neuronal vulnerability to tau propagation. 
A) The trans-neuronal spread model describes the direct physical transfer between 
neurons that make a synaptic connection. oTau is released into the extracellular 
space, internalised by the postsynaptic cell, and then stimulates the aggregation of 
endogenous tau.  B) The selective vulnerability model describes a paradigm in which 
some neurons are more susceptible to damage (vulnerable neurons; purple), perhaps 
due to the presence of misfolded tau protein. Here in response to neuronal stress, 
diffusible metabolic factors are released and transferred across the synapse, inducing 
aggregation in the target cell. As disease progresses further, eventually the 
aggregates will be able to transmit from cell to cell via internalisation and release and 
even the less vulnerable neurons can be affected (yellow) (Walsh and Selkoe, 2016).  
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1.1.7 Alzheimer’s disease and other tauopathies 
Tauopathies are a group of diseases in which misfolded or aggregated tau 
plays a key role in mediating neuronal dysfunction and subsequent loss. They 
can be sub-categorised broadly by whether tau plays a primary role, these are 
termed ‘primary tauopathies’, or whether tau contributes in combination with 
other proteins such as Aβ or alpha synuclein (αSyn), these are termed 
‘secondary tauopathies’. Although tauopathies share some common 
mechanisms, they can be distinguished by the isoforms and ultrastructure of 
the tau aggregates (Dickson et al., 2011; Rademakers et al., 2012).  
Alzheimer’s disease (AD), a secondary tauopathy, is the most prevalent 
neurodegenerative disorder. AD has two major pathological hallmarks; 
extracellular amyloid beta and intracellular neurofibrillary tangles (NFTs) (Jack 
et al., 2013). AD is characterised by progressive and irreversible neuronal 
atrophy. Acetylcholine neurons are predominantly affected, initially in the 
entorhinal cortex, but as the disease progresses also the hippocampus and 
the cortex are affected with tau pathology. AD pathology then progresses 
progressively around the brain following the pathways described in Braak and 
Braak (1991; Fig 1.6). 
1.1.8 Causes of Alzheimer’s disease
Only ~1 % of cases of AD are inherited, with the remaining majority idiopathic, 
occurring as the result of a combination of genetic and environmental factors 
(Mayeux, 2003). There are four genes responsible for a large proportion of the 
mutations seen in AD: APP, presenilin 1 and 2 and apolipoprotein-E (APOE; 
Bekris et al., 2010). Mutations in APP alter the activity of the secretases 
responsible the production of Aβ, resulting in increased production of the toxic 
form of Aβ. Although excess Aβ can be cleared from the brain by transport 
across the vascular endothelium or by degradation by proteases or microglia, 
the clearance rate declines over time and this results in a build-up. Presenilin 
(PS) is part of the gamma secretase, therefore mutations in PS1 or PS2 also 
increase the production of the toxic form of Aβ (Citron et al., 1997; De Strooper 
et al., 1998; Scheuner et al., 1996). While APP mutations will not always result 
in AD, mutations in PS1 or PS2 will always result in fully penetrant early onset 
34 
AD (Raux et al., 2005). APOE is found in the extracellular space as a 
component of high-density lipoproteins and is involved in lipid and cholesterol 
transport. Its risk is determined by the combination of E2, E3 and E4 alleles 
held (Corder et al., 1993; Huang, 2006). Although, to date, there have been no 
reported mutations in MAPT (the gene encoding tau) that are related to 
Alzheimer’s disease, there are a number reported for other tauopathies 
including frontotemporal dementia (Strang et al., 2019). These mutations have 
been used to generate transgenic tauopathy models to explore the pathology 
of dysfunctional tau on a general level (Ren et al., 2015). There are many other 
risk factors for tauopathies including diet, exercise and environmental factors 
(Barnard et al., 2014), which in combination with the genetic architecture will 
dictate whether someone will develop the disease, the age of onset and speed 
of progression.  
Figure 1.6: Progression of AD pathology throughout the brain. 
A) Amyloid beta pathology as described by Thal and Braak (Thal et al., 2002). 
Progression from the neocortex to the entorhinal area and the hippocampus, then 
onto the cerebellum and brainstem. B) Tau NFT pathology as described by Braak 
(Braak and Braak, 1991). Progression starting in the entorhinal region, spreading to 
the hippocampus and then later onto the neocortex. A difference in the starting 
regions and pattern of spread can be observed. Amyloid pathology is more 
widespread in earlier stages than tau pathology, which is typical of the biomarker 
presentation clinically. Figure reproduced from (Jouanne et al., 2017). 
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1.1.9 Symptoms  
Patients with Alzheimer’s disease can present with a range of symptoms and 
the average life span post diagnosis is around 10 years (Fig 1.7). In the 
preclinical stages, they may display mild cognitive difficulties but not enough 
to affect their day-to-day functioning. This then develops further into mild 
cognitive impairment (MCI) in the ‘prodromal stage’ where the presence of AD 
biomarkers can be detected (Albert et al., 2011; Parnetti et al., 2019; Winblad 
et al., 2004). MCI/prodromal AD is an ideal stage to target therapeutically 
before widespread pathology spread, but is hindered by the fact very few cases 
are diagnosed at this early stage (Petersen, 2004). As the disease progresses 
to different brain regions, patients can suffer from severe loss of cognitive 
function which then results in major changes to behaviour as well as loss of 
functionality such as language and motor skills. In the late stages of the 
disease, symptoms become more varied and patients can also suffer from 
anxiety and depression (Atri, 2019).  
Figure 1.7: Timeline of AD progression paired with clinical presentation. 
Details the progression from pre-symptomatic to MCI, through to mild, moderate, and 
severe AD. In most cases, AD is only clinically observable from the orange (moderate) 
stage, however this might be too late to act for treatment due to the widespread 
pathology by this stage.  
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1.1.10 Diagnosis and biomarkers 
It can be difficult to diagnose AD with certainty due to the overlap of symptoms 
with other neurodegenerative diseases. The presence of amyloid-beta 
aggregates and phosphorylated tau aggregates (NFTs) are used for 
pathological confirmation of AD diagnosis post-mortem and correlate well with 
disease progression (Nelson et al., 2012). However, Aβ and tau pathology also 
precede the onset of cognitive impairment in AD by as much as 15-20 years 
before clinical loss of function or changes to brain structure so provide 
attractive targets for clinical biomarker development for early stage AD (Fig 
1.8; Bateman et al., 2012; Buchhave et al., 2012; Fagan et al., 2014; 
Villemagne et al., 2013). 
Figure 1.8: A schematic to show the best diagnostic biomarkers for 
Alzheimer’s disease. 
Clinical presentation of symptoms such as memory loss, loss of clinical function and 
changes to brain structure are preceded by changes to amyloid beta and tau 
pathology. This gives a window in which treatment can be administered before 
extensive pathology spreading, if successfully diagnosed in time (Jack et al., 2010). 
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Clinical biomarkers are molecules that can provide a ‘measurable indicator of 
pathology’, allowing the detection of disease at earlier stages. They can both 
aid diagnosis of diseases like AD but also assist in predicting the underlying 
pathologies (Zetterberg, 2019; Zetterberg and Burnham, 2019). The use of 
11C Pittsburgh Compound B, florbetapir and florbetaben positron emission 
tomography (PET) imaging for Aβ pathology are well validated for Alzheimer’s 
disease and can provide 85–95% sensitivity and specificity (Zetterberg and 
Bendlin, 2021). It is worth noting that not all AD patients will have amyloid 
pathology and not all people with amyloid positive PET scans go on to develop 
the disease. It is therefore needed in combination with other tests in order to 
make an accurate diagnosis. CSF biomarkers for amyloid beta 1-42 (Aβ42), 
total tau (T-tau) and phosphorylated tau181 (P-tau181) can also be used for 
AD and provide similar sensitivity to PET scans (Zetterberg and Bendlin, 
2021). Although showing a good level of accuracy, the collection of CSF 
samples involves minor surgery and PET scans need expensive brain imaging 
techniques, so cheaper less invasive methods are required.
Blood-based biomarkers allow for the possibility of screening for the same 
pathological markers but using a quick, relatively cheap and less-invasive 
assay (Toombs and Zetterberg, 2020). For example, using specific targeted 
biomarkers, such as P-tau181, a similar level of specificity and sensitivity as 
CSF Aβ42/Aβ40 and CSF T-tau can be achieved when comparing cohorts of 
Alzheimer’s disease patients to those that are cognitively normal (Janelidze et 
al., 2020; Karikari et al., 2020; Mielke et al., 2019; Thijssen et al., 2020). For 
example, plasma P-tau181 correlates well with CSF P-tau181 (Mattsson et al., 
2016) with Aβ PET and tau PET (Mielke et al., 2019; Thijssen et al., 2020) and 
with Braak stage (Karikari et al., 2020), whilst not with neurofilament light (NFL; 
a common marker of neurodegeneration) (Thijssen et al., 2020).  
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1.1.11 Treating tauopathies: Alzheimer’s disease 
Brain atrophy cannot be reversed and so treating AD at the earliest possible 
stage is imperative. Alzheimer’s disease and dementia are distinct from one 
another. People who have clinical Alzheimer’s disease can develop dementia 
and the majority do although there are people who, despite having amyloid 
pathology, will never go on to develop Alzheimer’s dementia within their 
lifetime. This provides a challenge for accurate diagnosis. Given the small 
proportion of cases that are heritable, mass genetic screening is unlikely to be 
an effective solution.  
Initially, it was thought that by introducing small compounds termed ‘plaque 
busters’ or synthetic peptides, amyloid beta deposition in plaques could be 
reversed and that it may be possible to drive down amyloid pathology in the 
brain (Soto, 1999). Although initially promising, in some cases these peptides 
were found to brake the plaques down into small soluble toxic aggregates, and, 
even in cases where they were successful in driving down the levels of soluble 
amyloid beta, this did not correlate with an improvement in cognitive function 
(Mullane and Williams, 2020).  
Another idea for targeting tau pathology is the use of peptides that prevent 
aggregation. Tau has two hexapeptide motifs with enhanced β-propensity that 
make it more likely to form beta sheets. By generating a peptide that binds and 
blocks this region, aggregation can be reduced (Pir et al., 2019). However, the 
problem with peptide-based therapy that there is a low level of blood-brain-
barrier permeability and a high likelihood of degradation by proteases. There 
are a number of other approaches for targeting tau pathology that are also 
emerging including anti-aggregation agents (Bulic et al., 2010; Jouanne et al., 
2017; Wischik et al., 2014) and antisense therapies for  tauopathies with 
targetable mutations such as frontotemporal dementia (Schoch et al., 2016).  
Perhaps the most promising of all treatment approaches over the last decade 
has been immunotherapy, for both Aβ and tau. By introducing antibodies 
targeting Aβ in rodent models, protein deposits were reduced, and cognitive 
function improved. Solanezumab, an example of immunotherapy targeted at 
Aβ failed in phase III trials in 2018 after not significantly altering cognitive 
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decline (even though it had shown promise in animal and early human trials) 
(Honig et al, 2018). Solanezumab is one example of many immunotherapy 
trials for Aβ; all have failed at the clinical trial stage to meet their endpoints 
(Wang et al, 2017; Panza et al, 2020). This may be because the administration 
is too late in the course of disease progression or that not enough of the dose 
enters the brain. However, it might still be a good approach if delivered to pre-
symptomatic patients, dependent on advancements and availability of 
biomarker technology. The field is now shifting to also explore the possibility 
of anti-tau-based immunotherapy. There are a range of trials which aim to 
neutralise either monomeric (Boutajangout et al., 2011; Yanamandra et al., 
2015, 2013), phosphorylated, mutated (Boutajangout et al., 2011; Chai et al., 
2011; Congdon et al., 2013; d’Abramo et al., 2013; Kontsekova et al., 2014) or 
aggregated versions of the tau protein (Castillo-Carranza et al., 2014). When 
choosing an immunotherapy target there are many considerations, including, 
but not limited to, the epitope, the isotope of tau that it targets, the charge of 
the antibody and whether a whole or fragment of antibody is used (Sigurdsson, 
2018). These factors will all alter the efficiency of the immunotherapy.  
Immunotherapy must be targeted at a certain epitope of the protein and the 
target will determine the effects on tau function. This highlights the importance 
of understanding the underlying biological basis. It also means that just 
because a trial fails for one disease, it does not mean that it cannot be 
repurposed for another pathology with the same proteinopathies. For example, 
the Gosuranemab (Biogen) antibody failed at stage 2 in progressive 
supranuclear palsy but is now repurposed for tau targeting in AD. It is unlikely 
that one form of immunotherapy will be sufficient to work across all pathologies 
of tau or of amyloid beta (Sigurdsson, 2018). Basic science underpins the 
understanding of the mechanisms of protein-mediated degeneration and 
needs to guide the development of potential treatment strategies, to facilitate 
their timely success. 
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1.2.1 Parkinson’s disease  
Parkinson’s disease (PD) was initially named ‘The Shaking Palsy’ by James 
Parkinson in 1817 when he observed, weakened muscle tone, resting tremor 
and stooping in his patients (Parkinson, 1817). It was later renamed by Jean-
Martin Charcot to reflect its discoverer James Parkinson (Charcot, 1877). As 
scientists and clinicians began to understand more about the symptoms and 
the progression of this disease, a better understanding and methodology for 
diagnosis emerged. The discovery of Lewy bodies as a key pathology was first 
reported by Lewy (1912) and they are now known to be one of the major 
hallmarks of PD, as well as in Lewy body dementia and Parkinson’s disease 
dementia. PD is a disorder that follows a typical spreading pattern around the 
brain and can be categorised by the location of pathology and clinical 
symptoms to give a measure of the stage of disease. These stages were 
outlined by Braak (Braak et al., 2003, 2002). PD is a disorder affecting many 
areas of the brain but one of the predominant and most susceptible to damage 
is the basal ganglia. The substantia nigra (SN) is a region within the basal 
ganglia and is an integral part of the circuitry. It is an area that suffers 
substantial neuronal loss throughout the disease and is well characterised as 
a key target for degeneration (Gibb and Lees, 1991; Paulus and Jellinger, 
1991). The SN is home to one of the key populations of dopaminergic neurons 
in the brain and these are primarily lost over the course of the disease. 
Dopamine is a monoamine neurotransmitter involved in the processes of 
movement, reward and emotion, amongst many others. It was first discovered 
to be a neurotransmitter in the late 1950’s (Bertler and Rosengren, 1959; 
Carlsson, 1959). The dopamine circuitry in the basal ganglia is complex and 
its projections need to be finely managed in order to be able to perform 
movements. Loss of dopaminergic neurons over the course of the disease lead 
to this balance being compromised and thus patients have difficulty controlling 
movement and co-ordination. The main changes to the pathway circuitry 
during PD are highlighted in Figure 1.9. They demonstrate the shift in the 
balance of the direct and indirect pathways, and the resulting effects on both 
the basal ganglia itself and the surrounding regions of the cortex, the brain 
stem, and the thalamus (Fig 1.9). 
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Figure 1.9: Schematic of the changes to basal ganglia circuitry that occur 
during Parkinson’s disease. 
Illustrated are the main regions of the basal ganglia, as well as the cortex, the 
brainstem, and the thalamus. The circuitry is complicated and can be divided into two 
pathways, the direct (through D1 dopamine receptors) and the indirect (through D2 
dopamine receptors). The left-hand side demonstrates the physiological condition, 
with teal arrows representing excitatory projections and magenta representing 
inhibitory projections. The right-hand side demonstrates the changes that occur in 
Parkinson’s disease, starting from the loss of dopaminergic neuron projection from 
the substantia nigra pars compacta (SNpc) and the subsequent changes to the 
strength of connections across the circuit. Thinner arrows represent a decrease in the 
activity of the projection compared to physiology. Thicker arrows, on the other hand 
represent an increase in activity of that projection compared to the physiological 
circuit. CM, centromedian nucleus; VA/VL, ventra; anterior/ ventral lateral nucleus; 
SNc, substantia nigra pars compacta; GPe, globus pallidus, external segment; STN, 
Subthalamic nucleus; GPi, globus pallidus, internal segment; SNr, substantia nigra 
pars reticula; PPN, pedunculopontine nucleus. (Figure concept from Smith et al., 
2012). 
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1.2.2 Parkinson’s disease - causes  
Parkinson’s disease has a complex aetiology, with a lifetime incidence of 
around 2% (Polymeropoulos et al., 1997). The biggest risk factor for 
developing PD is age (Eriksen et al., 2009; Hindle, 2010; Morgan and Finch, 
1988; Niccoli and Partridge, 2012; Samii et al., 2004). Dopaminergic neurons 
are lost naturally over time and around 1 % of people over the age of 60 and 
4 % of people over the age of 80 are affected (de Lau and Breteler, 2006). 
There is a slightly higher prevalence of disease in men than women (Haaxma 
et al., 2007; Shulman, 2007; Van Den Eeden et al., 2003), which might be due 
to oestrogen-mediated increase in dopamine release in the striatum (Haaxma 
et al., 2007). There is, however, no discrimination in prevalence across 
ethnicities (Van Den Eeden et al., 2003).  
Parkinson’s disease can be hereditary, and this accounts for between 5 and 
10 % of cases. Mutations in the genes SNCA, which encodes alpha synuclein, 
or LRRK2, which encodes Leucine-rich repeat kinase 2, are known to be linked 
to the autosomal dominant form of familial PD. The link between SNCA and 
alpha synuclein was established in 1997 (Spillantini et al., 1997). Mutations 
lead to the misfolding and aggression of alpha synuclein protein which cannot 
be degraded by the ubiquitin-proteasomal-pathway and hence alpha synuclein 
is accumulated into inclusions. These toxic inclusions affect basic cellular 
functions, trafficking and transmission, eventually leading to cell death (Winner 
et al., 2011). LRRK2 harbours the most common familial mutations for PD and 
encodes a kinase that controls the phosphorylation of alpha synuclein and tau. 
LRRK2 mutations cause disruption to the level of phosphorylation and 
increase the amount of pathologically aggregated alpha synuclein and tau 
within neurons (Zimprich et al., 2004). A second set of genes PARK2, PINK1, 
DJ-1 and ATP13A2 are all linked to the autosomal recessive forms of familial 
Parkinson’s disease and affect various other cellular processes (Lesage and 
Brice, 2009).  
For the other 90% of cases, there are numerous risk factors, including genetic 
risk factors which have been highlighted using genome-wide-association-
studies (Klein and Westenberger, 2012) as well as lifestyle factors including 
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smoking, caffeine and vitamin C and E intake; all of which are reported to 
reduce the risk of developing PD and thus could be neuroprotective 
(Checkoway et al., 2002; de Lau et al., 2005; Hantikainen et al., 2021; Hernán 
et al., 2003, 2002; Quik et al., 2012; Zhang et al., 2002). The mechanisms 
underlying these inverse relationships are yet to be established. For example, 
in meta-analysis studies, smoking has been associated with a significantly 
lower risk of developing PD (Li et al., 2015; Chen et al., 2010), however it is 
not clear which element of cigarette smoking is responsible for this reduction 
in risk. Studies have demonstrated that the reduced risk is also present in 
cases of smokeless tobacco use over non-smokers (O’Reilly et al., 2005), as 
well as those who have been exposed to environmental tobacco smoke 
(Nielsen et al., 2012). For example, nicotine, which is found in tobacco smoke 
can bind to and activate nicotinic acetylcholine receptors on dopaminergic 
terminals and modulate dopamine release and striatal activity (Ma et al., 2017; 
Quik et al., 2012, 2009). Nicotine has been shown to have protective effects in 
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of PD; 
reducing striatal damage and improving motor function (Bordia et al., 2006; 
Janson et al., 1992; Parain et al., 2001). It also reduced levodopa-induced 
dyskinesias in rodents and monkeys (Quik et al., 2013a, 2013b; Zhang et al., 
2014a, 2014b). However clinical trials in humans have yielded inconsistent 
results (Lemay et al., 2004; Mitsuoka et al., 2002; Villafane et al., 2007).  
Systemic analysis of over 100 observational studies of human caffeine intake 
confirms that it also confers a reduction in the risk of developing PD (Bakshi et 
al., 2020; Grosso et al., 2017; Hong et al., 2020; Li et al., 2012). In the MPTP 
(PD) animal model, caffeine consumption can reduce degeneration when 
given before treatment with MPTP (Xu et al., 2002), but can also confer 
neuroprotection when administered after the MPTP treatment (Sonsalla et al., 
2012). Caffeine acts mainly at the adenosine A2A receptor (A2AR) as an 
antagonist to promote wakefulness (Huang et al., 2005). Studies to block A2A
receptors or genetically deleting them have demonstrated protection of 
dopaminergic neurons in PD animals (Chen and Schwarzschild, 2020; Ferreira 
et al., 2017; Kachroo and Schwarzschild, 2012). The action on A2A receptors 
is of particular interest in PD as they are highly expressed in the striatum of 
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neurons in the indirect pathway (Figure 1.9). Here the A2A receptors are co-
localised with D2 receptors allowing dopamine and adenosine to have 
antagonistic effects on the same neurons (Cieślak et al., 2008). Activation of 
A2A receptors therefore reduces the affinity of D2 dopamine receptors for 
dopamine and therefore reduces the ability to control movement (Cieślak et 
al., 2008; Popoli et al., 1994). It is also known that A2A receptor activation 
inhibits the release of GABA in the striatum while enhancing GABA 
transmission in the globus pallidus, which also disrupts the balance of the 
direct and indirect dopaminergic pathways (Cieślak et al., 2008). Thus, it was 
proposed that A2AR antagonists could provide a viable treatment option for PD 
(Berger et al., 2020; Munoz and Fujioka, 2018). Over 25 clinical trials in 
humans have been carried out to assess the efficacy of A2AR antagonists in 
PD (Ren and Chen, 2020), culminating in the FDA approval of Istradefylline 
(an A2AR antagonist) which is now prescribed as a combination therapy 
levodopa/carbidopa to help to manage ‘off’ periods (Berger et al., 2020).  
Another confounding factor in PD pathogenesis is mitochondrial dysfunction 
and the subsequent accumulation of reactive oxidative species (ROS; Lesage 
and Brice, 2009). The high levels of ROS in PD are thought to result from a 
combination of high levels of iron in the SNpc and from dopamine metabolism. 
Dopamine undergoes oxidation to form dopamine quinones and free radicals 
(Muñoz et al., 2012). Dopamine levels are normally regulated through by the 
neuronal enzyme MAO-A, however in PD, the glial enzyme MAO-B becomes 
the primary dopamine metabolising enzyme (Riederer et al., 1987). A by-
product of MAO-B-mediated dopamine metabolism is H2O2 which can enter 
dopaminergic neurons, react with iron, and form hydroxyl radicals (Kumar and 
Andersen, 2004; Nagatsu and Sawada, 2006). This explains the rationale 
behind the addition of MAO-B inhibitors as a clinical PD treatment in humans 
(Binde et al., 2020).  
The MPTP primate model is one of the most commonly used PD animal 
models and works by blocking mitochondrial complex one, increasing ROS 
and leading to similar degeneration patterns to those observed in PD (Sian et 
al., 1999). Environmental stress in the form of pesticides found in drinking 
water or on farms has been correlated with risk due to a higher reported 
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prevalence in rural areas of the United States (Lai et al., 2002). There is also 
evidence that exposure to certain metals like iron and copper can increase risk 
due to their ability to bind to and disrupt alpha synuclein’s function (Bush, 2000; 
Dexter et al., 1991, 1989; Gorell et al., 1997).  
1.2.3 Parkinson’s disease – diagnosis and symptoms  
Diagnosis of PD is challenging as several the symptoms overlap with those of 
other neurodegenerative disorders. The Unified Parkinson’s Disease Rating 
Scale (UPDRS) is a series of questions and tasks designed to characterise if 
a patient displays characteristic PD phenotypes and is then used post-
diagnosis to track progression. The UPDRS scale is used internationally 
across clinical trials and for diagnoses allow worldwide uniformity (Fahn and 
Elton, 1987). Symptoms of PD only present clinically when 70-80 % of the 
dopamine input to the striatum is lost (Bernheimer et al., 1973). Motor 
deficiencies are the most common early symptoms, resulting from the 
reduction of dopamine in the substantia nigra, including a unilateral resting 
tremor, increased rigidity and a loss of postural control (Hisahara and 
Shimohama, 2011; Fig 1.10). Sometimes if the balance of medication is not 
correct, patients can experience bradykinesia (slow movement) or tardive 
dyskinesia (unwanted jerks or movement).  As the disease progresses, finer 
motor control becomes affected leading to further symptoms including 
micrographia (progressively small handwriting) and loss of control over facial 
expressions (Lesage and Brice, 2009). One of the most disabling symptoms 
of PD, which tends to occur in the later stages of disease is freezing of gait, 
where there is a delay between deciding to move and initialising the movement 
(Schapira et al., 2009; Fig 1.10). Patients can also develop mental health 
complications such as depression and anxiety as PD progresses. However, it 
is unclear whether these are part of the pathology or a consequence of the 
effects the other symptoms on quality of life. As patients become more heavily 
medicated over time, medication-induced side effects can present and can be 
as, if not even more, disabling as the pathology itself (Chaudhuri et al., 2006).  
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Figure 1.10: The non-motor symptoms of Parkinson’s disease (PD). 
Parkinson’s disease is often miscategorized as just a movement disorder, affecting 
posture, movement control and gait problems as the image in the center shows. 
However, often overlooked, there are also widespread non-motor symptoms that can 
have a large effect on patients’ quality of life, some of the main symptoms are 
categorized and listed. A number of these side effects will occur in the later stages of 
the disease and may be a result of the drug regime rather than as a direct result of 
the pathology.  
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1.2.4 Parkinson’s disease - spread of disease pathology 
The early stages (1 and 2) of PD are known as the ‘pre-symptomatic stages 
and represent the time period before patients present with a substantial clinical 
motor deficit but do exhibit pathology in the form of inclusion bodies in the 
brainstem. PD is believed to originate in the dorsal motor nucleus of the vagus 
nerve (Del Tredici et al., 2002), however at this stage, Lewy body pathology 
can also found in the olfactory bulb (Barz et al., 1997; Fig 1.11). By stage 2 the 
pathology has also spread to the medulla and pons. One of the first symptoms 
of PD that is almost universal (~90%) across patients is olfactory loss and this 
tends to occur in these early stages of the disease (Haehner et al., 2007; Ross 
et al., 2008; Sommer et al., 2004). Stages 3 and 4 are the first symptomatic 
stages and these are characterised pathologically by the spread of Lewy 
bodies to the basal ganglia, specifically into the substantia nigra pars 
compacta (SNPc; Eriksen et al., 2009; Fig 1.11), which is the primary site for 
dopaminergic cell loss in PD. Dopaminergic neurons can be located by their 
neuromelanin content which appears as a black pigment. Lewy bodies when 
they form tend to displace neuromelanin within dopaminergic neurons. 
Dopaminergic neuronal loss is accelerated in stage 4. Other affected regions 
include the basal forebrain and the hippocampus (Dickson et al., 1991; Divac, 
1975). Stage 5 and 6 are the final stages of the disease and represent the 
advanced stages of the disease where patients begin to suffer from a range of 
non-motor and autonomic deficits alongside their symptoms.  
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Figure 1.11: Illustration of the pathological spread in cases of idiopathic Parkinson’s disease. 
A) In stages 1 and 2, pathology is found in the olfactory bulb and the medulla oblongata. B) By stages 3 and 4, the substantia nigra and areas of 
the basal forebrain start to become affected, first mildly, but then progressing to more severe. This is where the symptomatic clinical presentation 
usually arises. By stage 5 and 6, pathology has spread further into the neocortex and surrounding regions and symptoms increase in severity 
(Braak et al, 2002).
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1.2.5 Alpha-synuclein - physiology and pathology 
Alpha synuclein (αSyn) is a small intracellular protein of only 140 amino acids 
that is abundantly expressed throughout the brain. It is found primarily at 
presynaptic terminals where it plays a role in vesicle trafficking and recycling 
via interactions with SNARE proteins (Fig 1.12 and 1.13; Lashuel et al., 2013) 
but can also be found in the mitochondria and nucleus. Like tau, monomeric 
αSyn is an intrinsically disordered protein (IDP). IDPs do not show a well-
defined three-dimensional structure, often due to having a high proportion of 
charged or polar amino acids in their sequence (Skrabana et al., 2006). This 
structural flexibility allows them to carry out their roles within neurons and is 
lost upon aggregation when the protein becomes ordered and rigid. 
Pathological αSyn was first discovered in the amyloid beta inclusions of 
Alzheimer’s patients (Uéda et al., 1993) and only later was its role in PD 
uncovered. Aggregation is commonly induced by reactive oxygen species 
(ROS) following damage to the structure of αSyn and follows a similar pattern 
of aggregation to tau, starting with accumulation into soluble oligomers, then 
to fibrils and through to Lewy bodies and Lewy neurites.  
Oligomers of αSyn cause toxicity by a range of cellular mechanisms (Fig 1.12). 
αSyn aggregates decrease the ability of the ubiquitin proteasome pathway 
(UPP) to remove abnormal proteins, so ubiquitin-bound proteins are often 
found as a component of Lewy bodies (Alves-Rodrigues et al., 1998; Dehay et 
al., 2015). They can also induce mitochondrial dysfunction by depolarising 
mitochondria, which results in intracellular calcium retention and cell swelling 
(Luth et al., 2014), or by targeting the mitochondria itself, accumulating on the 
outer membrane and making it permeable which leads to mitochondrial 
fragmentation and mitophagy. αSyn aggregates can directly interact with 
complex 1 to increase the levels of reactive oxygen species which then in turn 
increase the oxidative damage within the cell. Extracellularly applied oligomers 
of αSyn can also impair LTP by binding and activating NMDA receptors  
(Diógenes et al., 2012). At presynaptic terminals, oligomeric Syn can induce 
synaptic dysfunction by disrupting vesicle trafficking (Jakes et al., 1994). It can 
also interfere with synaptobrevin in the SNARE complex, which is vital for the 
fusion of vesicles with the membrane ready for neurotransmitter release (Burré 
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et al., 2010; Choi et al., 2013; Lashuel et al., 2013; Murphy et al., 2000; Figure 
1.13) 
Figure 1.12: Effects of alpha synuclein aggregates within individual neurons 
Pink shell: details the proposed mechanisms of toxicity of the oligomers. Yellow shell: 
examples of some of the effects that the oligomers have within neurons. Green shell: 
disruption caused to cellular systems by the accumulation of aggregates. Blue outline: 
pathological outcomes. ER—endoplasmic reticulum. UPR—unfolded protein 
response. Figure reproduced from (Roberts and Brown, 2015).  
Toxic αSyn oligomers can be transmitted between cells, providing a possible 
mechanism for disease progression. When autophagy fails, exosomes are 
used to release the oligomers into the extracellular space (Danzer et al., 2012).  
Rostami et al., (2017) demonstrated that the cellular distress induced by 
aggregates causes tunnelling nanotubes to form. These are utilised by 
neighbouring astrocytes to send mitochondria as an additional energy source. 
At the same time, the aggregates can travel down these microtubules to 
neighbouring astrocytes, transferring the pathology. 
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Figure 1.13: Presynaptic roles of alpha synuclein in physiology and pathology. 
Physiologically, alpha synuclein (αSyn, purple; left panel) assists in the trafficking of vesicles via their interactions with the vesicle-associated 
SNARE (v-SNARE) and the target membrane associated SNARE (t-SNARE). It also assists in the refilling of neurotransmitters into vesicles after 
release. Pathologically, when aggregated (red; right panel), it can impair neurotransmitter release in a number of ways, it can directly inhibit 
release, alter vesicle trafficking, and also slow the recycling process by inhibiting vesicle refilling (Figure concept from Lashuel et al, 2013).
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1.2.6 Treatments for Parkinson’s disease 
All current pharmacological treatments for Parkinson’s disease act by relieving 
symptoms rather than by targeting the underlying cause. Having established 
that a loss of dopaminergic signalling is central to disease progression, 
researchers searched for a method to boost the dopamine signal that declines 
in the brains of PD patients. This came in the form of levodopa (L-3,4-
dihydroxyphenylalanine; L-DOPA), which is then converted into dopamine via 
DOPA decarboxylase dopamine and noradrenaline neurons (Cotzias et al., 
1969, 1967; Yahr et al., 1969; Fig 1.14). This was a revolutionary discovery in 
its time and is still the current frontline treatment for newly diagnosed 
Parkinson’s disease patents. The rate limiting step in the production of 
dopamine lies between tyrosine and L-DOPA and so the administration allows 
this to be bypassed and a quicker boost to dopamine levels. Unfortunately, 
only 1% of the dose that is taken orally will reach the target site in the brain. 
As with many pharmaceutical therapies the issue is tolerance and over time 
patients develop tolerance and need to increase their levels of medication. At 
the peak of the dose of L-DOPA, patients can sometimes suffer from motor 
overload, which is referred to as dyskinesia, unwanted jerk 
movements (Schapira et al., 2009). There is therefore a ceiling to which the 
dose can be increased as all of these medications have side effects that have 
to be managed. This means that as the disease progresses, patients need to 
supplement L-DOPA with various other drugs (Fig 1.14). As the disease 
progresses, patients can suffer from ‘on’ and ‘off’ periods. ‘On’ periods refer to 
a period of time in which the anti-parkinsonian dopaminergic medications are 
working, and symptoms are improved. ‘Off periods’ refer to a worsening of 
symptoms despite continued anti-parkinsonian medication, which can 
manifest as a delay to symptom alleviation after a dose of levodopa, a decline 
in benefit of the treatment (at the end of a dose) or the complete lack of efficacy 
of a therapeutic dose altogether (Swope, 2004).  
To prevent loss of orally administered L-DOPA in the periphery, DOPA 
decarboxylase inhibitors can be prescribed which prevent the breakdown to 
dopamine. They cannot pass the blood brain barrier, so they only prevent 
peripheral breakdown. This means that instead of only 1% of the dose reaching 
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the brain, up to 10% can. Dopamine agonists can also be used which mimic 
the activity of dopamine at dopamine receptors without the need for the dopa 
decarboxylase step needed for L-DOPA (Schapira et al., 2009). MAO and 
COMT inhibitors can also be used to supplement drug regimens when patients 
develop tolerance to L-DOPA (Hammond et al., 2007).  
Long-term pharmacological therapy results in decreased efficacy and can 
induce complex side effects (Poewe et al., 2017). In these cases, deep brain 
stimulation can be considered. Candidates must have had PD for a minimum 
of 5 years and must have originally responded to L-DOPA treatment to be 
considered for deep-brain stimulation. Microelectrodes are implanted 
surgically into one of the following regions STN, GPi or Ventralis intermedius 
(VIM) and connected to a pulse delivery device to target the overactive indirect 
pathway.
Figure 1.14: Pharmacological approaches to treating Parkinson’s disease. 
The symptoms of Parkinson's disease can be managed using a variety of drugs. The 
drugs increase dopamine signalling by regulating various components of dopamine 
metabolism, synthesis, release, and signal transduction. The frontline treatment is L-
DOPA; however, this often needs to be supplemented with dopamine agonists, MAO-
B and COMT inhibitors as the disease progresses.  
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1.2.7 Gene therapy 
There are several potential ways to utilise gene therapy to help patients 
suffering from PD (Chen et al., 2005). Firstly, via increasing the production of 
dopamine, thus improving quality of life through symptom reduction. This can 
be done by delivering a combination of three different enzymes aminoacid 
decarboxylase (AADC), tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 
(GCH-1). Tyrosine hydroxylase converts tyrosine to DOPA, AADC (DOPA 
decarboxylase) converts DOPA to dopamine and GCH-1 is the rate limiting 
step in the synthesis of tetrahydrobiopterin, which acts as a cofactor for 
tyrosine hydroxylase. In human trials, bilateral intra-striatal delivery of a 
combination of these three enzymes (a treatment called ProSavin) into the 
putamen was well tolerated and significantly improved motor symptoms by 1 
year compared to baseline (Palfi et al., 2014). Moderate improvements could 
still be observed at the 5-year follow up stage (Palfi et al., 2018). There is 
evidence that level of dopamine replacement achieved, although enough to 
give significant reduction in symptoms, could be enhanced further. Parallel 
trials are now underway to discover different viral options that could increase 
efficiency, such as OXB-102 which is currently in pre-clinical trials (Badin et 
al., 2019).  
The second is to introduce adeno-associated viral vectors (AAV) encoding 
glutamic acid decarboxylase (GAD), the enzyme which is the rate limiting step 
in the synthesis of GABA, into the subthalamic nucleus (STN). Increased 
GABA transmission in the STN inhibits glutamatergic neurons, thus increases 
movement (Emborg et al., 2007). Results from Phase I (Luo et al., 2002) and 
Phase II clinical trials (LeWitt et al., 2011) showed that bilateral delivery of 
AAV-GAD into the STN was safe and tolerable and that there was significant 
improvement in motor impairment, with little off-target effects.  
A third approach would be to deliver neurotrophic factors such as glial derived 
neurotrophic factor (GDNF) or cerebral dopamine neurotrophic factor (CDNF) 
(Coune et al., 2012). This approach is hindered by these factors being too 
large to readily cross the blood brain barrier (Boado and Pardridge, 2009; 
Wang et al., 2012). Recent trials have shown promise in the delivery of GDNF 
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directly into the brain. Dopamine activity was increased by 54 %, although no 
corresponding change to UPDRS score meant that they did not successfully 
meet their clinical endpoints (Whone et al., 2019). This may be due to the 
length of the study period. For GDNF, the drug can be delivered via bilateral 
intraputamenal implanted catheters which are connected to a port which is 
fixed behind the patient’s ear (Fig 1.15). This overcomes the lack of access 
across the blood brain barrier and the surgery itself proved successful, safe 
and effective (Fig 1.15; Whone et al., 2019). 
Figure 1.15: GDNF trial using the new investigational drug delivery system. 
(Left) Schematic of the delivery system designed for this trial. Four catheters are 
implanted to deliver intermittent bilateral intraputamenal infusions of GDNF. The 
catheters are attached to an external pump which is fitted behind the patient’s ear to 
allow delivery (Marshall, 2019). (Right) 18F-DOPA images (PET imaging) to assess 
whether GDNF can increase the levels of L-DOPA in the striatum. A significant 
increase from baseline levels was seen in GDNF but not placebo receiving patients 
(Whone et al, 2019). 
There are now 2 clinical trials underway (by Herantis Pharma) utilising the 
same delivery system to deliver a different neurotrophic factor called CDNF 
(Phase I/II trial; NCT03295786). Early results after 6 months show that delivery 
is safe and tolerable. The same company is also working on a non-invasive 
fragment of CDNF (xCDNF) which is able to cross the blood brain barrier, 
clinical trials for this are due to begin in 2023 (Herantis Pharma, 2020).  
56 
1.2.8 Stem cells  
The DNs that are lost during PD progression cannot be naturally regenerated. 
As the neuronal loss is selective to midbrain dopaminergic neurons in PD, 
targeted cell replacement has been an attractive strategy for a number of 
decades (Backlund et al., 1985; Freed et al., 1992; Lindvall et al., 1990; Widner 
et al., 1992). There are two options to produce stem cells: those that originate 
from embryos and then differentiate, and those that come from adult cells and 
are reprogrammed. In the 1990’s DNs were generated from embryonic stem 
cells (from foetal mesencephalic tissue) and grafted into the striatum of PD 
patients. Although successfully boosting levels of dopamine (for ~20 years), 
the grafted neurons were still susceptible to the pathology (Barker et al., 2015; 
Kefalopoulou et al., 2014; Li et al., 2016). There are also ethical issues 
surrounding the use of embryonic stem cells, making tissue acquisition 
challenging for the current TRANSEURO trial (Fan et al., 2020).  
The second option is to harvest adult stem cells from the patient, which 
ensures that there will be no immunorejection and reduces the risk of 
tumorigenesis. Using Yamanaka transcription factors (Oct4, Sox2, Klf4 and c-
Myc) pluripotency can be induced into adult stem cells (iPSCs) and they can 
then be differentiated into midbrain dopaminergic neurons (Kirkeby et al., 
2012; Kriks et al., 2011). Editing tools like CRISPR/Cas9 can then be used 
generate isogenic cell lines of patient mutations. This is as close as in vitro
biology can get to modelling human disease cells (Soldner et al., 2011). It is a 
costly and time consuming process so generating a way to produce HLA-
homozygous ‘universal stem cells’ that can match large groups of the 
population rather than be individualised to the patient is the next step (Fan et 
al., 2020; Taylor et al., 2012).  
The next challenge is to develop cells to graft that are resistant to 
degeneration. There is growing evidence that endogenous alpha synuclein is 
needed in order for Lewy pathology propagation and so generating graft cells 
with alpha synuclein knocked out is an attractive prospect for generating 
pathology-resistant midbrain DNs (Abeliovich et al., 2000; Chen et al., 2019; 
Luk et al., 2009).  
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1.3 Electrophysiological evaluation of oligomer pathology 
Electrophysiology provides a valuable tool for evaluating the effects of 
aggregated proteins on neuronal function. Given that changes on this cellular 
level likely precede symptom development, it can give valuable insights into 
the early changes and how they might be able to be targeted to alter the 
progression of pathology. This thesis will deal only with in vitro
electrophysiology in acute brain slices, but these electrophysiological 
techniques can also be used in vivo under different circumstances. In vivo 
experiments would give a greater level of translatability as the whole brain 
remains intact. However, I used in vitro experiments as they allow much 
greater control over the structure and concentration of aggregates and allow 
for fine pharmacological manipulations.  In vitro, there are two commonly used 
electrophysiology techniques which can be implemented (Fig 1.16). The first 
is extracellular field recording which can provide an overview of the local 
network in the area of recording, detailing changes on a circuit level (Fig 
1.16A). This can be useful for the study of synaptic transmission and synaptic 
plasticity and sample many synapses, providing an average response. Field 
recordings can be performed in a number of regions but are commonly 
performed in the hippocampus by stimulating Schaffer collateral/commissural 
fibres where they make synapses onto CA1 pyramidal cells, and recording 
excitatory postsynaptic potentials (EPSPs) in the CA1 region (Zhang et al., 
2014).  
The second, more targeted, technique is patch clamp recording which can 
provide access to specific changes within a single neuron (Fig 1.16B). The 
technique was developed by Neher and Sakmann (1976) in order to record the 
current flowing through single channels on a small patch of membrane. It was 
then later extended to measure from channels distributed across whole-cell 
membranes (Hamill et al., 1981). It can provide high resolution measurements 
from single neurons including sub-threshold information (such as changes in 
membrane potential and input resistance) which is not obtainable from 
extracellular field recordings. It works by forming a high resistance seal 
between the end of a glass recording pipette and the cell of interest. Negative 
pressure is then applied which ruptures the membrane and allows the contents 
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of the patch pipette to dialyse the cell. This type of recording is known as 
‘whole-cell’ recording and allows for simultaneous current and voltage 
measurements to be taken from the cell. There are other forms of patch clamp 
recording which differ slightly in the initial patch protocol (inside out, outside 
out, cell attached, nucleated patch), with the form of recording defined by the 
experimental question (Van Hook and Thoreson, 2014). Once in whole-cell 
configuration, recordings can be made in one of two ways, either using the 
current clamp or voltage clamp configuration (Van Hook and Thoreson, 2014). 
In voltage clamp, the voltage across the cell membrane is clamped (usually 
around -60 mV) and the current needed to maintain this voltage level can be 
recorded. In current clamp, the cells resting membrane potential (mV) can be 
measured. This method allows the membrane potential to fluctuate in 
response to synaptic inputs or other membrane currents. Current can be 
injected (via the patch pipette) in order to elicit and record a voltage response.  
Figure 1.16: Electrophysiological approaches to measuring neuronal function. 
A schematic to demonstrate the two most used in vitro approaches to evaluate the 
effect of tau dysfunction on neuronal activity. A) Extracellular field recordings in the 
CA1 region of the hippocampus use an electrode to stimulate the Schaffer collateral 
fibers and recording where they synapse onto CA1 pyramidal neurons. Recording 
field excitatory post-synaptic potentials (fEPSPs) allows the study of circuit activity. B) 
Whole-cell patch clamp recording allows for the parameterisation of single neurons 
and the study of the intracellular effects of structure and concentration-defined protein 
aggregates.  
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There are three main delivery approaches used to evaluate the effects of 
protein aggregates, these are: transgenic mice, extracellular bath application/ 
viral infection, or delivery into single cells via the patch pipette.   
1.3.1 Transgenic models 
A classic approach to study physiological protein function is to generate 
transgenic mouse models and compare them to their wild-type littermates. This 
approach has several limitations, including compensation from other proteins 
during development. For example, in MAPT -/- mouse models there are limited 
functional effects observed, as other axonal proteins such as microtubule-
associated protein 1A (MAP1A) can compensate to perform the microtubule-
stabilization functions of tau (Dawson et al., 2001; Fujio et al., 2007; Harada et 
al., 1994; Tucker et al., 2001). Most studies of oligomer pathology using 
transgenic models depend upon promoting the overexpression of protein or by 
enhancing the level of aggregation and measuring the electrophysiological or 
behavioural phenotypes (Andorfer et al., 2005, 2003; Cowan et al., 2010; Lee 
et al., 2001; Polydoro et al., 2009; Spires et al., 2006; Tanemura et al., 2002; 
Tatebayashi et al., 2002; Wittmann et al., 2001; Yoshiyama et al., 2007). 
Another limitation in this case is that it is hard to quantify the exact form of 
protein responsible (e.g., small soluble oligomer, fibrils, insoluble aggregates, 
tangles), or the concentration of protein needed to see these effects. This 
introduces variation into data and makes equating changes in neuronal 
properties with tau aggregate structure and concentration difficult.  
1.3.2 Extracellular bath application or viral injection 
A different approach to study oligomer pathology is to perfuse the protein 
aggregates (recombinant or isolated from patient samples) onto the acute 
brain slices or by injecting them in vivo (Lasagna-Reeves et al., 2012). This 
method will circumvent the challenges of compensation observed with 
transgenic models and has been used successfully to elucidate many 
elements of aggregate pathology (Acquarone et al., 2019; Fá et al., 2016; 
Lasagna-Reeves et al., 2012; Ondrejcak et al., 2018). It does however have 
similar limitations in that the pathological effects cannot be easily attributed to 
the structure or concentration of protein aggregate. It can be hard to know how 
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much of the aggregate has been taken up into each neuron as in both cases 
they are applied extracellularly and thus they cannot determine whether the 
effects observed are due to the internalisation of aggregates or indirectly 
through the proteins acting extracellularly or indirectly through other cells, such 
as glia and astrocytes.  
1.3.3 Delivery via patch-pipette 
The lab of Dr Wall (where the work for this PhD thesis was undertaken), 
developed a novel approach utilising structurally defined, concentration-
controlled preparations of oligomers, delivered via the patch pipette to 
characterise changes in neuronal function using whole-cell patch clamp 
recording (Kaufmann et al., 2016). Utilising a single-neuron approach allows 
one cell to be targeted in a network free from pathology, thus allowing direct 
time- and concentration- dependent effects of protein aggregates to be 
measured. This technique permits the targeting to pre- or post-synaptic cells 
to study synaptic transmission and plasticity as well as tracking of aggregate 
movement through the cell from the soma to processes. This technique 
provides an unparalleled level of mechanistic detail and will be implemented 
throughout this thesis to study aggregate-induced pathology. This technique 
does have a number of limitations including that the maximum recording 
timescale is defied by the lifetime of the slice and that the timescale from the 
introduction of aggregates to effects can vary from cell to cell. It can also be 
challenging to translate the single cell findings into an in vivo functional assay 
(for example behavioural tests) as only on neuron is targeted rather than the 
network.  
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1.4 Carbon dioxide in health and disease 
1.4.1 Carbon dioxide 
Carbon dioxide (CO2) is excreted by breathing and its regulation is vital for life. 
The levels of CO2 in the blood fluctuate around the physiological normal level 
of 40 mm Hg (Huckstepp et al., 2010b). If the level of blood CO2 rises and the 
lungs can’t remove it quickly enough then respiratory acidosis will occur, this 
is normally characterised by blood pH falling below 7.35 (normally the pH is 
between 7.35 and 7.45).  In severe cases, this can lead to heart failure or death 
(Patel and Sharma, 2021). CO2 levels can be altered by many situations, for 
example they will be increased in people who suffer from asthma, sleep 
apnoea or chronic obstructive pulmonary disease (COPD)(Owens and 
Malhotra, 2010). On the contrary, levels can be lowered when people 
hyperventilate (Brown, 1953; Wilson et al., 1991).  
The ventilatory response to changes in the levels of PCO2 consists of both a 
peripheral and a central response. The central CO2 chemoreceptors are 
responsible for around 60-70% of the hypercapnic respiratory response, while 
the peripheral CO2 chemoreceptors are responsible for the remaining 30-40 % 
of the response. The ventilatory response to PCO2 changes can be modelled 
using a two component model, whereby the peripheral and central 
chemoreceptor responses (components) can be separated by the differences 
in their time constants (Dahan et al., 2007; Pedersen et al., 1999). In humans, 
when PCO2 levels are increased from 44 to 55 mm Hg CO2 and ventilation 
was measured, the peripheral chemoreceptors correspond to the fast 
component of the response (time constant ~ 3-10 s) whereas central 
chemoreceptors correspond to the slower component of the response (time 
constant ~ 2 mins; Dahan et al., 2007)). Central chemoreceptors are mainly 
localised on the surface of the ventral medulla but also on the nucleus of the 
solitary tract, locus coeruleus, caudal medullary raphe and the fastigial nucleus 
of the cerebellum. There will be some degree of temporal specificity depending 
on the site of CO2 detection (Nattie, 1999). 
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1.4.2 Connexins  
Connexins are a family of proteins that are embedded in cell membranes and 
can form large-pored channels. They assemble in groups of six into large 
conductance hexameric channels called connexons (Fig 1.17). Assembly of 
connexons occurs before delivery to the plasma membrane (Goodenough et 
al., 1996; Kumar and Gilula, 1996; Willecke et al., 2002) and once formed may 
either be delivered to the membrane or maintained in intracellular stores for a 
later timepoint (George et al., 1999).  Two connexons on plasma membranes 
of neighbouring cells can then co-assemble to form a ‘gap junction’. These 
channels allow the passage of both ions and other small molecules such as 
glucose and lactate. This inter-neuron connection is a key form of cell-to-cell 
communication. If there is just the one connexon that opens into the 
extracellular space and is not docked to an adjacent cell, they are known as a 
‘hemichannels’ and have functions that are distinct from those of gap junctions. 
(Dale, 2008; Huckstepp et al., 2010b; Pearson et al., 2005; Stout et al., 2002; 
Weissman et al., 2004). Hemichannels can release adenosine triphosphate 
(ATP) to signal via ionotropic P2X and metabotropic P2Y receptors to mediate 
intracellular communication (Huckstepp et al., 2010b; Pearson et al., 2005). 
They can also, through opening, drastically alter both neuronal excitability and 
whole-cell conductance (Moore et al., 2014). Hemichannels can be homomeric 
if they consist of six of the same connexin proteins or heteromeric if they 
consist of a combination of different connexins and can have varying different 
effects to the homomeric channels. This is a complicating factor when studying 
the functional effects of specific connexins.  
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Figure 1.17: Connexin assembly into gap junctions and hemichannels. 
(Left) Connexin channels assemble in groups of 6 to form connexons. These then 
either co-assemble with another connexon on a neighbouring neuron and form a ‘gap 
junction’ or remain as a single connexon open to the extracellular space, in which 
case they are known as ‘hemichannel’. (Right) Structure of Cx26 showing the position 
of residues K125 (blue) and R104 (red) that form the carbamate bridge under 
alterations of CO2 levels. Mutations of these two important residues abolishes the 
sensitivity to CO2 (Adapted from Nijjar et al., 2021).  
1.4.3 Carbon dioxide and connexins 
There are 21 connexin genes in the human genome. There are a subfamily of 
these connexins that have evolved to be directly sensitive (not through a pH 
change) to CO2 (connexin 26 (Cx26), connexin 30 (Cx30) and connexin 32 
(32)) (de Wolf et al., 2016; Huckstepp et al., 2010b, 2010a; Meigh et al., 2013). 
Of these, Cx26 shows the strongest sensitivity and this is known to be 
mediated directly via the carbamylation of lysine residue 125 (Huckstepp et al., 
2010b; Meigh et al., 2013). This is supported by compelling evidence that if 
this carbamylation motif is inserted into a CO2-insensitive connexin (connexin 
31), then CO2 sensitivity can be induced in these channels (Meigh et al., 2014). 
Further evidence of this direct action through the carbamylation site comes 
from mutation studies: if either K125R or R104A are mutated within connexin 
26, the CO2 sensitivity is abolished (Meigh et al., 2014). If K125 is mutated to 
C125 instead then the hemichannel instead becomes sensitive to NO or NO2
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(Meigh et al., 2015). There is also no evidence of connexin 26 sensitivity to 
carbon monoxide (personal communication, Dale 2020). Finally, there are now 
cryoEM structures of gap junctions that support the carbamylation of K125 at 
different levels of PCO2 (Brotherton et al., 2020). Since the physiological 
midpoint for Cx26 hemichannel opening is ~40 mm Hg CO2, there will be a 
proportion of Cx26 hemichannels that are open at rest.  
There is substantial additional functional research to support the direct 
interaction between CO2 and Cx26 hemichannels. Firstly, in early patch clamp 
experiments, clear conductance changes were observed when the level of 
CO2 was altered in cell lines (expressing Cx26; Fig 1.18). Raising the level of 
CO2 to 55 mm Hg caused an increase in whole-cell conductance and in 
contrast, reducing to 20 mm Hg caused a decrease in whole-cell conductance. 
These effects are completely independent of any changes to pH (as all 
experiments were performed with isohydric solutions) (Huckstepp et al., 
2010a, 2010b).  
Connexin 26 is capable of forming heteromeric hemichannels or gap junctions 
with a number of other connexins, including Cx32, which is also sensitive to 
CO2, although at higher levels (~ 70 mm Hg; Koval et al., 2014). Both Cx26 
and Cx32 are expressed on the surface of the ventral medulla and thus it is 
feasible that they could form heteromeric channels, but the function of these 
channels is currently unknown.  
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Figure 1.18: The results of changing the level of PCO2 on connexin 26 
hemichannels, effects on conductance. 
(A) Through direct interactions between CO2 and then connexins themselves, open 
probability can be shifted. Increasing the level of PCO2 results in the opening of more 
hemichannels. Decreasing the level of PCO2 results in the closing of more 
hemichannels. (B) Initial patch clamp recordings (Huckstepp et al, 2010) in cell lines 
expressing connexin 26 hemichannels. Altering the level of CO2 (under isohydric 
conditions), results in changes to channel open probability and consequently to 
conductance changes. (C) Schematic to demonstrate how the dominant negative 
version of Cx26 allows hemichannel responses to be evaluated. This innovative 
method uses two mutations (K125R and R104A) to the connexin 26 gene that result 
in a subunit that can assemble with wild type connexin 26 subunits to form 
hemichannels but these resulting hemichannels are unable to change conformation 
and open in response to CO2.  
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1.4.4 Physiological consequences of CO2 sensitivity on breathing 
Altering the level of CO2 (without compensation) will result a change in pH 
which has been linked in a number of studies to the regulation of control of 
breathing (Gourine et al., 2010; Hosford et al., 2018; Kumar et al., 2014; 
Loeschcke, 1982; Trapp et al., 2008; S. Wang et al., 2013). There is also 
compelling evidence that CO2 can have direct effects on breathing (Eldridge 
et al., 1985; Shams, 1985).  
Raised CO2 levels trigger the release of ATP from glial cells in the brainstem 
and this has direct effects on breathing (Gourine et al., 2005; Huckstepp et al., 
2010a). Over many years, increased understanding of the direct mechanism 
of CO2 interaction with connexin 26 has allowed the development of genetic 
tools with which to understand the physiological functions that this sensitivity 
contributes to. By generating a dominant negative subunit of Cx26, the 
functional effects of the sensitivity can be studied. This innovative method uses 
two mutations (K125R and R104A) to the Cx26 gene that result in a subunit 
that can assemble with wild type Cx26 subunits to form hemichannels, but the 
resulting hemichannels are unable to change conformation and open in 
response to CO2 (Fig 1.18). In initial in vivo experiments, the dominant 
negative subunit of Cx26 was expressed in the glial cells within the medulla 
oblongata. It was demonstrated that CO2 binding to Cx26 contributes to 
roughly half of the adaptive ventilatory response to hypercapnia that is 
controlled by central chemosensors (van de Wiel et al., 2020).  
1.4.5 Conservation of Cx26-mediated CO2 sensitivity across 
species
CO2-sensitive Connexin 26 homologs are found in humans, rats, chickens, and 
naked mole rats. However, the level of CO2 needed to open the channels 
differs across species. In humans and in rats the resting pCO2 is ~ 40 mm Hg 
CO2 and a shift to 55 mm Hg CO2 is sufficient to significantly open the 
channels. However, in chickens, Cx26-mediated CO2 sensitivity is lower, and 
they show significant channel opening at 35 mm Hg CO2. The mole rat, in 
contrast is only CO2 sensitive if the level is increased to 70 mm Hg CO2 (de 
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Wolf et al., 2017). These distinctions are particularly interesting when one 
considers the environments in which these species reside and how this could 
be beneficial for respiratory chemoreception. Naked mole rats reside 
underground in burrows, with low gas permeability, therefore, will be 
rebreathing air and will thus experience hypoxia and hypercapnia. They are 
therefore adapted to survive better and maintain body weight in these 
conditions than standard laboratory rats (Arieli et al., 1977). It has further been 
shown that the level of CO2 equilibrated in subepidermal gas pockets of the 
mole rat is considerably higher than that of the standard laboratory rat, thus 
suggesting that the resting pCO2 may be higher (Ar et al., 1977). Whereas 
birds need to be able to fly at high altitudes. At higher altitudes, the birds will 
breathe more frequently and thus lower their pCO2. Therefore, they need to be 
able to tolerate much lower pCO2 levels than mammals in order to regulate 
their breathing (Osborne et al., 1977; Osborne and Mitchell, 1978) and 
maintain blood flow (Faraci and Fedde, 1986).  They have adapted to have a 
lower resting pCO2 of ~30 mm Hg, for example in chickens it is reported to be 
~33 mm Hg CO2 (Calder and Schmidt-Nielsen, 1968; de Wolf et al., 2017).  
1.4.6 Not just a glial connexin
Although widely considered to be a primarily glial connexin (Nagy et al., 2011), 
connexin 26 is also expressed in a small number of neuronal populations 
throughout the brain. DN coupling via gap junctions was first described by 
Grace and Bunney (1983). A study by Vandecasteele et al. (2005) confirmed 
the presence of functional gap junctions between pairs of neighbouring DNs in 
the SNpc (Vandecasteele et al., 2007; Fig 1.19). They followed this with a 
second study to look at which connexins were present in the dopaminergic 
neurons (Fig 1.19). At postnatal day (P)7-10, connexins 26, 30 36, 23 and 43 
are expressed (mRNA, from single cell RT-PCR). There is then a 
developmental shift and by P17-21 there is expression instead of Cx31.1, 36 
and 43 (Vandecasteele et al., 2006). This is of particular interest given that 
connexins 26 and 30 are known to be directly sensitive to changes in CO2
levels. Note that this demonstration of the mRNA being present does not mean 
that there are functional hemichannels. They performed dye loading 
experiments with luciferase yellow to look for functional hemichannels. By 
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lowering the calcium, hemichannels should open and allow the dye to be taken 
up, however they did not find evidence of this. This may have been because 
the connexins assemble as heteromers and this prevents the uptake.  
Figure 1.19: Demonstration of functional gap junctions between neighbouring 
dopaminergic neurons of the substantial nigra and the corresponding connexin 
expression 
A. Whole-cell patch clamp recording of pairs of neighbouring dopaminergic neurons 
demonstrating functional gap junctions (electrical coupling) between cell 1 and cell 2. 
By injecting current (either +100 pA or -200 pA) only into one cell, a voltage response 
can be elicited in both cells. (Vandecasteele et al., 2005) B. A follow up study in which 
single cell RT-PCR was used to establish which members of the connexin subfamilies 
are expressed (mRNA) in representative example dopaminergic neurons within the 
substantia nigra. At postnatal day (P)7-10, connexins 26, 30 36, 23 and 43 can be 
found. There is then a developmental shift and by P17-21 there is expression instead 
of Cx31.1, 36 and 43. (Vandecasteele et al., 2006).  
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1.5 Recording regions and their physiological functions 
1.5.1 Hippocampus – structure and connectivity 
The hippocampus is divided into 4 main subfields CA1, CA2, CA3 and the 
dentate gyrus (DG). It is a region of the brain that is well characterised, and 
the circuitry of innervation is well established (Figure 1.20A). Input arrives to 
the hippocampus from the entorhinal cortex (EC) via two pathways, the 
perforant pathway (PP) and the temporoammonic (TA) pathway. The PP is the 
main input to the hippocampus, and it encompasses the traditional excitatory 
tri-synaptic pathway (Knierim, 2015). Axons from layer II of the EC project to 
the granule cells in the dentate gyrus (DG). DG axons are known as Mossy 
Fibres (MF) and they relay the signal from the DG to CA3 neurons. Then the 
signal is relayed along CA3 axons, which are known as Schaffer Collaterals 
(SC) to CA1 neurons. Finally, CA1 neurons can the relay the signal back to 
the EC, which forms the major output pathway of the hippocampus (Anderson 
et al., 2009; Neves et al., 2008). There are also additional projections from the 
EC directly to CA3 through the PP and also from the EC directly to CA1 through 
the TA pathway (Deng et al., 2010; Kajiwara et al., 2008; Figure 1.20A). 
The CA1 layer of cells was chosen for my experiments as it contains pyramidal 
cells that are easy to locate and characterise (Figure 1.20B, C) and are easy 
to parameterise due to existing models developed and already implemented 
in the lab (Badel et al., 2008a, 2008b). 
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Figure 1.20: Structure and connectivity at the level of the hippocampus and a 
detailed example of CA1 neuron morphology
A. A schematic to demonstrate the circuitry of the hippocampus. There are two main 
input pathways from the entorhinal cortex (EC) - the perforant pathway (PP) and the 
temporoammonic (TA) pathway. The traditional excitatory tri-synaptic pathway runs 
from layer II of the EC to the dentate gyrus, then project to the pyramidal neurons in 
CA3 through the Mossy fibers (MF). These neurons then relay the message onto CA1 
neurons through the Schaffer collaterals (SC). Followed by a projection back to the 
EC. There are additional projections from the EC directly to CA3 through the PP and 
also from the EC directly to CA1 through the TA pathway. The hippocampal 
recordings in this thesis were made from CA1 neurons in acutely prepared slices. 
Figure adapted from (Deng et al., 2010). B. Representative example of a recorded 
CA1 neuron that was filled with Alexa Fluor 488 to allow its morphology and 
localization to be examined. Imaged using Leica 770 confocal microscopy over bright 
field to highlight its position in the slice, scale bar = 14 µm. C. An illustration of the 
morphology of a CA1 pyramidal neuron. Its soma is in the stratum pyramidale (SP) 
and basal dendrites project into the stratum oriens (SO). Its apical dendrite is long 
and through the stratum radiatum (SR; where the proximal apical dendrites are found) 
to the stratum lacunosum-moleculare (SLM, where the most distal apical dendrites 
are located). Both the basal and apical dendrites display branches of projections. 
Figure adapted from (Ishizuka et al., 1995). 
1.5.2 Hippocampus – role in learning and memory 
The hippocampus is a region of the brain with important physiological roles in 
learning and memory (Ballard et al., 2019; Knierim, 2015; Scoville and Milner, 
1957; Squire, 2009; Squire et al., 2015). It is also one of the key sites of 
pathology in Alzheimer’s disease, where atrophy results in impaired cognition, 
working and episodic memory (Jack et al., 1999; O’Shea et al., 2016). 
Synaptic plasticity in the form of long-term potentiation (LTP) and long-term 
depression (LTD) are key processes involved the in the storage and 
maintenance of memory (Abraham et al., 2019; Nabavi et al., 2014; Neves et 
al., 2008; Ryan et al., 2015). The CA1 region of the hippocampus provides a 
good site for studying synaptic plasticity as its circuitry is well characterised 
and it readily displays both long term potentiation (LTP) and long term 
depression (LTD) (Bliss and Gardner-Medwin, 1973; Bliss and Collingridge, 
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1993; Bliss and Lømo, 1973; Dhuriya and Sharma, 2020; Lüscher and 
Malenka, 2012; Malenka and Bear, 2004).  
1.5.3 Neocortex 
A subset of my experiments were performed in the neocortex, which has roles 
in memory storage and reasoning as well as perception and the generation of 
motor command. The structure and inter-layer connectivity is well conserved 
across species (Kozloski et al., 2001; Silberberg et al., 2002) which has 
allowed for effective characterisation in animal models. The layered columnar 
structure of the sensory cortices was first proposed by Vernon Mountcastle, in 
1957 following initial characterisation in cats, but recent work (for ethical and 
practical reasons) tends to use rodent models instead (Mountcastle, 1998). 
The neocortex has a layered structure, with layer one at the outer edge of the 
slice, then layer II/III, layer IV, layer V and finally layer VI towards the border 
before the hippocampus. Neurons within each layer vary in size and project to 
different brain regions including the thalamus, the striatum and other areas of 
the cortex (Fig 1.21). Attempts have been made to use modelling approaches 
alongside electrophysiology to digitally reconstruct this network to understand 
its function better (Markram et al., 2015). In layer V, there are two subgroups 
of neurons, thick and thin tufted, which differ by the morphology of their apical 
dendrites and their neuronal inputs. In this study I targeted the thick tufted 
group, which are located deeper into layer V and whose axons project to the 
striatum, the pons, and the spinal cord. Thick tufted neurons are easily 
identifiable by their thicker apical dendrites and extensive branching in layer 1 
of the cortex and burst firing on whole-cell breakthrough (Romand et al., 2011). 
Neurons in layer V are able to form synaptic connections with neighbouring 
neurons (Markram et al., 1997; Ramaswamy et al., 2015) and therefore 
provide a useful tool for studying synaptic transmission. This was the rationale 
behind using this brain region, as the synaptic connection rate (between pairs 
of neurons) was higher than in the hippocampus. Thick-tufted neurons in layer 
V were targeted as they have a connection rate of 1 in 10 pairs (Markram et 
al., 1997). These neurons have also been shown previously to work well with 
the dynamic IV extraction method which our lab have used previously to 
73 
parameterise neurons (Badel et al., 2008a, 2008b; Harrison et al., 2015; 
Kaufmann et al., 2016).  
Figure 1.21: A simplified schematic of the microcircuitry of the neocortex. 
A) The layers of excitatory neurons and their projection pathways are indicated 
(Figure reproduced from Harris and Mrsic-Flogel, 2013). B) Golgi stain of the neurons 
in the neocortex, demonstrating their elaborate axonal and dendritic ramifications and
columnar structure (adapted from Ramón y Cajal, 1911). 
Although the neocortex is not the most recognised region of pathology in PD 
and AD, Lewy body pathology can develop in the cortex and this is often paired 
with the loss of cholinergic input from the basal forebrain to the cerebral cortex 
and consequent neurodegeneration (Bohnen and Albin, 2011; Müller and 
Bohnen, 2013; Sugiyama et al., 1994). It is therefore a useful target region for 
evaluating protein aggregate pathology for my studies. 
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1.5.4 Pyramidal neurons 
Layer V neurons in the cortex and CA1 neurons in the hippocampus are both 
examples of pyramidal neurons, which have a characteristic structure 
(Spruston, 2008). Pyramidal neurons are extensively studied and therefore 
provide an attractive target, both for electrophysiological characterisation and 
for modelling studies. Their structure is well conserved across brain regions 
(Fig 1.22) and consists of a soma with a single projecting axon which projects 
via collaterals both locally and to long range targets. Their dendrites consist of 
both short (basal) and a long projecting apical dendrite. Both sets of dendrites 
are highly specialised and able to receive synaptic inputs (London and 
Häusser, 2005). They express several different types of ion channels, 
including GIRK and HCN channels and the number of channels increases with 
distance from the soma. This means that they can be activated and inhibited 
by a range of neuromodulators (Berger et al., 2001; Takigawa and Alzheimer, 
1999).  
Figure 1.22: A comparison of the structure of pyramidal neurons in Layer of the 
neocortex and the CA1 region of the hippocampus. 
A) Both examples of pyramidal neurons, they demonstrate considerable similarity in 
structure but differ in length of their apical dendrite and number of oblique dendrites. 
B) The apical tuft (purple) receives excitatory inputs that can differ from those 
targeting proximal apical dendrites or basal dendrites. For example, for in CA1 
pyramidal neurons, the dendrites in the apical tuft located receive synaptic input 
directly from the entorhinal cortex, whereas the basal and proximal apical dendrites 
75 
in the stratum radiatum receive input primarily from CA3 cells via the Schaffer 
Collaterals. (Amaral and Lavenex, 2007; Figure adapted from Spruston, 2008).  
1.5.5 Basal ganglia 
The basal ganglia is a region near the base of the brain that encompasses 
different sub-regions including the substantia nigra (pars compacta and pars 
reticulata), the striatum (caudate nucleus and putamen), the globus pallidus 
(external GPe and internal GPi) and the subthalamic nucleus (STN). The 
substantia nigra pars compacta (SNpc) is a one of the key dopaminergic nuclei 
in the brain and its neurons play important roles in the control of movement, 
reward, and sleep. Glutamatergic transmission into the basal ganglia is 
received from the neocortex. From the SNpc, the basal ganglia circuitry has 
two major pathways of dopaminergic innervation (Figure 1.9; Lanciego et al., 
2012).  
Dopamine is a small molecule excitatory neurotransmitter widely distributed 
throughout the brain. Dopamine receptors belong to the G-protein coupled 
receptor (GPCR) subfamily and can be classified into receptor families D1 and 
D2 by their physiology and pharmacology (Bhatia et al., 2021). Dopamine 
receptors from the D1 family (D1 and D5) are coupled to Gαs. When dopamine 
binds to a D1 family dopamine receptor, the globus pallidus interna/substantia 
nigra pars reticular (GPi/SNr) is inhibited directly and this results in the 
upregulation of the glutamatergic output from thalamus to neocortex, thus 
increasing movement (Bhatia et al., 2021; Keeler et al., 2014). Thus, when 
neurons are lost from the SNpc, there results a lack of regulation, a loss of 
excitation to the neocortex and thus impaired motor control.  
The D2 receptor family is comprised of receptors D2, D3 and D4, which couple 
to Gαi. When dopamine binds to a D2 receptor, it inhibits the subthalamic 
nucleus (STN) via a pathway through the globus pallidus externa (GPe). The 
STN can then send excitatory projections back to the GPi/SNR (Keeler et al., 
2014). The binding of dopamine to D2 family receptors has also been shown 
to decrease the activity of tyrosine hydroxylase by modulating its level of 
phosphorylation (Kehr, 1974; Roth, 1984; Wolf and Roth, 1990). A reduction 
in D2 receptors (after neurons are lost), will lead to less inhibition of movement 
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and dystonia (DeLong and Wichmann, 2007; Galvan and Wichmann, 2008; 
Keeler et al., 2014).  
There are two D2 receptor variants, D2S and D2L which are produced by 
alternative splicing, with the long version harbouring an extra 29 nucleotide 
cytoplasmic loop. D2S and D2L localise to the presynaptic and postsynaptic 
membranes respectively (Hisahara and Shimohama, 2011). Some populations 
also have local D2 autoreceptors which respond to dopamine and modulate 
the neuronal resting potential. These D2S receptors are found at pre-synapses 
and acts as a negative feedback loop so when dopamine is released, it binds 
and prevents further release of dopamine via hyperpolarisation of the 
membrane potential and thus a decrease in firing rate and excitability (Mercuri 
et al., 1997; Silva and Bunney, 1988). This occurs via activation of a GIRK 
conductance (Cathala and Paupardin-Tritsch, 1999; Lacey et al., 1987).  
1.5.6 Ventral tegmental area 
The ventral tegmental area (VTA) is a group of neurons located close to the 
midline on the floor of the midbrain and is one of the core regions of 
dopaminergic signalling in the brain. Several recent studies have shown that 
the VTA is highly heterogeneous containing different subtypes of neurons and 
many projection sites (Fig 1.23). Between 65-70 % of neurons are 
dopaminergic, with most of the remaining neurons (~35%) GABAergic and a 
small percentage being glutamatergic. In this thesis, I focus on the GABAergic 
neurons, of which ~32% are both VGAT- (vesicular transporter) and GAD67-
positive, ~67% are VGAT-positive and only 1% are positive for GAD67 but not 
for VGAT, highlighting the heterogeneity even within the GABAergic 
subgroups of the VTA (Chowdhury et al., 2019).  
Some of the GABAergic neurons can also co-release other transmitters such 
as glutamate and dopamine (Bouarab et al., 2019; Morales and Root, 2014; 
Root et al., 2018; Takata et al., 2018; Yoo et al., 2016; Fig 1.24). Although it is 
important to distinguish that dopaminergic neurons that co-release GABA 
cannot be identified by conventional markers as they synthesise their GABA 
using ALDH1a1 rather than GAD (Kim et al., 2015) and they load vesicles with 
VMAT2, independent of VGAT (Tritsch et al., 2012).  
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Figure 1.23: A simplified schematic of the complex circuitry of the ventral 
tegmental area and surrounding brain regions. 
Dopamine neurons receive excitatory inputs from a number of regions including the 
lateral hypothalamus, medial prefrontal cortex (mPFC) and the pedunculopontine 
tegmental nucleus/ laterodorsal tegmental nucleus. They then project to the 
basolateral amygdala, medial prefrontal cortex, and the nucleus accumbens (NAc). 
GABAergic neurons receive excitatory inputs from the lateral habenula and inhibit 
both the mPFC and the NAc as well locally inhibiting dopamine neurons in the VTA. 
Figure adapted from Stuber et al., (2012).  
VTA dopaminergic neurons have well-defined roles in motivation, 
reinforcement learning and reward processing (Holly and Miczek, 2016; 
Lammel et al., 2014; Morales and Margolis, 2017). GABAergic neurons play a 
modulatory role, with both local and long range projections (Bouarab et al., 
2019) and are believed to encode the prediction of reward (Eshel et al., 2015; 
Tan et al., 2012; van Zessen et al., 2012). Long-term potentiation of local 
GABAergic synapses onto VTA DA neurons, greatly increases the inhibition of 
DA neurons (Simmons et al., 2017) and this can be blocked by a single 
administration of drugs of abuse such as morphine, ethanol or cocaine (Guan 
and Ye, 2010; Niehaus et al., 2010; Nugent et al., 2009, 2007). Long range 
GABAergic projections from the VTA to the dorsal raphe nucleus (DRN) are 
involved in the encoding of both aversion (activation of rostral VTA neurons 
that project to DRN serotonergic neurons) and reward (activation of caudal 
VTA neurons that project to DRN GABAergic neurons (Li et al., 2019). 
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Figure 1.24: Complex heterogeneity of GABAergic inputs and outputs from the 
ventral tegmental area 
The VTA has a complex input and output pattern GABA neurons from a wide range 
of brain regions. It is complicated further by the presence of synapses that can co-
release combinations of other neurotransmitters too (e.g., dopamine and glutamate 
or GABA and glutamate). Abbreviations: BNST, bed nucleus of the stria terminalis; 
CeA, central amygdala; DRN, dorsal raphe nucleus; LHb, lateral habenula; LH, lateral 
hypothalamus; NAc, nucleus accumbens; PAG, periaqueductal gray; PFC, prefrontal 
cortex; SC, superior colliculus; VP, ventral pallidum; VTA, ventral tegmental area. 
(Adapted from Bouarab et al., 2019)  
Although this role in aversion and reward is well characterised, more recently 
the VTA has also been found to also have important roles in other behaviours. 
For example, it has been demonstrated that the VTA is a key component of 
the sleep/wake circuitry, with VTA-dopaminergic neuron activation sufficient to 
drive wakefulness and necessary for the maintenance of wakefulness (Eban-
Rothschild et al., 2016; Fifel et al., 2018). It has been shown that VTA 
GABAergic neurons can also mediate changes in activity across the 
sleep/wake cycle and their activation can alter the sleep/wake state (Takata et 
al., 2018; Yu et al., 2019) and that disruption of these GABAergic neurons can 
lead to mania (Yu et al., 2020). Given the important and varied roles of these 
neuronal populations in a wide range of behaviours, any factors that modulate 
their function and excitability could potentially also influence these behaviours.  
79 
1.6 PhD Aims 
1. To use whole-cell patch clamp recording to introduce oligomeric forms 
of tau protein into hippocampal neurons to evaluate its effects on 
neuronal function: (Chapter 3) 
a. Firstly, on action potential dynamics and subthreshold neuronal 
properties in single cells 
b. Then using synaptically connected pairs of cortical cells, to 
establish whether there are specific pre- or postsynaptic effects 
of oligomeric tau protein on synaptic transmission and plasticity 
(both short- and long-term)   
c. Finally using high-resolution imaging techniques to study oTau 
localisation  
2. To use truncations of the full-length tau protein to test if there are 
specific regions of the tau molecule that are responsible for the 
observed changes in neuronal properties, and to begin to decipher the 
mechanisms underlying these changes. (Chapter 4) 
3. To introduce alpha synuclein monomers and oligomers into identified 
dopaminergic cells in the substantia nigra and observe the time 
dependent electrophysiological effects, then to assess how they are 
mediated. (Chapter 5) 
4. To use electrophysiology, pharmacology and immunohistochemistry to 
evaluate the CO2 sensitivity of dopaminergic neurons in the substantia 
nigra and GABA neurons in the VTA. (Chapter 6)
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2. Methods and Materials 
2. Methods and Materials 
Parts of this chapter have been published previously:   
 Hill et al., 2020, Star protocols  
 Hill et al, 2021a, b (Invited book chapters, in press). 
2.1 Tau production 
I generated tau oligomers following the protocols published in Karikari et al., 
(2017; Fig 2.1). Some of the preparations were maintained unlabelled and 
some were labelled with a fluorescent dye to allow monitoring of cellular 
localisation following injection into neurons. Alongside the tau production, I 
also generated control samples which were not inoculated with a tau plasmid 
in stage 2.1.1. These controls (both labelled and unlabelled) were interleaved 
with the testing of the tau samples for comparison. 
Figure 2.1: A simplified diagram of the tau production protocol 
A schematic displaying the key stages from initial glycerol stocks of plasmids through 
expression and purification stages to detection of the purified protein via SDS-PAGE. 
Detailed methods follow (2.1.1-2.1.3)  
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2.1.1 Protein expression 
Escherichia coli BL21 (DE3) carrying pProEX plasmids (Promega, Fig 2.2) 
coding for wild-type full-length tau-441 (Uniprot ID: P10636-8; appendix ref) 
with N-terminal 6xHis and FLAG tags and cysteine modifications 
(C291A/C322A/I260C), were inoculated into Luria broth (15 ml) containing 
ampicillin (100 mg/ml) and chloramphenicol (35 μg/ml) and incubated at 37 °C 
at 180 rpm overnight. Cultures were then added to 750 ml LB broth with 
ampicillin (100 mg/ml) and returned to the shaking incubator for 90 minutes. 
When the OD600 reached 0.6, 0.5mM isopropyl β-D-1 thiogalactopyranoside 
(IPTG) was added for 1 hour. Samples were centrifuged for 10 minutes at 4 
°C at 9800 g. The supernatant was removed, and pellets washed with 10 mM 
7.4 buffer Na2HPO4 twice before being re-dissolved in 10 mM sodium 
phosphate buffer (pH 7.4) and stored at -20 ºC until use. 
Figure 2.2: pProEXHTA-Flag-Mtau40 plasmid structure. 
Escherichia coli BL21 (DE3) carrying pProEX plasmids (Promega) coding for wild-
type full-length tau-441 (Uniprot ID: P10636-8) with N-terminal 6xHis and FLAG tags 
and cysteine modifications (C291A/C322A/I260C).
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2.1.2 Protein purification 
Samples were defrosted on ice and boiled for 10 minutes at 100 °C. A protease 
inhibitor cocktail tablet was added (Thermofisher Scientific, #A32963) and left 
to dissociate for 1 hour at room temperature. Each sample was then sonicated 
at 70% power for 1 minute and centrifuged at 4 °C, at 48000 g for 15 minutes. 
The supernatant containing the crude extract was kept and purified using an 
immobilised metal affinity chromatography (IMAC) A Ni-NTA column.  
Buffer A: 50 mM Na2PO4 pH 7.0, 500 mM NaCl, 10 mM Imidazole 
Buffer B: 50 mM Na2PO4 pH 7.0, 500 mM NaCl, 25mM Imidazole 
Buffer C: 50 mM Na2PO4 pH 7.0, 500 mM NaCl, 500 mM Imidazole 
The column was first washed with 70% ethanol. The chelating sepharose 
resin, added to the column (GEHealthcare, UK), was charged with 10 mM 
NiCl2/CH3COONa pH 4.0 and equilibrated with buffer A followed by the 
addition of the crude extract.  The column was then washed once with buffer 
A, twice with buffer B (increased imidazole concentration for washing) and 
finally then washed once with buffer C to elute the purified protein from the 
column in 1 ml fractions. Eluted fractions were frozen at -20 ˚C until use.  
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2.1.3 Concentrating the tau protein 
Collected 1 ml fractions of eluted protein were run on six percent hand-cast 
non-denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) gels (Table 2.1) to find those with the highest yields. 
Resolving gel: Stacking gel: 
5.2 ml H2O 2.975 ml H2O 
2 ml bis-acrylamide (Sigma Aldrich 
#A3574) 
0.67 ml bis-acrylamide 
2.6 ml 1.5M Tris/HCl pH 8.8 1.25 ml 0.5M Tris/HCl pH 6.8 
100 ml 10% SDS (Sigma Aldrich 
#L3771) 
50 ml 10% SDS 
100 ml 10% APS (Sigma Aldrich 
#A3678) 
50 ml 10% APS (made fresh) 
10 ml TEMED (Sigma Aldrich #T-
7024) 
5 ml TEMED 
Table 2.1: Recipe for six percent hand-cast non-denaturing sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels. 
APS and TEMED were added immediately before use. Resolving gel was allowed to 
set for 30 minutes before stacking was added and then allowed to set for a further 30 
minutes. Gels were then used immediately.  
After running the gels, they were stained with Instant Blue (Expedeon, #ISB1L) 
for 1 hour at room temperature. Fractions that contained high protein yields 
were then pooled together for concentrating. Vivaspin falcons (5000 MWCO; 
Sigma Aldrich, #VS2011) were washed with 1 ml NaH2PO4 buffer pH 7.4 and 
then defrosted samples were added and centrifuged for 30 minutes x 2600 xg 
x 4 °C until ~80 % had gone through. A bicinchoninic acid (BCA, G-
Biosciences, #786-570) curve was used to calculate the concentration and 
where needed the remaining liquid concentrated with further spins and 
concentration recalculated until all samples reached 1 mg/ml. 
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2.1.4 Labelling of tau protein oligomers  
One of the aims of this project was to monitor the localisation of the introduced 
tau within neurons. A label that binds to cysteine residues (Alexa Fluor 488 
C5-maleimide (Molecular Probes, #A10254)) was chosen for this in order to 
reduce aggregation and maintain the tau at a low molecular weight. The initial 
tau plasmid had 3 cysteine modifications in order to maintain function and allow 
this labelling. These modifications have previously been shown to have no 
detrimental effects on tau function (Karikari et al., 2019a; Kumar et al., 2014; 
Michel et al., 2014; Shammas et al., 2015). Samples were adjusted to 1 mg/ml, 
with 1 ml tris(2-carboxyethyl)phosphine (TCEP, Sigma Aldrich, #C4706), and 
Buffer NA2HPO4 pH 7.4 and left for 1 hour to allow the 5 x molar excess of 
TCEP to reduce the protein down to monomers. The label (1.5 ml, 4x molar 
excess) was then added, and the samples allowed to reform oligomers 
overnight. Samples were freeze-dried on dry ice before being stored at -80 °C.  
The following day samples were defrosted on ice and the label dialysed out 
using dialysis buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl) in a Slide-A-
LyzerTM MINI Dialysis device (10K MWCO, Thermofisher Scientific, #69570). 
The buffer was changed 4 times over 12 hours and the sample recovered at 
the end of the day. Unlabelled controls were prepared following the same 
protocol but with equal volume of 10 mM NA2HPO4 pH 7.4 instead of the 
maleimide label. The entire labelling process was performed at room 
temperature. 
2.1.5 Structural characterisation of oTau using transmission 
electron microscopy  
Transmission electron microscopy was used to confirm the aggregated nature 
of the protein. Formvar/carbon-coated 300-mesh copper grids (Agar scientific, 
#162) were glow-discharged using the ELMO system from Cordouan 
Technologies. Samples (5 μl) of labelled or unlabelled tau-441 preparations 
were pipetted onto the grid and allowed to bind for 1 minute. Filter paper was 
then used to remove any excess liquid and 5 μl of 2 % uranyl acetate was 
added for 1 minute. Filter paper was then used to remove any excess uranyl 
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acetate stain and the grids were imaged using a JEOL-2100F transmission 
electron microscope. 
2.1.6 Preparation of tau monomers  
In order to confirm that any observed effects on neuron electrophysiology were 
specifically the result of oligomeric tau protein, the oligomeric samples were 
broken down into monomers and then tested. To do this, 5 mM of reducing 
agent dithiothreitol (DTT, Sigma Aldrich, #10197777001) was added to the 
samples which were then incubated at 60 ̊ C for 30 minutes. This was sufficient 
to break the tau oligomers down to monomers (Fá et al., 2016). This was 
confirmed using hand-cast non-denaturing SDS-PAGE 6% and staining with 
Instant blue (Expedeon, #ISB1L). I then validated that the monomers would 
remain monomeric for a 3-hour period following breakdown, if stored on ice, 
thus providing a period in which experiments could be carried out. A 
confirmatory gel was run at the end of the experiments to demonstrate that a 
partner sample, treated with this monomerisation protocol also remained 
monomeric after 3 hours.  
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2.2 Tau N-terminal mutant production 
2.2.1 Plasmid modification and primer design   
A New England Biolabs Q5 site-directed mutagenesis kit (NEB, #E0554S) was 
used to generate the deletion of the N-terminal region of the tau protein from 
the original full-length plasmid (Appendix; 8.3). I left the first methionine amino 
acid in place for structural integrity and designed the primers to cut out amino 
acids 2-122 (pink region, Fig 2.3; Table 2.2).  
Primer: Sequence (5’ to 3’): 
Forward AGCCTGGAAGACGAAGCT
Reverse CATGGATCCCTTATCGTCATC
Table 2.2: Primers for plasmid modification 
i500 mM primer stocks in EB buffer and stored at -20 degrees. Working stocks 
of 10 mM were made fresh with nuclease-free water for each SDM protocol.  
Figure 2.3: pProEXHTA-Flag-Mtau40 plasmid with deletion and primers marked. 
Plasmid encodes full length human wild type 441- Tau, preceded by His and Flag tags 
upstream. The pink region marks the proposed deletion of t77he N-terminal region (2-
122). Purple arrows represent the forwards and reverse primers used to complete the 
site directed mutagenesis.
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2.2.2 Site directed mutagenesis 
Site directed mutagenesis was carried out using the template plasmid DNA 
and primers detailed in 2.2.1. For full protocol details please see kit, but briefly:
Volume Final concentration 
Master Mix 12.6 ml 1x 
10 mM forward primer 1.25 ml 0.5 mM 
10 mM reverse primer 1.25 ml 0.5 mM 
Template DNA 0.5 ml 1-25 ng  
Nuclease-free water 9.5 ml 
The following cycle conditions were used to carry out the initial mutagenesis: 
Temperature Time 
Initial denaturing  98 degrees 30 seconds 
25 cycles  98 degrees 10 seconds 
56 degrees 20 seconds 
72 degrees 20 seconds per kb (6.5kb) 
Final extension 72 degrees 2 minutes 
Hold 4 degrees 
The PCR product was used to set up three KLD reactions using 1 - 3 ml starting 
material: 
PCR product 1 ml 2 ml 3 ml 
2 x KLD reaction buffer  5 ml (1x FC) 5 ml (1x FC) 5 ml (1x FC)
10 x KLD Enzyme mix 1 ml (1x FC) 1 ml (1x FC) 1 ml (1x FC)
Nuclease free water 3 ml 2 ml 1 ml 
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2.2.3 Transformation into competent cells 
5 ml of the KLD product was added to 50 ml of competent cells (from the NEB 
SDM kit, #E0554S), incubated on ice for 30 minutes and heat shocked at 42˚C 
for 30 seconds. After a 5-minute incubation on ice, 950 ml SOC medium 
(Sigma Aldrich, #S1797) was added to each sample and placed in a shaking 
incubator at 37 ˚C for 1 hour. Dilutions of 50, 100 and 850 ml were plated onto 
LB + ampicillin (100 mg/ml) plates and allowed to incubate and grow overnight 
at 37 ˚C in a shaking incubator. The following day, 12 colonies were picked, 
and added to 5-10 ml fresh LB buffer + ampicillin (100 mg/ml). Samples were 
incubated shaking at 37 ˚C overnight.  
2.2.4 Miniprep and DNA double digest 
A Monarch Plasmid Miniprep Kit (NEB, #T1010) was used to isolate the 
plasmid DNA from E.Coli and stored at 4˚C. A DNA double digest of the 
isolated plasmid DNA was carried out using 2 ml DNA, restriction enzymes 
BamHI and EcoRI (0.5 ml each), chosen as they cut either side of tau (Fig 2.3), 
CutSmart buffer (NEB, #B7204S) 2 ml and 15 ml Nuclease-free water. 
Reactions were left at 37 ˚C in water bath overnight. Undigested full-length 
samples should give a 1.4kb fragment and successful mutagenesis should 
give a 1.1kb fragment. DNA gel electrophoresis was used to confirm the 
presence of the truncated fragment. Proteins were separated using SDS-
PAGE electrophoresis in a 1 % gel. A protein ladder was used for size 
reference (#P7712 or #P7712S from New England BioLabs, size range = 11 – 
245 kDa). 25 ml of each sample was loaded and ran for 1 hour (120 V, 200 
mA, 50 W). Gel detection performed using an ImageQuant™ LAS4000 
biomolecular imaging system (GE Healthcare). 
2.2.5 Sequencing  
Sequencing was performed to check that the mutagenesis had been 
successful for all samples that showed deletions on gel electrophoresis (5 ml 
DNA 80-100 ng, 5 ml primer). Sequencing primers were made up to 500 mM 
stock in EB buffer and stored at -20 ˚C. A working stock was created in water 
and used for the sequencing preparations. Sequencing was outsourced to 
Eurofins. Snap gene was used to evaluate the sequencing data. 
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2.2.6 Transformation of successful colonies 
1 ml DNA was added to 100 ml competent cells (thawed on ice) and incubated 
for 40 minutes on ice. Heat shock was performed for 90 seconds at 43 ˚C and 
then 1 ml SOC medium (Sigma Aldrich, #S1797) added. Samples were 
incubated for 1 hour at 37 ˚C and then 10 ml and 100 ml spread onto LB + 
ampicillin (100 mg/ml) plates for each of the samples. The remaining sample 
was spun for 5 minutes at 13000 g to pellet, the supernatant removed, and 
pellet resuspended in 100 ml LB. 100 ml was then plated onto a LB + ampicillin 
(100 mg/ml) plate and all plates were incubated at 37 ˚C overnight. The 
following morning colonies were inoculated into LB + ampicillin (100 mg/ml) 
and left to grow overnight. After 24 hours, samples were either used to make 
50% glycerol stocks and frozen at -80 ˚C or inoculated into larger 750 ml 
cultures of LB + ampicillin (100 mg/ml) and the protocol for producing full-
length tau was initiated (as in 2.1.1-2.1.3).  
2.2.7 Western blot protocol 
Blocking solution: TBS + Tween 20 with 2 % dried skimmed milk (Marvel, UK) 
Transfer solution: 200 ml blocking x10, 400 ml methanol, 1400 ml water 
Following purification, to ensure that the observed bands on SDS-page were 
tau-positive, a western blot was used. The resolving gel was washed in transfer 
solution to remove SDS and then was transferred to an ECL nitrocellulose 
membrane (Amersham Biosciences, #10600002). The gel was packed into a 
Mini Trans-Blot Cell (Bio-Rad) and submerged in transfer solution at 4 °C. 
Electrophoresis was used to enable transfer to the membrane at 200 mA for 
2.5 hours. The membrane was then removed and blocked with TBS + Tween 
20 (TBST) containing 2 % dried skimmed milk (Marvel, UK) for 1 hour to 
prevent non-specific binding. The primary antibody was added against tau 
(HT7, ThermoFisher, 1:1000, #MN1000) for 2 hours and the washed 4 times 
with TBST. The secondary antibody (horseradish peroxidase (HRP)-
conjugated anti-mouse antibody, 1:1000 dilution; ThermoFisher #61-6520)
was then added for 1 hour at room temperature. Finally, the membrane was 
washed a further 4 times with TBST and then imaged using an 
electrochemiluminescent detection kit (BIORAD Clarity Western ECL, #170-
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5060). Gel detection performed using an ImageQuant™ LAS4000 
biomolecular imaging system (GE Healthcare). 
2.3 Methods: Alpha Synuclein preparation 
2.3.1 Alpha synuclein sonication to produce oligomers 
Due to time constraints, alpha synuclein aggregates were bought from Abcam 
(ab218819) in the form of pre-formed fibrils. In order to introduce alpha 
synuclein as oligomers into neurons (as with the tau protein), the pre-formed 
fibrils were added to a 500 µl vial of intracellular solution (to produce the correct 
final concentration, always after filtration) then sonicated on full power for 15 
minutes in an ultrasonic water bath. Samples were then kept on ice until use.  
2.3.2 Structural confirmation 
Confirmation the proteins were in oligomeric form was completed with negative 
stain transmission electron microscopy.  
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2.4 Methods: Electrophysiology  
2.4.1 Preparation of tissue 
C57/Bl6 wild type mice (2-4 weeks) were used for experiments. The precise 
postnatal age of the mice used can be found in individual Chapters. Mice were 
killed by cervical dislocation and then decapitated in accordance with the U.K. 
Animals (Scientific Procedures) Act (1986). All experiments were approved by 
the University of Warwick local Animals Welfare and Ethics Board (AWERB).  
2.4.2 Solutions 
Solution Contains (mM): 
Cutting aCSF 127 NaCl, 1.9 KCl, 8 MgCl2, 0.5 CaCl2, 1.2 KH2PO4, 26 
NaHCO3, 10 D-glucose (pH 7.4 when bubbled with 95% 
O2 and 5% CO2, 300 mOSM) 
Recording 
aCSF 
127 NaCl, 1.9 KCl, 1 MgCl2, 2 CaCl2, 1.2 KH2PO4, 26 
NaHCO3, 10 D-glucose (pH 7.4 when bubbled with 95% 
O2 and 5% CO2, 300 mOSM) 
Intracellular 
patch solution 
135 Potassium gluconate, 7 NaCl, 10 HEPES, 0.5 
EGTA, 10 Phosphocreatine, 2 MgATP, 0.3 NaGTP (293 
mOSM, pH 7.2) 
(to allow identification of the recorded cells, in a subset 
of experiments, Alexa Fluor Hydrazide dyes (488 or 
594) were added to intracellular solution to a final 
concentration of 0.05 mM final concentration 
Table 2.3: Recipes for the solutions needed for whole-cell patch clamp 
recording in mouse brain slices 
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2.4.2 Sub-dissection and slicing 
The brain was rapidly removed and submerged in cold (2-4°C) high Mg2+, low 
Ca2+ cutting aCSF (Table 2.3). Specific dissections were carried out depending 
on the regions of interest: 
Hippocampus: The cerebellum was removed, and a cut made down the 
midline to separate the hemispheres. These were glued midline down onto a 
metal stage to allow the cutting of parasagittal hippocampal slices.  
Neocortex: The cerebellum was removed, and a cut made down the midline 
to separate the hemispheres. These were glued midline down onto a metal 
stage which was tilted by +15˚, such that the blade started cutting from the 
surface (layer 1) of the neocortex towards the caudal border of the neocortex. 
This ensured the integrity of layer V pyramidal cell dendrites in slices close to 
the midline (Kerr et al., 2013).  
Substantia nigra and ventral tegmental area: The cerebellum and a small 
rostral section were removed and then the brain was glued onto a metal stage 
rostral end facing downwards to allow the cutting of coronal slices. 
Dorsal striatum for fast scan cyclic voltammetry recording: The 
cerebellum and a small rostral section were cut off and then the brain was 
glued onto a metal stage rostral end facing upwards to allow the cutting of 
coronal slices. 
350 µM slices were cut using a Microm HM 650V microslicer and transferred 
into a Gibbs chamber filled with oxygenated recording aCSF (Table 2.3). The 
slices were stored at 34 °C in until they were used for recording or dye loading 
(between 1 and 8 hours after slicing).  
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2.4.3 Preparation of pipettes 
Glass pipettes were pulled with a micropipette puller (Sutter Instruments 
P1000) using borosilicate glass capillary tubes (Multichannel systems, 
#300057, OD=1.5 mm, ID=0.86 mm). Pipette resistance was between 5 and 
10 mΩ for all experiments.  
2.4.4 Whole-cell patch clamp recording 
A slice was transferred to the recording chamber, perfused with recording 
aCSF (rate: 2-3 ml/minute) and oxygenated at 30 °C. Slices were visualized 
using IR-DIC optics with an Olympus BX151W microscope (Scientifica) and a 
CCD camera (Hitachi). Whole-cell current clamp recordings (Fig 2.4) were 
made from pyramidal cells in area CA1 of the hippocampus, layer V thick-tufted 
neurons in the somatosensory cortex, dopaminergic neurons in the substantia 
nigra and GABAergic neurons in the ventral tegmental area using patch 
pipettes (5–10 MΩ) manufactured from thick-walled glass (Multichannel 
systems, #300057). Cells were identified by their position in the slice which 
was confirmed from their electrophysiological properties and their morphology 
visualised with fluorescence imaging. Recordings of voltage responses were 
made at several different time points in current clamp using an Axon 
Multiclamp 700B amplifier (Molecular Devices, USA) and digitised at 20 kHz. 
Axon pClamp 10 software (Molecular Devices) was used for data acquisition 
and to perform analysis. For all recordings, only cells that had resting 
membrane potentials of between -60 mV and -75 mV at whole-cell break 
through were analysed. Bridge balance was monitored throughout and any 
cells that had changes of more than 20 % over the course of the experiments 
were discarded.   
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Figure 2.4: Simplified schematic of the whole-cell patch clamp protocol. 
Neurons are identified using brightfield imaging. A) Then using a glass pipette (5-10 
MΩ resistance), the neuron is approached with positive pressure to dimple the 
membrane. A square current step is applied of 5-10 mV (as shown in A) as it makes 
the sealing process easier to monitor. B) Once the dimple is observed, pressure is 
released, and this allows a high resistance seal to form between the end of the pipette 
and the cell membrane. This seal needs to be at least 1 GΩ. At this point the trace 
will appear flat with only fast electrode capacitance transients visible these can be 
zeroed off at this step. C) Gently applied negative pressure ruptures the membrane 
and this allows breakthrough into whole-cell mode at which point the capacitance is 
now greater as it reflects the capacitance of the whole-cell. Recording can then be 
moved from voltage clamp into current clamp mode (D) to start the experiment, during 
which time the contents of the patch pipette will start to dialyse the cell. Oligomeric 
protein can be introduced via the patch pipette for efficient dialysis into the recorded 
neuron.  
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2.4.5 Dot blots to determine filtration effects 
Intracellular patch solution is usually filtered before use to prevent debris from 
blocking the patch pipettes. However, the filtering may remove the added tau 
protein and thus dot blots were performed to determine whether tau protein 
should be added to the intracellular solution before or after filtration (Fig 2.5). 
For each sample, 2 ml was spotted onto nitrocellulose membrane, allowed to 
dry for 15 minutes, and then blocked with 10 % non-fat milk in TBST for 1 hour. 
The membranes were then washed 5 times with TBST and incubated for 2 
hours with primary antibodies diluted in TBST: T22 (Merck; 1:1000 dilution), 
HT7 (ThermoFisher; 1:1000 dilution), K9JA (Dako; 1:5000 dilution). The 
membranes were washed 5 times with 10 % TBST and then treated for 2 hours 
with secondary antibody (anti-rabbit IgG or anti-mouse IgG, Thermofisher, 
#31460, #61-6520). Following further washes, the membranes were 
developed with an electrochemiluminescent detection kit (BIORAD Clarity 
Western ECL #170-5060). Gel detection performed using an ImageQuant™ 
LAS4000 biomolecular imaging system (GE Healthcare).  
Figure 2.5: Dot blot analysis to confirm when the most effective time is to add 
oTau to the intracellular recording solution. 
Samples (2 µl) were blotted onto a nitrocellulose membrane, blocked, and treated 
with one of the primary antibodies (T22, K9JA or HT7), followed by their respective 
secondary. Three different conditions were tested: 1) Control: filtered intracellular 
solution 2) Intracellular solution with oTau added and then filtered and 3) Filtered 
intracellular solution with oTau added after the filtering. It is clear that some oTau is 
lost in condition 2 and therefore condition 3 was used for all experiments. 
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Blots confirmed the tau was oligomeric (T22, oligomer specific), and showed 
that the tau reacted strongly with HT7 and K9JA antibodies, which bind to the 
mid-region and microtubule binding region of tau respectively (Chen et al, 
2019). There was loss of oTau when it was added pre-filtration. oTau was 
therefore added after the solutions had been filtered. For individual 
experiments, tau oligomers from a 22 mM stock (monomer concentration) 
were added to filtered patch solution to give a final concentration of either 44 
nM, 133 nM or 444 nM (2, 6 and 20 µg/ml tau) for CA1 neurons and 666 nM 
for layer V cells to account for their increased size (30 µg/ml tau). 
2.4.6 Stimulation protocols 
All cells were allowed to stabilise for a few minutes after breaking through into 
whole-cell mode before data was acquired. A range of different stimulation 
protocols have been used across experiments.  
Standard IV protocol 
The standard current-voltage relationship was constructed by injecting step 
currents (1 s) from -200 pA (CA1 pyramidal cells), -600 to -400 pA (layer V 
pyramidal cells) and -300 pA (dopaminergic neurons) incrementing by 100 pA 
until a regular firing pattern was induced (Fig 2.6). A plot of step current against 
voltage response around the resting potential was used to measure the input 
resistance (gradient of the fitted line).  
Hyperpolarising step protocol  
Hyperpolarising step currents (50 pA, 100 ms) were injected at 1 Hz with the 
corresponding voltage responses recorded (Fig 2.6). This allowed 
quantification of the time course of changes in input resistance/conductance. 
For analysis, average voltage responses can be constructed for 10-minute 
periods. 
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Dynamic IV protocol 
The dynamic-IV current provides a more naturalistic current to the neurons 
(Badel et al., 2008b, 2008a). It is generated using the summed numerical 
output of two Ornstein–Uhlenbeck processes (Uhlenbeck & Ornstein, 1930) 
with time constants τfast = 3 ms and τslow = 10 ms. This current waveform, which 
mimics the stochastic actions of AMPA and GABAA receptor channel 
activation, is injected into cells and the resulting voltage recorded (a fluctuating 
noisy trace) (Fig 2.6). The current trace is the same for all recordings to allow 
a comparison over time, however the amplitude of the current (gain) can be 
altered to achieve a consistent firing rate across recordings. The voltage trace 
was used to measure the frequency of action potential firing and to construct 
a dynamic-IV curve. The firing rate was measured from voltage traces evoked 
by injecting a current waveform of the same gain and offset for all timepoints 
(to achieve a firing rate ~1-3 Hz). Action potentials were detected by a 
manually set threshold and the interval between action potentials measured.  
The dynamic membrane current (Iion) can be calculated using: 
    ( ,  ) +         =      ( ) −  
  
  
for which the injected current (Iinj) is known, the derivative (dV/dt) can be 
calculated from the experimentally measured voltage response, and the 
capacitance (C) is calculated as in (Badel et al., 2008b). A scatter plot of the 
transmembrane current against voltage (Fig 2.6D) illustrates the dynamic 
relationship between the two, with the effects of weak background synaptic 
activity and other sources of high‐frequency variability being accounted for as 
intrinsic noise (      ) (Badel et al., 2008b). Averaging the transmembrane 
current in 1 mV bins removes the time dependence of      (V, t) to yield the 
typical ionic current at a particular voltage, and thus defines the dynamic I–V 
curve (    ): 
    ( ) =      [    ( ,  )]
The exponential integrate‐and‐fire model (Fourcaud-Trocmé et al., 2003) 
provides an excellent fit to the dynamic I-V curve (Badel et al., 2008b, 2008a; 
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Harrison et al., 2015; Fig 2.6E). The exponential integrate‐and‐fire (EIF) model 








   −   + ∆      
  −   
∆ 
   =  −
    ( )
 
By fitting the dynamic curve to the EIF model, I could then extract four 
parameters: membrane time constant (τ), resting potential (E), spike‐initiation 
threshold (VT) and spike‐onset sharpness (ΔT), which describes the voltage 
range over which an AP initiates (Badel et al., 2008a, 2008b; Harrison et al., 
2015; Kaufmann et al., 2016). Dynamic I–V curves are constructed from the 
pre‐spike voltage response (subthreshold and run up to spike) with all data 
falling within a 200 ms window after each spike being excluded from analysis. 
All analysis of the Dynamic IV traces was completed using MATLAB and Julia 
software platforms (Bezanson et al., 2017). 
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Figure 2.6: Extraction of electrophysiological parameters 
A number of different techniques are used in this thesis in order to parameterise 
neurons electrophysiologically. A) The simplest is the continuous injection of a 100 
ms 50 pA hyperpolarizing current step delivered every 1 s. The resulting voltage 
response time course is recorded and can be used as a measure of input resistance 
change over time. (B) The next is the standard IV protocol used to extract neural 
parameters. In this example, current steps (1 s long) start at -300 pA and are 
increased by 50 pA (top panel) until a regular firing pattern is induced (bottom panel).  
Current steps around the resting potential can be used to extract the input resistance.  
(C) The third current injection protocol (dynamic IV) injects a naturalistic current into 
the cell (top panel) and the voltage recorded (bottom panel) can be used to determine 
the firing rate under a naturalistic state, and it can also extract a number of other 
parameters (Badel et al, 2008, Harrison et al, 2015). (D) From the voltage response, 
the mean ionic current Iion is plotted against membrane potential (grey). The black line 
is the dynamic IV curve generated by the average current at a particular voltage (in 1 
mV time bins). (E) The negative of Iion/C is then plotted (grey) along with the EIF 
(exponential integrate-and-fire) computational model fit (black line). From this curve 
subthreshold parameters can be extracted (such as resting potential E, time constant 
Ƭ, spike-onset sharpness, capacitance, and spike-threshold voltage VT).  
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Synaptic transmission 
To measure synaptic transmission between connected neighbouring 
neocortical thick-tufted layer-V pyramidal cells, 3 simultaneous whole-cell 
current-clamp recordings were made in somatosensory cortex (Markram et al 
1997; Kerr et al 2013). Recordings were made from neurons in slices from 
P12-18 mice since unitary EPSPs from younger mice have a larger amplitude 
than unitary EPSPs in slices from older mice, and younger mice show marked 
short-term depression (Reyes and Sakmann 1999; Kerr et al 2013) which can 
be used to measure the effects of oligomeric tau (oTau) on release probability. 
Once synaptic connectivity was confirmed, 6 action potentials were evoked in 
the presynaptic neuron (5 at 20 Hz followed by a single recovery action 
potential after a 1 second interval) using 5 ms current steps. The amplitude of 
the current steps was carefully monitored throughout experiments to ensure 
they reliably induced the firing of single action potentials. These stimulus trains 
were separated by 10 seconds and repeated for the duration of recordings. 
The amplitude of overlapping unitary EPSPs was accurately measured using 
voltage deconvolution (Kerr et al., 2013; Richardson and Silberberg, 2008a). 
Long term synaptic plasticity  
To measure long-term potentiation (LTP), whole-cell current-clamp recordings 
were made from CA1 hippocampal pyramidal cells in the presence of 50 µM 
picrotoxin (to block GABAA receptors). Schaffer collaterals were stimulated 
with a concentric bipolar electrode (FHC, Maine USA) every 20 s. The 
stimulation strength was set to evoke reliable and robust synaptic transmission 
(EPSP amplitude ~ 3 mV) without producing action potential firing in the 
postsynaptic cell. Stimulations of the theta-frequency (4-12 Hz) are commonly 
used to induce LTP (Grover, Kim, Cooke and Holmes, 2009; Bland, 1986; 
Buzsáki, 2002).  After a 15-minute baseline with stable EPSP amplitudes, LTP 
was induced by theta-burst stimulation (10 trains of 10 stimuli (100 Hz) 
separated by 100 ms) and EPSPs were recorded for at least 30 minutes. 
Theta-burst stimulation is a robust and commonly used approach to generate 
LTP (Larson and Munkácsy, 2015).  
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To measure metabotropic glutamate receptor (mGluR) -mediated long-term 
depression (LTD), whole-cell current-clamp recordings were made from CA1 
hippocampal pyramidal cells in the presence of 50 µM picrotoxin (to block 
GABAA receptors) and 5 mM L689,500 to block NMDA receptors. Schaffer 
collaterals were stimulated (as above) to evoke reliable and robust synaptic 
transmission (EPSP amplitude ~ 3 mV) without producing action potential firing 
in the postsynaptic cell. After a 10-minute baseline, LTD was induced by 100 
µM of the mGluR5 agonist DHPG for 10 minutes and EPSPs were recorded 
for 30 minutes further following wash.  
Recording isolated voltage-gated sodium currents  
To record voltage-gated sodium channel currents in isolation, the intracellular 
and extracellular solutions used were modified from Milescu, et al (2010) (Fig 
2.7). The extracellular solution contained the following (in mM): 124 NaCl, 25 
NaHCO3, 3 KCl, 1.5 CoCl2, 1.0 MgSO4, 0.5 NaH2PO4, and 30 D-glucose, 
equilibrated with 95% O2 and 5% CO2 (pH 7.4). Calcium chloride was replaced 
with cobalt chloride in order to block the voltage-gated calcium channel 
currents. Experiments were performed at room temperature (~ 22ºC to 
improve the quality of the voltage clamp, (Milescu et al., 2010)). To reduce the 
amplitude of the sodium channel currents, 50 mM Na+ was present in the 
intracellular solution: 70 Cs-gluconate, 30 Na-gluconate, 10 TEA-Cl, 5 4-AP, 
10 EGTA, 1 CaCl2, 10 HEPES, 4 Mg-ATP, 0.3 Na3-GTP, 10 Na2-
phosphocreatine. Series resistance (Rs) was measured throughout the 
recording and were typically in the range of 6-12 MΩ. Cells with Rs over 15 MΩ 
or those that varied by more than 20 % over the period of recording were 
discarded.  R s was not compensated, but the liquid junction potential of ~ 8 
mV was corrected for. Leak currents were subtracted using a standard P/N 
protocol (Bezanilla and Armstrong, 1977), where a scaled down version of the 
protocol is given (in this case ¼ of the size) in order to measure the passive 
(leak) current. This response is assumed to be linear, so can be scaled and 
subtracted from the recorded trace to display only active changes (voltage-
gated sodium currents).  
The stimulation protocol was adapted from Milescu et al., (2010) to allow fully 
clamped somatic Na+ channel currents to be recorded. Neurons were held at 
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-80 mV.  A depolarising pre-pulse was given (5 ms, -40 mV) to activate axonal, 
but not somatic, sodium channels. This was followed by a 1 ms step to -55 mV 
and then voltage steps (from -60 to 60 mV, 5 ms duration) were used to elicit 
controlled Na+ channel current responses. The inter-sweep interval was 2 s. 
From the current responses, plots of current vs voltage or conductance vs 
voltage were calculated. Conductance is given by the following equation: 
            ( ) =    /(      −          )
The plot of conductance vs voltage was fitted with a Boltzmann equation:  
  =  
   −    
1 +   (    )/  
+   
and then the half activation voltage and the rate constant of activation were 
extracted and compared between control and oTau introduced neurons.  
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Figure 2.7: Protocol for recording voltage-gated sodium currents in acute 
slices 
Recording voltage-gated sodium currents in acute slices is complicated by the inability 
to efficiently voltage clamp them, and this arises due to their size and 
multicompartment nature. In this protocol developed by Milescu et al., (2010), a 
solution is described. A) The result of attempting to record the currents with no 
additional intervention; the currents are uncontrolled due to inefficient clamp. B) 
Introducing a pre-pulse ahead of the current steps activates the axonal but not 
somatic sodium channels, allowing for controlled (well-clamped) recordings to be 
made of somatic voltage-gated sodium channels. C) Subtraction of trace B from A to 
give the uncontrolled axial current D) Protocol for stimulation to perform the pre-pulse 
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and recording steps in voltage clamp. Specific stimulation and response pairs are 
indicated via colour coding.  
Hodgkin Huxley modelling  
The Hodgkin-Huxley (HH; Hodgkin & Huxley, 1952) model provides a unified 
framework for modelling the ionic conductances that generate APs. The HH 
model can be applied to study voltage-gated sodium and potassium channels. 
It proposes that each sodium channel contains a set of 3 identical, rapidly 
responding, activation gates (the m-gates), and a single, slower-responding, 
inactivation gate (the h-gate) (Hodgkin & Huxley, 1952).  
The membrane current is given by:  
  =    
   
  
+   (   −   ) +    (   −    ) +   (   −   )
Where   is the total membrane current and    is the membrane capacitance, 
  ,     and    are the potassium, sodium and leak conductances per unit area, 
and    ,     and    are reversal potentials.  
The sodium conductance can be given by: 
   ( ) = ḡ   (  )
 ℎ(  )(   −    )
Where ḡNa is the maximal sodium conductance and m and h are quantities 
between 0 and 1 that are associated with sodium channel activation and 
inactivation, respectively. Vm is the membrane potential and ENa is the reversal 
potential for sodium.  
Initial parameters were assigned as follows: ḡ  : 120   /  
 , ḡ : 36   /  
 , 
  : 0.3   /  
  ,   : 1 µ /  
 ,   : − 70   ,    : 60   ,    : −88   ,
  : −54.4    in line with Hodgkin and Huxley 1952; for the squid giant axon). 
105 
2.5 Methods specific to connexin hemichannel measurements 
2.5.1 Isohydric solution preparation 
Solutions with different bicarbonate content were used to alter the levels of 
CO2 perfusing the brain slices under isohydric conditions (constant pH, as in 
de Wolf et al, 2006). The standard baseline solution is 35 mm Hg CO2 aCSF. 
This is then either increased to 55 mm Hg CO2 to raise CO2 levels or decreased 
to 20 mm Hg CO2 to lower CO2 levels. The composition of these aCSF recipes 
is given in Table 2.4 and differ in their concentrations of NaCl and NaHCO3.  
Solution Contains (mM): 
Control (35 mmHg 
CO2) aCSF 
124 NaCl, 26 NaHCO3, 1.25 NaH2PO4, 3 KCl, 10 D‐
glucose, 1 MgSO4, 2 CaCl2, (pH 7.4 when bubbled 
with 95% O2 and 5% CO2) 
Hypercapnic (55 
mmHg CO2) aCSF 
100 NaCl, 50 NaHCO3, 1.25 NaH2PO4, 3 KCl, 10 D‐
glucose, 1 MgSO4, 2 CaCl2, (pH 7.4 when bubbled 
with 95% O2 and 5% CO2) 
Hypocapnic (20 
mmHg CO2) aCSF 
140 NaCl, 10 NaHCO3, 1.25 NaH2PO4, 3 KCl, 10 D‐
glucose, 1 MgSO4, 2 CaCl2, (pH 7.4 when bubbled 
with 95% O2 and 5% CO2) 
Table 2.4: Recipes for the solutions needed for isohydric aCSF buffers for 
altering the level of CO2 at a constant pH.  
To ensure that the solutions remain isohydric (constant pH) then the pH was 
adjusted by perfusing with different CO2/O2 mixtures to match the pH of the 35 
mm Hg CO2 solution (Fig 2.8): 
For 20 mm Hg CO2, two 0-10 cc/MIN AIR x 100 (6831) mixers were used, one 
for the 100 % O2 line and one for the 95% O2/5% CO2 line to mix the two gases 
in a roughly 1:1 proportion.  
For 55 mm Hg CO2, one 0-250 cc/MIN AIR x 100 (6831) mixer was used for 
the 95% O2/5% CO2 line and one 0 -10 cc/min AIR (6387) mixer was used for 
the 100 % CO2 line, to mix the gases in a roughly 0.96 to 0.04 proportion. 
Throughout the day, pH was monitored to ensure that it did not change.  
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Figure 2.8: Mixer set up to enable smooth isohydric CO2 level change. 
The 35 mm Hg CO2 buffer was bubbled with 95% O2 5% CO2. The pH of this buffer 
was ~7.4. The 55 mm Hg CO2 buffer was saturated with 9% CO2 (with the balance 
being O2) with pH maintained to match control (35 mm Hg). This was achieved by 
mixing the 95% O2 5% CO2 line with a 100 % CO2 line (adjustments were made using 
the mixer dials). The 20 mm Hg CO2 buffer was saturated with 2% CO2 (with the 
balance being O2), with pH maintained to match control (35 mm Hg). This was 
achieved by mixing the 95% O2 5% CO2 line with a 100 % O2 line (adjustments were 
made using the mixer dials).  
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2.5.2 Dye loading 
The methods were based on the protocols published in Huckstepp et al., 
(2010). Whole-cell patch clamp recordings were first used to confirm that the 
dye loading was performed in the correct regions (substantia nigra pars 
compacta and ventral tegmental area). Slices were then incubated in 35 
mmHg CO2 aCSF for 20 minutes. The perfusion solution was changed over to 
the 55 mmHg CO2 (high CO2, hypercapnic) solution containing 5(6)-carboxy-
fluorescein dye (CBF, 100 µM, Novabiochem, #8.51082.001) for 20 minutes. 
This allowed any CO2-sensitive hemichannels to open and the CBF dye to 
diffuse into the cells. The perfusion solution was then changed to 35 mmHg 
CO2 solution containing CBF, to allow the CO2-sensitive hemichannels to 
close, trapping the dye within the cells (Fig 2.9). The slice was washed for 3 
hours to reduce background staining before imaging. Images were rapidly 
acquired using the CCD camera (Hitachi) with 488 nm fluorescence (CoolLED) 
since CBF bleaches quickly and cannot be fixed with PFA.  
Figure 2.9: Simplified schematic of the dye loading protocol. 
A schematic to demonstrate the dye loading protocol. The slice is equilibrated for 20 
mins in control aCSF (35 mmHg CO2) at 30 °C. 55 mmHg CO2 aCSF (hypercapnic) 
containing 5(6)-carboxy-fluorescein (CBF, 100 µM) was then applied for 20 mins to 
allow CO2 sensitive-hemichannels to open. Then 35 mmHg CO2 aCSF containing 
CBF (100 µM) was applied for 5 minutes to allow the hemichannels to close. Finally, 
the slice was washed with 35 mmHg CO2 aCSF for 3 hours to reduce the background 
staining before imaging. The dye loading method is based on that described in 
Huckstepp et al., (2010).  
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2.6 Immunohistochemistry 
Mice (P7-10 and P17-20) were either cardiac perfused with 4% PFA and then 
post-fixed overnight at 4 ˚C (Chapter 6) or slices were cut as normal then fixed 
with 4% PFA for 1 hour at room temperature (Chapters 3 and 5). For the 
cardiac perfused mice, an overdose via intraperitoneal injection of sodium 
pentobarbital (>100 mg/kg) was given, followed directly by transcardial 
perfusion with non-heparinized PFA (4%; made in PBS). All cardiac perfusions 
were kindly performed by appropriate licence holders (Dr Huckstepp, Dr 
Bhandare or Dr Van de Wiel). If cardiac perfused, the tissue was washed 
thoroughly with PBS and then sliced coronally (350 µm). All slices were 
washed 5 times with PBS and then blocked for an hour (1% BSA, 0.4% Triton 
100X in PBS, 400 µl per slice), then washed 3 times for 5 minutes with PBS. 
The relevant primary antibodies were applied (200 µl per slice, see individual 
chapters for details) for an hour at room temperature and then kept at 4 - 8 ˚C 
overnight. Slices were washed 5 times for 5 minutes with PBS and the 
corresponding secondary antibody (200 µl per slice) added for 4 hours at room 
temperature. Slices were then washed 5 times for 5 minutes with PBS and 
mounted on glass slides with Vectashield (Vector laboratories, #H-5000). All 
imaging was carried with confocal microscopy (Leica 710 and Zen Black for 
image acquisition and processing, respectively). Controls were carried out 
without the primary antibodies and showed no fluorescence.   
2.7 Transmission electron microscopy 
Formvar/carbon-coated 300-mesh copper grids (#S162, Agar Scientific) were 
glow-discharged using the ELMO system from Cordouan Technologies. Five 
microliters of labelled or unlabelled tau-441 preparations were pipetted onto 
the grid and allowed to bind for 1 min. Excess samples were removed with a 
strip of filter paper, and 5 μl of 2% uranyl acetate added for 1 min. After 
removing the excess stain with a strip of filter paper, the grids were imaged 
using a JEOL-2100F transmission electron microscope. 
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2.8 Statistical analysis and software 
All statistical analysis was performed in GraphPad Prism using non-parametric 
methods: Kruskal–Wallis analysis of variance (ANOVA), Mann Whitney and 
Wilcoxon signed-rank tests as required for non-parametric data.  
Parametric tests such as t-tests or ANOVAs assume that the data is normally 
distributed (Hodges Jr and Lehmann, 1956). However, tests for normality such 
as Kolmogorov‐Smirnov or Shapiro‐Wilk are only useful for large sample sizes. 
If it is not possible to assume normality, then the most conservative strategy is 
to use a nonparametric test designed for non-normal data (Ghasemi and 
Zahediasl, 2012; Morgan, 2017). Therefore, while non-parametric tests have 
lower statistical power than their parametric equivalents, they are the correct 
choice for these studies with low sample sizes (Sullivan et al., 2016). Non-
parametric analyses were performed for all comparisons. 
All data is represented as mean and standard error of the mean with individual 
experiments represented by single data points. Each recorded cell is one data 
point. All experimental conditions were measured using multiple animals and 
recording conditions were interleaved to remove bias introduced from 
individual animals. Data points for each experimental condition were derived 
from a minimum of 4 individual animals. No experimenter blinding was 
performed as the same quality control criteria was applied to all recordings.  
Biorender.com was used for the generation of figures under an appropriate 
personal software license.  
2.9 Drugs and pharmacological agents 
Drugs were stored as stock solutions in dH2O or DMSO as required (1-100 
mM) and diluted freshly into aCSF on the day of use. See 8.1 (Appendix) for 
full materials and reagents list.  
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3. Chapter 3:  
3. Oligomeric tau injection alters action 
potential dynamics and disrupts synaptic 
transmission in vitro
Parts of this chapter have been published previously (Hill et al., 2019): 
Figure 3.1: oTau mediated effects on neuronal function, synaptic 
transmission, and plasticity.  
Visual abstract to represent the key findings of this results chapter. oTau introduced 
into single neurons alters action potential waveform, disrupts synaptic transmission 
(pre-synaptic action) and alters synaptic plasticity (post-synaptic action).  
3.1 Introduction  
Tau is a highly soluble microtubule-associated protein that acts within neurons 
to modify their stability (Baas and Qiang, 2019; Binder et al., 1985; Caceres 
and Kosik, 1990; Hirokawa et al., 1988). Aside from its role in stabilising axonal 
microtubules, physiologically tau is also found elsewhere in neurons. It is 
known to be expressed in the dendrites and plays important roles in regulating 
plasticity at the synapse. Endogenous (non-misfolded) tau has been recorded 
at both pre-synaptic terminals (Pooler et al., 2013; Sokolow et al., 2015; 
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Yamada et al., 2014) and post-synaptic boutons (Gómez-Ramos et al., 2009; 
Ittner et al., 2010; Regan et al., 2015; Tai et al., 2012). Pathologically, tau 
contributes to several diseases, commonly termed tauopathies. Here, 
abnormally phosphorylated tau can dissociate from microtubules to form 
oligomers and fibrils (Avila et al., 2006) which associate in the soma-dendritic 
compartment. Tau can aggregate further to form neurofibrillary tangles (NFTs) 
and, although their presence strongly correlates with disease progression 
(Nelson et al., 2009), it is the soluble oligomers that appear to be the toxic 
species in terms of disrupting neuronal function and these disruptions can 
occur in the absence of any NFT pathology (Andorfer et al., 2003; Cowan et 
al., 2010; Lee et al., 2001; Spires et al., 2006; Tanemura et al., 2002; 
Tatebayashi et al., 2002; Wittmann et al., 2001; Yoshiyama et al., 2007). 
Understanding which forms of the tau protein within the aggregation cascade 
are the most toxic will allow the generation of more targeted treatments for 
tauopathies in the future. 
There is relatively little quantitative information on the concentration- and time-
dependent actions of soluble tau oligomers (oTau) on the electrophysiological 
and synaptic properties of single neurons. To address this problem, in this 
Chapter, whole-cell patch clamp recording was used to introduce known 
concentrations of oligomeric full-length human tau-441 into mouse 
hippocampal CA1 pyramidal and neocortical layer-V thick-tufted pyramidal 
cells. A combination of standard electrophysiological profiling and detailed 
computational modelling was implemented to allow the full characterisation of 
the effects of oTau. Standard current-voltage relationships were constructed 
at regular time intervals (every 10 mins), to confirm the cell type, to monitor the 
quality of the recording and to provide an overview of electrophysiological 
deterioration in response to the introduced oligomers. This is a standard 
method for assessing neuronal responses, first described in Hodgkin and 
Huxley (1952). Working with my collaborators in the Zeeman Institute 
(Warwick), I also implemented a simplified reduced refractory integrate and 
fire (rEIF) model to enhance my analysis of the effects of oTau.  Dynamic I-V 
curves were generated from the voltage responses to injected noisy fluctuating 
currents (see Methods for full details; (Badel et al., 2008a) at each of the 
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recorded time points (every 10 mins). These were then used to fit to the rEIF 
model and allowed full parameterisation of changes in the electrophysiological 
properties over time.  
3.2 Results  
3.2.1 Preparation of tau oligomers (oTau) 
The recombinant tau used for this project was generated under the guidance 
of Dr Karikari. This allowed me to fully characterise the structure of the protein 
and the stage of aggregation, ensuring consistency across the range of my 
experiments. Recombinant full-length human tau-441 was expressed in E. coli, 
purified and aggregated following the protocols outlined in Karikari et al., 
(2019b, 2017). This is the longest of the six isoforms of tau found in humans 
(2N4R; Fig 3.2) and harbours no disease-related mutations or additional post 
translational modifications such as phosphorylation.  
Figure 3.2: Structure of the full-length human tau used in this study. 
Based on full-length human wild type tau, this construct has both N-terminal repeats 
(N1 and N2) and 4 microtubule binding repeat domains (R1, R2, R3 and R4). Also 
known as Tau-441, it is the longest isoform of the six commonly found in humans. To 
allow visualisation, oTau was labelled with an Alexa Fluor 488 maleimide dye which 
binds to cysteine residues. As there are two native cysteines within important 
microtubule binding regions, these were modified to alanine (C291A and C322A, 
shown as black dots below R2 and R3) and replaced with one at the edge of this 
region (residue 260 (I260C) in R1). This tau construct has been used previously 
(Karikari et al., 2017). 
Tau was labelled with an Alexa Fluor maleimide dye (488) that binds to 
cysteine residues to allow localisation and to maintain the oligomeric species 
at a low molecular weight. Three mutations were introduced into tau to ensure 
that this labelling did not disrupt function: two cysteines that normally reside in 
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the microtubule binding region were modified to alanines (C291A and C322A), 
and a cysteine was introduced to allow binding at the edge of the repeat region 
(I260C). Labelling limits aggregation because tau can aggregate via the 
formation of disulphide bonds; this aggregation is reduced by blocking cysteine 
residues with the label (Karikari et al., 2017). 
3.2.2 Electron microscopy to characterise the oTau 
This study focussed on oligomeric tau, which is known to disrupt neuronal 
function (Fá et al., 2016; Ondrejcak et al., 2018). As transmission electron 
microscopy (TEM) allows the identification and quantification of the size and 
shape of protein species, I used negative-stain TEM to analyse the 
aggregation state. My observations confirmed that the oTau had a spherical 
granular form, typical of oligomeric species, that were of similar size and profile 
to previous preparations using the same protocol (Karikari et al., 2017; Fig 
3.3A). No protein aggregates were observed in the control sample (Fig 3.3B).  
Figure 3.3: Characterisation of the aggregation level of the recombinant tau 
samples using negative-stain transmission electron microscopy. 
A. Example negative-stain electron micrograph of oTau to assess the state of 
aggregation. Clear granular structures can be observed which indicate oligomeric 
form. Scale Bar = 200 nm. Insert, a higher magnification of a single spherical oligomer 
structure. Scale bar = 20 nm. B. Example negative-stain electron micrograph of 
labelled control (buffer and label only) shows no oligomeric protein present. Scale bar 
= 200 nm.
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3.2.4 Immunohistochemistry to monitor localisation of oTau 
The fluorescent labelling of oTau allows it to be visualised within neurons 
following its introduction via the patch pipette. This allowed me to determine 
where oTau could diffuse within the period of recording, and if it became 
concentrated in specific regions of the cell. This could then be correlated with 
any changes seen in the neuron’s electrophysiology (Figure 3.4A). As a 
marker for the recorded cells, and to ensure being able to locate them with 
confocal microscopy, recorded neurons were also filled with Alexa Fluor 594 
dye (red; Figure 3.4B). This, in combination with the labelled oTau (green), 
facilitated the imaging of oTau localisation. For these studies, neurons were 
recorded from for at least 20 minutes, the pipette carefully removed, and the 
slice fixed in 4% PFA, washed and mounted. Initially standard confocal 
imaging was used using a Leica 710 and Zen software for acquisition and 
processing, respectively. Constructing a Z-stack for the whole neuron 
confirmed that the oTau (green) was emerging from the pipette and entering 
the soma of the recorded cell, where it appeared to aggregate. This imaging 
method was unable to detect tau outside of the cell body, likely due to the low 
resolution of imaging and low concentration of oligomer.  
I therefore repeated the experiments but imaged this time with the Airy Scan 
module of the Leica 880 in combination with Zen software for acquisition and 
processing, respectively. This allowed me to observe a diffuse spread of tau 
throughout the recorded neuron in both the axon and in the dendrites. Within 
the dendrites oTau could be observed parallel to the dendritic bifurcation and 
at localised in regions that could be postsynaptic sites (Figure 3.4C). This is 
the first time such widespread diffusion of oTau has been documented in such 
a short timeframe, facilitated by the introduction via patch-pipette (30 minutes, 
Fig 3.4B, C).  
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Figure 3.4: Localisation of oTau within a CA1 neuron after 30 minutes after 
introduction at the soma 
A. SIV response for the recorded CA1 PC (steps from -200 pA, by +100 pA). The SIV 
trace clearly fits the profile of a CA1 pyramidal neuron. B. Alexa Fluor dye was 
introduced (in the patch solution) to allow the neuron and its processes to be 
identified. The AiryScan module of the Leica 880 was used to perform a tile-scan of 
Z-stacks (28 tiles, 258 Z-planes) to image the entire neuron. The Z-stacks were then 
processed and stitched using the Zen software suite. The neuronal morphology 
matches that of a CA1 pyramidal neuron (Figure 1.20). Scale bar = 20 µm. C. oTau 
(labelled green) was introduced via at the soma. Clear aggregation in the soma can 
be observed (left). However, oTau was also observed to have spread throughout the 
processes, including down a dendrite adjacent to the bifurcation. Scale bar = 10 µm. 
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3.2.5 Electrophysiological effects of oTau introduction on CA1 
pyramidal cell subthreshold properties 
The aim of the next stage of the project was to fully characterise the effects of 
oTau on CA1 pyramidal neurons in the hippocampus. To ensure the validity of 
my observations, I carried out several interleaved control experiments. Firstly, 
alongside tau production, I generated labelled and unlabelled control samples 
(no inoculation with tau plasmids, using the same volume of sodium phosphate 
buffer pH 7.4 in its place). oTau or the control samples were added each day 
in the same volume to intracellular solution to ensure that there was no effect 
on cell properties from the dilution of the intracellular solution. Secondly, to 
ensure that the observed effects were not the results of the non-specific 
actions of introducing any aggregation-competent molecule, I used bovine 
serum albumin (BSA). BSA has a similar molecular weight to tau. I used it at a 
much higher concentration than oTau (20 µM compared to 44-666 nM) and did 
not observe any significant differences from vehicle introduced recordings. 
This observation is further complimented by my results in Chapter 5 where 
introduction of alpha synuclein aggregates produces very different changes in 
electrophysiological properties.    
During these experiments, I wanted to extract a full set of electrophysiological 
parameters over the time course of the recordings. For this I used two different 
stimulation protocols (see Methods for full details).  The first, a step current 
injection, is used to develop a standard current-voltage relationship plot. From 
which, voltage steps close to the resting membrane potential were used to 
calculate input resistance manually using the gradient of the fitted line. The 
second stimulation protocol was the dynamic current-voltage relationship, 
which is generated from the voltage response to a fluctuating noisy current 
input that mimics native channel activity, providing a more natural stimulus for 
the neuron allowing a more thorough parameterisation. Using both standard 
and dynamic IV protocols, several concentrations of oligomeric tau were tested 
(44 nM, 133 nM and 444 nM oTau) to determine concentration-dependent 
effects. These oTau tests were interleaved with both control (vehicle) and BSA 
solutions. I had originally hoped to use both standard and dynamic 
relationships over the whole period of recording, but while the dynamic IV 
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parameter extraction was effective for all conditions at 0 mins (mean spike 
match of 72.2 ± 1.7 %, predicted vs experimental data), for the cells with oTau 
introduced, by 40 mins the model predictions were unable to accurately match 
the experimental spike data (mean spike match of 46.1 ± 5.5 %) (Fig 3.5). 
Therefore, this method was not used to extract parameters at later time points. 
The poor spike match could be due to the altered action potential waveform or 
a hidden threshold within the code, this needs to be investigated further. 
Despite not being able to use the dynamic current-voltage protocol to compare 
over time, the step current-voltage responses could be used to examine 
changes to resting membrane potential and input resistance. 
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Figure 3.5: Analysis using the dynamic IV method at 40 mins. 
Dynamic IV curve (pink) and EIF computational model fit (blue) for a control (left) and 
444 nM oTau (right) cell after 40 minutes of recording. From this curve a number of 
subthreshold parameters can be extracted (such as resting potential E, time constant 
τ, and spike-threshold voltage VT; see Methods for more details). Recorded (grey) 
and simulated (purple) voltage traces are overlaid. (Left) For the control cell, the 
experimental and simulated traces are well matched (85%). (Right) For the oTau 
introduced cell however, the experimental and simulated traces are poorly matched 
(29%) and therefore the EIF model cannot be used to parameterise the oTau induced 
neurons over time.  
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The introduced oTau took varying lengths of time to have its effects in each 
cell. This could be due to several factors including cell size, morphology and 
series resistance. Regardless of the observed effects of oTau, recordings were 
maintained as long as they remained stable (defined as: membrane potential 
that did not depolarise above -50 mV and less than 20% alteration in series 
resistance). The average recording time was 40 minutes and so this was 
chosen as the final time point to be compared with the results at 0 mins (whole-
cell breakthrough).  
There was no significant difference in any of the extracted parameters (resting 
membrane potential, capacitance, cell time constant, spike-onset sharpness, 
spike threshold) at 0 mins (0-5 minutes after whole-cell breakthrough) across 
all of the experimental treatments as determined with Kruskal-Wallis tests (n = 
10 for vehicle, n = 5 for BSA, n = 9 for oTau 44 nM, n =11 for oTau 133 nM 
and n =10 for oTau 444 nM, Table 3.1). Although for most conditions, there 
were no significant changes to most of the measured parameters over the 
period of recording, 444 nM oTau significantly increased input resistance (0 
mins, 176.8 ± 4.7 mΩ, 40 mins, 239.3 ± 36.3 mΩ, p = 0.002) and depolarised 
the resting membrane potential (from -68.0 ± 1.7 mV at 0 mins to -61.8 ± 1.7 
mV at 40 mins, p = 0.050; Fig 3.6C). This is consistent with previously reported 
data from the rTg4510 mouse model, which expresses human tau variant 
P301L, where the pyramidal cells are depolarised by ~ 8 mV compared to wild 
type littermates (Rocher et al., 2010). These changes were not observed with 
the introduction of vehicle, BSA, 44 or 133 nM oTau. Consistent with this 
increase in input resistance and depolarisation, there was also a significant 
increase in the action potential firing rate in cells injected with 444 nM oTau (p 
= 0.025, measured from the voltage response to dynamic noisy current input 
at time 0 and after 40 mins) and although not reaching significance, six out of 
seven cells injected with 133 nM oTau also had an increased firing rate (Table 
3.4). 
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Table 3.1: Electrophysiological parameters for all conditions made at time 0 (whole-cell breakthrough) for CA1 neurons. 
All recordings are made from hippocampal CA1 neurons. There was no significant difference between any of the measured parameters at time 
0 minutes (whole-cell breakthrough), using Kruskal Wallis ANOVAs. Data shown as mean and SEM for each experimental condition.  
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Figure 3.6: oTau introduction into CA1 hippocampal neurons has little effect on 
sub-threshold electrophysiological properties at low concentrations and at 
early time points (up to 30 minutes). 
A. (Left) Example voltage response of a CA1 hippocampal neuron in response to a 
standard fluctuating noisy current injection in a cell injected with vehicle solution at 
time 0 mins (breakthrough, top) and after 40 mins of recording (bottom). (Middle, top, 
and bottom) Middle column demonstrate the voltage response over identical time 
periods on an expanded time base, showing that there is no change over time. Right 
panel shows the voltage response to stepwise current injections for 0 and 40 mins. 
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The voltage response also does not change over time. B. (Left) Example voltage 
response of a CA1 hippocampal neuron in response to a fluctuating noisy current 
injection in a cell injected with 133 nM oTau at time 0 mins (breakthrough, top) and 
after 40 mins of recording (bottom). (Middle, top, and bottom) Insets demonstrate the 
same voltage response on an expanded time base, demonstrating that there is little 
change to the voltage response over time, but that the action potential amplitudes are 
smaller. (Right) shows the voltage response to stepwise current injections for 0 and 
40 mins. The voltage response does not change over time C.  (Left) Example voltage 
response of a CA1 hippocampal neuron in response to a fluctuating noisy current 
injection in a cell injected with 444 nM oTau at time 0 mins (breakthrough, top) and 
after 30 (middle) and 40 mins of recording (bottom). (Middle, top and bottom) Insets 
demonstrate the same voltage response on an expanded time base, demonstrating 
that there is little change to the voltage response over time at 30 minutes but 
significant changes at 40 mins. (Right) Similarly, there are clear changes at 40 
minutes, to the current-voltage relationship for the stepwise current injections to action 
potential amplitude and input resistance. 
3.2.6 oTau markedly slows action potential dynamics and reduces 
action potential amplitude 
To establish why there is a marked reduction in the spike match efficiency (Fig 
3.5) for cells where oTau was introduced using the dynamic current-voltage 
protocol, I investigated whether there were changes to the action potential 
waveform (amplitude, duration, rate of rise and decay). Significant changes 
were observed at the 40-minute time-point for all concentrations of oTau (Fig 
3.7) but were not observed when neurons were injected with either vehicle or 
BSA (Fig 3.7). For all three concentrations of oTau (44, 133, and 444 nM), 
there was a significant decrease in action potential amplitude, speed of rise 
and speed of decay at 40 minutes compared to time 0 mins (Fig 3.7). The time-
course for these changes in action potential parameters (amplitude and rate of 
rise) were examined for the different concentrations of oTau. The effects of 
444 nM oTau were significantly different from time 0 (whole-cell breakthrough) 
earlier than for 44 and 133 nM oTau (10 vs 20 minutes), characteristic of a 
concentration-dependent effect (Fig 3.7C).   
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Figure 3.7: Introduction of oligomeric tau causes a significant change to action 
potential dynamics. 
A. Representative voltage traces of a single action potential from single experiments 
at 0 mins (left) and 40 mins (right) for all conditions (vehicle, BSA, 44 nM oTau, 133 
nM oTau and 444 nM oTau). B. Mean data for analysis of changes to action potential 
waveform for each of the conditions (vehicle, BSA, 44 nM oTau, 133 nM oTau and 
444 nM oTau). Parameters measured were amplitude, duration, rate of rise and rate 
of decay. Bar charts displaying the mean and SEM data for each condition at the two 
timepoints (clear bar 0 mins, striped bar 40 mins), with individual data points overlaid. 
Action potential amplitude was decreased significantly from 0 minutes to 40 minutes 
with all concentrations of oTau tested (44 nM p = 0.004, 133 nM p = 0.002, 444 nM p 
= 0.002). Only the highest concentration of oTau (444 nM) gave a significant increase 
in action potential duration (p = 0.016). Rate of rise and decay was significantly slower 
for all three concentrations of introduced oTau (rise: 44 nM p = 0.004, 133 nM p = 
0.002 and 444 nM p = 0.004; decay: 44 nM p = 0.008, 133 nM p = 0.002 and 444 nM 
p = 0008). C. Action potential amplitude evaluated over 10-minute time intervals. The 
left panel shows the mean amplitude normalised to the baseline (0 mins) for the three 
different concentrations of oTau (44 nM, 133 nM, and 444 nM). This demonstrates 
the drop in amplitude for all three concentrations of oTau over time. The right panel 
shows action potential waveforms from individual representative experiments at time 
points from 0 mins to 40 mins for 133 nM or 444 nM oTau introduction demonstrating 
the decrease in amplitude and which also highlights the concentration-dependent 
effect. D. Rate of rise evaluated over 10-minute time intervals. The left panel shows 
the mean rate of rise normalised to the baseline (0 mins) for the three different 
concentrations of oTau (44 nM, 133 nM, and 444 nM). This demonstrates the slower 
rate of rise for all three concentrations of oTau over time. The right panel shows 
normalised and superimposed examples of action potentials to demonstrate the effect 
on oTau introduction on action potential rate of rise over the period of recording. 
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3.2.7 The changes in action potential kinetics do not occur with 
monomeric tau  
Given that some species of monomeric tau (seed-competent) can trigger 
intracellular tau aggregation (Mirbaha et al., 2018), it was important to 
distinguish whether the effects that I observed were specific to tau oligomers 
or just the result of increasing the concentration of tau in the cells. Oligomeric 
tau was monomerised using DTT and heat (see Methods) and maintained on 
ice to prevent re-aggregation while the experiments were carried out (Fig 
3.8A). This monomeric tau (mTau; 444 nM) was introduced into hippocampal 
pyramidal cells to evaluate whether it gave similar effects to oTau. There was 
no significant change in the current-voltage relationship over-time (Fig 3.8B, 
C) and no change in action potential amplitude (at 40 mins the mean amplitude 
was 98.6% of the amplitude at time 0, Fig 3.8C). Therefore, it is only the 
oligomeric forms of tau that give rise to the observed changes to action 
potential waveform and input resistance over the 40-minute time period of my 
recordings.  
3.2.8 The changes to action potential waveform are not due to 
changes in series resistance 
oTau was delivered into cells through a glass pipette with a small tip with 
relatively high resistance (5-10 MΩ). As the tau is aggregated, it is feasible that 
it could block the pipette tip and impede the correct measurement of voltage. 
To check that this was not the case, series resistance was monitored 
throughout the experiments and any recordings where it altered by more than 
20 % throughout the duration of the recording were excluded from analysis. 
There was no influence of the experimental condition on stability of series 
resistance throughout the recording. In general, I observed no significant 
change to series resistance over time and there was also no difference in the 
series resistance measurements for each of the conditions at 0 mins (Fig 
3.8D). 
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Figure 3.8: Evaluation of the effect of mTau on AP waveform showed no effect. 
A. SDS-Page gel demonstrating dimeric tau protein (lane A) and tau protein converted 
to monomers (mTau, lanes B), stained with Instant Blue, and imaged using Image 
Quant (see Methods). B. There were no significant differences between current-
voltage responses from a hippocampal CA1 neurons injected with 444 nM of mTau 
measured at 0 mins and after 40 mins of recording. C. (Top panel) Examples of action 
potential waveforms recorded at 0 mins and after 40 mins of recording from a neuron 
injected with 444 nM mTau. mTau does not change the amplitude or kinetics of the 
action potential waveform. (Bottom panel) summarises data from 5 neurons, showing 
that action potential amplitude does not change over time when neurons are injected 
with 444 nM mTau. D. The mean series resistance plotted against time for neurons 
injected with vehicle, BSA or oTau (44, 133, or 444 nM).  There was no significant 
difference in series resistance between treatments and the series resistance did not 
significantly alter during recordings. 
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3.2.9 Re-patching experiments confirm observations result from the 
introduction of oTau into the cell 
I used an experimental design, termed ‘re-patching’ previously published by 
(Qui et al., 2014) to further exclude the possibility that tau was blocking the 
pipette tip or accumulating inside the cell impeding voltage measurement. 
oTau was introduced into CA1 pyramidal cells and recordings (step and 
dynamic current inputs) taken for ~ 20 mins until the change in AP waveform 
phenotype was observed. The pipette was then carefully removed from the cell 
and the cell ‘re-patched’ with a fresh pipette containing only vehicle solution. If 
the action potential waveform remained altered, then it was the result of the 
oTau and not simply a blockage of the pipette (n= 3 oTau; Fig 3.9 A-C) There 
was no significant difference in the first and re-patch for double vehicle injected 
cells (n= 4 control, Fig 3.9 D-F).   
Figure 3.9: Re-patching experiments confirm that the observations are not due 
to blockage of the pipette tip. 
A. Schematic to illustrate the protocol for repatching experiments. Recordings were 
made in CA1 pyramidal neurons of the hippocampus for 20 minutes using a pipette 
filled with intracellular solution and vehicle. The pipette was then carefully removed 
and then the cell was immediately re-patched with a clean pipette containing 
intracellular solution + vehicle. B. In the control (vehicle) cells, there was little change 
over time (at 20 mins, it was 102.0 ± 4.0 % of the amplitude at time 0) and very little 
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change to action potential amplitude was observed between patches 1 and 2 (108.0 
± 11.0 % of amplitude at time zero, n = 4 neurons) suggesting that the re-patching 
protocol is stable. C. Example traces shown for the initial patch at time zero, 20 
minutes into the patch and then the re-recorded pipette for vehicle injected cells. D. A 
schematic to illustrate the protocol for repatching experiments with oTau injection. 
Recordings were made in CA1 pyramidal neurons of the hippocampus for 20 minutes 
using a pipette filled with intracellular solution + 444 nM oTau. The pipette was then 
carefully removed and then the cell re-patched with a clean pipette containing 
intracellular solution + vehicle. E. In cells injected with oTau (444 nM), action potential 
amplitude decreased over the course of 20 minutes (at 20 mins, it was 84.0 ± 3.1 % 
of the amplitude at time 0) and then remained reduced when the cell was re-patched 
with a separate pipette + vehicle (81.0 ± 5.0 % of amplitude at time zero, n = 3). F. 
Example traces shown in (F) for the initial patch at time zero, 20 minutes into the patch 
and then the re-recorded pipette.  
3.2.10 Introduction of oTau into presynaptic neurons markedly 
impairs basal synaptic transmission 
Given the marked effects of oTau on action potentials, I next investigated 
whether this translated into deficits in synaptic transmission. Such deficits have 
been reported previously, usually by using a stimulating electrode to activate 
many synaptic pathways in transgenic mice or mice that have had oTau 
perfused extracellularly. There are many limitations to these approaches. 
Firstly, using a stimulating electrode, it is not possible to know how many cells 
are being activated, whereas with paired recordings I could measure the effect 
of activating a single cell. Secondly, these methods expose every cell to the 
effects of tau to varying degrees which may lead to adaptation as the circuit 
could be changed. Using paired recordings, I was able to target oTau to either 
the pre- or post-synaptic cell and introduce the oTau into a small number of 
cells, which is unlikely to change the circuit. I initially considered studying the 
connection between CA1 and CA3 pyramidal cells (PCs) of the hippocampus, 
as I had already detailed the effects of oTau in CA1 PCs. However, the 
connection rate is low - between 1 and 5% (Debanne et al., 2008), which 
means large numbers of recordings will have to be made to find enough 
synaptic connections for significance. In contrast, neighbouring thick-tufted 
PCs in Layer V of the neocortex have a higher connection rate of ~ 10 % 
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(Markram et al., 1997). I located the somatosensory region of the neocortex 
under low magnification relative to the position of the hippocampus. I then 
identified thick-tufted layer V PCs using two methods. Firstly, I introduced dye 
via the intracellular solution to examine cellular morphology. Thick-tufted layer 
V PCs are large in size and have a distinct apical dendrite, projecting from 
layer Vb and bifurcating within layer II/III. Secondly, they have a distinct 
electrophysiological phenotype, as can be examined from the stepwise 
current-voltage relationship, typically exhibiting burst-firing action potentials 
(Kasper et al., 1994; Ramaswamy et al., 2015). Neurons that did not fit with 
expected morphological and electrophysiological phenotype were discarded 
from analysis (thin-tufted layer V PCs and interneurons). As I had moved to a 
new cell type, it was firstly important to validate that the results observed in the 
hippocampus were comparable to that of thick-tufted layer V PCs in the 
neocortex. In order to achieve similar results on a comparable timescale, the 
concentration of oTau was increased from 444 nM to 666 nM to account for 
the larger size of these cells relative to CA1 neurons (mean capacitance in 
CA1 neurons: 121.0 pF ± 6.2, in thick-tufted layer V PCs: 191.3 pF ± 20.8). 
There was no change in action potential amplitude for thick-tufted layer V PCs 
that were injected with vehicle (mean of 80.9 mV ± 1.8 vs 77.9 mV ± 2.1, p = 
0.134, n =10). Action potential amplitude was significantly reduced from 74.45 
± 2.1 mV at time zero to 60.1 ± 6.3 mV after 40 minutes (p = 0.014) in cells 
where oTau was injected (n = 8, Fig 3.10A). There was no change to input 
resistance for vehicle injected cells (90.1 ± 12.0 MΩ vs. 92.2 ± 13.0 MΩ, p = 
0.672), but for cells in which 666 nM oTau was introduced, the input resistance 
did increase over the course of 40 minutes of recording (from 92.5 MΩ ± 7.58 
at time zero to 108.2 ± 8.1 MΩ at 40 minutes p = 0.045, Fig 3.10A).  
In order to determine whether pairs of neighbouring thick-tufted layer V PCs 
were synaptically connected (Fig 3.10B-C), a stimulus train of 5 action 
potentials (20 Hz) was given with a one second pause and then a 6th recovery 
action potential (as in Kerr et al., 2013; Fig 3.10D). This allowed the effects on 
amplitude and latency of EPSPs along with the degree of depression and 
recovery to be examined. I performed these experiments in young (P12-P21 
mice as their unitary EPSPs have a larger amplitude than those from older 
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mice and show marked short-term depression (Kerr et al., 2013; Reyes and 
Sakmann, 1999), which can be used to measure the effects of oTau on release 
probability.  For each synaptically connected pair, oTau was either introduced 
into the pre- or the postsynaptic cell or neither (vehicle introduced instead) (Fig 
3.10C) Once a connection was found, the stimulus protocol was repeated 
every 10 seconds for the duration of the recording. Due to the small amplitude 
of many of the EPSPs, (average amplitude ~ 0.8 mV, in line with Markram et 
al., 1997), averages of the sweeps were taken at 10-minute time intervals (30-
50 sweeps per average). To establish whether there were changes to synaptic 
depression, the amplitude of each EPSP across the train needed to accurately 
be determined. This can be confounded as the EPSPs are superimposed on 
the decay (or tail) of the previous EPSP. Deconvolution and re-convolution of 
the traces allowed for the amplitude to be accurately measured (Richardson 
and Silberberg, 2008b). Briefly, EPSPs were averaged (after correcting for 
baseline drift) and then deconvolved. Each deconvolved EPSP was cropped 
and then reconvolved so that the individual average EPSPs were no longer 
superimposed on the decay of the previous EPSP (Fig 3.10 E-F). With 
assistance from collaborators at the Zeeman Institute, I wrote the code to 
perform this in Julia (available on request). The accuracy of the program was 
confirmed by reconvolving the uncropped EPSPs and the comparing the 
resulting waveform to the untransformed EPSPs.  There were a small number 
of EPSPs that were still too small to run the re-convolution, so these were used 




Figure 3.10: Protocols for testing the effect of oTau on membrane properties 
and synaptic transmission in layer V pyramidal neurons. 
A. Voltage response to stepwise current injection protocol at 0 and 40-minute 
timepoints for control cells injected with vehicle (top) or 666 nM oTau (bottom). There 
was no significant change in the control cells but a reduction in action potential 
amplitude and an increase in input resistance. B. Micrograph of three Layer V PCs 
labeled with Alexa Fluor 488. Recordings were routinely made from three neighboring 
pyramidal cells to increase the probability of finding synaptically connected cells. C.  
Diagram of the protocol used to record pairs of synaptically coupled thick-tufted layer 
V PCs. Either both pipettes contained vehicle (bottom), or tau was targeted at the pre- 
or post-synaptic cell of the pair (top). D. Diagram to represent the stimulus delivered 
to the pairs of connected cells. A train of 5 action potentials (20 Hz) were stimulated 
in the presynaptic oTau cell using short depolarising current steps followed by a 1 
second gap and then a recovery action potential. EPSPs resulting from APs were then 
recorded in the postsynaptic vehicle cell. E. Example AP and corresponding EPSP to 
illustrate the recorded parameters (EPSP amplitude and latency). F. Method of 
accurately measuring the amplitude of the 2nd to 5th EPSPs in the train.  EPSPs were 
averaged (after removing any baseline drift; 1) and then deconvolved (top right; 2). 
The deconvolved EPSPs were cropped (3) and then reconvolved so that individual 
average EPSPs were not superimposed on the decay of the previous EPSP average 
(4). The accuracy of the deconvolution method was confirmed by reconvolving the 
uncropped EPSPs (5) and comparing the resultant waveforms to the original 
untransformed EPSPs (6). 
3.2.11 Introduction of oTau into the presynaptic cell of a connected 
pair impairs the synaptic transmission 
In total, 230 pairs of thick-tufted layer V PCs were recorded from, of which 24 
were connected synaptically. This gave an overall connection probability of 1 
in 9.6 pairs, comparable with the 1 in 10 pairs that were synaptically connected 
in a previous study of these neurons (Markram et al., 1997).  In 10 control 
pairs, vehicle was introduced into both the presynaptic and postsynaptic cells 
in the pair. For the remaining recordings, oTau was introduced in one pipette 
and vehicle in the other pipette. Therefore, once a connection was found, the 
tau would be in either the presynaptic or the postsynaptic cell. In 10 of the pairs 
133 
oTau was introduced into the presynaptic cell and vehicle into the postsynaptic 
cell. In the remaining 4 pairs, oTau was targeted to the postsynaptic cell, with 
vehicle introduced into the presynaptic cell. At early time points (0-10 minutes) 
there was no significant difference in the amplitude of the first EPSP in the train 
(p = 0.510) or its latency (p = 0.581) when either vehicle or oTau were 
introduced into the presynaptic cell (mean unitary EPSP amplitude: vehicle 0.8 
± 0.1 mV; oTau 0.6 ± 0.1 mV; latency: vehicle 2.2 ± 0.0002 ms, oTau 2.1 ± 
0.0001 ms). In control pairs (both vehicle), the amplitude of the EPSP 
remained stable throughout the recording (the amplitude of the first EPSP after 
40-50 minutes of recording was 80.5 ± 14.0 % (n = 10) of the EPSP amplitude 
at 0-10 minutes of recording, p = 0.375). However, when oTau was introduced 
into the presynaptic cell, at 40-50 minutes, the amplitude of the first EPSP was 
significantly reduced in 7 out of 10 of the paired recordings to 30.0 ± 10.0 % of 
the amplitude of EPSPs at 0-10 minutes (p = 0.034, n = 10, Fig 3.11 A-B). This 
was not a result of the recordings becoming unstable as the mean membrane 
potential at time zero, -67.5 ± 1.5 mV, was not significantly (p = 0.095) different 
from the membrane potential 40 minutes, -62.5 ± 1.3 mV. To ensure that the 
decrease in EPSP amplitude was not due to failure of action potential firing, 
every sweep was reanalysed and any with failed AP firing were removed from 
analysis (46 out of 3900 sweeps, ~ 1.2 %).  
3.2.12 Deficits in synaptic transmission are associated with 
increased short-term depression 
Changes to short term synaptic plasticity were measured using the train of 5 
AP (20 Hz, 50 ms interval) and evaluating the degree of depression across 
conditions. For analysis, the amplitude of EPSPs in the train (2nd- 5th EPSP) 
were measured relative to the amplitude of the first EPSP. In 9 out of 10 
recordings (in one recording the connection was too weak to accurately 
measure the amplitude of the 2nd -5th EPSPs) with vehicle introduced into both 
the pre- and postsynaptic cells, there was little change in the degree of short-
term depression over the duration of the recordings (Fig 3.11C, D). There was 
a small (but significant) increase in depression and a decrease in the paired-
pulse ratio (second EPSP/first EPSP amplitude) from 0 to 30 minutes (Fig 
3.11G). In the recordings (8 out of 10, two connections were too weak to 
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accurately measure) where oTau was introduced into the presynaptic cell there 
was an increase in the degree of short-term depression (Fig 3.11E, F).  If the 
reduction in EPSP amplitude induced by oTau was a consequence of a fall in 
the probability of neurotransmitter release, then short-term depression would 
have been expected to reduce (equivalent to the activation of presynaptic 
receptors such as adenosine A1, as in Kerr et al., 2013). This was not the case 
with oTau introduction and therefore the changes to short term plasticity are 
unlikely to be due to a fall in release probability. In 4 out of the 8 connections 
there was a complete failure of transmission during the train: the 2nd-5th EPSPs 
were absent (Fig 3.11E). Changes to AP waveform were not characterised 
from the pairs data due to the waveform being contaminated by the stimulus 
used to evoke the APs. All sweeps were, however, manually checked for AP 
failures and any sweeps that did have action potential failures were removed 
from analysis. Finally, paired-pulse ratio (amplitude of first EPSP/ amplitude of 
second EPSP) was calculated. Although there was a significant decrease in 
the ratio over time it is comparable between oTau and control. 
The recovery EPSP (evoked 1 s after the train of EPSPs) was used to 
determine the duration of the enhanced depression observed with oTau. The 
amplitude of the recovery EPSP was measured relative to the first EPSP in the 
train. Even though the degree of depression was significantly higher in the 
oTau introduced pairs, the recovery (amplitude of recovery EPSP/ amplitude 
of first EPSP) was not different between the conditions. Therefore 1 s is a long 
enough time for recovery of the enhanced depression and shows the 
depression is reversible.   
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Figure 3.11: Introduction of oTau into the presynaptic cell of a connected pair 
impairs the synaptic transmission. 
A. Mean normalised amplitude of the first EPSP in the train (normalised to the EPSP 
at 0-10mins). Each timepoint is an average of EPSPs across the 10-minute time 
window (~50 sweeps). The black line represents the pairs with vehicle in both pipettes 
and the red line represents pairs in which oTau (666 nM) was introduced into the 
presynaptic cell of the pair. For the control pairs there was no significant change over 
time (p = 0.375). However, for those with oTau introduced, there was a significant 
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decline in amplitude over time (control vs oTau 30-40 mins p = 0.029, 40-50 mins p = 
0.034). B.  At each timepoint, representative EPSP averages are shown for vehicle 
and oTau introduced pairs. They have been deconvolved, cropped and re-convolved 
so that the full rise and decay of each EPSP can be observed. A clear reduction can 
be observed for oTau introduced pairs. C. The 2nd to 5th EPSP amplitudes were also 
analysed following the deconvolution and reconvolution process. They are presented 
normalised to the first EPSP in the train’s amplitude in vehicle. Data is shown for 0-
10 minutes and at 30-40 minutes. There was a small but significant increase in 
depression between 0 mins and 30-40 mins for the 2nd EPSP (p = 0.032) and the 5th 
EPSP (p = 0.041). D. A representative single recording to show the average EPSP 
waveforms in vehicle for all 5 EPSPs in the train after vehicle introduction. Averages 
are shown for 0-10 mins and 30-40 mins of recording. The EPSP traces were 
normalised so the amplitude of the first EPSP remains the same, to highlight changes 
in depression. E. The 2nd to 5th EPSP amplitudes were also analysed following the 
deconvolution and reconvolution process. They are presented normalised to the first 
EPSP in the train’s amplitude when oTau has been injected into the presynaptic cell. 
Data is shown for 0-10 minutes and at 30-40 minutes. There was a significant increase 
in depression between 0-10 and 30-40 mins for the 2nd EPSP (p =0.0347), 3rd EPSP 
(p = 0.037) and 4th EPSP (p = 0.009). F. A representative single recording to show 
the average EPSP waveforms in vehicle for all 5 EPSPs in the train after oTau (666 
nM) introduction. Averages are shown for 0-10 mins and 30-40 mins of recording. The 
EPSP traces were normalised so the amplitude of the first EPSP remains the same, 
to highlight changes in depression. Although it is clear that the 3rd, 4th, and 5th EPSPs 
are absent, this was not a result of failed action potentials. G. Graphs to demonstrate 
the paired pulse ratio for cells with vehicle or oTau introduced (amplitude of the 
second EPSP/ amplitude of the first EPSP). The points are means from single 
experiments and the bars show the overall mean and SEMs for all recordings. For 
both conditions, there was a significant fall in the paired-pulse ratio over the duration 
of the recording (vehicle p = 0.032 and oTau p = 0.035). H. Following a 1 second 
recovery period a final EPSP was evoked (left). The amount of recovery (recovery 
EPSP/ first EPSP) decreases over time and is similar for cells for both conditions. 
Waveforms after 30-40 minutes (right, same recording as in F) showing the absence 
of the 3rd-5th EPSPs, but there is some recovery after the 1s interval (inset).  
137 
3.2.13 Introducing oTau into the postsynaptic cell does not impair 
basal synaptic transmission 
In the remaining 4 pairs of synaptically connected thick-tufted layer V PCs, 
where the oTau was introduced only into the postsynaptic cell, there was no 
significant reduction in EPSP amplitude over the recording period (average 
EPSP amplitude after 40 minutes was 91.8 % of the EPSP recorded at 0-10 
minutes) and there was no change to the degree of short-term depression (Fig 
3.12). Therefore, introduction of oTau over ~40 mins results in significant 
changes to basal synaptic transmission specifically at presynaptic sites.  
Figure 3.12: Introduction of oTau into postsynaptic neurons has no significant 
effect on basal synaptic transmission 
A. Using a similar protocol as was used for measuring the pre-synaptic effects of 
oTau, oTau (666 nM) is introduced to only the postsynaptic cell. Diagram illustrates 
the experimental setup. B. Normalised first EPSP amplitude (1st in the train of 5) at 10 
minute-averaged timepoints between 0 and 40 mins after tau (666 nM) introduction. 
Normalisation is done at each time point to the amplitude of the EPSP over the first 
0-10 minutes of recording. There was no significant change over the period of 
recording. C. Representative examples of EPSPs from single experiments. The 
EPSPs were averaged over 10 minutes and have been deconvolved, cropped and re-
convolved to show the full-time course for each EPSP waveform. Traces are shown 
for each of the averaged timepoints. D. The 2nd to 5th EPSP amplitudes were also 
analysed following the deconvolution and reconvolution process. They are presented 
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normalised to the first EPSP in the train’s amplitude. Data is shown for 0-10 minutes 
and at 30-40 minutes. There is no significant change over the period of recording. E. 
A representative single recording to show the average EPSP waveforms for all 5 
EPSPs in the train after oTau (666 nM) introduction. Averages are shown for 0-10 
mins and 30-40 mins of recording. The EPSP traces are not normalised. 
3.2.14 Post-synaptic oTau disrupts long term potentiation 
It has previously been demonstrated that extracellular application of oTau, but 
not monomeric (m)Tau can impair synaptic plasticity, both long-term 
potentiation (LTP) and long-term depression (LTD), (Fá et al., 2016; Lasagna-
Reeves et al., 2012). Ondrejcak et al., (2018) demonstrated that for a subset 
of AD brain extracts that produced an amyloid beta-independent reduction in 
LTP, immunodepletion of the extract with the Tau5 monoclonal antibody 
prevented the impairment of LTP, suggesting the importance of tau in 
mediating the changes to synaptic plasticity. However, from these 
experiments, it is not clear what the actual concentration of oTau is inside the 
cells or whether the actions on plasticity are pre- or postsynaptic. 
To investigate this, I made whole-cell current clamp recordings from CA1 
hippocampal neurons and stimulated the Schaffer collateral fibres (Fig 3.13A). 
oTau, vehicle or mTau were introduced into the postsynaptic neuron and the 
effects on long-term potentiation (LTP, induced with theta burst stimulation 
TBS) measured. There was no significant difference in the amplitude of EPSPs 
across all of the conditions at 0 mins (one-way ANOVA, p = 0.148). Although 
there was considerable variability between cells regarding the response to the 
TBS, there was no significant difference in the area under the curve (of the 
response to TBS) across conditions (p = 0.787). When vehicle was introduced 
into the postsynaptic cell, theta-burst stimulation (TBS) induced robust 
potentiation (30 minutes after the stimulation, EPSP amplitude was 3.9 ± 1.2 x 
the baseline amplitude, n = 7, Fig 3.13A). This potentiation was NMDA 
receptor dependent as it was abolished by the NMDA receptor antagonist 
L689,560 (5 µM, 0.4 ± 0.1 x the baseline EPSP amplitude after 30 minutes, n 
= 3, Fig 3.13B). In initial experiments I found that oTau (444 nM) abolished 
both STP and LTP (n = 7 slices, Fig 3.13C). The experiments were then 
repeated with a 10-fold reduction in the concentration of oTau (44 nM) which 
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also abolished LTP but did not completely prevent STP (n = 5, Fig 3.13D).  
Monomeric tau (444 nM) had little effect on the degree of potentiation 
compared to control (LTP p = 0.151 or STP p = 0.429, n = 5, Fig 3.13E, F). 
Therefore, even though there were no effects on basal synaptic transmission 
when oTau was introduced into the postsynaptic cell, it abolishes LTP, a 
measure of synaptic plasticity which could be one of the mechanisms 
underlying the learning and memory deficits in diseases involving tau 
oligomers such as Alzheimer’s disease.  
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Figure 3.13: Introduction of oTau into the postsynaptic neuron blocks the 
induction of long-term potentiation 
A. Illustration of the protocol used to measure long-term potentiation (LTP).  
Stimulation of the Schaffer collaterals evoked EPSPs in CA1 hippocampal cells. LTP 
was induced by theta burst stimulation (TBS). Vehicle or oTau were introduced via 
patch pipette to the CA1 neuron being recorded. B. Mean EPSP amplitude against 
time for vehicle controls (n = 7) and for 3 slices where 5 µM L689,560 was added to 
block NMDA receptors. The TBS protocol evoked robust potentiation which was 
abolished by the NMDA antagonist. Inset shows example average waveforms before 
TBS (1) and 30 mins after TBS (2) for both control and 5 µM L689,560. C. Mean EPSP 
amplitude against time for 444 nM oTau introduced cells (n = 7). STP and LTP were 
completely abolished by oTau. Inset shows example average waveforms before TBS 
(1) and 30 mins after TBS (2). D. Mean EPSP amplitude against time for 44 nM oTau 
introduced cells (n = 5). LTP was completely abolished by oTau. However, there was 
some short-term potentiation. Inset shows example average waveforms before TBS 
(1) and 30 mins after TBS (2). E. Mean EPSP amplitude against time for monomeric 
444 nM tau (mTau) introduced cells (n = 5). LTP was induced with mTau. Inset shows 
example average waveforms before TBS (1) and 30 mins after TBS (2). F. A summary 
graph demonstrating the mean potentiation. In control conditions (vehicle in the 
intracellular solution) after 30 minutes following TBS, EPSP amplitude was 
potentiated to 331.0 ± 132.0 % of the baseline amplitudes (n = 7). This potentiation 
was lost in the presence of L689,560 (53.0 ± 14.0 % of the baseline amplitude, n = 
3), with oTau 444 nM in the intracellular solution (99.0 ± 31.0 % of the baseline 
amplitude p = 0.042, n = 7, control vs 444 nM) and with 44 nM oTau in the intracellular 
solution (111.0 ± 10.0 % of the baseline amplitude, n = 5). In contrast potentiation 
persisted with mTau (444 nM) in the intracellular solution (335.0 ± 90.0 % of the 
baseline amplitudes, n = 5). A Kruskal Wallis one-way ANOVA gives a significant 
effect of treatment condition against vehicle (p = 0.003) and Dunn’s post hoc analysis 
shows significant differences between the potentiation of cells injected with vehicle 
and L689,560, 44 nM or 444 nM oTau (p = 0.006, p = 0.008 and p = 0.002 
respectively) compared to control. G. Example voltage responses to the TBS used to 
induce potentiation for a vehicle, 444 nM oTau and a 44 nM Tau introduced neuron. 
H. Mean voltage responses to TBS (measured as area under the curve; AUC) for a 
vehicle, 444 nM oTau and a 44 nM oTau introduced neuron. Graph shows mean and 
SEM data with individual data points overlaid. There was no difference across 
experimental group in response to TBS.  
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3.2.15 Post-synaptic oTau disrupts long term depression 
In preliminary experiments, I also began to evaluate the effects of post-
synaptic oligomeric tau on metabotropic glutamate receptor (mGluR)-
mediated long-term depression (LTD) with whole-cell current-clamp recordings 
from CA1 hippocampal pyramidal cells in the presence of 50 µM picrotoxin (to 
block GABAA receptors) and 5 µM L689,500 (to block NMDA receptors). As 
with the LTP protocol, the Schaffer collaterals were stimulated every 20 
seconds to evoke reliable and robust synaptic transmission (EPSP amplitude 
~ 3 mV). After a 10-minute baseline, LTD was induced by 100 µM of the 
mGluR5 agonist DHPG for 10 minutes and EPSPs were recorded for 30 
minutes further following induction (Fig 3.14A). When oTau (444 nM) was 
introduced into the CA1 neuron, the mean LTD at 30-minutes post induction 
was 56.0 ± 0.1% of baseline (n=6) in control cells and 106.0 ± 0.2 of baseline 
(n=5) in oTau cells (Fig 3.14B-D). Although only a preliminary study, this a 
significant reduction in depression at 30 mins following induction (Kruskal 
Wallis ANOVA, control vs oTau, p = 0.028). 
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Figure 3.14: Introduction of oTau into the postsynaptic neuron reduced long-
term depression. 
A. Illustration of the protocol used to measure long-term depression (LTD).  
Stimulation of the Schaffer collaterals evoked EPSPs in CA1 hippocampal cells. LTD 
was induced by application of 100 µM of the mGluR5 agonist DHPG for 10 minutes. 
Vehicle or oTau were introduced via the patch pipette to the CA1 neuron being 
recorded. B. Mean normalised EPSP amplitude against time for 444 nM oTau 
introduced cells (n = 6). LTD was completely abolished by oTau. Inset shows example 
average waveforms before DHPG application to induce LTD (1) and 30 mins after 
induction (2). C. Mean normalised EPSP amplitude against time for control cells (n = 
5). LTD was reliably achieved in controlled cells. Inset shows example average 
waveforms before DHPG application to induce LTD (1) and 30 mins after induction 
(2). D. Mean depression (normalised to baseline) for control and Tau introduced cells 
at 30-minutes post induction. Graph shows mean and SEM, data points are individual 
experiments overlaid. A significant reduction in depression can be observed in the 
oTau cells compared to control (p = 0.028). 
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3.3 Conclusion  
The aim of the work in this Chapter was to provide further understanding of the 
role of tau oligomers in the disruption of neuronal function. This field of 
research is important given the ageing global population and an increased 
pressure to understand neurodegenerative conditions like Alzheimer’s 
disease, in which tau is a key pathological player. Previous studies have 
utilised transgenic animal models of tauopathies (Booth et al., 2016; McInnes 
et al., 2018; Rudinskiy et al., 2014; Zhou et al., 2017), but it is difficult to 
determine the concentration or the form of tau that is responsible for the 
toxicity. Other approaches use extracellular bath-application of tau oligomers 
(Fá et al., 2016; Lasagna-Reeves et al., 2012; Puzzo et al., 2017) but it is 
difficult to know how much of the applied tau oligomers are taken up into 
neurons and then act directly inside the cells or whether the tau oligomers have 
indirect effects. It is also impossible to quantify the exact concentration of 
oligomers within the recorded cells. For both transgenic animals and 
extracellular application methods, it is not possible to say whether any effects 
synaptic transmission or plasticity are pre- or postsynaptic. Using my method, 
introducing tau through the patch pipette, I can directly target the characterised 
oTau into single neurons in a network that is free from pathology and allowing 
targeting of oTau to pre- or post-synaptic cells. In comparison with the other 
methods, I have outlined that:  i) my method requires a much lower quantity of 
oligomer per experiment; ii) each cell acts as its own control (upon whole-cell 
breakthrough) and iii) effects can be observed in real time; allowing for a direct 
correlation between the observed effects and the different concentrations of 
injected oligomer. I have demonstrated in this study comparable 
concentration-dependent effects for oTau introduction into CA1 neurons in the 
hippocampus and Layer V pyramidal neurons in the cortex. Marked changes 
to action potential dynamics, synaptic transmission and plasticity were 
mediated by oligomeric, but not monomeric, tau protein. Consistent with these 
electrophysiological changes, I have also demonstrated that oTau can diffuse 
from the injection site (soma) to synaptic sites within 30 minutes of recording. 
This study provides valuable new insight into the actions of tau oligomers 
within single neurons. It answered questions that have never before been 
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possible to explore with traditional methods. Though this study greatly 
enhances the field of knowledge regarding the actions of oligomeric tau in 
neurons, there are many unanswered questions regarding underlying 
mechanisms that will need to be investigated in future experiments (see 
Chapter 4).  
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4. Chapter 4:  
4. Truncating Tau Reveals Different 
Pathophysiological Actions of Oligomers in 
Single Neurons 
Results of this chapter have been published previously: (Hill et al., 2021, in review) 
Figure 4.1: Tau truncations can dissect apart the effects on action potential 
and neuronal excitability, a summary of identified mechanisms 
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4.1 Introduction  
In Chapter 3, in order to study the acute effects of tau oligomers, I used whole-
cell patch-clamp recording to introduce known concentrations of structurally 
defined oligomeric full-length human tau-441 (oTau) into mouse hippocampal 
CA1 pyramidal and neocortical layer-V thick-tufted pyramidal cells (Hill et al., 
2019). In this study, I have begun determining the mechanisms underlying 
these changes to excitability, conductance and action potential waveform. My 
strategy was to use recombinantly produced tau truncations to determine 
whether specific regions of tau are responsible for the observed effects. 
Identifying the regions of tau mediating neuronal dysfunction will assist in 
tracking down protein-protein interactions, help design assays for interacting 
partners and provide a mechanistic framework for drug development.  
To decide on the truncations to use, I considered two factors. Firstly, to find 
tau fragments that exist in the human brain, as this will also provide information 
on the pathological actions of these truncated tau molecules.  A fraction of the 
toxic oTau pool in human AD brains is released into cerebrospinal fluid (CSF) 
in a manner that associates with pathological AD markers. The majority of this 
tau appears as fragments or truncations, for example as N-terminal fragments 
of amino acids 1-123 or 1-224 (Cicognola et al., 2019). I then investigated if 
any of these fragments had already been evaluated in previous studies. Zhou 
et al., (2017) had used a similar N-terminal truncation of tau (to the 1-123 
fragment) to identify synaptic transmission deficits in cell culture models. 
Taking these two factors together, I decided to study the N-terminal truncation 
of amino acids 124-444 (CFRAG) and the resulting fragment of amino acids 1-
123 (NFRAG).  
I have implemented the same single-cell approach in combination with detailed 
computational modelling to start to determine the underlying mechanisms of 
the changes to excitability, conductance and action potential waveform. This 
approach provides a simple, yet highly effective way to generate detailed 
quantitative information on the functional effects of different mutations and 
truncations of tau oligomers, as well as to test pharmacological drugs and 
interventions. Understanding the direct actions of tau oligomers will lead to 
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better understanding of the disease process and provide new avenues for 
diagnostics and therapeutics. 
4.2 Results  
4.2.1 Structural characterisation of the tau samples 
In this study, the actions of oligomeric full length (FL) tau were compared to 
the effects of oligomers formed from two truncated forms of tau. The first is an 
N-terminal truncation (CFRAG) consisting of amino acids 124-444 (Fig 4.2A). 
The second is the N-terminal fragment that is removed by this truncation 
(NFRAG) and consists of amino acids 1-123 (Fig 4.2A).  
One of the goals of my previous study (Hill et al, 2019), was to visualise the 
localisation of the introduced tau oligomers in the recorded neuron. To achieve 
this, the tau oligomers were labelled (Alexa Fluor maleimide 488 bound to 
cysteine residues). This required the introduction of mutations to the tau 
molecule, to move the cysteine residues to enable efficient label binding 
without impeding tau function (Hill et al, 2019). In this study, I have used tau 
that was not labelled and therefore does not require these cysteine 
modifications. It therefore represents full length tau in its native state (Fig 
4.2A).  
The recombinant full length and truncation of tau used in the study were initially 
going to be produced by myself but due to time constraints were produced by 
collaborators at the University of Gothenburg.  
All three samples (FL, CFRAG and NFRAG) were examined in both aggregated 
and monomeric form. Negative-stain transmission electron microscopy (TEM) 
was used to evaluate the samples. TEM confirmed that all the oligomeric 
species were in the form of small aggregates rather than longer fibrils and that 
none of the monomeric species showed aggregates (Fig 4.2B). 
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Figure 4.2: Structure and characterisation of the tau truncations 
A) Schematic to illustrate the tau constructs used in this study. Full length (FL) tau 
has two N terminus repeats (N1, N2) and four microtubule-binding repeat domains 
(R1–R4). Two other truncations were tested. The first is an N-terminal truncation 
(termed CFRAG) which consists of amino acids 124-444. The second, is the N-terminal 
fragment that is removed by the CFRAG truncation (termed NFRAG) which consists of 
amino acids 1-123. All three versions of tau (FL, CFRAG and NFRAG) were characterised 
as monomers and after undergoing the oligomerisation protocol. B) The structure of 
the aggregates formed will differ significantly due to the structure of the monomeric 
forms. However negative-stain transmission electron microscopy was used to confirm 
that the monomeric samples had no aggregation and the samples that had undergone 
aggregation process demonstrated small, aggregated forms (resembling oligomeric 
form rather than fibrils), scale bar = 200 nm, inset: higher magnification scale bar = 
20 nm.  
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4.2.2 Using oligomeric CFRAG to separate effects on whole-cell 
conductance, neuronal excitability and action potential waveform 
I first compared the effects of oligomers made from N-terminal truncated tau 
(CFRAG) to full length (FL) tau with vehicle (PBS) as the control. I used the same 
concentration (444 nM) of tau oligomers as in Hill et al., (2019) which gave 
reproducible results. This concentration is based on the molecular weight of 
the monomer, as oligomeric composition is heterogeneous. This will result in 
an overestimate of the actual concentration of oligomers introduced (see Hill 
et al 2020). Following their introduction into hippocampal pyramidal neurons, 
standard and dynamic IV protocols (see Methods) were used to extract 
electrophysiological parameters. There was no significant difference in the 
electrophysiological parameters at time 0 (whole-cell breakthrough) across the 
three conditions (Kruskal-Wallis One-Way ANOVAs resting potential p = 
0.139, peak input resistance p = 0.229, firing rate p = 0.644, action potential 
amplitude p = 0.753 or action potential width p = 0.910, n = 12 for each 
condition, see Table 4.1). Therefore, the initial quality of recordings and 
neuronal properties were comparable across the experimental treatments.  
In neurons with vehicle (control) introduced, there were no significant changes 
to any of the measured parameters over the 40-minute period of recording (0 
vs 40 mins, peak input resistance p = 0.146, firing rate p = 0.183, action 
potential amplitude p = 0.073 or action potential width p = 0.227, see Table 
4.1, Fig 4.3). There were also no changes to the resting membrane potential 
over the duration of the recordings for any of the experimental conditions 
(vehicle, full length tau and truncated tau, p = 0.090, 0.086 and 0.080 
respectively, Fig 4.3A, B).  
Unmodified FL oTau had comparable effects to labelled FL oTau (Hill et al., 
2019): increased input resistance, increased neuronal excitability and changed 
the action potential waveform (reduced amplitude and increased width). This 
confirms that the effects of tau oligomers observed in my previous study were 
not altered by the cysteine mutations and label. I have previously 
demonstrated that the effects of FL tau were specific to oligomers and that 
monomeric versions had no significant effect on any of the neuronal properties 
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over the duration of the recordings, therefore I did not repeat this for the 
unmodified FL tau. I observed a significant increase in input resistance (Rin) 
upon introduction of FL tau (at 40 mins, the Rin was 130.0 ± 6.3 % of the 
resistance at time 0, whole-cell breakthrough, p = 0.001, Fig 4.3C). In contrast 
CFRAG introduction did not significantly alter Rin (at 40 mins, the Rin was 100.0 
± 2.1 % of the input resistance at time 0, p = 0.926, Fig 4.3C). There was a 
significant increase in neuronal excitability mediated by FL Tau (at 40 mins, 
the firing rate, measured from the voltage response to naturalistic current 
injection, was 171.0 ± 19.3 % of that at time 0, p = 0.020, Fig 4.3 E, F). I had 
originally assumed that the FL oTau-mediated increase in neuronal excitability 
resulted from the increase in input resistance. Therefore, as CFRAG had no 
effect on input resistance, I predicted that it would not affect neuronal 
excitability. However, surprisingly CFRAG significantly increased excitability (at 
40 mins, the firing rate was 164.0 ± 22.5 % of that at time 0, p = 0.013, Fig 
4.3E, F). This suggests that the effects on neuronal excitability can occur 
independently of changes in input resistance.  
As I previously reported for modified FL tau (Hill et al., 2019) native FL tau 
significantly changed the action potential (AP) waveform, with action potential 
amplitude at 40 minutes significantly (p =  0.001) reduced to 70.0 ± 7.4 % of 
that at time 0 minutes (Fig 4.3D, G) and action potential width at 40 minutes 
significantly (p = 0.035) increased to 134.0 ± 17.2 % of that at time 0 minutes 
(Fig 4.3D, H). Introduction of CFRAG tau did not replicate the changes to action 
potential waveform observed with FL tau. Neither the action potential 
amplitude (at 40 minutes 91.0 ± 1.6 % of that at time 0 minutes, p = 0.079, Fig 
51F) or action potential width (at 40 minutes 102.0 ± 3.0 % of that at time 0 
minutes p = 0.475, Fig 4.3D, G, H) were significantly changed. This suggests 
that the effects of oligomeric tau on the action potential waveform could either 
be a direct result of the N-terminal sequence or could result from a specific 
structure of the oligomers, which will probably differ following truncation. Thus, 
removing amino acids 1-122 from full length tau resulted in the loss of effects 
on the action potential waveform and on the input resistance, although the 
increase in excitability remained. 
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Figure 4.3: Tau effects on neuronal excitability, input resistance, and action 
potential waveform 
A) Standard current−voltage response in control (vehicle) neurons (grey), FL tau (red) 
and CFRAG tau (blue) over the 40-minute period of recording. B) Graph showing that 
there is no change to the resting membrane potential over the period of recording for 
any of the conditions. C) Graph plotting input resistance against time. FL tau 
significantly increased input resistance whereas control neurons and neurons with 
CFRAG tau showed no significant changes. D) Representative examples of action 
potential waveforms for an individual neuron with one of the three conditions 
introduced (control, 444 nM FL-oTau, 444 nM CFRAG oTau). There is no effect on AP 
waveform in the control or CFRAG oTau cells, but a comparable effect on action 
potential height and width to Chapter 3 with FL-oTau is observed. E) Example 
membrane-potential responses to naturalistic current injection at time 0 (after whole-
cell breakthrough, top) and after 40 min of recording for each of the three conditions 
(vehicle, FL tau and CFRAG tau). There is a reduction in action potential amplitude with 
FL tau coupled with an increase in excitability. CFRAG tau has no effect on action 
potential amplitude but increases excitability whereas vehicle has no effect. F) Graph 
plotting normalised firing rate (normalised to time 0) against time. Both FL and CFRAG
tau oligomers produce a significant increase in neuronal excitability that is not seen 
in vehicle cells. (G) Graph plotting action potential amplitude against time and (H) 
action potential width against time. A reduction in action potential amplitude (G) and 
increase in width (H) are only produced by FL tau and not by CFRAG tau or vehicle.  
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Table 4.1: Electrophysiological parameters measured for CA1 neurons with either vehicle, CFRAG or NFRAG introduced. 
Recordings were made from hippocampal CA1 neurons. There was no significant difference between any of the measured parameters at 0 
minutes (whole-cell breakthrough), using Kruskal Wallis ANOVAs (see text for p values). Comparisons were then made between 0 and 40 minutes 
for each of the conditions using non-parametric Wilcoxon-signed rank tests (see text for p values). Data shown as mean and SEM. 
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4.2.3 The increase in neuronal excitability by CFRAG is confirmed by 
a reduction in the rheobase current. 
To evaluate the effects on neuronal excitability in more detail I examined the 
rheobase, the minimum current required to elicit an action potential. I used a 
protocol (see Methods) where a current ramp (from – 50 pA to 100 pA over 1 
s; Fig 4.4A) was injected every 10 minutes throughout the recording.  There 
was no significant difference in the minimum current (rheobase) to evoke an 
action potential in control vs FL or CFRAG neurons at time 0 (whole-cell 
breakthrough) using a Kruskal-Wallis One-Way ANOVA (at 0 mins, the mean 
rheobase in control was 61.0 ± 3.5 pA, with FL the mean rheobase was 68.0 
± 5.4 pA and with CFRAG the mean rheobase was 79.0 ± 7.7 pA, p = 0.129, 
Table 4.1, Fig 4.4), thus the recordings are comparable. In control neurons, 
there was no significant difference in the rheobase current over the duration 
of the recording (at 40 minutes, the rheobase was 105.0 ± 3.0 % of the value 
at time 0 mins, p = 0.083, Table 4.1, Fig 4.4).  
However, when full length and CFRAG aggregated forms of tau were introduced, 
the rheobase was significantly reduced (reflecting an increase in excitability, 
Table 4.1, Fig 4.4). For FL tau, at 40 minutes the rheobase was 66.0 ± 7.0 % 
of the value at time 0 mins (p = 0.002). When CFRAG tau was introduced, at 40 
minutes the rheobase was 70.0 ± 5.0 % of the value at time 0 mins (p = 0.001, 
Table 4.1, Fig 4.4). A non-parametric two-way ANOVA was then used to 
evaluate whether the shift in rheobase was dependent solely on the treatment 
condition, on the timescale of recording, or a combination of both. A significant 
effect of time (p <0.0001) and condition (vehicle or truncated tau; p < 0.0001) 
were observed to contribute to the alteration of rheobase, with significance 
observed from the 20-minute time-point onwards (as determined by Dunn’s 
post-hoc analysis; 20 mins p = 0.006, 30 mins p < 0.0001, 40 mins p < 0.0001). 
This data is also consistent with the effect on the frequency of action potentials 
in response to fluctuating noisy current traces, where the action potential 
waveform is altered in the cells that had FL introduced, but not CFRAG
introduced (Fig 4.3F, G).  
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Figure 4.4: oTau alters the rheobase current. 
A) Examples from representative cells (control, full length, and N-terminally truncated 
tau oligomers) demonstrating the effects on rheobase over time. B) Graph plotting 
mean and SEM for control (vehicle), full length and CFRAG tau oligomers on rheobase 
over time. Both full length and CFRAG tau oligomers significantly reduced the current 
needed to elicit an action potential, reflecting an increase in neuronal excitability.  
4.2.4 CFRAG truncated tau alters excitability by moving the spike 
initiation threshold 
I then examined how oligomeric tau might be decreasing the rheobase current 
(increasing excitability) and hypothesized it might be because the difference 
between the resting membrane potential and spike initiation threshold is 
reduced. Since there is no change in resting membrane potential caused by 
oTau, this could only occur if there was a hyperpolarising shift in spike initiation 
threshold. The dynamic IV method (Badel et al., 2008b, 2008a) provides a 
method to accurately parameterise neurons (see Methods for more details). 
One of the parameters that it can extract is the spike initiation threshold. In my 
original study (Hill et al., 2019), I was unable to use this technique to map 
changes in neuronal parameters over time as the method is not very effective 
if there are significant changes in the action potential waveform. However, as 
the truncated form of tau has no effect on the action potential waveform (Figure 
4.3), I was able to use the dynamic IV protocol to examine changes to the 
spike initiation threshold.  
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There was no significant difference between the spike initiation threshold in 
control vs CFRAG neurons at time 0 (whole-cell breakthrough), thus the 
recordings were comparable (mean threshold in control neurons was -53.8 ± 
1.5 mV, n=12, compared to the mean threshold in CFRAG neurons which was 
– 51.0 ± 1.3 mV, n=12, p = 0.519). In control neurons, there was no significant 
difference in spike threshold over the duration of the recording (at 40 minutes, 
the spike threshold was -52.5 ± 1.6 mV, p = 0.477). Whereas for neurons 
where 444 nM CFRAG oTau was introduced, the spike initiation threshold was 
significantly reduced (more negative) at 40 minutes as compared to 0 minutes 
(at 40 minutes, the spike threshold was -54.0 ± 1.3 mV, p = 0.001, Fig 4.5 A, 
B). A non-parametric two-way ANOVA was then used to evaluate whether the 
shift in threshold was dependent solely on the treatment condition, on the 
timescale of recording, or a combination of both. A significant effect of time (p 
= 0.013) and condition (vehicle or truncated tau; p = 0.0001) were observed to 
contribute to the alteration of spike initiation threshold, with significance 
observed from the 20-minute timepoint onwards (as determined by post-hoc 
analysis; 20 mins p = 0.008, 30 mins p = 0.047, 40 mins p = 0.020). Although 
a change in threshold of 4 mV might seem small, across a network this could 
cause a significant shift in network excitability.  
I also noted an increase in spike-onset sharpness which is a measure of the 
time from a cell reaching the spike initiation threshold and the subsequent 
onset of the action potential (spike). This increase in spike-onset sharpness 
(sharper DIV curve, decrease in time) fits with the increase in neuronal 
excitability. There was no significant difference between the onset in control 
vs CFRAG neurons at time 0 (whole-cell breakthrough), thus the recordings were 
comparable in quality and stability (mean spike-onset sharpness in control 
neurons was 0.74 ± 0.04 mV, n=12, compared to the mean threshold in CFRAG
neurons which was 0.9 ± 0.1 mV, n=12, p = 0.129, Fig 4.5C). In control 
neurons, there was no significant difference in spike-onset sharpness over the 
duration of the recording (at 40 minutes, the spike-onset sharpness was 0.81 
± 0.04 mV, p = 0.910). In contrast, for neurons where 444 nM aggregated 
CFRAG tau was introduced, the onset was increased (steeper, reflecting 
increased excitability) at 40 minutes compared to 0 minutes (at 40 minutes, 
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the spike-onset sharpness was 1.18 ± 0.07 mV, p = 0.001). A non-parametric 
two-way ANOVA was then used to evaluate whether the shift in spike-onset 
sharpness was dependent solely on the treatment condition, on the timescale 
of recording, or an interaction between both. A significant effect of time (p = 
0.005) and condition (vehicle or truncated tau; p = 0.0001) were observed to 
contribute to the alteration of spike-onset sharpness, with significance 
observed from the 30-minute timepoint onwards (as determined by post-hoc 
analysis; 30 mins p = 0.002, 40 mins p = 0.0001).  
I then implemented a complimentary modelling approach to evaluate whether 
either of these effects, either on spike initiation threshold or on spike onset 
sharpness, could account solely for the increase in excitability observed. To 
do this I used the refractory integrate and fire (rEIF) model (see Methods for 
more details) to simulate a voltage response given the parameters extracted 
from the DIV curves at 0 mins (Fig 4.5E); the firing rate matched the 
experimental trace (Fig 4.5D). I manually shifted only the spike threshold by -
4 mV (in line with the change in the experimental traces) and re-ran the 
simulation. Comparing this to the experimental trace at 40 minutes, it is clear 
the change in spike threshold alone is sufficient to mediate the increase in 
neuronal excitability (Fig 4.5E). I then repeated the same procedure but 
instead shifted the spike-onset sharpness, the simulation predicted little effect 
on neuronal excitability (Fig 4.5E), suggesting that the change is 
predominantly mediated by the change in spike threshold.  
159 
160 
Figure 4.5: oTau- mediates a shift in spike initiation threshold. 
For the dynamic I-V protocol, a naturalistic current is injected into the cell and the 
voltage recorded is then used to extract a set of parameters (resting potential E, time 
constant τ, and spike-threshold voltage VT; see methods for more details). The 
second point where the DIV curve crosses 0 (mV/ms) represents the spike initiation 
threshold. A) Representative example of the dynamic IV curve for a neuron with the 
N-terminal truncation of tau introduced at 0 mins (green) and 40 mins (pink). A shift 
in spike initiation threshold (circled) of 4 mV (more negative) can be observed, thus 
the neurons are more excitable. B) The mean normalised spike threshold data is 
plotted against time (with SEM) to show the reduction in spike threshold in CFRAG cells 
compared with cells where vehicle was introduced. Data is normalised to the spike 
initiation threshold at time 0 mins. C) Graph plotting spike-onset sharpness against 
time. There is an increase in spike-onset sharpness observed in neurons where CFRAG 
was introduced, reflecting faster spike generation after reaching threshold, again 
fitting with the increase in excitability. (D) Membrane-potential responses to 
naturalistic current injection for the neuron modelled in (A) demonstrates the increase 
in neuronal excitability mediated by the introduction of CFRAG tau oligomers. (E) 
Simulated membrane- potential response based on the extracted neuronal 
parameters at time 0 mins (left), using the refractory integrate and fire model. The 
neuronal firing rate matches the experimental trace well. The spike threshold was then 
manually shifted by -4 mV and the simulation re-run (right, blue), resulting in an 
increase in excitability, comparable with the experimental trace at 40 mins (D). The 
same procedure was performed, but only shifting spike-onset sharpness and re-
simulating with little effect on excitability or firing rate (right, purple), thus confirming 
that the increase in excitability is predominantly mediated by a shift in spike threshold. 
4.2.5 NFRAG aggregate introduction generates a rapid onset 
increase in input resistance and decrease in action potential 
amplitude  
As CFRAG oligomers did not replicate the changes to input resistance and action 
potential waveform observed with FL tau oligomers, I next introduced NFRAG 
tau (at 444 nM) into neurons and measured changes to neuronal parameters 
to investigate if this fragment of tau was responsible. Unexpectedly, in 
preliminary experiments, I observed a large increase in input resistance within 
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the first 5 minutes of recording. At 5 minutes the input resistance was 169.0 ± 
24.2 % of that at 0 minutes (whole-cell breakthrough, n = 4, Fig 4.6A). I have 
previously shown through re-patching experiments that tau oligomers do not 
aggregate in the end of the pipette tip and impede voltage measurements (Hill 
et al., 2019 and Chapter 3). However, this rapid change could be due to the 
tau oligomers aggregating close to the introduction site in the soma and 
making the electrotonic size of the soma appear reduced (this would result in 
a smaller capacitance measurement at 5 minutes). To test this I extracted the 
time constant by fitting the voltage step (exponential) and used this to calculate 
cellular capacitance using the following equation: 
              ( ) =                  (   )               ( )
As well as the rapid increase in input resistance, by 5 minutes the time constant 
was reduced to 77.0 ± 3.2 % of that at 0 minutes (n = 4, Fig 4.6A). This change 
in time constant reflected a change in whole-cell capacitance (by 5 minutes 
the capacitance was reduced to 53.0 ± 5.4 % of that at 0 minutes (n = 4, Fig 
4.6A). I considered whether this rapid change to whole-cell resistance and 
capacitance could be due to aggregation of the NFRAG tau in the soma impeding 
current flow.  
To test this possibility further, I performed a subset of experiments where two 
simultaneous whole-cell patch clamp recordings were made to the same CA1 
pyramidal neuron (Fig 4.6B). In turn I injected a 200 pA hyperpolarising (1s) 
step via one of the pipettes and recorded the voltage response in both of the 
pipettes. (Fig 4.6C). As the current needs to flow to the ‘recording only’ pipette, 
the voltage response was always slightly smaller than the response at the 
‘inject and record’ pipette as some of the current is lost. In cells where both 
pipettes were filled with vehicle, there was no change to the relative size of 
responses (Vrec/Vrec+inject) between 0 mins (whole-cell breakthrough) and 5 
mins (the relative response was 97.0 ± 1.7 % of the response at 0 minutes, p 
= 0.148, n = 8, Fig 4.6D). However, when 444 nM of NFRAG tau was introduced 
in the ‘inject and record pipette’, the same large rapid increase in input 
resistance (as in Fig 4.6A) was observed. This was not reflected in an increase 
in the voltage step as measured by the second ‘recording only’ pipette with, in 
fact, the response becoming considerably smaller (Fig 4.6 E, F). Thus, the ratio 
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of the responses would be expected to change. At 5 minutes the relative 
response was 58.4 ± 7.0 % of the response at 0 minutes, p = 0.008, n = 8, Fig 
4.6 E, F).  
A non-parametric two-way ANOVA was also used to evaluate whether the 
resistance change was dependent solely on the treatment condition, on the 
timescale of recording, or a combination of both. A significant effect of time (p 
= 0.049) and condition (vehicle or NFRAG, p < 0.0001) were observed to 
contribute to the change in resistance. Thus, confirming that for this 
concentration of introduced NFRAG aggregates, they must be accumulating 
around the introduction site, impeding the flow of current between the two 
pipettes, resulting in an ‘artificial’ increase in input resistance and decrease in 
the observed capacitance due to the cell appearing electrotonically smaller.  
Figure 4.6: Rapid increase in input resistance mediated by 444 nM NFRAG 
aggregates is due to aggregation around the site of introduction impeding 
current flow. 
A) Representative examples of rheobase and SIV protocols at 0 mins (whole-cell 
breakthrough) and after 5 mins, demonstrating a rapid, large increase in input 
resistance and reduction in spike amplitude. B) Bright-field image of a CA1 neuron in 
the hippocampus with two patch pipettes recording simultaneously at the soma. C) 
Schematic of the stimulation protocol used. A 200 pA hyperpolarising current step 
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was given to Ch0 or Ch1 in turn and the voltage response was recorded in both 
channels (Ch0 or Ch1). D) Representative example where both pipettes were filled 
with vehicle, and where there was no change to the relative size of responses 
between 0 mins (whole-cell breakthrough) and 5 mins. E) Representative example 
when 444 nM NFRAG was introduced via the ‘inject and record pipette’; the same rapid 
increase in input resistance (as in A) was observed. This is not reflected in an increase 
in the voltage step as measured by the second ‘recording only’ pipette, thus 
suggesting that the aggregates are impeding current flow between the pipettes. F) 
Mean and SEM data for control (n = 8) and 444 nM NFRAG recordings (n=8). A clear 
reduction in the ratio of voltage of the ‘record’ pipette compared to the ‘inject and 
record’ pipette (where tau was introduced) can be observed.  
4.2.6 At lower concentrations NFRAG selectively changes the action 
potential waveform, an effect independent of the structural form 
In my original study with full length tau (Hill et al., 2019; Chapter 3), the 
increase in input resistance and changes to action potential waveform 
occurred at much later time points than the 5 minutes into the recording I 
observed with NFRAG. Thus, to examine the effects of NFRAG in more detail I 
used a lower concentration of NFRAG tau (133 nM).  There was no NFRAG tau-
mediated change in RMP (at 40 mins, the RMP was 99.0 ± 1.0 % of that at 
time 0, p = 0.961, n = 12, Fig 4.7A) or input resistance (at 40 mins, the peak 
input resistance, measured from the voltage response to step current injection, 
was 102.0 ± 7.7 % of that at time 0, p = 0.953, Fig 4.7B). There was also no 
significant change in firing rate (at 40 mins, the firing rate, measured from the 
voltage response to naturalistic current injection, was 107.0 ± 13.6 % of that at 
time 0, p = 0.747, Figure 4.7C) or rheobase current (at 40 mins, the rheobase 
was 127.0 ± 11.9 % of that at time 0, p = 0.129, Fig 4.7D). However, the 
changes to action potential waveform (increased width and decreased 
amplitude) that were observed both in my original study (Hill et al, 2019; 
Chapter 3) and with the full-length tau in this Chapter were also observed with 
133 nM NFRAG. Action potential amplitude at 40 minutes was significantly 
reduced to 76.0 ± 2.9 % of that at time 0 minutes (p = 0.001, Fig 4.7 E, F) and 
action potential width at 40 minutes was significantly increased to 118.0 ± 7.4 
% of that at time 0 minutes (p = 0.019, Fig 4.7 E, G). This was unexpected as 
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the N-terminal fragment will form structurally different aggregates to FL tau. I 
therefore wondered whether the effects on action potential waveform were 
independent of structure and related directly to the N-terminal sequence 
(amino acids 1-123).  
As an initial test I repeated the same experiments with the monomeric version 
of the NFRAG. There was no NFRAG monomeric tau-mediated change in RMP (at 
40 mins, the RMP was 104.0 ± 2.4 % of that at time 0, p = 0.094, n = 12, Fig 
4.7A) or input resistance (at 40 mins, the peak input resistance, measured from 
the voltage response to step current injection, was 102.0 ± 4.1 % of that at 
time 0, p = 0.940, Fig 4.7B). There was also no significant change in firing rate 
(at 40 mins, the firing rate, measured from the voltage response to naturalistic 
current injection, was 106.0 ± 10.5 % of that at time 0, p = 0.507, Fig 4.7C) or 
rheobase current (at 40 mins, the rheobase was 116.0 ± 10.1 % of that at time 
0, p = 0.240, Fig 4.7D). However, a comparable change to action potential 
waveform was observed with monomeric forms of NFRAG. Action potential 
amplitude at 40 minutes was significantly reduced to 82.0 ± 2.6 % of that at 
time 0 minutes (p = 0.001, Fig 4.7E, F) and action potential width at 40 minutes 
was significantly increased to 123.0 ± 2.0 % of that at time 0 minutes (p = 
0.030, Fig 4.7E, G). 
Given that the oTau-induced changes to action potential waveform (reduced 
amplitude, increased width and increased rate or rise and decay) that occur 
with full length tau (Hill et al., 2019) also occurred with the N-terminal fragment 
(NFRAG), both as a monomer and an oligomer, it is likely that there is a region 
in that 1-123 amino acid region that is directly interacting with an intracellular 
component or process, rather than being an effect due to the structure. Given 
that for NFRAG both the rise and decay of action potentials are slower and for 
CFRAG that the spike initiation threshold is also shifted, making the cells more 
excitable, I next decided to use FL oTau look at whether either of these 
changes were mediated by interactions with voltage-gated sodium channels. 
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Figure 4.7: The effects of FL-oTau on action potential waveform are 
maintained by NFRAG aggregates and monomers. 
(A) Graph showing that there is no change to the resting membrane potential over the 
period of recording for any of the conditions. (B) Graph showing that there is no 
change to the input resistance over the period of recording for 133 nM NFRAG
aggregates or monomers, whereas FL oTau increased input resistance (C) Graph 
showing that there is no change to firing rate over the period of recording for 133 nM 
NFRAG aggregates or monomers, whereas FL oTau increased excitability (D) Graph 
showing that there is no change to the rheobase current over the period of recording 
for 133 nM NFRAG aggregates or monomers, whereas FL-oTau reduced it (E) 
Representative examples of action potential waveforms for an individual neuron with 
one of the three conditions introduced (444 nM FL-oTau, 133 nM NFRAG aggregates 
or monomers). A comparable effect on action potential height and width is observed. 
(F) Graph showing that there is a comparable change to action potential amplitude 
over the period of recording for 133 nM NFRAG aggregates or monomers and FL-oTau. 
(G) Graph showing that there is a comparable change to action potential width over 
the period of recording for 133 nM NFRAG aggregates or monomers and FL-oTau. Pale 
dashed red lines demonstrate the effects of FL-oTau for comparison (from data 
presented in Figure 4.3) Action potential (AP), Firing rate (FR), Input resistance (IR), 
Resting membrane potential (RMP) 
4.2.7 Oligomeric tau alters reduces Na+ channel half activation 
voltage and slows the rate of activation 
Recording sodium channel currents in hippocampal neurons in acute brain 
slices is difficult as there are considerable problems with space clamp due to 
their size and the large amplitude and speed of the currents. One way to 
effectively clamp the currents is to electrotonically isolate the soma. To do this 
I followed the protocol outlined in Milescu et al., (2010), using a short 
depolarising pre-pulse to inactivate the axonal sodium channels, leaving only 
the somatic channels able to be activated. Sodium channel current amplitude 
was also reduced (by increasing intracellular Na+ concentration) and 
recordings were carried out at room temperature to slow the currents (see 
Methods for details).  It was then possible to achieve reasonable voltage clamp 
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(Fig 4.8A). Steps from -60 mV by 5 mV to 60 mV were used to evoke sodium 
channel currents.  
Conductance was calculated using the following equation: 
            ( ) =         ( )/(      −          )
Conductance was plotted against voltage and a Boltzmann fit was applied. The 
fit (Fig 4.8B, C) can be used to extract the half activation and the rate of 
activation constant. The half activation was stable in control recordings. At 20 
mins, the half activation was 98.0 ± 1.0 % of that at time 0, p = 0.203, Fig 4.8B, 
D). In contrast, in cells that had 444 nM FL tau oligomers introduced, by 20 
minutes the half activation had shifted significantly to be more negative 
(activate earlier, reflective of an increase in excitability). At 20 minutes, the half 
activation was 150.0 ± 11.7 % of that at time 0, activating at ~4 mV earlier (p 
= 0.008, Fig 4.8C, D). This could explain the change in spike threshold that I 
observed. I also extracted the rate constant of activation (indicative of the rate 
of rise in conductance relative to change in voltage). The time constant was 
stable in control recordings: at 20 mins, it was 101.0 ± 3.6 % of that at time 0 
(p = 0.938, Fig 4.8B, E), whereas in tau cells, by 20 minutes the time constant 
had increased significantly (flatter slope, reflective of slower channel 
activation). At 20 minutes, the rate of activation constant was 171.0 ± 15.4 % 
of that at time 0 (p = 0.008, Fig 4.8C, E). This could explain the slowing of the 
action potential rise observed in (Hill et al., 2019) and in this study.  
I then implemented a simplified model of the neuronal action potential (AP) 
with general applicability (Hodgkin and Huxley, 1952) to evaluate whether the 
conductance changes mediated by FL-oTau could feasibly underlie the 
changes that I observed in AP waveform. My experimental voltage gated 
sodium current recordings showed that FL-oTau mediates a reduction of ḡ  
to by two thirds of the value at 0 minutes after 20 minutes (Fig. 4.8F-I). 
Therefore, I first simulated an AP with ḡ   = 120   /  
  (Hodgkin and 
Huxley, 1952, Figure 4.8J, red) and then again with  ḡ   = 40   /  
  (Figure 
56J, red trace). I found that this reduction in ḡ   matches the experimental 
phenotype well (the changes in AP amplitude and speed of rise to threshold; 
Figure 4.8K).  
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Figure 4.8: Tau directly modifies somatic sodium currents in CA1 neurons, 
recorded using whole-cell voltage clamp in acute slices. 
A) Example of the recording protocol (adapted from Milescu et al, 2010). A pre-pulse 
step of 5 ms from the holding value of -80 mV to -40 mV elicits a current response 
from axonal (but not somatic) Na+ channels. A brief step to -55 mV (1 ms) follows 
before the step used to evoke the controlled sodium channel current (15 ms). The 
steps were given on consecutive sweeps from -60 V to + 60 mV with a 2 s gap 
between each sweep. Leak currents were subtracted with the P/N protocol (1/4) and 
the junction potential (+ 8 mV) was corrected for. B) Conductance was calculated 
using the following equation: conductance (g) = current (I)/ (Vstep –Vreversal). The 
conductance in response to steps up to 0 mV is plotted as a mean (and SEM) of all 
control cells (n=7). C) The conductance in response to steps up to 0 mV is plotted as 
a mean (and SEM) of all tau introduced cells (n=7). For B and C, the grey line is 0 
mins and the red 20 mins. A Boltzmann fit allows half activation voltage and the time 
constant (measure of the speed of activation). D) Mean change from 0 mins to 20 
mins for control and tau cells in half activation; data is given relative to the value at 
time 0. Mean and SEM are shown, and individual data points are overlaid on top. 
While control cells are stable over 20 mins, tau introduced cells see a significant 
decrease in half activation (activate at lower voltages; increase in excitability), but 
they also see a doubling of the time constant (reflecting a much slower activation – 
fitting with the slower rise time of action potentials observed in Chapter 3 (and Hill et 
al, (2019) and Chapter 3. D) Change in half activation, relative to the value at time 0. 
Mean and SEM are shown, and individual data points are overlaid on top. While 
control cells are stable over 20 mins, FL-oTau introduced cells see a significant 
decrease in half activation (activate at lower voltages; increase in excitability). I also 
see a doubling of the rate constant of activation (E). F, G) Representative example 
current sodium current recordings for control and FL-oTau at 0 mins and 20 mins 
demonstrating the reduction in peak current induced by FL oTau. H, I) Raw 
conductance data (averaged) for control (H) and FL-oTau (I) to highlight the reduction 
in maximal conductance for FL-oTau after 20 mins. Inset demonstrates the crossover 
at low voltages, where FL oTau at 20 mins has higher conductance, despite the 
maximal conductance being reduced at higher voltages. J) Implementing a simple 
Hodgkin Huxley model of action potential dynamics to predict the effect of reducing 
the maximal sodium conductance by 2/3 (as measured experimentally (I)). The 
simulated reduction in current amplitude and rise to threshold appears to match the 
experimental phenotype for FL-oTau (K). 
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4.3 Conclusion 
I have used two fragments of tau to dissect the actions of full length (FL) tau 
oligomers on neuronal properties (Chapter 3; Hill et al., 2019), and have 
started to define the underlying mechanisms. Two different truncated forms of 
tau oligomers were introduced into CA1 hippocampal neurons via the patch 
pipette during whole cell recording. I found that both labelled (Hill et al 2019; 
Chapter 3) and unlabelled FL tau oligomers had very similar effects: they both 
increased input resistance, increased excitability, increased action potential 
width and reduced action potential amplitude. When the first 123 amino acids 
of tau were removed (124-444, termed CFRAG) only the effects on excitability 
remained. If the first 123 amino acid fragment was introduced into neurons (1-
123, NFRAG), then depending on the concentration, there were changes to input 
resistance and action potential waveform. This work has shown that by 
modifying the tau molecule it is possible to dissect apart the multiple effects it 
has on neuronal function. Using truncations of tau as a tool to establish the 
pathological mechanisms of action will enhance the understanding of tau 
pathology and could lead to the discovery of new therapeutic targets and 
opportunities.  
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5. Chapter 5:  
5.Alpha-synuclein aggregates increase the 
conductance of substantia nigra dopamine 
neurons, an effect partly reversed by the 
KATP channel inhibitor glibenclamide.  
This chapter has been in part published previously: (Hill et al., 2021)
Figure 5.1 – Alpha synuclein aggregates induce a change in whole cell 
conductance and neuronal excitability via KATP channel activation 
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5.1 Introduction  
Dopaminergic neurons (DNs) in the substantia nigra pars compacta (SNpc) 
form a key part of the basal ganglia circuitry and play important roles in 
modulating movement, emotion, arousal, and reward behaviour (Barter, 2015; 
Berker and Rutledge, 2014; Lavezzi et al., 2020; Pierce and Péron, 2020). 
They have large branches of projections, fire action potentials at rest (tonic 
pacemaker firing) and require large amounts of ATP to maintain function. This 
makes them particularly sensitive to damage from oxidative stress, which can 
lead to mitochondrial dysfunction (Muñoz et al., 2012). This vulnerability 
makes them amongst the most susceptible neurons to degeneration in 
Parkinson’s disease (PD; Damier et al., 1999; Michel et al., 2014). DNs are 
lost over the progression of PD, primarily from the SNpc in the early stages, 
but later in the disease are also lost from the ventral tegmental area (VTA). 
When DNs degenerate in PD, it often leads to reduced control of movement 
(akinesia, bradykinesia) and the development of a resting tremor.  
Alpha synuclein (αSyn) is a small, native intracellular protein. It is found 
primarily at presynaptic terminals where it contributes to neurotransmitter 
uptake and vesicle recycling (Figure 1.13; Iwai et al., 1995). Alpha synuclein 
is intrinsically disordered but becomes ordered upon aggregation (Alderson 
and Markley, 2013). This triggers the beginning of its pathological cascade 
from monomers through to Lewy bodies, of which soluble oligomers are 
believed to be amongst the most toxic of the intermediates (Burré et al., 2010; 
Jakes et al., 1994; Lashuel et al., 2013; Murphy et al., 2000). Alpha synuclein 
(αSyn), specifically in an oligomeric conformation, has a well-established role 
as a major pathological species in PD, with its deposition in Lewy bodies 
closely correlated with disease progression. However, there is currently very 
little quantitative information about the mechanisms underlying the 
pathological actions of αSyn on neuronal function. Understanding these early 
changes could provide insights into how treatments can be better targeted for 
PD. 
In this study, I have used a combination of whole-cell patch-clamp recording 
and computational modelling to provide a detailed characterisation of the early 
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electrophysiological effects of acutely introducing oligomeric αSyn into single 
DNs in the SNpc. The same method of introducing the alpha synuclein 
oligomers as outlined in Chapters 3 and 4 was implemented (delivery through 
the patch pipette during whole-cell patch clamp recording). Thus, it has the 
same major advantages: no compensation within the circuit, removal of any 
slow uptake steps, control over the structure and concentration of the 
introduced oligomers, and each cell acts as its own internal control (at time 
zero after whole-cell breakthrough). By using a combination of standard and 
dynamic-IV protocols (Badel et al., 2008b, 2008a; Harrison et al., 2015), I have 
parameterised dopaminergic neurons and the effects of acute oligomeric αSyn 
exposure.  
5.2 Results 
5.2.1 Characterising dopaminergic neurons in the substantia nigra 
Putative dopaminergic neurons (DNs) in the substantia nigra pars compacta 
(SNpc) were recorded from using whole-cell patch clamp. Neurons were 
identified initially by their morphology and position in the slice and were further 
confirmed to be dopaminergic by their characteristic electrophysiological 
profile including: their sensitivity to dopamine, display of pacemaker firing and 
a large hyperpolarising (IH) current, as well as rebound firing in response to the 
injection of hyperpolarising current steps (Grace and Onn, 1989; Krashia et al., 
2017; Richards et al., 1997; Fig 5.2). All recorded DNs were sensitive to 
dopamine (Figure 5.2A). Dopamine binds to D2 auto-receptors and prevents 
further release of dopamine via hyperpolarisation of the membrane potential 
and thus a decrease in firing rate and excitability (Mercuri et al., 1997; Silva 
and Bunney, 1988). This occurs via activation of a GIRK conductance (Cathala 
and Paupardin-Tritsch, 1999; Lacey et al., 1987). The application of 30 µM 
dopamine inducing a hyperpolarisation of the membrane potential by 7.4 ± 1.2 
mV (n = 49; data not shown). Standard step and dynamic current injections 
were used to assess electrophysiological; properties of putative DNs (Figure 
5.2B).  
Most of the recorded DNs displayed spontaneous pacemaker firing (36 out of 
49 neurons, 73 %, mean firing rate of 1.1 ± 0.1 Hz) which was abolished after 
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application of 30 µM dopamine, as is characteristic for DNs in the SNpc (Figure 
5.2A; Grace and Onn, 1989; Lacey et al., 1989). In DNs, in response to the 
injection of negative current steps, a characteristic large sag can be observed 
(Neuhoff et al., 2002) and, following termination of the hyperpolarising step, 
rebound firing was observed in 33 out of 49 neurons (68 %) which are both 
characteristic of the presence of large IH currents in DNs (Figure 5.2C). In 
response to the application of 30 µM dopamine, rebound firing was abolished 
and the voltage response to the injection of hyperpolarising current steps was 
reduced, reflecting an increase in whole-cell conductance (Figure 5.2D). 
Dopamine application also reduced the firing rate in response to positive 
current injection for both the current step (SIV) and naturalistic (DIV) protocols 
(firing rate reduced to 62.7 ± 0.2 % of that in control). Both the sag response 
and rebound firing could be abolished by applying 100 µM ZD7288, a 
pharmacological inhibitor of IH in dopamine neurons (Figure 5.2E; Harris and 
Constanti, 1995; n=6), confirming that they were IH-mediated. Finally, to 
confirm that the location of recording was being identified correctly, for a subset 
of neurons, immunohistochemistry was used to further confirm that the 
recorded neurons were dopaminergic (n = 9). Neurons were filled with AF594 
(red) via the patch pipette and then immunohistochemistry was used to show 
co-localisation with tyrosine hydroxylase (TH; Figure 5.2F). All of the filled 
neurons (n=9) correctly co-localised with TH.  
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Figure 5.2: Whole-cell patch clamp of dopaminergic neurons in the SNpc, 
characterised by electrophysiology and immunohistochemistry. 
(A) A representative membrane potential trace recorded from a putative dopaminergic 
neuron (DN) in the substantia nigra pars compacta (SNpc) which showed 
characteristic spontaneous pacemaker action potential firing. Application of dopamine 
hyperpolarised the neuron from -62 mV to -70 mV and also completely abolished the 
tonic firing. (B) The different input currents delivered to putative DNs. The standard 
IV (SIV) is the standard step current protocol, 3 s steps are given, starting at -200 pA 
and increasing by 50 pA until the neuron exhibits a regular firing pattern. The dynamic 
IV (DIV) protocol uses a fluctuating naturalistic noisy current trace (see Methods for 
more details) to elicit a more ‘natural’ action potential response and can be used to 
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give a more accurate measure of the firing rate (C) (Top) Representative membrane 
potential traces in response to injected current steps. The recorded neuron displays 
characteristic features of DNs: a large sag current in response to hyperpolarising 
steps (arrow) and rebound firing (*). (Bottom) The recorded membrane potential trace 
from the same cell in response to naturalistic current injection. The neuron can be 
seen to be firing at rest (*) which is also a characteristic feature.  (D) (Top) 
Representative membrane potential traces in response to current steps following 
application of dopamine (30 µM). The sag current is reduced, the membrane potential 
hyperpolarised, the firing rate (excitability) reduced, and the rebound firing is now 
absent. (Bottom) Membrane potential trace from the same cell in response to the 
naturalistic current in dopamine (30 µM). The neuron has stopped tonic firing, fires 
less frequently during current application and is hyperpolarised. (E) (Top) 
Representative membrane potential traces in response to current steps in the 
presence of the IH blocker ZD7288 (100 µM). The sag current is markedly reduced, 
the membrane potential is hyperpolarised, the firing rate reduced and the voltage 
response following the spike is altered, in line with previous studies (Harris and 
Constanti, 1995). (Bottom) The recorded membrane potential trace from the same 
cell in response to the naturalistic injected current in ZD7288 (100 µM). (F) Tyrosine 
hydroxylase immunohistochemistry confirms that the recorded neurons were DNs. 
Neurons were filled with AF594 dye (red) via the patch pipette and then slices were 
stained for tyrosine hydroxylase (TH; green). The merged image shows that the 
recorded neurons express TH and are therefore dopaminergic. The scale bar is 50 
µm.  
5.2.2 Characterising the structure of the alpha synuclein oligomers 
using transmission electron microscopy 
Recombinant alpha synuclein aggregates, in the form of pre-formed fibrils 
(PFFs) were purchased from Abcam (ab218819) along with the monomeric 
form (ab218818). Negative-stain transmission electron microscopy (TEM) was 
used to confirm that the structure of the alpha synuclein samples were PFFs 
and monomers, respectively (Fig 5.3). Tau oligomers produced for Chapter 4 
were analysed alongside the alpha synuclein for comparison (Fig 5.3A).  
The aggregated alpha synuclein samples initially presented as small fibrils, as 
expected (Fig 5.3B). These fibrils would be too large to perfuse out of the end 
of the patch pipette and so were broken down into oligomeric form. To do this, 
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I added the PFFs to the filtered intracellular solution and sonicated them for 15 
mins (50-60 Hz) in an ultrasonic bath (Polinski et al., 2018) to break them down 
to oligomers. I confirmed that this sonication successfully resulted in the 
breakdown from fibril form to oligomers (Fig 5.3C). Following sonication, the 
samples were kept on ice to ensure they remained as oligomers for the 
duration of the experiments (all performed within 3 hours of the initial 
sonication). TEM confirmed that they remained in the oligomeric form on ice 
for this period of 3 hours (not shown). Although the vast majority of the alpha 
synuclein species in the sample appeared oligomeric, I cannot rule out the 
possibility that there may be a small amount of other species present (for 
example small ~50 nm fibrils; Polinski et al., 2018) for this reason I have 
chosen to refer to the species as aggregates. The monomeric alpha synuclein 
samples displayed no signs of aggregation (Fig 5.3D).  
Figure 5.3: Structural analysis of alpha synuclein samples using negative-
stain transmission electron microscopy. 
Negative-stain-TEM of protein samples to confirm the structure of the purchased 
alpha synuclein. A) Tau oligomers (recombinant, from Chapter 3) for comparison of 
oligomeric form. B) Alpha synuclein aggregates as purchased from Abcam as pre-
formed fibrils (PFFs). C) PFFs were sonicated for 15 mins (50-60 Hz) in an ultrasonic 
bath (Polinski et al, 2018; Dave et al, 2018) to reduce them to oligomers. This change 
in form can be observed by the small oligomer-like appearance. D) Monomeric alpha 
synuclein sample also purchased from Abcam show no aggregation. Scale bars = 200 
nm, insets: higher magnification scale bar = 20 nm 
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5.2.3 Alpha-synuclein aggregates, but not monomers, alter the 
electrophysiological properties of SN dopaminergic neurons. 
Monomeric or aggregated alpha synuclein samples (500 nM) were introduced 
into DNs and the effects on neuronal function explored over a 32-minute 
timeframe. This concentration was selected as it matches the concentration 
used in a previous alpha synuclein study conducted in the Wall lab (Kaufmann 
et al., 2016). This concentration was calculated from the monomeric molecular 
weight of alpha synuclein as it is not possible to know the exact number of 
monomers of alpha synuclein in each of the aggregates following sonication. 
This will therefore mean that the reported value is an overestimate of the actual 
oligomeric concentration in the patch solution (see Methods for more details). 
The alpha synuclein species were delivered via the patch pipette into single 
DNs in the SNpc of mice, and whole-cell patch clamp recordings were used to 
assess changes to electrophysiological properties. Both SIV and DIV current 
protocols were run at 8-minute intervals (for up to 32 minutes) and the voltage 
response to current input recorded. From this changes to input resistance, 
firing rate and resting membrane potential were evaluated. As a control, in a 
subset of neurons (termed vehicle), the same volume (2 µl) of PBS was added 
to the intracellular solution (200 µl) to ensure the effects were not due to 
dilution of the patch solution, although this is unlikely given the small volume 
added. At least one control recording was made at the start of each day to 
ensure the quality of the slices and then recordings with either vehicle, alpha 
synuclein monomers or alpha synuclein aggregates were interleaved to ensure 
that there was no recording bias.  
Using this technique, the cell can act as its own internal control, which is a 
major advantage. Upon whole-cell breakthrough, there would be little or no 
time for the alpha synuclein aggregates to dialyse into the cell, therefore 
recordings taken immediately (time 0) are effectively ‘control’ cells. Therefore, 
the recordings at time 0 for all conditions should not be statistically significantly 
different from each other. As expected, there was no significant difference in 
the measured parameters from SIVs (membrane potential p = 0.466, input 
resistance p = 0.275 and firing rate p = 0.851, Table 5.1) between neurons that 
had received either vehicle, alpha synuclein monomers or aggregates. 
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Table 5.1: Electrophysiological parameters measured for dopaminergic neurons at time zero (whole-cell breakthrough) for all 
experimental treatments.
All recordings are made from substantia nigra pars compacta dopaminergic neurons. There was no significant difference between any of the 
measured parameters at time 0 minutes (whole-cell breakthrough), using Kruskal Wallis ANOVAs. Data shown as mean, SD and SEM for each 
experimental condition.  
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There were significant changes highlighted by the SIV traces over time (0 to 
32 mins) for neurons where alpha synuclein aggregates were introduced via 
the patch pipette. After 32 mins of recording, the input resistance was 
significantly reduced to 63.0 ± 9.2 % of the input resistance measured at 0 
mins (p = 0.003, n = 11; Fig 5.4A), reflecting the opening of a membrane 
channel. There was no change to the input resistance in either vehicle 
recordings (at 32 mins input resistance was 94.0 ± 5.0% of input resistance 
measured at time 0 mins, P = 0.065, n = 10, 6 animals, Fig 5.4B) or neurons 
with alpha synuclein monomers introduced (at 32 mins input resistance was 
99.0 ± 9.0 % of input resistance measured at time 0 mins, p = 0.469, n = 6, 3 
animals, Fig 5.4C). Comparing the three conditions (monomers, aggregates, 
and vehicle) using a Kruskal Wallis ANOVA, showed a significant difference in 
input resistance at 32 minutes (p = 0.0002; n = 6, 10, 11 respectively, Fig 
5.4D). The change in input resistance between control and aggregated αSyn 
neurons first became significant at the 16-minute time point (p = 0.001; Fig 
5.4D) suggesting that the opening of membrane channels occurred between 8 
to 16 minutes after αSyn aggregate introduction into neurons.  
The resting membrane potential at time 0 (whole-cell breakthrough) for all 
conditions was around -55 mV (see Table 5.1). Over the period of recording, 
neurons slowly depolarised by a small amount (Fig 5.4E). For vehicle, the 
mean depolarisation (ΔVm) was 6.2 ± 1.8 mV after 32 minutes of recording (P 
= 0.023, n = 10), for αSyn monomers ΔVm was 3.8 ± 1.2 mV (p = 0.094, n = 
6) and for αSyn aggregates ΔVm was 6.8 ± 1.9 mV (p = 0.011, n = 11). This 
slight depolarisation was comparable between conditions and there was no 
significant difference over the period of recording between the membrane 
potential of the control neurons (vehicle and monomers) and neurons with 
αSyn aggregates introduced (p = 0.931).  
Firing rate (FR) was measured from the voltage response to the naturalistic 
current injection and was used as a measure of neuronal excitability. For 
control neurons (vehicle), despite the slight depolarisation, there was no 
significant (p = 0.190) change in the firing rate (at 32 mins the FR was 124.7 ± 
1.3 % of the FR at time 0 mins, n = 10, Fig 5.4F, G). There was also no 
significant change (p > 0.9999) in FR for neurons in which monomeric αSyn 
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was introduced (at 32 mins the FR was 120.4 ± 2.4 % of the FR at time 0 mins, 
n = 6, Fig 5.4F, G). Whereas, for the neurons that had αSyn aggregates 
introduced, there was a significant (p = 0.002) reduction in the firing rate (at 32 
mins the FR was 42.3 ± 9.3 % of the FR at time 0 mins, n = 11, Fig 5.4F, G).  
When comparing control (vehicle and monomeric αSyn introduced cells) with 
cells that received αSyn aggregates, there was a significant difference in the 
firing rate at 32 minutes (p = 0.013). This fall in firing rate induced by αSyn 
aggregates is consistent with the marked reduction in input resistance.  
The introduction of alpha-synuclein aggregates also affected some of the 
characteristic features of dopaminergic neurons including tonic and rebound 
firing. Tonic firing was reduced by αSyn aggregates with 64 % of neurons 
(7/11) initially being spontaneously active but after 32 minutes only 27 % (3/11) 
of neurons were still active. This is in comparison to control (vehicle) neurons, 
where 80 % (8/10) initially displayed tonic firing, with 60 % (6/10) still active 
after 32 minutes of recording. The occurrence of rebound firing (following the 
termination of the hyperpolarising step) also reduced with αSyn aggregates 
227 % of neurons (8/11) showed rebound firing at 0 mins, but only 18 % (2/11) 
still showed it after 32 minutes of recording).  In contrast, all the control neurons 
that initially displayed rebound firing (60 %, (6/10)) still showed rebound firing 
after 32 minutes of recording.   
182 
Figure 5.4: Alpha synuclein oligomers induce a time-dependent decline in firing 
rate and input resistance. 
(A-C) Representative current-voltage relationship (SIV) traces for an example neuron 
injected with either alpha synuclein aggregates (A), vehicle (B) or alpha synuclein 
monomers (C). Current steps (1 s, starting at -200 pA and rising by 50 or 100 pA) 
were injected until a regular firing pattern was induced. The voltage traces are at time 
points at 8-minute intervals starting from whole-cell breakthrough (0 mins to 32 mins). 
(A) With 500 nM aggregated αSyn, a decrease in input resistance and firing rate 
(during positive current steps) can be observed over the 32 minutes of recording. (B) 
Control cells are stable throughout the period of recording. (C) With 500 nM 
monomeric αSyn, cells were also stable throughout the recording. (D) Mean input 
resistance plotted against time for control (vehicle), alpha synuclein monomers or 
aggregates. Alpha synuclein aggregates induced a clear reduction in input resistance 
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that was not observed in the control cells or those with alpha synuclein monomers 
introduced. (E) Mean resting membrane potential plotted against time for control 
(vehicle), alpha synuclein monomers or aggregates. For all three conditions, the cells 
slowly depolarised by comparable amounts over the 40 minutes of recording. (F) 
Firing rate was the only parameter that I used the voltage response to naturalistic 
current injection to measure (see Methods for details). Due to the variability in firing 
rate between cells, firing rate was normalised to the firing rate at time 0 mins. Despite 
being depolarised by a comparable amount to the control and monomer-introduced 
cells (a corresponding increase in firing rate would be expected), alpha synuclein 
aggregates induced a marked reduction in firing rate that was not observed in the 
control cells. This is consistent with the fall in input resistance. (G) A section of the 
voltage response to naturalistic current injection (NT) for a representative example of 
a control (vehicle), alpha synuclein monomer and alpha synuclein aggregates cell at 
0 mins and 32 mins. Though the firing rate of control and monomer-introduced cells 
are stable over time, the neuron with alpha synuclein aggregates introduced exhibits 
a significant reduction in firing rate over time.  
5.2.4 The decrease in conductance and firing rate caused by alpha 
synuclein is in part due to the opening of KATP channels 
ATP-sensitive potassium channels (KATP) have well established roles in 
dopaminergic neurons. Previous studies have shown that in rodent models of 
PD, neurodegenerative effects can be at least partially rescued by either 
blocking them or deleting them genetically (Liss et al., 2005). A pre-print 
(Thakur et al., 2019) reported that alpha synuclein aggregates may act to open 
KATP channels within dopamine neurons and that by preventing this opening, 
the aggregated αSyn-mediated effects on tonic firing that they describe 
(reduction) can be prevented.  
In my study, I have shown an aggregated αSyn-mediated increase in whole-
cell conductance, indicative of the opening of a membrane channel. I therefore 
wanted to investigate whether this could be a KATP channel. I repeated the 
same set of experiments (as outlined above) following pre-incubation of the 
slices in 1 µM glibenclamide for at least 1 hour. Glibenclamide is a commonly 
used antidiabetic drug and an effective KATP channel blocker (Jiang and 
Haddad, 1997; Light and French, 1994). Initially, I first checked whether there 
were any changes to the electrophysiological properties of the SNpc DNs 
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produced by glibenclamide itself. I did this by comparing control cells from 
slices that were either preincubated or not preincubated with 1 M 
glibenclamide for at least 1 hour. At 0 mins (whole-cell breakthrough), there 
was no significant difference between control cells from slices in normal aCSF 
(n = 6, 3 animals) vs control cells from slices that had been preincubated with 
glibenclamide (n = 6, 5 animals) for any of the parameters that I measured 
from SIVs (membrane potential p = 0.379, input resistance p = 0.229 and firing 
rate p = 0.655, Table 5.1). Over the duration of recording, glibenclamide pre-
incubation did not significantly alter the input resistance (after 32 mins 99.0 ± 
7.5 % of the input resistance at time 0 mins, p = 0.0.845, Fig 5.5A) or the firing 
rate (after 32 mins 112.1 ± 26.6 % of the FR at time 0 mins, p = 0.563, Fig 
5.5A). Thus, preincubation of slices with 1 µM glibenclamide had no significant 
effect and should therefore not occlude any observable effects of the alpha 
synuclein aggregates.  
I then introduced αSyn-aggregates (500 nM) into cells in slices that had been 
preincubated with 1 µM glibenclamide (Fig 5.5B). The fall in input resistance 
and reduction in firing rate that I showed previously to be induced by alpha 
synuclein aggregates was significantly reduced after pre-incubation (Fig 5.5B), 
suggesting that these effects are, at least partly, mediated through KATP
channels. The input resistance at 32 mins was 90.0 ± 8.6 % of that input 
resistance at time 0 mins (compared to 63 % without preincubation with 
glibenclamide) which was not statistically significant (p = 0.250, n = 6) from the 
input resistance at time zero (Fig 5.5C). The firing rate was 80.1 ± 12.9 % of 
the rate at time 0 mins (compared to 42 % without preincubation with 
glibenclamide) which was not statistically significant from the firing rate at time 
zero (p = 0.353, n = 6, Fig 5.5 1E, F). Both sets of recorded neurons (control 
and αSyn aggregates) depolarised over the 32 minutes of recording to a similar 
degree to that of non-glibenclamide-treated slices (vehicle, ΔVm 4.7 ± 2.6 mV 
and αSyn aggregates, ΔVm 5.5 ± 2.1 mV, Fig 5.5D). If these changes to 
electrophysiological properties were solely down to the opening of KATP
channels, the cells would be expected to hyperpolarise (as reported in many 
studies). As I did not observe this, there must be something else happening 
counterbalancing this effect (see Chapter 7).  
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Figure 5.5: The effects of alpha synuclein aggregates on electrophysiological 
properties are partially prevented by pre-incubation of slices with 
glibenclamide. 
(A) Representative current-voltage relationship (SIV) plots for an example control cell 
(injected with PBS as a vehicle) in the presence of glibenclamide 1 M. Current steps 
(starting at -200 pA and rising by 50 pA) were injected until a regular firing pattern was 
induced. Recordings display time points between whole-cell breakthrough (0 mins) 
and 32 mins. Cells are stable throughout the period of recording, with no consistent 
changes to the SIV over time.  (B) as in A), but with alpha synuclein 500 nM 
aggregates (final concentration) added to the intracellular solution. The decrease in 
input resistance and firing rate normally observed with alpha synuclein over the 32 
minutes of recording is reduced in the presence of the glibenclamide (1 M). (C) Mean 
input resistance measurements (measured at the peak deflection; before the sag) 
plotted against time for control (vehicle) vs alpha synuclein aggregates in the 
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presence of glibenclamide (1 M). The fall in input resistance was reduced compared 
to that for alpha synuclein cells in normal aCSF (dashed line). (D) Mean resting 
membrane potential measurements plotted against time for vehicle vs alpha synuclein 
in the presence of glibenclamide 1 M. Both conditions showed a slow, but 
comparable depolarisation over time. (E) Mean firing rate measurements plotted 
against time for vehicle vs alpha synuclein in the presence of glibenclamide 1 µM. 
The drop-in firing rate was reduced compared to that for alpha synuclein aggregate 
introduced into cells in normal aCSF (red dotted line for reference; data repeated from 
Fig 5.4 as a visual reference). Firing rate is normalised to the firing rate at time 0 mins. 
(G) A section of the voltage response to naturalistic current injection (NT) for a 
representative vehicle vs alpha synuclein cell in the presence of glibenclamide 1 µM 
at 0 mins and 32 mins. Under both conditions, the firing rate was stable over time.  
5.3 Conclusion 
I have used a combination of electrophysiological recording with detailed 
analysis to characterise fully the effects of introducing aggregated αSyn 
directly into single mouse dopaminergic neurons in the substantia nigra. 
Aggregates were introduced via the patch electrode during whole-cell patch 
clamp recordings. Aggregated αSyn caused a significant increase in 
conductance and decrease in firing rate without altering the resting membrane 
potential. Changes to conductance and firing rate occurred 8-16 minutes after 
whole-cell breakthrough and were specific to aggregates (they were not 
observed when monomeric alpha synuclein was introduced). The effects could 
be prevented by pre-incubating the slices in ATP-sensitive potassium channel 
(KATP) inhibitor glibenclamide, despite the high concentration of ATP present 
in the patch electrode. These data suggest that by accumulating in DNs, αSyn 
aggregates may chronically open KATP channels leading to a significant 
increase in conductance, loss of neuronal excitability and likely also a 
decrease in dopamine release and overall cell function. 
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6. Chapter 6:  
6.Physiological changes in CO2 modulate 
VTA and substantia nigra neuronal function 
Results of this chapter have been published previously: (Hill et al., 2020a, 
2020b)
Figure 6.1: Physiological changes in the level of CO2 alter neuronal function in 




Dopaminergic neurons (DNs) possess large branches of projections, have 
important roles in the modulation of many behaviours and have therefore been 
extensively studied. They have unique electrophysiological profiles (Fig 5.2) 
and fire at rest (tonic firing), thus making them highly energy intensive. The 
substantia nigra (SN) and the ventral tegmental area (VTA) represent two 
major dopaminergic nuclei in the mammalian brain. The SN forms a key part 
of the basal ganglia circuitry and its dopaminergic neurons play vital roles in 
the initiation and co-ordination of movement. The SN can be further divided 
into two regions, the substantia nigra pars reticular (SNpr) and the substantia 
nigra pars compacta (SNpc). The SNpc is sensitive to damage from oxidative 
stress and its DNs are amongst the most susceptible neurons to degeneration 
in Parkinson’s disease (PD). Neurons in the neighbouring ventral tegmental 
area (VTA) play important roles in the modulation of emotion, reward and 
sleep- wake behaviours (Eban-Rothschild et al., 2016; Holly and Miczek, 2016; 
Lammel et al., 2014; Morales and Margolis, 2017; Yu et al., 2019). They are 
less susceptible to damage in the early stages of PD but do become affected 
at later stages. Important questions remain as to why dopaminergic neurons 
between these two regions are differentially affected and why they display 
varying levels of susceptibility to neurodegeneration. As complex cells, with 
influence on so many aspects of behaviour, it is vital to fully understand their 
physiology, in order to then understand how they might be implicated in 
pathology.  
Carbon dioxide (CO2) is a waste product of cellular metabolism, exhaled by 
the lungs and its levels are a key regulator of breathing. Levels will vary 
between people, but the average in human blood (PCO2) at rest is around 40 
mm Hg and will fluctuate around this baseline. PCO2 is increased 
(hypercapnia) in diseases such chronic obstructive pulmonary disease 
(COPD), asthma and sleep apnoea (Owens and Malhotra, 2010). Low levels 
of blood PCO2 (hypocapnia) can occur in kidney failure, diabetic acidosis and 
with hyperventilation (Brown, 1953; Wilson et al., 1991).  
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A subfamily of connexins (Cx26 and Cx30) have evolved to develop CO2 
sensitivity. The most sensitive of these is Cx26 and its sensitivity is directly 
mediated through the carbamylation of lysine residue 125, resulting in an 
increase in open probability (Huckstepp et al., 2010b, 2010a; Meigh et al., 
2013). Since the physiological midpoint for hemichannel opening is ~ 40 mm 
Hg, there will be some connexin 26 channels open at rest. Increases in CO2 
levels will result in the opening of more Cx26 hemichannels and an increase 
in whole-cell conductance. Whereas a decrease in CO2 level will result in the 
closing of Cx26 hemichannels and a decrease in whole-cell conductance 
(Huckstepp et al., 2010b, 2010a; Meigh et al., 2013). It is well established that 
CO2 binding to connexin 26 on glial cells in the brainstem allows ATP to be 
released and that this regulates breathing (Gourine et al, 2005; Huckstepp et 
al 2010; Weifer et al 2010).  
The discovery of gap junction coupling between dopaminergic neurons in the 
substantia nigra was first described by Grace and Bunney (1983) using 
electrophysiology. They further confirmed the coupling using Lucifer Yellow 
transfer between neighbouring ‘coupled’ cells.  While reading around the vast 
literature on DNs electrophysiological and morphological properties, to assist 
in making the recordings outlined in Chapter 5, I discovered an unexpected 
property of SNpc DNs that I thought might be worth exploring further. 
Vandecasteele et al. (2005) confirmed that pairs of DNs in the SNpc are 
coupled by gap junctions and that they express a range of connexin proteins, 
as determined by single cell RT-PCR (Vandecasteele et al., 2006). They 
demonstrated that in young rodents (P7-10), SNpc DNs express mRNA for 
Cx26, Cx30, Cx32, Cx36 and Cx43 but by P17-21 a developmental switch has 
occurred and they now only express Cx36, Cx43 and Cx31.1 (Fig 6.2). I was 
particularly interested in two of these connexins which have been previously 
described to be directly sensitive to carbon dioxide (CO2): connexin 26 and 
connexin 30 (Huckstepp et al., 2010b; Meigh et al., 2013). I set out to 
determine whether the mRNA profile described by Vandecasteele et al., (2006) 
resulted in functional hemichannel expression which could confer CO2
sensitivity to the neurons. This would be particularly interesting as it would be 
the first discovery in neurons (Nagy et al., 2011). If so, I wanted to explore 
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whether there were functional consequences of the CO2 sensitivity in terms of 
neuronal output, and whether there could be any implications of this in 
pathology.   
Figure 6.2: Connexin mRNA expression analysed by single-cell RT-PCR in SNpc 
DA neurons from P7-10 (left) and from P17-21 (right) rats. 
There is a developmental shift in connexin expression in rodents. This study 
confirmed the presence of Cx26, Cx30, Cx36, Cx32 and Cx43 in the P7-10 rats and 
Cx31.1, Cx36 and Cx43 in P17-21 rats (reproduced from Vandecasteele et al., 2006)
Whole-cell patch clamp recordings were made from dopaminergic neurons 
(DNs) in the SNpc in acute coronal slices from P7-10 wild type mice. To test 
the sensitivity of DNs to CO2, the level of CO2 (35 mm Hg, basal level) was 
either increased to 55 mm Hg or decreased to 20 mm Hg under isohydric 
conditions (compensatory changes in bicarbonate concentration to maintain 
constant extracellular pH during the CO2 stimulus, see Methods). If Cx26 
hemichannels are present, then an increase in PCO2 will cause them to open 
(Huckstepp et al., 2010b; Meigh et al., 2013), resulting in an increase in whole-
cell conductance (decreasing excitability). By contrast, a reduction in PCO2
would close the hemichannels, resulting in a reduction in whole-cell 




6.2.1 Developmental changes to SN DN electrophysiological 
properties  
Dopaminergic neurons in the SNpc were located from their position in the slice 
and their characteristic electrophysiological profile (as in chapter 5). Given that 
mRNA for the CO2 sensitive connexins 26 and 30 was reported to be only 
present in P7-10 pups and absent by P17-21 (Vandecasteele et al., 2006) I 
decided to test neurons for CO2 sensitivity in both age groups, using neurons 
in the older mice as a control group. If the mRNA is no longer present, then 
any phenotype of CO2 sensitivity (that is present in the P7-10 pups) should be 
lost. This comparison between age groups could potentially be complicated by 
developmental changes to electrophysiological properties, which are known to 
occur over this period. Therefore firstly, I compared the input resistance and 
resting membrane potential measurements from SNpc DNs of the two age 
groups without any intervention. There was no significant difference in input 
resistance between the two age groups of mice (P7-10, Rin = 380 ± 28.16 MΩ, 
P17-21, Rin = 290 ± 22.45 MΩ, p = 0.307; Fig 8.3). There was also no 
significant difference in the resting membrane potential (P7-10, RMP = -59.3 ± 
1.33 mV, P17-21, RMP = -60 ± 2.08 mV, p = 0.835; Fig 8.3) or the size of the 
sag response, measured between the peak hyperpolarisation and steady state 
after IH has activated (P7-10: 22.6 ± 2.25 mV, P17-21 20.1 ± 2.3 mV, p = 
0.454). These results are consistent with expected values for these age groups 
of mice as reported in (Dufour et al., 2014).  
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6.2.2 Increase in PCO2 significantly reduces the excitability of early 
postnatal substantia nigra dopaminergic neurons  
Next, I wanted to check whether there were functional hemichannels in the 
SNpc P7-10 DNs and if so, whether they conferred sensitivity to CO2. Whilst 
recording from single dopaminergic neurons, I increased the level of CO2 from 
35 mm Hg to 55 mm Hg (isohydric; constant pH) and recorded the response 
to single hyperpolarising (-50 pA, 100 ms) current step injections. Increasing 
the level of CO2 gave a time-dependent reduction in the amplitude of the 
voltage response to the hyperpolarising current steps consistent with a fall in 
input resistance. At steady state, the voltage response to the current steps had 
fallen to 70.0 ± 9.6 % of control (p = 0.002; Fig 6.3A, B), input resistance had 
fallen from 380.0 ± 28.2 MΩ to 217.0 ± 27.9 MΩ (p = 0.003 n = 10) and the 
tonic action potential firing was abolished (Fig 6.3). All of these effects are 
characteristic of an increase in the resting conductance consistent with the 
opening of hemichannels. I observed partial recovery in a subset of recordings 
when the solution was returned to 35 mmHg (normal CO2). Due to a lack of 
experimental repeats (n = 3), this data was not quantified, but an example 
demonstrating partial recovery is illustrated in Fig 6.3C. DNs in the SN of older 
rats (P17-21) do not express mRNA for CO2 sensitive connexins 
(Vandecasteele et al., 2006) thus they should be insensitive to CO2 if it is 
connexin hemichannel-dependent. When the same protocol was repeated with 
older (P17-21) mice, there were no significant effects of the increased PCO2
(voltage response was 101.0 ± 0.9 % of control, p = 0.330, n = 4, Fig 6.3 D, 
E). 
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Figure 6.3: CO2 sensitivity of dopaminergic neurons in the substantia nigra 
(A) Example of a time course for changes in voltage responses to hyperpolarising 
current steps for a neuron from a P7-10 mouse (each point is a mean of 15 sweeps) 
when CO2 was increased from 35 to 55 mm Hg (red). (B) Associated voltage traces 
(40 superimposed traces) and voltage responses to step currents (from -200 pA to 
50pA) at the indicated time points from A. (C) Representative voltage responses (P7-
10) demonstrating that input resistance and firing rate changes could be partially 
reversed (bottom traces are an average of 25 sweeps) when CO2 was reduced back 
to 35 mmHg. (D) There was no significant change in the voltage response to 
hyperpolarising current steps in a dopaminergic neuron from a P17-21 mouse (each 
point is a mean of 15 sweeps) when CO2 was changed from 35 to 55 mm Hg. (E) 
Associated voltage traces (40 superimposed traces) and voltage responses to step 




diigure 6.4: Example raw data traces for the full timeframe of raised CO2 exposure.
 representative example from a P7-10 substantia nigra dopaminergic neuron. Membrane potential traces in response to -50 pA current 
eps in 35 mmHg CO2 (black), then switched over to 55 mmHg CO2 (red). Each plot represents a timepoint from Figure 6.3B and 
splays 9 overlaid sweeps within each 15 second time interval. A clear reduction in voltage response can be observed over time.  194 
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6.2.3 Changes in excitability are not due to the exchange of 
solutions or drift in recording quality over time  
To confirm that the observed effects of CO2 were not an experimental artefact, 
I repeated the experiment without altering the level of PCO2 but still switched 
between two solutions that were both at 35 mmHg CO2). The resting 
conductance and of the neurons did not significantly alter over the time course 
of the experiment (Fig 6.4), confirming that the observed changes are 
mediated by variation in the PCO2 level rather than from an artefact resulting 
from the mechanical change in solution or from rundown in the quality of 
recordings over time.  
Figure 6.5: A control for solution exchange during the protocol 
(A) Time course of changes in voltage response to a 50 pA hyperpolarising step 
current (P10 SNpc, each point is a mean of 15 sweeps) when CO2 was maintained at 
35 mm Hg, but solutions were exchanged to ensure the observations are not a result 
of the exchange process or loss of recording quality over time (arrow). (B) Associated 
voltage traces (50 superimposed traces) and voltage responses to step currents at 
indicated time points from A. (C) Quantification of the voltage response changes when 
the solution was swapped, relative to the amplitude of the response at breakthrough, 
data is presented as mean ± SEM. Red dashed line represents the relative level of 
decrease in response for cells which were exposed to high CO2 (55 mm Hg) after an 
equal amount of time.  
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6.2.4 Changes in neuronal excitability are blocked by the 
hemichannel inhibitor carbenoxolone  
I had now confirmed that the electrophysiological consequences of altering the 
level of CO2 are not an experimental artefact, but I have not yet proved that 
they are mediated by connexins. The next stage was to confirm the effects 
were hemichannel-mediated using the blocker carbenoxolone (100 µM, n=6; 
Fig 6.5; Meigh et al., 2013). The level of CO2 was raised from 35 mm Hg to 55 
mm Hg CO2 in the presence of carbenoxolone (100 µM; Fig 5.6A). The 
reduction in input resistance was abolished (after 5 mins in 55 mmHg CO2, 
input resistance was 103.0 ± 1.4 % of the value at 0 mins, p = 0.094: Fig 6.5 
B, C). There was also no change in RMP (at 40 mins, RMP was 97.0 ± 2.5 % 
of the value at 0 mins). Due to the wide-ranging effects reported for 
carbenoxolone acting directly on neuronal properties and synaptic 
transmission (Tovar et al., 2009), I did not examine changes to firing rate. The 
significant block of CO2-mediated effects (Fig 6.5) confirms that the effects are 
hemichannel mediated.  
Figure 6.6: Carbenoxolone blocks changes to excitability in P71-10 SNpc DNs 
(A) If slices are incubated in carbenoxolone, there is no significant change in voltage 
response (P7-10, each point is a mean of 15 sweeps) when the CO2 level was 
changed from 35 to 55 mm Hg. (B) Associated mean voltage traces (average of 40 
sweeps) and voltage responses to step currents at indicated time points from A. (C) 
Quantification of voltage response changes (35 to 55 mm Hg CO2) for P7-10 mice 
(with and without carbenoxolone incubation) as well as P17-21 mice for reference. 
Inset: Example control response and response in carbenoxolone for P7-10 mice (1, 
35 mm Hg and 2, 55 mm Hg).  
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6.2.5 Decreasing PCO2 significantly increases the excitability of 
early postnatal substantia nigra dopaminergic neurons  
Given that the midpoint for connexin 26 channel opening is ~ 40 mm Hg CO2
(Huckstepp et al., 2010b), I next wanted to test whether I could increase the 
excitability of the SNpc DNs (in P7-10 mice) by reducing the level of PCO2. 
Closing hemichannels should increase input resistance, excitability and firing 
rate. In a separate group of SNpc DNs cells, I decreased the PCO2 level to 
evaluate this hypothesis.  Reducing PCO2 from 35 to 20 mm Hg (hypocapnia) 
increased the firing rate (the mean firing rate in 20 mm Hg CO2 was 184.0 ± 
28.7 % of that in 35 mm Hg CO2, p =0.015, Fig 6.6 A, D). It also increased the 
amplitude of the voltage response to current steps (the mean voltage response 
in 20 mm Hg CO2 was 104.0 ± 1.2 % of that in 35 mm Hg CO2, p = 0.008; Fig 
6.6 B, C, E), consistent with a decrease in conductance.  
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Figure 6.7: Dopaminergic neurons in the substantia nigra are sensitive to 
lowering CO2. 
(A) An example recording from an SN dopaminergic neuron in a P7 mouse. Black 
traces represent recordings in 35 mmHg (normal CO2) and green traces represent 
recordings in 20 mmHg (low CO2). An increase in firing rate can be observed from the 
membrane potential responses to step and fluctuating current injections (see 
Methods). (B) The voltage response to a 50 pA hyperpolarising step (top, traces are 
an average of 40 sweeps) and the membrane potential response to the -100-pA step 
injection (bottom). They demonstrate subtle increases to input resistance with lowered 
CO2. Both the left and right panels show a partial recovery of both firing rate and input 
resistance after washing back into 35 mm Hg CO2. (C) An example of the time course 
of changes in voltage response (for a single P7-10 slice, each point is a mean of 15 
sweeps) when CO2 was changed from 35 to 20 mm Hg. (D) Quantification of the mean 
change to firing rate when CO2 was lowered from 35 to 20 mm Hg. Firing rate was 
measured from the voltage response to fluctuating current input. (E) Quantification of 
the mean change to the voltage response to hyperpolarising step input.  
































































20 mm Hg (low CO
2
)
35 mm Hg (normal CO
2
)
35 mm Hg (normal CO
2
)




























6.2.6 Early postnatal substantia nigra dopamine neurons dye load 
during hypercapnia and express connexin 26 
A characteristic of hemichannels is that when they open, they allow entry of 
membrane-impermeant fluorescent dyes into cells, and once the 
hemichannels close, the dye will become trapped. Therefore, dye loading can 
be used as a marker for showing which cells express CO2–sensitive
hemichannels (Huckstepp et al., 2010b; Meigh et al., 2013; Fig 6.7A). When 
(Vandecasteele et al., 2006) attempted this with Lucifer yellow, they did not 
find evidence for functional hemichannels. However, this may be because the 
channels are heteromeric and therefore may be impermeable to this dye. I 
therefore used the impermeant dye, Carboxyfluorescein (CBF) that passes 
through open Cx26 hemichannels (Huckstepp et al., 2010b) and confirmed 
that neurons in the SN of P7-P10 mice could be loaded with the dye following 
hypercapnia (Fig 6.7A). No dye loading occurred if PCO2 was not increased, 
and it did not occur in the SN of older mice (P17-21; Fig 6.7A) or in 
hippocampal pyramidal cells (Fig 6.11). Unfortunately, CBF cannot be fixed 
and so the dye-filled cells cannot be subsequently labelled with antibodies. 
However, I can be confident that the dye-filled cells were either SN DNs or 
VTA GABAergic neurons, as patch clamp recording was carried out before the 
dye loading (to confirm the identity of the cells from their electrophysiological 
properties and pharmacology) and then the same cells were subsequently dye 
filled.
To further confirm that early postnatal SN DNs express connexin 26 I used 
immunohistochemistry. The connexin 26 antibody has been used extensively 
in previous studies and prior publications can confirm correspondence for 
Cx26 immunostaining with a reporter driven from the endogenous Cx26 
promoter (Huckstepp et al., 2010b; Sun et al., 2009). In slices from P7-10 mice, 
Cx26 expression was present in tyrosine hydroxylase positive (TH+) neurons 
in SN (Fig 6.7B). However, in older mice (P17-21), Cx26 was not expressed in 
in TH+ neurons (Fig 6.7C) but was expressed in leptomeninges of 
corresponding sections, providing a positive control (Fig 6.7D; Condorelli et 
al., 2003).  
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Figure 6.8: Dye loading and Cx26 expression in substantia nigra. 
(A) Carboxyfluorescein (CBF) dye loading following hypercapnia (55 mm Hg CO2) in 
P7-10 mouse slices. No dye loading occurred if CO2 was not changed or if CO2 was 
increased in P17-21 slices, scale bar = 50 µm. (B) Immunofluorescent staining of P7-
10 SN for Cx26 (red, arrows) in TH+ neurons (green) in single optical planes. (C) No 
co-localisation of Cx26 (red) in TH+ neurons (green) in the SN at P17-21, scale bar = 
30 µm. (D) Staining was deemed successful due to the positive leptomeninge staining 
from corresponding sections of the same mouse brain, scale bar = 30 µm.  
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6.2.7 FITC dye loads glial cells in high CO2 but not neurons 
Having demonstrated that cells in the region of SNpc DNs can uptake 
Carboxyfluorescein on exposure to high levels of CO2, I wanted to prove 
definitively that they were dopaminergic. As CBF cannot be fixed (personal 
communication Robert Huckstepp), I instead loaded with a different dye 
fluorescein (FITC), which can be fixed with PFA, then counterstained with 
tyrosine hydroxylase. I would have expected neuronal dye loading in the P7-
10 mice as there was with CBF. However, I did not see any dye loading in 
neurons. Depending on the profile of connexins available, they can assemble 
into homomers or heteromers. For example, it is known that connexin 26 and 
connexin 30 can form heteromeric channels that maintain their sensitivity to 
CO2. I do not know whether the connexins are assembling in a homomeric or 
heteromeric form in my in vitro slice experiments. However, it is possible that 
FITC cannot pass through hemichannels that are not homomeric (of Cx26) and 
thus the presence of heteromeric channels potentially prevents the influx of 
the dye.  
I then repeated this in P17-21 mice, expecting not to see any dye-loading. 
However, I observed FITC dye loading in the cells surrounding SNpc DNs (Fig 
6.8A). I hypothesised that they might be glial cells. I therefore performed 
immunohistochemistry for connexin 26 (red) and GFAP (green) and confirmed 
co-localisation (Fig 6.8B). Perhaps glial cells are more likely to have 
homomeric Cx26 conformations than neurons. They may also have increased 
numbers of Cx26 hemichannels. Connexin 26 expression on glia is known to 
release ATP (Gourine et al, 2005; Huckstepp et al 2010; Weifer et al 2010) in 
response to raised CO2. Thus, I propose here a potential developmental switch 
in connexin 26 action from neurons (P7-10; directly inhibitory) into glia (P17-
21; indirectly excitatory). This needs to be explored further in future 
experiments. 
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Figure 6.9: FITC dye loading suggests CO2 presence in glial cells of P17-21 mice 
and is confirmed with immunohistochemistry. 
No dye loading of FITC was observed in SNpc DNs of P17-21 mice. However, 
surrounding smaller cells were loaded with FITC. It is possible that these cells could 
be GABAergic neurons or glial cells (B) To test this immunohistochemistry to look for 
co-localisation was performed. This confirms co-localisation of connexin 26 (red) and 
glial fibrillary acidic protein (GFAP; green) in the SNpc of P17-21 mice. Note that the 
connexin 26 antibody will stain both connexin 26 (punctate appearance; white arrows) 
and blood vessels (long thin staining). These images are taken of single optical planes 
and demonstrate co-localisation of punctate Cx26 and GFAP positive glial cells.  
6.2.8 Changes in PCO2 significantly modify the excitability of 
neurons in the VTA  
Consistent with the lack of electrophysiological changes, there was no CBF 
dye loading into P17-21 SNpc DNs (where there had been at younger ages). 
However, I observed in a neighbouring region, the ventral tegmental area 
(VTA) what appeared to be some neurons that loaded with the dye (Fig 6.9A). 
This area is another prominent nuclei for dopaminergic cells within the brain 
and is central to the circuits controlling reward and motivation behaviours 
(Morales and Margolis, 2017).  
To confirm that these cells were part of the VTA, I first made recordings from 
a subset of the dye-filled neurons. I was surprised to discover that they were 
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not hyperpolarised by dopamine (30 µM) but found instead that they were 
hyperpolarised by application of the opioid receptor agonist [Met]-Enkephalin 
(10 µM). This is consistent with the neuron classification described in Johnson 
and North (1992); that there are a subset of neurons that are positioned close 
to the substantia nigra that respond in a very similar manner to SN 
dopaminergic neurons: a large IH (sag) in response to hyperpolarising current 
steps and are hyperpolarised by dopamine. The second subgroup does not 
show as large IH (sag) in response to hyperpolarising current steps and do not 
hyperpolarise with dopamine, but instead hyperpolarise with [Met]enkephalin 
(Fig 6.9B-D). The CO2 sensitive neurons appear to belong to this second 
subgroup. The differences in action potential dynamics of these two different 
groups allows them to be distinguished from one another.  
Figure 6.10: Localisation of the recorded neurons in the ventral tegmental area 
(A) Carboxyfluorescein (CBF) dye loading following hypercapnia (55 mmHg CO2) in 
P7-10 and P17-21 mouse slices demonstrates dye loading in putative VTA neurons. 
No dye loading occurred if PCO2 was not changed scale bar = 50 µm. (B) Location of 
the VTA in a coronal mouse brain slice (Adapted from Allen Mouse Brain Atlas, 2004). 
(C) Membrane potential traces recorded from a putative dopaminergic neuron in the 
VTA in response to current steps in 35 mm Hg CO2. Current steps (3 s duration) 
started at -200 pA and were increased by 50 pA until the neuron exhibited a regular 
firing pattern. (Inset) Membrane potential response to the injection of a +100 pA 
current step. There is a clear difference in the action potential dynamics of 
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dopaminergic neurons in the SN and VTA regions, as previously reported (Johnson 
and North, 1992). (D) Membrane potential traces from a putative VTA dopaminergic 
neuron. Application of dopamine (30 µM) had no effect on the membrane potential 
whereas [Met]enkephalin (10 µM) markedly hyperpolarised the neuron. This is 
consistent with previous reports (Johnson and North, 1992) that DNs in this region of 
the VTA are not responsive to dopamine but are hyperpolarised by [Met]enkephalin.  
In response to an increase in PCO2, these (P17-21) neurons in the VTA 
showed similar electrophysiological changes to P7-10 SN DNs in response to 
changes in PCO2: increased PCO2 (55 mm Hg) decreased input resistance 
(voltage response reduced to 71.0 ± 13.2% of control p = 0.001, 335.0 ± 66.7 
MΩ to 222.0 ± 39.4 MΩ, p =0.0446, before the sag n = 5;) and firing rate Fig 
6.10 A-C. Reducing PCO2 to 20 mm Hg increased input resistance (voltage 
response increased to 118.0 ± 6.1 % of the baseline amplitude, p = 0.043) and 
firing rate (193.0 ± 35.0 % of the baseline firing rate, p = 0.049, of control; Fig 
6.10 D-F). 
Given that the ventral tegmental area (VTA) is highly heterogenous and 
neurons can release dopamine, glutamate, GABA, or any combination of the 
three, I performed separate immunostaining protocols of connexin 26 paired 
with tyrosine hydroxylase for dopaminergic neurons and of connexin 26 paired 
with GAD65/67 for GABAergic neurons. I saw co-localisation of connexin 26 
(red, AF594) with GAD65/67 GABAergic neurons which is consistent with the 
[Met]enkephalin sensitivity electrophysiological phenotype (Fig 6.10G). To 
establish whether these neurons were also dopamine releasing I looked for 
colocalization with tyrosine hydroxylase but saw no evidence of this (Fig 
6.10G). I therefore concluded that these neurons were likely GABAergic 
neurons. They could either be or long-range projecting GABAergic neurons to 
a range of different sites or local GABAergic neurons which within the VTA are 
known to modulate the activity of the neighbouring dopaminergic neurons. 
Thus, changes in CO2 levels could potentially indirectly modulate dopamine 
release into regions like the nucleus accumbens.  
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Figure 6.11: GABAergic neurons in the VTA are sensitive to CO2. 
(A) An example of the time course of changes in voltage response for a single P17-
21 slice (CO2 increased from 35 to 55 mm Hg; each point is a mean of 15 sweeps). 
(B) Voltage responses to step currents at indicated time points in B. (C) Quantification 
of changes in voltage response to increased PCO2. (D) An example of the time course 
of changes in voltage response for a single P17-21 slice (CO2 decreased from 35 to 
20 mm Hg; each point is a mean of 15 sweeps). (E) Voltage responses to step and 
fluctuating current inputs at indicated time points in F demonstrating increased input 
resistance and firing rate. (F) Quantification of changes in voltage response to 
decreased PCO2. (G, H) Representative single optical plane confocal microscopy 
immunohistochemistry images. (G), Immunofluorescent staining of P17-21 VTA for 
Cx26 (red) which is not expressed by TH+ neurons (green, no co-localisation), scale 
bar = 50 µm. (H), co-localisation of Cx26 (red) with the soma of GAD+ neurons (green) 
in the VTA (scale bar 20 µm). 
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6.2.9 Carbon dioxide sensitivity is not present in hippocampal CA1 
pyramidal neurons 
To ensure that the observed CO2 sensitivity was not a blanket response across 
all neurons, I recorded from pyramidal cells (PCs) in the CA1 region of the 
hippocampus of P7-10 mice, in slices where the DNs had responded to 
changes in CO2 levels (Fig 6.11A). I chose to examine these neurons as they 
are easy to identify and have well-defined properties.  I observed no significant 
change in CA1 PC electrophysiological parameters (voltage response was 
100.3 ± 1.6% of control, p = 0.680, n = 6) in response to increasing the level 
of carbon dioxide (from 35 mmHg to 55 mm Hg CO2; hypercapnia; Fig 6.11B-
D).  
Figure 6.12: CA1 pyramidal cells show no dye loading or electrophysiological 
changes in response to high CO2. 
 (A) The localisation of CA1 region of the hippocampus in a sagittal slice (Adapted 
from Allen Mouse Brain Atlas, 2004). (B) (Left) Bright-field image of the CA1 region 
demonstrating the location of a recorded pyramidal cell. The slice was then subjected 
to carboxy-fluorescein (CBF) dye-loading (see Methods). There was no visible dye 
loading of the neurons (right). (C) (Top) Membrane potential traces recorded from a 
CA1 pyramidal neuron in response to current steps (3 s steps starting at -200 pA, 
increasing by 50 pA until regular firing pattern) in 35 mmHg CO2. (Inset) Single 
membrane potential trace in response to the injection of -200 pA (3 s) in 35 mmHg 
CO2. CO2 levels were increased over a period of 300 seconds from 35 mm Hg to 55 
mmHg CO2, as in the SN and VTA experiments. (Bottom) Membrane potential traces 
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recorded from the same CA1 pyramidal neuron in response to current steps in 55 
mmHg CO2. Single membrane potential trace in response to a -200 pA (3 s) current 
step in 55 mmHg CO2. (D) Example membrane potential responses to a (100 ms) - 
50 pA current step. Traces (averaged from 20 sweeps) shown for 35 mmHg CO2 (left) 
and 55 mmHg CO2 (right). No difference in voltage response is observed when the 
level of CO2 is increased.  
6.3 Conclusion 
I have demonstrated an unexpected CO2-sensitivity phenotype for neurons in 
the SN and VTA, with increases in PCO2 markedly increasing whole-cell 
conductance. This effect appears to occur in only specific subtypes of neurons, 
as for example it was not observed in hippocampal CA1 pyramidal cells. I have 
provided several lines of evidence that suggest that the CO2 sensitive 
conductance results from the opening of Cx26 hemichannels, whose open 
probability increases through CO2-mediated carbamylation of lysine residues 
(Meigh et al., 2013). I have shown that the effects of CO2 in SN DNs occur 
over the same developmental period as they express Cx26 mRNA (measured 
in an independent study; Vandecasteele et al., 2006). The effects of increasing 
CO2 on resting conductance could be blocked by the hemichannel inhibitor 
carbenoxolone. SN dopaminergic neurons and VTA GABAergic neurons could 
also be filled with a fluorescent dye (Carboxyfluorescein, CBF) when PCO2
was increased (this is termed dye loading).  My findings reveal an unexpected 
role for CO2 in regulating the activity of these key brain regions and 
demonstrates a mechanism by which an CO2 could alter complex goal-directed 
behaviours. There is no data in this current study on the physiological 
significance of CO2 sensitivity, in particular regarding movement and reward 
behaviour; this will need to be examined in future studies.  
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7. Chapter 7: Discussion 
7. D iscussion  
I have undertaken four separate projects, three of which have focussed on 
quantitatively analysing the cellular and sub-cellular effects of various 
pathological agents on neuronal and synaptic function and the fourth on the 
discovery of CO2 sensitivity in two key dopaminergic nuclei. I will now consider 
how my results fit in the context of their fields, discuss the limitations of the 
approaches I have taken and indicate how these projects could be extended 
in future studies to answer any remaining questions.  
7.1 Chapter 3 – oTau mediated pathology 
Although this is the first study of its kind for tau oligomers (oTau), the delivery 
of an oligomeric protein using whole-cell patch clamp has previously been 
published previously by my lab (Kaufmann et al., 2016). The estimated 
physiological concentration of tau within neurons is 2 µM (Avila, 2010) which 
is much higher than I have introduced here (44 - 666 nM). In this study, three 
different concentrations of oTau were tested to establish whether the effects 
were concentration-dependent. For layer V pyramidal cells (PCs), a higher 
concentration (666 nM) was used to give effects over a comparable timescale 
to that observed in CA1 neurons in the hippocampus, as they are larger 
neurons.  
7.1.1 oTau alters action potential dynamics, input resistance and 
neuronal excitability 
Both standard current-voltage relationships (SIV, with step current injections) 
and dynamic current-voltage relationships (DIV, with naturalistic current 
injection) were used to extract neuronal parameters and evaluate the effects 
of oligomer introduction at 10-minute time intervals (see Methods). As the time 
course for oTau to have effects varied between cells, for consistency of 
analysis the first and last time points of recordings were compared throughout. 
The last time point was selected to be 40-minutes as this is the time point in 
which most recordings still remained stable. I had hoped to be able to 
implement the dynamic IV modelling protocol (Badel et al., 2008a, 2008b; 
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Harrison et al., 2015) over the full time course of recording, however due to 
the increasing effects on action potential waveform, the protocol became less 
effective over time. I therefore only used it to parameterise the cells at 0 
minutes to ensure that the recording quality and neuronal properties were 
comparable. The introduction of oTau into single cells produced significant 
changes to input resistance and firing rate. 
With collaborators in the Zeeman Institute, I adapted and implemented a 
program to analyse action potential dynamics using Julia (Bezanson et al., 
2017). It measures action potential amplitude (peak height), duration (full 
width-half max) and the rate of rise and decay from action potentials induced 
by the fluctuating naturalistic current input. This analysis allowed me to 
quantify the decrease in action potential amplitude and increase in duration as 
well as the slowing of both action potential rate of rise and decay. Lower 
concentrations of oTau took longer to achieve the same effects, thus 
illustrating the concentration-dependence of the effects.  
A number of control experiments were used to validate the results. Firstly, no 
significant effect was observed when introducing the similarly sized 
aggregation-competent molecule BSA into cells. The effects of oTau were not 
due to blockage of the pipette tip as confirmed by stable series resistance 
measurements across the duration of the recordings and successful ‘re-
patching’ experiments (Qui et al., 2014). This protocol gave stable responses 
in my control experiments. However, with oTau I demonstrated that the 
changes in action potential waveform are not simply a filtering effect and result 
may instead result from the modulation of specific voltage gated ion channels.  
7.1.3 oTau impairs synaptic transmission and enhances synaptic 
depression 
Next, given the effects on action potential dynamics, I wanted to investigate 
whether this translates into a change in transmission to neighbouring 
synaptically connected neurons. I made paired recordings in layer V neurons 
in the cortex and delivered oTau targeted to either the presynaptic or 
postsynaptic cell, while the rest of the network remained unaffected. In pairs 
where the presynaptic cell had been injected with oTau, the EPSPs were 
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reduced in amplitude over time even though the cells were still stable for the 
course of the recording. Even though the postsynaptic cell (generating the 
EPSPs) had no oTau introduced, the decline in transmission was clearly 
observed. This ruled out any changes in ligand gated ion channels (in 
particular AMPA receptors) in the postsynaptic cell being responsible for these 
changes. This is in contrast to the control cells, where the EPSP amplitude 
stayed constant over an hour of stable recording. There was also an 
enhancement of synaptic depression in the pairs when oTau was introduced 
into the presynaptic cell.  
Though the effects on synaptic transmission could be a result of the changes 
to action potential waveform, it is more likely that there are two separate effects 
because the significant changes to the action potential waveform occurred 
around 30-40 minutes after whole breakthrough whereas the changes to 
synaptic transmission began much earlier (after 10-20 minutes). It has also 
been reported previously in squid giant axons that injection of human tau could 
directly alter synaptic transmission without changing the waveform of the 
action potentials. It could be that as the action potentials get smaller, they are 
unable to be propagated down the axon. However, this is unlikely as it has 
been shown that ‘spikelet’s’, which are much smaller than full size action 
potentials, can be fully propagated down the axons of CA1 cells (Apostolides 
et al., 2016). Further work could confirm this by performing paired recordings 
at the soma (site of oTau introduction) and the axonal bleb of the same neuron 
and looking at conductance of action potentials down the axon to look for 
branch-point failure.  
The synaptic transmission deficits observed in my study match the published 
literature (McInnes et al., 2018; Zhou et al., 2017). In cultured hippocampal 
neurons, where a P301l tau construct had been delivered using an AAV viral 
vector, there was also enhanced synaptic depression with a train of stimuli, 
which resulted from the crosslinking of vesicles and actin (tau binds via the C-
terminus to actin and via the N-terminus to the vesicles), this reduced vesicle 
mobility and the speed at which the vesicles could restock, interrupting 
trafficking and recycling. They were able to counteract these effects with a 
truncation of the N-terminal region of tau and also using a peptide that is 
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targeted to bind and block the N-terminus of full-length tau. Both approaches 
prevented the N-terminus binding to vesicles and restored vesicle motility 
(Zhou et al. 2017; Fig 7.1).  
Figure 7.1: oTau crosslinks actin and vesicles, slowing vesicle recycling.  
Schematic to explain the main findings by Zhou et al (2017) whereby tau binds via the 
C-terminus to actin and via the N-terminus to the vesicles, this reduces vesicle 
mobility and reduces the speed at which the vesicles can restock, interrupting 
trafficking and recycling. This results in enhanced synaptic depression and could be 
counteracted using a peptide targeting the vesicle binding region on the N terminus.  
I have demonstrated a comparable increase in depression, consistent with 
their hypothesis of slower vesicle restock. However, this does not account for 
the changes to the first EPSP amplitude. Following on from the work conducted 
in this paper, it would be an interesting idea to test whether an N-terminal 
truncation of tau would rescue the effects that I observed in paired recordings, 
more specifically the oTau-mediated enhanced depression. This work directly 
complements a number of ongoing immunotherapy trials of N-terminally 
truncated tau in early Alzheimer’s disease (e.g., BIIB092; Biogen). This study 
could provide evidence as to what is functionally happening in these individual 
neurons. 
7.1.4 oTau does not affect basal synaptic transmission from 
postsynaptic sites 
I observed no basal synaptic transmission defect when tau was introduced into 
the postsynaptic cell in the synaptically connected pair. In tauopathies, a high 
proportion of the native tau that does aggregate is hyperphosphorylated. This 
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is complicated to study as tau has 85 possible phosphorylation sites (Mair et 
al., 2016; Silva et al., 2016). Early phosphorylation of tau is known to play a 
role in its detachment from microtubules and mis-localisation to dendrites, but 
it has not been shown which residues are responsible. Teravskis et al., (2018) 
demonstrated that phosphorylation of Ser396 and Ser404 at the C-terminus 
are required for tau mis-localisation and then in order to disrupt AMPA receptor 
trafficking one of the following residues also needs to be phosphorylated 
(Ser202, Thr205, Thr212, Thr217 or Thr231), all of which can be found in the 
N-terminal domain. It is important to highlight that during the production of my 
oligomers there was no phosphorylation of the tau. However, they may be 
phosphorylated within the cell after introduction. I did not measure 
phosphorylation inside the single cells given the large number of phosphor-
epitopes and that the fluorescence signal from a single phospho-epitope of 
introduced tau in a single cell would be too small to pick up with conventional 
confocal microscopy. Maybe this is because the oligomers were produced 
from a mechanism not reliant on hyperphosphorylation. They are however mis-
localising so it would be interesting to find a way to check if Ser396 and Ser404 
are being phosphorylated inside the cells from which I am recording. It is also 
worth noting that the sites needed for mediating the synaptic dysfunction are 
in the N-terminus; which fits nicely with my N-terminal truncation theory.  
7.1.5 oTau impairs long term synaptic plasticity  
Aggregated tau has been previously reported to impair some forms of synaptic 
plasticity including long-term potentiation (LTP) and long-term depression 
(LTD) (Fá et al 2016; Lasagna-Reeves et al, 2012; Ondrejack et al, 2018). In 
the next part of this project, I aimed to investigate whether impairment in LTP 
was a direct intracellular action of oTau rather than an extracellular action, and 
whether the effects were specific to the oligomeric forms of tau. I induced LTP 
in single cells using a high frequency tetanus stimulation. Upon receiving the 
stimulation, Na+ flows in through AMPA receptors, depolarising the post 
synaptic compartment and activating NMDA receptors causing the influx of 
Ca2+ and an increase in the number of AMPA receptors at the membrane and 
potentiating transmission (Lu et al 2001, Chater and Goda, 2014). LTP was 
reliably induced in control cells and abolished with L689,560 confirming it to 
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be NMDA receptor-dependent. Tau oligomers at concentrations of 44 nM and 
444 nM completely abolished long-term potentiation (and short-term 
potentiation) whereas monomers (444 nM) had little effect. The potentiation 
was slightly reduced compared to control but that could be due to 
reaggregation of tau inside the cell during the 45 minutes of recording.  
In future experiments, I would like to investigate the mechanism of how oTau 
mediates this inhibition. It could be that it is increasing the threshold for eliciting 
LTP, and therefore as a result the depolarisation reaching the dendritic spines 
is not sufficiently high enough to remove the NMDA receptor Mg2+ block. If this 
were the case, a stronger stimulus would be required for the oTau cells to be 
potentiated, which would be a fairly simple hypothesis to test. If this was not 
the case, then the LTP would still be inhibited with a larger stimulus. 
Alternatively, it could be that oTau is directly affecting potentiation by altering 
some of the necessary molecular machinery or pathways required to generate 
plasticity. For example, tau could interrupt AMPA receptor insertion (Jurado, 
2018). There is a wealth of evidence in tauopathy models showing that tau 
modulates AMPA trafficking and thus can alter synaptic strength in physiology 
(Suzuki and Kimura, 2017) and pathology, both in the presence of and 
independently of amyloid beta or alpha synuclein  (Chang et al., 2006; Crimins 
et al., 2011; D’Amelio et al., 2011; Miller et al., 2014; Polydoro et al., 2009; 
Shrivastava et al., 2019). This would require a more in-depth pharmacological 
molecular approach.  
A number of groups in the field have investigated other mechanisms of how 
tau might be mediating this reduction in LTP. To induce and maintain long-
term potentiation, a number of plasticity-related genes need to be transcribed. 
Transcription factor cAMP response element-binding protein (CREB) can be 
activated by a range of kinases including mitogen- and stress-activated protein 
kinase 1 (MSK1), cAMP-dependent protein kinases (PKA) or mitogen-
activated protein kinase/extracellular regulated kinase (MAPK/ERK) (Arthur et 
al., 2004; Privitera et al., 2020; Reyskens and Arthur, 2016; Teich et al., 2015). 
Once activated, transcription of plasticity related genes will occur, which are 
needed for successful long-term potentiation (Balschun et al., 2003; Barco et 
al., 2002; Bourtchuladze et al., 1994; Lee and Silva, 2009; Ran et al., 2012). 
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Thus, changes to CREB activity can alter synaptic plasticity. The level of 
phosphorylation of pCREB at serine 133, a key site for phosphorylation, has 
been shown to be considerably lower in Alzheimer’s disease (Yamamoto-
Sasaki et al., 1999). It was confirmed that oTau mediates a reduction in 
phospho-CREB and thus a reduction in the expression of immediate early 
genes c-fos and Arc, leading to impaired LTP (Acquarone et al., 2019). In 
future experiments, I would like to use RT-PCR to establish whether there are 
changes to these genes in my single cell assay to see if this is responsible for 
the reduction in potentiation. An alternative theory may be that ‘non-
pathological’ tau could have important roles in plasticity physiologically and 
that oTau might bind to and sequester this native tau, removing it from the site 
where it normally acts at in the dendrites, thus affecting plasticity (Regan et al., 
2015).  
I also looked at long-term depression, another key form of plasticity at these 
synapses. Given that Acquarone et al., (2019) report reduced levels of ARC in 
the presence of tau oligomers and given that ARC is a key mediator of mGluR-
LTD by causing the endocytosis of AMPA receptors (Wall et al., 2018; Waung 
et al., 2008), maybe ARC could be involved in the changes to LTD that I 
observe. This is something else that I could look at using single cell RT-PCR.  
7.1.1 oTau can diffuse to synaptic sites during 30-minutes of 
recording 
In a number of experiments Alexa fluor 594 hydrazide dye and Alexa fluor 488 
labelled tau oligomers were both added to intracellular solution to look at 
mislocalisation of oTau within CA1 cells over 30-minutes of recording. Given 
the small amount of oTau introduced, it is not possible to visualise it within the 
recorded neuron during recordings or by using standard confocal imaging, 
hence the need for long timeframe AiryScan detection. Developed by Zeiss, it 
allows significantly better resolution and improved signal-to noise ratios (Huff, 
2015). It enabled me to visualise the introduced oTau, at high resolution, 
determining where it had spread during the period of recording. oTau is able 
to travel from the site of introduction (soma) down the axon and reach distal 
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dendrites (beyond the bifurcation). This substantial finding is important as it is 
the first study to detail such rapid mislocalisation in a single neuron for tau 
oligomers. Given the short time frame, it is probably travelling by active 
transport, this could be evaluated in future studies. It would also be interesting 
to establish whether there is a specific region of tau required for mislocalisation 
and if so, what this is. It has been shown previously that tau can bind to vesicles 
via its N-terminus (Zhou et al., 2017). Theoretically tau might bind to vesicles 
in the soma and then get transported around the cell (attached to vesicles) and 
into the dendrites to the sites where synaptic sites can be found. If so, then a 
truncation of the binding region may prevent the mis-localisation. A limitation 
of this current study is that while I can confirm the localisation of the tau within 
the distal dendrites, I cannot confirm that the tau is localised specifically at 
post-synaptic sites without further co-staining for example with PSD-95. This 
approach is more complicated due to the length of time needed for imaging 
and the bleaching that occurs as a result of obtaining many large z-stacks as 
a tile scan over a period of ~24 hours across multiple wavelengths. It would 
finally also be beneficial to be able to visualise the oTau during my experiments 
to look at the time course of tau movement. In order to do this, a technique 
permitting the high resolution of Airyscan imaging whilst simultaneously 
making whole-cell patch clamp recording would be needed. This would also 
allow me to measure whether the introduced tau oligomers are secreted out of 
the introduced cell during the 30-minute timeframe.  
7.1.6 Can the observations with recombinant tau be replicated with 
human Alzheimer’s disease CSF samples? 
Although recombinant tau allows precise control over what is introduced into 
neurons (in terms of concentration, structure, and form), it is not fully 
representative of the range of oligomers that are present in AD.  A fraction of 
the toxic oTau pool in human AD brains is released into cerebrospinal fluid 
(CSF) in a manner that associates with pathological AD markers. CSF samples 
of patients with Alzheimer’s disease will contain raised levels of amyloid-beta 
(Aβ42), total-tau and phospho-tau and can therefore be used as biomarkers 
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(Song et al., 2018). In future experiments, I would like to use human AD CSF 
samples to investigate if my single cell protocol can correlate the observed 
changes in neuronal and synaptic properties with the composition and 
concentration of oTau in CSF samples from AD patients and whether this then 
also correlates with patient data on disease severity.  
To do this, I would first define the composition of each of the samples with a 
range of diagnostic parameters, including measurements of total tau, phospho-
tau, amyloid beta 42, neurofilament light (a marker of neuronal damage or 
injury) and GFAP (glial cell marker). The samples would contain a range of tau 
concentrations depending on the degree of disease progression. The clinical 
cut off to define an AD-positive case are p-tau181 >60 ng/L, and total-tau >350 
ng/L (Hansson et al., 2006). However, for advanced disease, samples will 
contain much higher concentrations of both tau and phospho-tau. The CSF 
samples will also contain other molecules e.g., amyloid beta, which could also 
potentially affect neuronal properties. To differentiate which effects are due to 
tau, a portion of each CSF sample would be immunodepleted for tau, using an 
established protocol (Cicognola et al., 2019) to complete removal of N-terminal 
region containing tau fragments (using an N-terminal antigen; confirmed with 
mass spectrometry imaging). In subsets of samples, a similar approach would 
be used to remove amyloid-beta, to explore independent and synergistic 
effects of tau and amyloid oligomers. I would compare the effects of introducing 
CSF from patients of varying pathological stages (AD, MCI, biomarker positive 
but cognitively normal along with age-matched healthy controls (experimenter 
blinded). The data I have obtained from recombinant tau gives me valuable 
information to guide the expected concentration-dependence of effects.  
I have acquired these samples from collaborators at the University of 
Gothenburg. However, in initial experiments, I came across a complication in 
the implementation of this protocol. It would be best to introduce the same 
concentration of sample obtained from the patients into cells. However, it 
would be diluted by 50 x into patch solution. Samples will therefore need to be 
freeze dried and then buffer exchanged in order to concentrate the protein 
species without concentrating the salts, as ensuring the correct osmolarity is 
vital for patch clamp recording. Initially I would use standard and dynamic IV 
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curves to extract electrophysiological data over time as this is robust and 
reliable. To compliment this, I would then investigate the profiles of the CSF 
samples using common biomarkers for synaptic dysfunction. Established 
assays to measure SNAP-25, GAP-43, PSD-95 would be implemented and 
combined with the profiling of AD biomarkers. These samples could then be 
tested using my electrophysiological assay to assess effects on synaptic 
transmission and plasticity. 
7.2 Truncating Tau Reveals Different Pathophysiological 
Actions of Oligomers in Single Neurons 
In conditions such as Alzheimer’s disease (AD), tau can dissociate from 
microtubules and then aggregate, with the small soluble oligomers (oTau) the 
most toxic species. However, the mechanisms of how oTau produces neuronal 
dysfunction are still not fully defined. By delivering oTau via the patch pipette 
(Hill et al., 2021, 2019; Kaufmann et al., 2016), I have demonstrated that full 
length oTau (FL-oTau) changes neuronal excitability, action potential 
dynamics, basal synaptic transmission and plasticity. Both labelled (Hill et al., 
2019; Chapter 3) and unlabelled (this study; Chapter 4) FL-oTau had very 
similar effects: they both increased input resistance, increased excitability, 
increased action potential width and reduced action potential amplitude. This 
confirms that the labelling of tau and modifying the positions of the cysteine 
residues in tau (Hill et al., 2019) had little or no effect on the actions of oTau 
on neuronal properties. 
7.2.1 Rationale of truncations 
Since monomeric tau did not exert any oligomer-mediated toxicities, I 
hypothesised that the observed effects were due to conformational changes 
that occur to form soluble aggregates. However, given previous reports that 
the extreme N-terminus of tau inhibits oligomer and fibril formation (Horowitz 
et al., 2006; Lapointe et al., 2009), I reasoned that N-terminal and C-terminal 
fragments of tau should have different effects on neuronal function. The site of 
truncation was informed by the recent discovery of two clinically-relevant N-
terminal fragments in human AD brains and CSF (N123 and N224; Cicognola 
et al., 2019) and the previously published evaluation of the role of the N-
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terminal truncation (aa124-444) in mediating synaptic dysfunction (Largo-
Barrientos et al., 2021; McInnes et al., 2018; Zhou et al., 2017). I therefore 
acquired recombinant versions of tau (from the University of Gothenburg) 
informed by a physiologically-relevant truncation at amino acid 123 that they 
had recently discovered in human AD brains and cerebrospinal fluid 
(Cicognola et al., 2019). I hypothesise that oligomers formed from N-terminal 
truncated tau (amino acids 124-444; CFRAG) and soluble aggregates of the non-
oligomer forming N-terminal fragment (amino acids 1-123; NFRAG), will elicit 
distinct effects on single neuron physiology. 
7.2.2 CFRAG tau produces oligomers that increase excitability by 
changing spike threshold 
I began investigating the mechanisms underlying the actions of FL oTau using 
an N-terminal truncation (CFRAG). I found that CFRAG tau oligomers did not 
replicate the effects on action potential kinetics or input resistance that I 
observed with FL oTau but despite this, they did increase excitability. I went 
on to demonstrate that this is mediated by a negative shift in rheobase (the 
minimum current needed to elicit an action potential), thus resulting in the 
neurons being more excitable. In my previous study (Hill et al., 2019; Chapter 
3), I was unable to use the dynamic IV method (Badel et al., 2008a, 2008b; 
Harrison et al., 2015) to fully parameterise neuronal changes over the time 
course of the experiments due to the changes to action potential shape. As the 
action potential waveform was unaffected with the truncation, I was able to use 
the dynamic IV protocol and found that CFRAG tau oligomers reduce the spike 
initiation threshold (making it ~ 4mV more hyperpolarised). There was no 
change in membrane potential and thus the difference between spike 
threshold and resting potential is reduced, increasing the likelihood of firing 
action potentials. To further confirm this observation, I used the parameters 
extracted from the dynamic IV curve at 0 minutes to simulate a voltage 
response using the exponential integrate and fire model (Fourcaud and Brunel, 
2002; Fourcaud-Trocmé et al., 2003), demonstrating a comparable firing rate 
to the experimental traces. Then by manipulating only the spike initiation 
threshold by the mean reduction (4 mV), and re-running the simulation, I 
generated a trace which had comparable increase in firing rate as seen in the 
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experimental voltage recording at 40 minutes. Thus, confirming that the 
change in spike threshold alone is sufficient to mediate the change in neuronal 
excitability (Table 7). 
7.2.3 The N-terminal fragment changes input resistance at high 
concentrations 
I then investigated the fragment that had been removed to generate the 
truncation (amino acids 1-123; NFRAG). This tau fragment has also been 
reported to make up a large proportion of the tau found in the CSF of 
Alzheimer’s disease patients and it has been suggested that N-123 tau could 
represent a general marker of tau metabolism (Cicognola et al., 2019). NFRAG
does form aggregates but will not form the same structured oligomers as FL-
oTau does, thus I expected it to have different effects. When the N-terminal 
fragment of tau was introduced into neurons at an equivalent concentration 
used for the FL tau (444 nM) it produced a rapid and large increase in input 
resistance together with a reduction in action potential amplitude and a marked 
slowing of action potential kinetics. These effects occurred within 5 minutes of 
whole-cell break-through. By measuring the neuronal time constant I found 
that the apparent cell capacitance had significantly decreased. This led me to 
hypothesise that the tau could be inferring with current flow in the cell soma 
and making it seem electrotonically more compact. I tested this by making 
double patch clamp recordings from the soma of a single neuron, introducing 
NFRAG into one pipette and recording form both. I showed that although the 
input resistance had increased after 5 mins, the current flow between the two 
electrodes had significantly decreased. This suggests that the NFRAG tau is 
aggregating and reducing current flow across the cell (Table 7). Given that in 
my original study (Hill et al, 2019; Chapter 3) I demonstrated a concentration-
dependence of tau effects, I reduced the concentration of NFRAG tau in order to 
be able to record for the full 40 minutes for comparison with the other species.  
7.2.4 The N fragment changes action potential amplitude and width 
at low concentrations 
Introducing the NFRAG tau at lower concentrations (133 nM) selectively 
changed action potential amplitude and width without changing input 
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resistance. This suggests that the changes in action potential waveform are 
not simply due to increased filtering. To confirm this further, I tested NFRAG tau 
monomers and observed comparable changes to action potentials. This was 
surprising given that tau-mediated dysfunction has been almost solely 
replicated with oligomers and aggregates, while monomeric versions are 
largely assumed not to be pathologically relevant. 133 nM NFRAG tau 
monomers also altered the action potential waveform; thus, the effect is likely 
unrelated to structure and maybe instead due to a sequence in the N-terminus 
binding directly (Table 7). Given that both the rate of rise and decay are 
affected (Hill et al, 2019; Chapter 3), I hypothesised that the tau might be 
interacting with voltage-gated sodium channels and altering their function.  
7.2.5 FL-oTau alters voltage-gated sodium currents 
The neuronal function of sodium channels can be inferred from their kinetic 
properties as measured using whole-cell voltage clamp (Hodgkin and Huxley, 
1952). Recording voltage-gated sodium currents in neurons in a brain slice is 
difficult because it is challenging to achieve a good voltage clamp due to the 
size of the neurons and resultant space clamp problems (Bar-Yehuda and 
Korngreen, 2008; Hartline and Castelfranco, 2003; Rall and Segev, 1985; 
Spruston et al., 1993; White et al., 1995). A large proportion of sodium 
channels are clustered in the axon initial segment (Castelli et al., 2007; 
Diwakar et al., 2009; Kole et al., 2008; Osorio et al., 2005; Royeck et al., 2008), 
and their voltage can differ significantly from that at the soma (Kole et al., 2008; 
Stuart et al., 1997). Therefore, when attempting to voltage clamp at the soma, 
these electrotonically remote sodium channels (to the site of recording) will 
generate unclamped action potentials, impeding the ability to measure 
controlled responses. To counteract this space clamp problem, most 
experiments looking at sodium currents are performed in reduced models such 
as nucleated patches, dissociated or cultured neurons. However, this is less 
relevant physiologically because the distribution and density of channels may 
not reflect the natural condition. Being able to record currents in slices provides 
information about channel function in their natural environment. I adapted a 
protocol (Milescu et al., 2010) which enabled me to make controlled voltage 
clamp recordings of sodium currents from neurons in acute brain slices.  
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Voltage-gated sodium channels are widely expressed across the CNS and 
PNS (de Lera Ruiz and Kraus, 2015). In the central nervous system (CNS), 
the channels that are the most abundant are Nav1.1, Nav1.2, Nav1.3, Nav1.5, 
and Nav1.6 (Wang et al., 2017). While Nav1.7, Nav1.8, and Nav1.9 are mainly 
found in the peripheral nervous system (PNS; Wang et al., 2017), they can 
also be found in certain regions of the brain. For example, Nav1.7 channels, 
located in the hypothalamus, are involved in the regulation of body weight 
(Branco et al., 2016). At the axon initial segment (AIS) of CA1 pyramidal 
neurons, NaV1.1, NaV1.2, and NaV1.6 channels have been detected (Akin et 
al., 2015; Boiko et al., 2001; Garrido et al., 2003; Hossain et al., 2005; Ogiwara 
et al., 2007; Van Wart et al., 2007; Van Wart and Matthews, 2006). NaV1.6 
channels are highly abundant and have a more hyperpolarized voltage of 
activation compared with the other sodium channel isoforms, contributing to 
the lower activation threshold (Royeck et al., 2008). The sodium channels in 
the AIS probably make only a small contribution to the sodium currents I 
measured. This is a possible limitation of the technique that I have used. 
However, NaV1.6 is also present in the soma, although at less abundance than 
at AIS (Lorincz and Nusser, 2010). Despite this, the technique I have used 
allows controlled measurements of sodium channel currents in acute slices 
and provides more physiologically realistic information than recombinant 
sodium channels in cell lines.   
FL-oTau had three effects on sodium channel currents: Firstly, the half 
activation was reduced, reflecting the increase in neuronal excitability, 
consistent with the effects of CFRAG.  Secondly, the rate of activation was 
reduced, underlying the slower AP rise, consistent with the effects of NFRAG 
introduction. Finally, FL-oTau reduced  ḡ   (maximum sodium conductance) 
by ~ two thirds. To investigate the effects that this would have on the AP, I 
implemented a simplified AP model (Hodgkin and Huxley, 1952). Reducing ḡ  
had effects that matched the experimental data (reducing AP amplitude and 
increasing rise to threshold). Thus, this reduction in conductance alone could 
account for the changes in AP waveform that were observed experimentally.  
From the unnormalized conductance plots, I noticed that the rate of 
conductance increase appeared faster for FL-oTau despite ḡ   being reduced 
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(Fig 4.8) therefore, the effects are non-monotonic. Overall, it appears that there 
is a lower maximal conductance at 20 mins (and therefore AP height is 
reduced), but there is a small region at low voltages where the conductance is 
higher for FL-oTau, which means the model is more excitable. This means the 
profile of the     activation has been changed by oTau; it is not just an issue 
of different maximal conductance magnitudes. It also suggests that an 
interaction with sodium channels could underlie both observed phenotypes. 
The simplest explanation for these observations is that specific a sequence in 
the NFRAG tau is binding to the sodium channel to change the activation 
kinetics. Since the sodium currents are recorded in isolation, the most likely 
mechanism is a direct binding of the tau oligomers to the sodium channel.  
The mammalian sodium channel is a molecular complex of an ∼2000 amino 
acid α-subunit, which mediates the main channel functions and contains drug 
interaction sites, and smaller β-subunits, which modulate membrane 
expression (Catterall, 2012, 1981; Patino and Isom, 2010). The α-subunit is 
divided into 4 domains each with 6 segments (S1-S6). S1-4 form the voltage 
sensing domain (Kontis et al., 1997) and S5-6 form the pore forming domain. 
Upon depolarisation, S6 segments move leading to channel opening via the 
P-loop between S5 and S6 which forms the channel pore (de Lera Ruiz and 
Kraus, 2015; Fozzard et al., 2011). The S4 segments contain a high proportion 
of positively charged amino acid residues that make it responsive to changes 
in the membrane potential of the cell (Bezanilla, 2000). It is interesting to 
speculate on whether the tau oligomers could bind to the sodium channels to 
change the coupling between depolarisation and pore opening. Many studies 
have shown that changes in the S4 segments, associated linkers and 
cytoplasmic loops can all change the activation of the channels (de Lera Ruiz 
and Kraus, 2015; Fozzard et al., 2011).  
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Table 2.1: Summary of findings using recombinant truncations of tau and 
identified mechanisms 
7.2.6 Future experiments 
In future experiments, I would like to identify the minimal region of tau that is 
responsible for interacting with sodium channels. This could be done most 
efficiently using the mammalian two-hybrid system (M2H) to look for 
interactions between a library of fragments of the tau protein and the sodium 
channels expressed in CA1 neurons. This approach would permit quick 
identification of protein-protein interactions in a native cellular environment 
where post-translational modifications such as phosphorylation, acylation and 
glycosylation are possible (Luo et al., 1997). I could then use site-directed 
mutagenesis to disrupt these interactions and generate plasmids for human 
tau that cannot interact with sodium channels (termed hTauMUT). Although my 
in vitro approach has provided detailed characterisation of the pathological 
actions of oTau; it cannot predict how these changes will modulate network 
function and ultimately behaviour. AAV-viral vectors provide a flexible 
approach to introduce tau (wild-type or mutant) via stereotaxic injection to a 
site of interest and then following tau expression, behaviour can be studied. 
This approach leaves endogenous mouse tau unaltered so there is less 
chance of unrelated effects (compared to transgenic approaches). Many 
studies using this approach have introduced versions of AAV-GFP-P301L-
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hTau (a Frontotemporal dementia mutation which increases the likelihood of 
abnormal hyperphosphorylation; Alonso et al., 2004) and in line with the 
corresponding transgenic methods have highlighted neuronal dysfunction and 
behavioural deficits consistent with AD pathology. As my recombinant studies 
have been carried out with wild type (WT) full length tau, I looked instead for 
studies introducing AAV-GFP-hTau (non-mutant). In Yin et al., (2016), six 
weeks after injection with AAV-hTau expression in the CA3 region of the 
hippocampus of wild-type mice, there were measurable deficits in excitatory 
synaptic transmission, spatial and contextual memory (Yin et al., 2016). Using 
this experimental design, GFP-tagged AAV viral vectors for wild-type tau and 
for the identified mutant (hTauMUT) could be generated and introduced into the 
hippocampus via stereotaxic injection to establish functional effects of binding 
(and lack thereof). The Barnes maze could also be used to measure spatial 
learning, memory retrieval, and cognitive flexibility. This would answer whether 
the role of the interaction with sodium channels is important in the synaptic and 
behavioural effects in the context of the cognitive dysfunction that typically 
occurs in AD.  
Conclusion 
I have demonstrated that by truncating tau and generating aggregates of 
specific regions, I am able to dissect apart a number of the effects observed 
with FL-oTau. This has allowed me to probe the mechanisms underlying the 
effects, discovering novel oTau-mediated changes to the spike initiation 
threshold and voltage-gated sodium channel kinetics (Table 8). Aside from 
providing a novel experimental tool, the findings with recombinant (but 
clinically-relevant) tau truncations pose an interesting hypothesis with regards 
to pathology too. If tau is primarily present as the CFRAG form, then it will mostly 
affect excitability and not change action potential waveform. However, if the 
NFRAG accumulates in the soma it will have large effects on neuronal integration 
and action potential waveform. Identifying the regions of tau mediating 
neuronal dysfunction will assist in tracking down protein-protein interactions, 
help design assays for interacting partners and provide a mechanistic 
framework for drug development. 
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7.3 Chapter 5 – αSyn mediated pathology 
Here I have used whole-cell patch-clamp recording to introduce a known 
concentration and form of aggregated alpha synuclein (αSyn) into single 
substantia nigra pars compacta (SNpc) dopaminergic neurons in acutely 
isolated mouse slices.  
7.3.1 Characterisation of the aggregates 
Alpha synuclein was purchased as preformed fibrils (PFFs) and ultrasonication  
was used to break them down to oligomeric form (as in Polinski et al., 2018). 
While the majority of the αSyn sample displayed clear oligomeric structure, I 
cannot rule out the presence of other small aggregates like small ~ 50 nm fibrils 
(Polinski et al., 2018). A recent study has developed a new method used 
emerging technologies to fully isolate just the oligomeric fractions of alpha 
synuclein (Kumar et al., 2020), it would be interesting in future experiments to 
repeat these experiments with a purely oligomeric prep  
7.3.2 Alpha-synuclein aggregates, but not monomers, alter the 
electrophysiological properties of SN DNs. 
Both standard current-voltage relationships (SIV, with step current injections) 
and dynamic current-voltage relationships (DIV, with naturalistic current 
injection) were used to extract neuronal parameters and evaluate the effects 
of aggregate introduction. A significant increase in whole-cell conductance (fall 
in input resistance) was observed between 8-16 minutes after whole-cell break 
through, indicative of the opening of a membrane channel. This increase in 
conductance was paired with a reduction of both the induced and spontaneous 
firing rate (a measure of neuronal excitability) as well as abolishing rebound 
firing, which is normally characteristic of dopaminergic neurons following the 
input of a hyperpolarising step. These effects were only seen with the 
aggregated forms of alpha synuclein, but not with monomeric alpha synuclein 
or in the control cells. Changes to conductance and excitability began to occur 
between 8-16 minutes post whole-cell breakthrough. It may be that the alpha 
synuclein aggregates need time to reach a certain concentration before the 
channels can be opened. By comparison, in Chapter 3, introduction of 
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aggregated tau (444 nM) into pyramidal neurons started to have effects on the 
action potential within the first 10 minutes (Hill et al., 2019). In future 
experiments, I would like to evaluate whether there is a concentration-
dependent effect of alpha synuclein aggregates, perhaps with lower 
concentrations having a slower onset (as in Chapter 3; Hill et al., 2019). 
7.3.3 Modelling DNs.  
I had originally hoped to be able to use the dynamic IV method to parameterise 
these dopaminergic neurons as it provides a good method to develop 
simplified, but empirically-verified models of neuronal responses based on 
experimental data. The protocol was originally developed for pyramidal 
neurons and interneurons (Badel et al., 2008a, 2008b) and has been applied 
in my lab to cortical layer V neurons and hippocampal CA1 neurons (Harrison 
et al., 2015; Hill et al., 2019; Kaufmann et al., 2016). The method is effective 
in these neurons as their currents are broadly linear away from the action 
potential threshold. Dopaminergic neurons, on the other hand express 
significant non-linear currents (Neuhoff et al., 2002; Richards et al., 1997), 
therefore the DIV curves diverge away from a standard ohmic linear response 
(Fig 7.2).  
Figure 7.2: Dopaminergic neurons have non-linear dynamic IV curves.  
A) Example dynamic IV curve for a dopaminergic neuron, clearly displays a non-linear 
form compared to the example dynamic IV curve for the pyramidal neuron in (B). The 
non-linearity is likely to result from their expression of significant non-linear currents 
(Neuhoff et al., 2002; Richards et al., 1997).  
227 
It would significantly aid the quantitative analysis of future experiments if the 
dynamic IV protocol could be adapted to better fit neurons that differ from the 
standard linear form. This would allow a greater investigation of the effects of 
alpha synuclein on neuronal function in dopaminergic neurons, however this 
modelling was outside the scope of my PhD.  
7.3.4 The decrease in conductance and firing rate caused by alpha 
synuclein is in part due to the opening of KATP channels 
KATP channels are inwardly rectifying K+-selective ion channels that are 
inhibited by intracellular ATP. They provide a link between the energy state of 
cells and their electrical activity acting as a metabolically controlled “brake on 
excitation”. When there is a decrease in sub-membrane ATP levels and an 
accompanying rise in ADP concentration (during activity), this triggers KATP 
channel opening, thus resulting in a drop in input resistance, K+ moves out of 
the cell, inducing hyperpolarisation of the membrane potential (Haller et al., 
2001; Seino, 1999; Stanford and Lacey, 1995). This mechanism protects 
against glutamate excitotoxicity and calcium overload and has thus important 
functions in neuroprotection in epilepsy or ischemia (Liss and Roeper, 2001). 
Conversely, when ATP levels are high, ATP binds to KATP channels and 
inactivates them, leading to increased neuronal firing and neurotransmitter 
release.  
KATP channels consist of a Kir6.x (inwardly rectifying Kir6.1 or Kir6.2) pore-
forming subunit and a sulfonylurea receptor (SUR1 or SUR2) subunit which 
binds ATP (Inagaki et al., 1995; Sakura et al., 1995). KATP channels are 
ubiquitously expressed across the basal ganglia and the cortex but the 
expression of subunits differs across regions (Liss et al., 2005; Schiemann et 
al., 2012). For example in the SN (an area with enhanced vulnerability to 
Parkinson’s pathology), the expression of SUR1 is two-fold higher than in the 
VTA (a region less susceptible to damage), providing a potential reason for the 
difference in vulnerability (Han et al., 2018; Liss et al., 2005). An upregulation 
of SUR1 (but not SUR2B or Kir6.2) has also been confirmed in both PD brains 
and in alpha synuclein overexpression cultured systems suggesting that SUR1 
expression will correlate well with vulnerability to pathology (Liss et al., 2005). 
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In dopaminergic neurons of the substantia nigra, KATP channels are more 
sensitive to mitochondrial complex I inhibitors, like rotenone or 1-methyl-4-
phenyl- 1,2,3,6-tetrahydropyridine (MPTP), which are commonly used to 
induce models of oxidative stress induced Parkinson’s disease pathology 
which may contribute to their enhanced vulnerability (Han et al., 2018; Röper 
and Ashcroft, 1995; Santos et al., 2019).  
KATP channels also have functions outside of neuroprotection, for example in 
glucose sensing. Within the hypothalamus there are regions of neurons that 
respond to changes in nutrients and hormones and can detect fluctuations in 
glucose levels (Anand et al., 1964; Levin et al., 1999; Oomura et al., 1964) 
which is important to help regulate energy intake (Navarro et al., 1996). These 
neurons can be divided into subgroups that are excited by or inhibited by rises 
in glucose level. In the neurons that are excited by raised glucose, in low 
glucose conditions for example hypoglycaemia, their activity can be regulated 
by the activation of KATP channels, hyperpolarising them and reducing neuronal 
activity (Oomura et al., 1969; Trapp and Ashcroft, 1997). This can occur in the 
absence of any change in ATP/ADP ratio (Dadak et al., 2017). Injection of 
glibenclamide into the ventromedial hypothalamus confirms the role of KATP
channels in neuronal defence against glucose deprivation (Evans et al., 2004).  
KATP channel activity can also be regulated indirectly through glia. The 
subfornical organ (SFO), which is located on the anterior wall of the third 
ventricle, is a key region for sensing Na concentration to regulate water and 
salt uptake. Here there are glial cells that express Nax channels are coupled 
to the Na+/K+-ATPase (Shimizu et al., 2007). When Nax channels open the 
Na+/K+-ATPase is activated and consumes more ATP. Glucose is taken up 
into glial cells which is used in anaerobic glycolysis to produce ATP to fuel the 
pump. Lactate is also produced as a by-product and is then released from the 
glial cells. The Nax-positive glial cells surround a population of GABAergic 
neurons in the SFO (Hiyama and Noda, 2016; Watanabe et al., 2006). The 
released lactate is taken up into these GABAergic neurons and oxidised 
causing an increase in intracellular ATP which closes KATP channels and thus 
depolarises the neurons and increases their firing rate (Hiyama and Noda, 
2016).  
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Glibenclamide is a commonly used antidiabetic KATP channel inhibitor which 
can act from both sides of the membrane and its action is normally antagonised 
by the presence of internal MgADP (Jiang and Haddad, 1997; Light and 
French, 1994; Ripoll et al., 1993). 100 nM Glibenclamide can counteract the 
opening of KATP channels (and the subsequent conductance changes) that 
occur with the rotenone model of PD (Liss et al., 1999). It has also recently 
been demonstrated (Thakur et al., 2019), that 10 nM alpha synuclein oligomers 
delivered via the patch pipette mediate a reduction in tonic firing and that this 
could be prevented by preincubation of slices (and bath application) with 1 µM 
glibenclamide.  
I therefore repeated my experiments (both control and alpha synuclein 
aggregate introduction after preincubating my slices with 1 µM glibenclamide.  
In control cells, there were no significant differences in any of the measured 
parameters between cells that had or had not been preincubated with 
glibenclamide, suggesting that there are very few KATP channels open 
physiologically. Given that they are inhibited by intracellular ATP and that my 
patch solution contained 2 mM ATP, the closure at rest is not surprising. 
However KATP channels can differ in their affinity for ATP and so there may be 
some channels that are not inhibited by this level of ATP (Allen and Brown, 
2004). There is also evidence that local levels of ATP surrounding the KATP
channel, which can be mediated by glucose transporters in close proximity to 
the KATP channel can influence activation, independently of the global ATP 
level of the neuron, which will be regulated by mitochondrial activity (López-
Gambero et al., 2019; Lynch et al, 1988). Thus despite the high ATP in my 
patch solution KATP channels may still be able to open. It is also possible that 
the effects of alpha synuclein are via a direct action on the channel rather than 
via a reduction in intracellular ATP (as is seen with mitochondrial dysfunction 
in models such as rotenone and MPTP detailed above). Channel openers like 
diazoxide have previously been shown to directly open KATP channels in 
despite the presence of ATP (Schwanstecher et al., 1998), so it is possible that 
αSyn aggregates could have a similar direct action. 
In glibenclamide-preincubated slices, cells that had alpha synuclein 
aggregates introduced displayed a reduction in the aggregate-mediated 
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changes in conductance and excitability, as would be consistent with the 
opening of KATP channels. However, I observed no associated membrane 
hyperpolarisation, which would be expected upon KATP channel activation due 
to the equilibrium potential for K+ being ~ -95 mV (Allen and Brown, 2004; 
Stanford and Lacey, 1995). It could be that this hyperpolarisation is being 
counteracted by the opening of other channels which could depolarise the 
membrane. For example it has been reported that alpha synuclein itself can 
form non-selective cation channels as well as inducing local spontaneous 
increases in intracellular Na+ and Ca+ channels, depolarising neurons and 
stimulating the opening of KATP channels (Mironov, 2015). Dopaminergic 
neurons in the substantia nigra have prominent cyclic nucleotide gated HCN 
channels I(h) which are activated by hyperpolarisation. They have a reversal 
potential of ~-40 to -30 mV (Mayer and Westbrook, 1983). It is possible that 
the introduction of alpha synuclein oligomers only opens a relatively small 
number of KATP channels so is insufficient to change the membrane potential 
against the responsive reaction of I(h), however enough are opened to 
generate the changes to the input resistance/conductance of neurons. 
Whereas, in models where the intracellular ATP concentration is depleted or 
in the presence of KATP channel openers, many more KATP channels may be 
opened, overcoming the effects of I(h) leading to robust membrane 
hyperpolarisation, as is commonly reported (Stanford and Lacey, 1995). To 
definitively show that KATP is the channel involved in this conductance change 
then a transgenic mouse where the KATP gene has been deleted or using a cell 
line expressing the KATP channels that are normally present in the substantia 
nigra would be needed. These would-be good follow up experiments from this 
study.  
In terms of pathology, it is possible that the accumulation of alpha synuclein 
aggregates in substantia nigra dopaminergic neurons during Parkinson’s 
disease progression could potentially result in the prolonged activation of KATP
channels which would chronically reduce electrical activity and also reduce the 
amount of dopamine released (Avshalumov and Rice, 2003; Patel et al., 2011), 
which will be detrimental to neuron function with the loss of the metabolic 
feedback mechanism. This is supported by retrospective epidemiological 
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evidence that there is a reduced risk for developing Parkinson’s disease in 
type 2 diabetic patients that have been treated with KATP inhibitors (Brauer et 
al., 2015; Cereda et al., 2013; Lu et al., 2014; Schernhammer et al., 2011; 
Wahlqvist et al., 2012).  
In future experiments, it would be good to be able to determine fully the 
relationship between aggregated αSyn and KATP channels. The opening of 
KATP channels by aggregated αSyn occurs despite the presence of 2 mM ATP 
and phosphocreatine in the patch pipette. Thus, it is likely to be a direct effect 
on the channel. To test this, I would express recombinant KATP channels and 
measure the effects of aggregated αSyn introduced via the patch pipette. I will 
also investigate whether there are smaller effects in less vulnerable regions of 
DNs to PD pathology (e.g., VTA) as they are known to have different KATP
subunit expression (Liss et al., 2005). Single-cell RT-PCR could also be used 
to quantify the expression of different KATP subunits which can be correlated 
with changes in neuronal function.  
7.3.5 Mosaic effect of aggregated alpha synuclein in layer V of the 
cortex 
My lab had previously published a study in which oligomeric forms of alpha 
synuclein protein (500 nM) were introduced into single layer V neurons in the 
neocortex via the patch pipette (Kaufmann et al., 2016). They reported a very 
rapid time-dependent decrease in input resistance (occurring in the first 8 
minutes of recording) and then a plateau for the remainder of the recording 
time. They also observed a decrease in both the firing rate of cells and the 
width of evoked action potentials (Kaufmann et al., 2016).  In a subset of 
experiments, I decided to replicate this study and check that my aggregates 
had the same effects. I recorded from layer V pyramidal neurons in the 
neocortex (identified by their location, electrophysiological phenotype, and 
profile after being filled with Alexa fluor dye) and introduced either alpha 
synuclein 500 nM (n=9) or PBS (vehicle, n=9), in the internal solution to single 
neurons through the patch pipette. The mice were age-matched to the original 
study and the same concentration of oligomer was used. I observed that half 
of the recorded neurons exhibited a similar phenotype (decrease in input 
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resistance and firing rate) but that there were also a number of unaffected 
neurons. In the original study, two mutations commonly found in PD which 
make alpha synuclein more prone to aggregation had been induced 
(E46K,Y39W; Kaufmann et al., 2016). The alpha synuclein used in my study 
was wild type, so will be less prone to aggregation which might explain why 
the effects that I observed were less rapid.  
In future studies it would be interesting to explore why only some neurons are 
affected. It is well established that the endogenous expression of alpha 
synuclein varies from cell to cell across regions like the cortex. Recently a 
number of important studies have indicated that the ability of alpha synuclein 
aggregates to seed pathology (upon spreading between neurons) is reliant on 
the recipient neuron expressing endogenous alpha synuclein (Courte et al., 
2020; Luna et al., 2018). In cell culture models where alpha synuclein was 
knocked out, it was not possible to seed the pathology into the neurons (Courte 
et al., 2020). In two further studies, antisense oligonucleotides were used to 
knockdown alpha synuclein mRNA and protein, both in vitro and in vivo and 
this prevented the seeding of pathology and ameliorated neurological deficits 
(Alarcón-Arís et al., 2018; Uehara et al., 2019). A limitation of these studies is 
that they cannot answer whether these neurons are directly affected (after the 
aggregates have been up taken into the cells) or whether the uptake of the 
aggregates are blocked by the lack of endogenous alpha synuclein. I would 
like to implement my single cell delivery method to assess whether the cells 
are actually immune to the aggregate-mediated pathology when it is 
introduced directly or whether it is just blocking the uptake step. This could be 
done effectively using single cell RT-PCR to quantify and correlate the 
electrophysiological responses with the expression of endogenous alpha 
synuclein or by performing the experiments in a recently developed alpha 
synuclein GFP tagged mouse model (Caputo et al., 2020).  
Therapeutically there is potential to utilise this to try to combat alpha synuclein-
mediated pathology and associated degeneration. A number of different 
approaches are being trialled including the application CRISPR-deactivated 
Cas9 to downregulate the levels of SNCA in patient-derived dopaminergic 
neurons. This downregulation was sufficient to prevent the mitochondrial ROS 
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production and rescue cellular viability. As discussed in the introduction, one 
of the key limitations to dopaminergic neuron grafts in gene therapy is that the 
grafted neurons are themselves susceptible to the pathology over time. If by 
knocking down alpha synuclein, these new neurons are no longer susceptible 
to pathology, then that would be a huge advance on the potential that the 
treatment can give in terms of longevity of quality of life.  
7.4 Chapter 6 – CO2 sensitivity in two key dopaminergic nuclei 
It is well established that Connexin 26 hemichannels are directly sensitive to 
physiological changes in the level of CO2. Raised CO2 directly mediates the 
carbamylation of lysine 125 (de Wolf et al., 2016; Huckstepp et al., 2010b, 
2010a; Meigh et al., 2013) and increases their open probability. Therefore, an 
increase in CO2 will increase whole-cell conductance. CO2 sensitive connexins 
are normally found in astrocytes or oligodendrocytes, for example on the 
surface of the medulla oblongata (Nagy et al., 2011; van de Wiel et al., 2020).  
Dopaminergic neurons were first discovered to be electrically coupled by gap 
junctions by Grace and Bunney, (1983) using a combination of 
electrophysiology and dye-coupling experiments. This was confirmed by a 
separate study (Vandecasteele et al., 2005) and later the same group went on 
to evaluate the expression profile of connexins in dopaminergic neurons using 
single cell RT-PCR (Vandecasteele et al., 2006). In P7-10 mice, connexins 26 
and 30 were both present, but the expression is gone by P17, demonstrating 
a developmental switch in expression (Vandecasteele et al 2006). It is well 
established that Connexin 26 hemichannels are directly sensitive to 
physiological changes in the level of CO2. Raised CO2 directly mediates the 
carbamylation of lysine 125 (de Wolf et al., 2016; Huckstepp et al., 2010b, 
2010a; Meigh et al., 2013) and increases their open probability. Therefore, an 
increase in CO2 will increase whole-cell conductance. It is particularly intriguing 
as CO2 sensitive connexins are normally found in astrocytes or 
oligodendrocytes, for example on the surface of the medulla oblongata (Nagy 
et al., 2011; van de Wiel et al., 2020). A limitation of single cell RT-PCR is that 
it does not tell you that the protein is there or that it is functional, just that there 
234 
Cx26 is expressed. I therefore used electrophysiology and dye-loading to look 
for the presence of functional connexin hemichannels.  
7.4.1 CO2-sensitivity in substantia nigra dopaminergic neurons is 
dependent on developmental stage 
Dopaminergic neurons were identified by their electrophysiological profile and 
using immunohistochemistry. I did not find evidence of dye coupling between 
neurons that I had filled for identification, this is likely because Alexa Fluor 594 
cannot easily pass through Cx26 channels (Weber et al., 2004). In substantia 
nigra DNs of P7-10 mice (but not P17-20 or control mice), when CO2 was 
raised from 35 mm Hg CO2 to 55 mm Hg CO2, an increase in whole-cell 
conductance was observed (indicating the opening of a membrane channel). 
In the same mice, the opposite effect (decrease in whole-cell conductance) 
was observed when CO2 was reduced from 35 mm Hg CO2 to 20 mm Hg CO2. 
These observations are in line with the developmental expression profile 
outlined in Vandecasteele’s study (2006). My observations were not an 
artefact of the dialysis of the cell following whole-cell breakthrough as the cells 
were firstly allowed time to equilibrate, then standard and naturalistic currents 
were injected to form IV curves. In a subset of neurons, pharmacological 
agents were applied to characterise the cells (~30 mins to apply and wash) 
prior to the alteration of CO2.  
7.4.2 Comparable sensitivity to CO2 in GABAergic neurons in the 
VTA 
The ventral tegmental area (VTA) is highly heterogeneous and a core region 
of dopaminergic signalling in the brain. It has subgroups of neurons that can 
singularly release dopamine, glutamate or GABA or co-release a combination, 
allowing the VTA to function flexibly (Bouarab et al., 2019; Morales and Root, 
2014; Root et al., 2018; Takata et al., 2018; Yoo et al., 2016). I have 
demonstrated that a subpopulation of VTA GABAergic neurons are also 
directly sensitive to level of CO2 and that this is mediated via connexin 26 
(Cx26) membrane hemichannels. This has potentially interesting implications 
in a number of VTA mediated behaviours including reward, sleep/wake and 
arousal (Bouarab et al., 2019, Eshel et al., 2015; Eban-Rothschild et al., 2016; 
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Fifel et al., 2018; Simmons et al., 2017; Tan et al., 2012; Takata et al., 2018; 
Yu et al., 2019; van Zessen et al., 2012).  
7.4.3 Changes are not mediated by an alteration in pH 
Changing the level of CO2 experimentally (without compensation) will result in 
a change in pH. The role of pH-sensitive receptors in the control of breathing 
is well established, both in the periphery and centrally in the medullary 
chemosensory areas such as the retrotrapezoid nucleus and the medullary 
raphe (Gourine et al., 2010; Hosford et al., 2018; Kumar et al., 2014; 
Loeschcke, 1982; Trapp et al., 2008; Wang et al., 2013). However, there is 
considerable evidence that CO2 can have additional effects that are completely 
independent from pH (Eldridge et al., 1985; Shams, 1985). To separate the 
effects of CO2 from any effects of changing pH, I kept extracellular pH constant 
using isohydric solutions (an increase in pCO2 under these conditions is often 
termed isohydric hypercapnia). It is also well documented that intracellular pH 
will transiently acidify when the level of CO2 is raised and transiently alkalinise 
on its removal (Filosa et al., 2002; Putnam, 2001). In my study, I did not 
measure intracellular changes in pH, however, a mild intracellular acidification 
would be expected to result in hemichannel closure and a decrease in 
conductance. Thus, these transient changes in pH cannot explain the marked 
and sustained changes in conductance that only occur in these specific 
subtypes of neuron. There was also no effect of changing CO2 (with isohydric 
solutions) both on dopaminergic neurons in the substantia nigra of older mice 
(P17-21) and in pyramidal cells in the CA1 region of the hippocampus. If the 
effect was due to pH change (and independent of connexin expression) then 
the same results would be expected in both age groups.  
7.4.4 Whole-cell conductance and neuronal excitability changes 
are mediated by the opening and closing of hemichannels  
Hemichannel function has been overlooked for a long time as focus was placed 
instead on understanding gap junction coupling. However, there is increasing 
evidence that hemichannels have important and independent roles from those 
mediated by gap junctions. Cx26 is a great example of this. It has opposite 
effects on conductance depending on whether it is assembled as part of a 
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hemichannel or as part of a gap junction. These effects observed in my study 
are unlikely to be gap junction-mediated as raised CO2 would close Cx26 gap 
junctions and result in a reduction of the current that can leave the cell, 
therefore increasing the input resistance and neuronal excitability, which is the 
opposite of what was observed in my study (Nijjar et al., 2021). Whereas, if the 
effect of CO2 on cell conductance is due to the opening of Cx26 hemichannels, 
it would be predicted, that since the midpoint of Cx26 hemichannel opening 
lies around the basal level of CO2 in my experiments (Huckstepp et al., 2010b, 
35 mm Hg), that a decrease in pCO2 would close Cx26 hemichannels leading 
to a decrease in the resting conductance. I have presented several lines of 
evidence to confirm that the observed effects are through hemichannels. 
Firstly, the changes in conductance were blocked by carbenoxolone which is 
an indiscriminate hemichannel blocker. It is important to note that although 
carbenoxolone alone can have effects on neuronal and synaptic function 
(Tovar et al., 2009), they would be expected to increase the conductance 
rather than reduce it so the native effects will not influence my results with CO2. 
To further confirm this, I observed no significant differences in 
electrophysiological properties of cells that had been pre-incubated in 
carbenoxolone compared to those that had not. In the Vandecasteele (2006) 
study they looked for functional hemichannels using dye loading with Lucifer 
yellow, in low calcium conditions and found no evidence of dye loading, 
therefore concluding that there are no hemichannels there. However, it could 
be that Lucifer yellow cannot pass through SNpc hemichannels, potentially if 
they are heteromeric they may not let the dye pass through. Instead, I used a 
dye that I knew would be able to pass through connexin 26 hemichannels – 
Carboxyfluorescein (CBF). SN dopaminergic neurons and VTA GABAergic 
neurons could be filled with CBF when pCO2 was increased. Unfortunately, 
CBF cannot be fixed as it does not have the correct chemical groups and so 
the dye-filled cells cannot be subsequently labelled with antibodies (personal 
communication, Dale). However, I can be confident that the dye-filled cells 
were either SN DNs or VTA GABAergic neurons, as patch clamp recording 
was carried out before the dye loading (to confirm the identity of the cells from 
their electrophysiological properties and pharmacology) and then the same 
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region of cells were subsequently dye filled. I have also used 
immunohistochemistry to show that Cx26 protein is expressed in these 
neurons and confirm their identity. The expression pattern of Cx26 across 
development in SN DNs matches that reported for Cx26 mRNA expression 
(Vandecasteele et al., 2006). The same Cx26 antibody has extensively been 
used to study the role of Cx26 in breathing and recent studies have shown that 
there is no Cx26 labelling in Cx26 KO mice, confirming its specificity (Dale, 
personal observation). Cx26 staining of the leptomeninges across 
development was also used as a positive control. A potential limitation of the 
study is that I did not quantify the expression pattern of Connexin 26 in either 
TH+ or GAD+ neurons. In the future, tools like fluorescent in situ hybridisation 
(FISH) could be used to produce more accurate measurements of expression.  
7.4.5 Functional implications in behaviour 
I have described a novel CO2-sensitivity phenotype of dopaminergic neurons 
in the substantia nigra and GABAergic neurons in the VTA. Cx26 open 
probability shifts when the CO2 level changes within a physiological range, 
therefore neuronal excitability and potentially network output could also be 
affected. Given that these regions have important roles in the modulation of 
many behaviours, it is interesting to speculate how this sensitivity could play a 
role in modulating these behaviours through altering neuronal conductance 
and excitability. It is also potentially of interest that it is maintained in the VTA 
but lost in the SN. Maybe it provides some protection by inhibiting activity and 
this is a reason for the vulnerability of SN vs VTA neurons in PD.  
Given that the substantia nigra is involved in the co-ordination of movement, 
in future experiments it would be interesting to evaluate whether CO2-mediated 
changes to neuronal excitability alter the amount of dopamine that is released 
in the striatum and whether this has functional implications. Another intriguing 
finding was that the expression of Cx26 switches from neurons in young mice 
to glial cells after P17. This may be representing a shift from inhibition to 
excitation as in the neurons, raising CO2 levels resulted in an inhibition of 
activity, whereas in glial cells that express connexin 26, when CO2 is raised, 
molecules such as ATP are released (Huckstepp et al., 2010a) which would 
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excite dopaminergic neurons. Changes to dopamine release could be 
measured with fast-scan cyclic voltammetry (FSCV), using carbon fibre 
microelectrodes for detection as they are highly sensitive to monoamines 
(Puthongkham and Venton, 2020; Stamford, 1990).  The age of the mice might 
make recording release challenging and it is not known whether connexin 26 
is present at the terminals in the striatum. The sensitivity in the VTA is 
maintained up to P17-21 (at least). However, I have only examined a subset 
of GABAergic VTA neurons, which show sensitivity to [Met]enkephalin. If other 
VTA GABAergic or DNs are insensitive to CO2, then exposure to CO2 could 
differentially shift the output of the VTA.  
VTA GABAergic neurons directly modulate the activity of neighbouring 
dopaminergic neurons (DNs) locally as well as have long range projections 
(Bouarab et al., 2019). I would like to explore whether the CO2-mediated 
changes in GABAergic firing pattern that I observe in vitro would translate into 
an alteration in dopamine release in vivo. FSCV can be used in vivo (Fortin et 
al., 2015), however recent advances in the generation of fluorescent dopamine 
sensors allow for easier detection using fibre photometry (Patriarchi et al., 
2018; Robinson et al., 2019). In order to determine which dopaminergic 
projections are affected by VTA GABAergic CO2 sensitivity, I could make viral 
injections into potential DN target sites including the nucleus accumbens and 
prefrontal cortex to induce expression of the fluorescent dopamine sensor, 
dLight (Patriarchi et al., 2018; Robinson et al., 2019). Then I could use fibre 
photometry in a simple open field test to look for changes in dopamine release 
as CO2 levels are manipulated.  
GABA neurons in the VTA also have established roles in sleep/ wake and 
arousal behaviours (Eban-Rothschild et al., 2016; Fifel et al., 2018; Takata et 
al., 2018; Yu et al., 2019). Thus, modulation of their activity by changing levels 
the of CO2 could potentially alter arousal and wakefulness and directly impact 
purposeful behaviours. To examine this, I could use a recently developed 
genetic tool, the viral construct Cx26DN (dominant negative), which allows 
connexin 26 to assemble into hemichannels but prevents them from opening 
in response to CO2. I would target this virus into GABAergic VTA neurons to 
remove the sensitivity. I could then verify the loss of sensitivity using 
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immunohistochemistry, electrophysiology and dye loading before investigating 
whether Cx26 contributes to the VTA GABAergic role in arousal. To do this, I 
could use fibre photometry to record dopamine release while monitoring sleep 
states with EEG/EMG recordings and combine this with whole body 
plethysmography to evaluate changes to breathing as I manipulate CO2 levels.  
In the VTA, both dopaminergic neurons and the neighbouring GABAergic 
neurons are directly involved in reward and aversion-related behaviours 
(Bouarab et al., 2019; Eshel et al., 2015; McCutcheon et al., 2012; Tan et al., 
2012; van Zessen et al., 2012). I could also combine fibre photometry with 
behavioural analysis to determine whether there is an alteration in normal 
reward responses (e.g., response to un-signalled sugar pellet delivery or 
reward-predictive stimuli) as CO2 levels are manipulated. Drugs of abuse can 
act to suppress the inhibitory activity of GABAergic neurons that synapse onto 
dopaminergic neurons, thus increasing their activity. I could explore whether 
the rewarding properties of these drugs (e.g., cocaine, opiates, 
benzodiazepines) are altered as I manipulate CO2 levels. This could lead to 
radically novel therapeutic possibilities for managing responses to these drugs. 
240 
References 
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.H., Castillo, 
P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., 
Phillips, H., Sulzer, D., Rosenthal, A., (2000). Mice lacking alpha-
synuclein display functional deficits in the nigrostriatal dopamine 
system. Neuron 25, 239–252. https://doi.org/10.1016/s0896-
6273(00)80886-7
Abraham, W.C., Jones, O.D., Glanzman, D.L., (2019). Is plasticity of synapses
 the mechanism of long-term memory storage? NPJ Science of 
Learning. 4, 1–10.  https://doi.org/10.1038/s41539-019-0048-y 
Acquarone, E., Argyrousi, E.K., van den Berg, M., Gulisano, W., Fà, M., 
Staniszewski, A., Calcagno, E., Zuccarello, E., D’Adamio, L., Deng, S.-
X., Puzzo, D., Arancio, O., Fiorito, J., (2019). Synaptic and memory 
dysfunction induced by tau oligomers is rescued by up-regulation of the 
nitric oxide cascade. Molecular Neurodegeneration 14, 26. 
https://doi.org/10.1186/s13024-019-0326-4 
Akin, E.J., Solé, L., Dib-Hajj, S.D., Waxman, S.G., Tamkun, M.M., (2015). 
Preferential Targeting of Nav1.6 Voltage-Gated Na+ Channels to the 
Axon Initial Segment during Development. PLoS One 10. 
https://doi.org/10.1371/journal.pone.0124397 
Alarcón-Arís, D., Recasens, A., Galofré, M., Carballo-Carbajal, I., Zacchi, N., 
Ruiz-Bronchal, E., Pavia-Collado, R., Chica, R., Ferrés-Coy, A., Santos, 
M., Revilla, R., Montefeltro, A., Fariñas, I., Artigas, F., Vila, M., 
Bortolozzi, A., (2018). Selective αSynuclein Knockdown in Monoamine 
Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for 
Parkinson’s Disease. Molecular Therapy: The Journal of the American 
Society of Gene Therapy 26, 550–567. 
https://doi.org/10.1016/j.ymthe.2017.11.015 
Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, 
N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, 
P.J., Carrillo, M.C., Thies, B., Phelps, C.H., (2011). The diagnosis of 
mild cognitive impairment due to Alzheimer’s disease: 
recommendations from the National Institute on Aging-Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s 
disease. Alzheimer's & Dementia: The Journal of the Alzheimer's 
Association 7, 270–279. https://doi.org/10.1016/j.jalz.2011.03.008 
Alderson, T.R., Markley, J.L., (2013). Biophysical characterization of 
αSynuclein and its controversial structure. Intrinsically Disordered 
Proteins 1, 18–39. https://doi.org/10.4161/idp.26255 
241 
Allen, T.G.J., Brown, D.A., (2004). Modulation of the excitability of cholinergic 
basal forebrain neurons by KATP channels. Journal of Physiology 554, 
353–370. https://doi.org/10.1113/jphysiol.2003.055889 
Alonso, A. del C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., Iqbal, K., 
(2004). Promotion of Hyperphosphorylation by Frontotemporal 
Dementia Tau Mutations. Journal of Biological Chemistry 279, 34873–
34881. https://doi.org/10.1074/jbc.M405131200 
Alonso, A.D., Beharry, C., Corbo, C.P., Cohen, L.S., (2016). Molecular 
mechanism of prion-like tau-induced neurodegeneration. Alzheimers 
Dementia 12, 1090–1097. https://doi.org/10.1016/j.jalz.2015.12.014 
Alves-Rodrigues, A., Gregori, L., Figueiredo-Pereira, M.E., (1998). Ubiquitin, 
cellular inclusions and their role in neurodegeneration. Trends in 
Neurosciences 21, 516–520. https://doi.org/10.1016/s0166-
2236(98)01276-4 
Amaral, D., Lavenex, P., (2007). Hippocampal neuroanatomy, in: The 
Hippocampus Book. Oxford University Press, New York, NY, US, pp. 
37–114. 
Anand, B.K., Chhina, G.S., Sharma, K.N., Dua, S., Singh, B., (1964). Activity 
of single neurons in the hypothalamic feeding centers: effect of glucose. 
American Journal of Physiology. 207, 1146–1154. 
https://doi.org/10.1152/ajplegacy.1964.207.5.1146 
Anderson, P., Morris, R., Amaral, D., Bliss, T., O’keefe, J., (2009). The 
Hippocampus Book, The Hippocampus Book. Oxford University Press, 
New York, NY, US. 
Andorfer, C., Acker, C.M., Kress, Y., Hof, P.R., Duff, K., Davies, P., (2005). 
Cell-cycle reentry and cell death in transgenic mice expressing 
nonmutant human tau isoforms. Journal of Neurosciences 25, 5446–
5454. https://doi.org/10.1523/JNEUROSCI.4637-04.2005 
Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K.L., Barde, Y.-A., 
Duff, K., Davies, P., (2003). Hyperphosphorylation and aggregation of 
tau in mice expressing normal human tau isoforms. Journal of 
Neurochemistry 86, 582–590. https://doi.org/10.1046/j.1471-
4159.2003.01879.x 
Apostolides, P.F., Milstein, A.D., Grienberger, C., Bittner, K.C., Magee, J.C., 
(2016). Axonal Filtering Allows Reliable Output during Dendritic 
Plateau-Driven Complex Spiking in CA1 Neurons. Neuron 89, 770–783. 
https://doi.org/10.1016/j.neuron.2015.12.040 
Ar, A., Arieli, R., Shkolnik, A., (1977). Blood-gas properties and function in the
 fossorial mole rat under normal and hypoxic-hypercapnic atmospheric
242 
 conditions. Respiration Physiology 30, 201–219. 
https://doi.org/10.1016/0034- 5687(77)90031-7 
Arieli, R., Ar, A., Shkolnik, A., (1977). Metabolic Responses of a Fossorial 
 Rodent (Spalax ehrenbergi) to Simulated Burrow Conditions. 
Physiological Zoology. 50, 61–75.
doi.org/10.1086/physzool.50.1.30155716 
Arthur, J.S.C., Fong, A.L., Dwyer, J.M., Davare, M., Reese, E., Obrietan, K., 
Impey, S., (2004). Mitogen- and Stress-Activated Protein Kinase 1 
Mediates cAMP Response Element-Binding Protein Phosphorylation 
and Activation by Neurotrophins. Journal of Neurosciences. 24, 4324–
4332. https://doi.org/10.1523/JNEUROSCI.5227-03.2004 
Atri, A., (2019). The Alzheimer’s Disease Clinical Spectrum: Diagnosis and 
Management. The Medical Clinics of North America 103, 263–293. 
https://doi.org/10.1016/j.mcna.2018.10.009 
Avila, J., (2010). Intracellular and Extracellular Tau. Frontiers in Neuroscience. 
4. https://doi.org/10.3389/fnins.2010.00049 
Avila, J., Santa-María, I., Pérez, M., Hernández, F., Moreno, F., (2006). Tau 
phosphorylation, aggregation, and cell toxicity. Journal of Biomedicine 
& Biotechnology 74539. https://doi.org/10.1155/JBB/2006/74539 
Avshalumov, M.V., Rice, M.E., (2003). Activation of ATP-sensitive K+ (KATP) 
channels by H2O2 underlies glutamate-dependent inhibition of striatal 
dopamine release. Proceedings of the National Academy of Sciences 
100, 11729–11734. https://doi.org/10.1073/pnas.1834314100 
Baas, P.W., Qiang, L., (2019). Tau: It’s Not What You Think. Trends in Cell 
Biology 29, 452–461. https://doi.org/10.1016/j.tcb.2019.02.007 
Backlund, E.O., Granberg, P.O., Hamberger, B., Knutsson, E., Mårtensson, 
A., Sedvall, G., Seiger, A., Olson, L., (1985). Transplantation of adrenal 
medullary tissue to striatum in parkinsonism. First clinical trials. Journal 
of Neurosurgery 62, 169–173, doi.org/10.3171/jns.1985.62.2.0169 
Badel, L., Lefort, S., Berger, T.K., Petersen, C.C.H., Gerstner, W., Richardson, 
M.J.E., (2008a). Extracting non-linear integrate-and-fire models from 
experimental data using dynamic I–V curves. Biological Cybernetics 99, 
361–370. https://doi.org/10.1007/s00422-008-0259-4 
Badel, L., Lefort, S., Brette, R., Petersen, C.C.H., Gerstner, W., Richardson, 
M.J.E., (2008b). Dynamic I-V Curves Are Reliable Predictors of 
Naturalistic Pyramidal-Neuron Voltage Traces. Journal of 
Neurophysiology 99, 656–666. https://doi.org/10.1152/jn.01107.2007 
Badin, R.A., Binley, K., Van Camp, N., Jan, C., Gourlay, J., Robert, C., 
Gipchtein, P., Fayard, A., Stewart, H., Ralph, G.S., Lad, Y., Kelleher, 
243 
M., Loader, J., Hosomi, K., Palfi, S., Mitrophanous, K.A., Hantraye, P., 
(2019). Gene Therapy for Parkinson’s Disease: Preclinical Evaluation 
of Optimally Configured TH:CH1 Fusion for Maximal Dopamine 
Synthesis. Molecular Therapy - Methods & Clinical Development 14, 
206–216. https://doi.org/10.1016/j.omtm.2019.07.002 
Bakshi, R., Macklin, E.A., Hung, A.Y., Hayes, M.T., Hyman, B.T., Wills, A.-M., 
Gomperts, S.N., Growdon, J.H., Ascherio, A., Scherzer, C.R., 
Schwarzschild, M.A., (2020). Associations of Lower Caffeine Intake and 
Plasma Urate Levels with Idiopathic Parkinson’s Disease in the Harvard 
Biomarkers Study. Journal of Parkinson's Disease. 10, 505–510. 
https://doi.org/10.3233/JPD-191882 
Ballard, I.C., Wagner, A.D., McClure, S.M., (2019). Hippocampal pattern 
separation supports reinforcement learning. Nature Communications 
10, 1073. https://doi.org/10.1038/s41467-019-08998-1 
Balschun, D., Wolfer, D.P., Gass, P., Mantamadiotis, T., Welzl, H., Schütz, G., 
Frey, J.U., Lipp, H.-P., (2003). Does cAMP Response Element-Binding 
Protein Have a Pivotal Role in Hippocampal Synaptic Plasticity and 
Hippocampus-Dependent Memory? Journal of Neuroscience 23, 6304–
6314. https://doi.org/10.1523/JNEUROSCI.23-15-06304.2003 
Barco, A., Alarcon, J.M., Kandel, E.R., (2002). Expression of constitutively 
active CREB protein facilitates the late phase of long-term potentiation 
by enhancing synaptic capture. Cell 108, 689–703. 
https://doi.org/10.1016/s0092-8674(02)00657-8 
Barghorn, S., Davies, P., Mandelkow, E., (2004). Tau paired helical filaments 
from Alzheimer’s disease brain and assembled in vitro are based on 
beta-structure in the core domain. Biochemistry 43, 1694–1703. 
https://doi.org/10.1021/bi0357006 
Barker, R.A., Drouin-Ouellet, J., Parmar, M., (2015). Cell-based therapies for 
Parkinson disease—past insights and future potential. Nature Reviews 
Neurology 11, 492–503. https://doi.org/10.1038/nrneurol.2015.123 
Barnard, N.D., Bush, A.I., Ceccarelli, A., Cooper, J., de Jager, C.A., Erickson, 
K.I., Fraser, G., Kesler, S., Levin, S.M., Lucey, B., Morris, M.C., Squitti, 
R., (2014). Dietary and lifestyle guidelines for the prevention of 
Alzheimer’s disease. Neurobiol. Aging, International Conference on 
Nutrition and the Brain 35, S74–S78. 
https://doi.org/10.1016/j.neurobiolaging.2014.03.033 
Barter, J.W., (2015). The Role of the Substantia Nigra in Goal Directed 
Behavior. 
Bar-Yehuda, D., Korngreen, A., (2008). Space-Clamp Problems When Voltage 
Clamping Neurons Expressing Voltage-Gated Conductances. Journal 
244 
of Neurophysiology 99, 1127–1136. 
https://doi.org/10.1152/jn.01232.2007 
Barz, S., Hummel, T., Pauli, E., Majer, M., Lang, C.J., Kobal, G., (1997). 
Chemosensory event-related potentials in response to trigeminal and 
olfactory stimulation in idiopathic Parkinson’s disease. Neurology 49, 
1424–1431. https://doi.org/10.1212/wnl.49.5.1424 
Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, 
N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., 
Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, 
B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., 
Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, 
S., Morris, J.C., (2012). Clinical and Biomarker Changes in Dominantly 
Inherited Alzheimer’s Disease. New England Journal of Medicine 367, 
795–804. https://doi.org/10.1056/NEJMoa1202753 
Beharry, C., Cohen, L.S., Di, J., Ibrahim, K., Briffa-Mirabella, S., Alonso, A. del 
C., (2014). Tau-induced neurodegeneration: mechanisms and targets. 
Neuroscience Bulletin 30, 346–358. https://doi.org/10.1007/s12264-
013-1414-z 
Bekris, L.M., Yu, C.-E., Bird, T.D., Tsuang, D.W., (2010). Genetics of 
Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology. 23, 
213–227.  https://doi.org/10.1177/0891988710383571 
Berker, A.O. de, Rutledge, R.B., (2014). A Role for the Human Substantia 
Nigra  in Reinforcement Learning. Journal of Neuroscience. 34, 12947–12949. 
https://doi.org/10.1523/JNEUROSCI.2854-14.2014 
Berger, A.A., Winnick, A., Welschmeyer, A., Kaneb, A., Berardino, K., Cornett, 
E.M., Kaye, A.D., Viswanath, O., Urits, I., (2020). Istradefylline to Treat 
Patients with Parkinson’s Disease Experiencing “Off” Episodes: A 
Comprehensive Review. Neurology International. 12, 109–129. 
https://doi.org/10.3390/neurolint12030017 
Berger, T., Larkum, M.E., Lüscher, H.-R., (2001). High I h Channel Density in 
the Distal Apical Dendrite of Layer V Pyramidal Cells Increases 
Bidirectional Attenuation of EPSPs. Journal of Neurophysiology 85, 
855–868. https://doi.org/10.1152/jn.2001.85.2.855 
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, 
F., (1973). Brain dopamine and the syndromes of Parkinson and 
Huntington. Clinical, morphological and neurochemical correlations. 
Journal of Neurological Sciences 20, 415–455. 
https://doi.org/10.1016/0022-510x(73)90175-5 
245 
Bertler, Å., Rosengren, E., (1959). Occurrence and distribution of dopamine in 
brain and other tissues. Experientia 15, 10–11. 
https://doi.org/10.1007/BF02157069 
Bezanilla, F., (2000). The Voltage Sensor in Voltage-Dependent Ion Channels. 
Physiological Reviews 80, 555–592. 
https://doi.org/10.1152/physrev.2000.80.2.555 
Bezanilla, F. and Armstrong, C., (1977). Inactivation of the sodium channel. I. 
Sodium current experiments. Journal of General Physiology, 70(5), 
 pp.549-566. 
Bezanson, J., Edelman, A., Karpinski, S., Shah, V.B., (2017). Julia: A Fresh 
Approach to Numerical Computing. SIAM Review 59, 65–98. 
https://doi.org/10.1137/141000671 
Bhatia, A., Lenchner, J.R., Saadabadi, A., (2021). Biochemistry, Dopamine 
Receptors, in: StatPearls. StatPearls Publishing, Treasure Island (FL). 
Binde, C.D., Tvete, I.F., Gåsemyr, J.I., Natvig, B., Klemp, M., (2020). 
Comparative effectiveness of dopamine agonists and monoamine 
oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment 
comparison meta-analysis. European Journal of Clinical Pharmacology. 
76, 1731–1743.  https://doi.org/10.1007/s00228-020-02961-6 
Binder, L.I., Frankfurter, A., Rebhun, L.I., (1985). The distribution of tau in the 
mammalian central nervous system. Journal of Cell Biology 101, 1371–
1378. https://doi.org/10.1083/jcb.101.4.1371 
Bland, B., (1986). The physiology and pharmacology of hippocampal formation 
theta rhythms. Progress in Neurobiology, 26(1), pp.1-54. 
Bliss, T.V., Gardner-Medwin, A.R., (1973). Long-lasting potentiation of 
synaptic transmission in the dentate area of the unanaestetized rabbit 
following stimulation of the perforant path. Journal of Physiology 232, 
357–374. https://doi.org/10.1113/jphysiol.1973.sp010274 
Bliss, T.V.P., Collingridge, G.L., (1993). A synaptic model of memory: long-
term potentiation in the hippocampus. Nature 361, 31–39. 
https://doi.org/10.1038/361031a0 
Bliss, T.V.P., Lømo, T., (1973). Long-lasting potentiation of synaptic 
transmission in the dentate area of the anaesthetized rabbit following 
stimulation of the perforant path. The Journal of Physiology 232, 331–
356. https://doi.org/10.1113/jphysiol.1973.sp010273 
Boado, R.J., Pardridge, W.M., (2009). Comparison of Blood-Brain Barrier 
Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-
GDNF Fusion Protein in the Rhesus Monkey. Drug Metabolism and 
Disposition. 37,  2299–2304. https://doi.org/10.1124/dmd.109.028787 
246 
Bohnen, N.I., Albin, R.L., (2011). The cholinergic system and Parkinson 
disease. Behavioural Brain Research 221, 564–573. 
https://doi.org/10.1016/j.bbr.2009.12.048 
Boiko, T., Rasband, M.N., Levinson, S.R., Caldwell, J.H., Mandel, G., Trimmer, 
J.S., Matthews, G., (2001). Compact myelin dictates the differential 
targeting of two sodium channel isoforms in the same axon. Neuron 30, 
91–104. https://doi.org/10.1016/s0896-6273(01)00265-3 
Boluda, S., Iba, M., Zhang, B., Raible, K.M., Lee, V.M.-Y., Trojanowski, J.Q., 
(2015). Differential induction and spread of tau pathology in young 
PS19 tau transgenic mice following intracerebral injections of 
pathological tau from Alzheimer’s disease or corticobasal degeneration 
brains. Acta Neuropathologica 129, 221–237. 
https://doi.org/10.1007/s00401-014-1373-0 
Booth, C.A., Witton, J., Nowacki, J., Tsaneva-Atanasova, K., Jones, M.W., 
Randall, A.D., Brown, J.T., (2016). Altered Intrinsic Pyramidal Neuron 
Properties and Pathway-Specific Synaptic Dysfunction Underlie 
Aberrant Hippocampal Network Function in a Mouse Model of 
Tauopathy. Journal of Neurosciences 36, 350–363. 
https://doi.org/10.1523/JNEUROSCI.2151-15.2016 
Bordia, T., Parameswaran, N., Fan, H., Langston, J.W., McIntosh, J.M., Quik, 
M., (2006). Partial recovery of striatal nicotinic receptors in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with 
chronic oral nicotine. Journal of Pharmacology and Experimental 
Therapeutics. 319, 285–292.  https://doi.org/10.1124/jpet.106.106997 
Bouarab, C., Thompson, B., Polter, A.M., (2019). VTA GABA Neurons at the 
Interface of Stress and Reward. Frontiers in Neural Circuits 13. 
https://doi.org/10.3389/fncir.2019.00078 
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., Silva, A.J., 
(1994). Deficient long-term memory in mice with a targeted mutation of 
the cAMP-responsive element-binding protein. Cell 79, 59–68. 
https://doi.org/10.1016/0092-8674(94)90400-6 
Boutajangout, A., Ingadottir, J., Davies, P., Sigurdsson, E.M., (2011). Passive 
immunization targeting pathological phospho-tau protein in a mouse 
model reduces functional decline and clears tau aggregates from the 
brain. Journal of Neurochemistry 118, 658–667. 
https://doi.org/10.1111/j.1471-4159.2011.07337.x 
Braak, H., Braak, E., (1991). Neuropathological stageing of Alzheimer-related 
changes. Acta Neuropathologica 82, 239–259. 
https://doi.org/10.1007/BF00308809 
247 
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., 
Rüb, U., (2002). Staging of the intracerebral inclusion body pathology 
associated with idiopathic Parkinson’s disease (preclinical and clinical 
stages). Journal of Neurology 249 Suppl 3, III/1-5. 
https://doi.org/10.1007/s00415-002-1301-4 
Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, 
E., (2003). Staging of brain pathology related to sporadic Parkinson’s 
disease. Neurobiology of Aging 24, 197–211. 
https://doi.org/10.1016/s0197-4580(02)00065-9 
Branco, T., Tozer, A., Magnus, C.J., Sugino, K., Tanaka, S., Lee, A.K., Wood, 
J.N., Sternson, S.M., (2016). Near-Perfect Synaptic Integration by 
Nav1.7 in Hypothalamic Neurons Regulates Body Weight. Cell 165, 
1749–1761. https://doi.org/10.1016/j.cell.2016.05.019 
Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D.T., Smeeth, L., Douglas, 
I., (2015). Glitazone Treatment and Incidence of Parkinson’s Disease 
among People with Diabetes: A Retrospective Cohort Study. PLoS Med 
12, e1001854. https://doi.org/10.1371/journal.pmed.1001854 
Brotherton, D.H., Savva, C.G., Ragan, T.J., Linthwaite, V.L., Cann, M.J., Dale, 
N., Cameron, A.D., (2020). Conformational changes and channel gating 
induced by CO2 binding to Connexin 26. bioRxiv preprint 
2020.08.11.243964. https://doi.org/10.1101/2020.08.11.243964 
Brown, E.B., (1953). Physiological Effects of Hyperventilation. Physiological 
Reviews  33, 445–471. https://doi.org/10.1152/physrev.1953.33.4.445 
Buchhave, P., Minthon, L., Zetterberg, H., Wallin, Å.K., Blennow, K., Hansson, 
O., (2012). Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, 
Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer 
Dementia. Archives of General Psychiatry 69, 98–106. 
https://doi.org/10.1001/archgenpsychiatry.2011.155 
Bulic, B., Pickhardt, M., Mandelkow, E.-M., Mandelkow, E., (2010). Tau protein 
and tau aggregation inhibitors. Neuropharmacology 59, 276–289. 
https://doi.org/10.1016/j.neuropharm.2010.01.016 
Burgoon, P.W., Boulant, J.A., (2001). Temperature-sensitive properties of rat 
suprachiasmatic nucleus neurons. American Journal of Physiology - 
Regulatory, Integrative and Comparative Physiology 281, R706-715. 
https://doi.org/10.1152/ajpregu.2001.281.3.R706 
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., Südhof, 
T.C., (2010). Alpha-synuclein promotes SNARE-complex assembly in 
vivo and in vitro. Science 329, 1663–1667. 
https://doi.org/10.1126/science.1195227 
248 
Bush, A.I., (2000). Metals and neuroscience. Current Opinions in Chemical 
Biology 4, 184–191. https://doi.org/10.1016/s1367-5931(99)00073-3 
Buzsáki, G., (2002). Theta Oscillations in the Hippocampus. Neuron, 33(3), 
pp.325-340. 
Caceres, A., Kosik, K.S., (1990). Inhibition of neurite polarity by tau antisense 
oligonucleotides in primary cerebellar neurons. Nature 343, 461–463. 
https://doi.org/10.1038/343461a0 
Cai, X.D., Golde, T.E., Younkin, S.G., (1993). Release of excess amyloid beta 
protein from a mutant amyloid beta protein precursor. Science 259, 
514–516. https://doi.org/10.1126/science.8424174 
Calder, W.A., Schmidt-Nielsen, K., (1968). Panting and blood carbon dioxide 
in birds. American Journal of Physiology 215, 477–482. 
https://doi.org/10.1152/ajplegacy.1968.215.2.477 
Caputo, A., Liang, Y., Raabe, T.D., Lo, A., Horvath, M., Zhang, B., Brown, H.J., 
Stieber, A., Luk, K.C., (2020). Snca-GFP Knock-In Mice Reflect 
Patterns of Endogenous Expression and Pathological Seeding. eNeuro 
7. https://doi.org/10.1523/ENEURO.0007-20.2020 
Carlsson, A., (1959). The occurrence, distribution and physiological role of 
catecholamines in the nervous system. Pharmacological Reviews 11, 
490–493. 
Castelli, L., Biella, G., Toselli, M., Magistretti, J., (2007). Resurgent Na+ 
current in pyramidal neurones of rat perirhinal cortex: axonal location of 
channels and contribution to depolarizing drive during repetitive firing. 
The Journal of Physiology 582, 1179–1193. 
https://doi.org/10.1113/jphysiol.2007.135350 
Castillo-Carranza, D.L., Sengupta, U., Guerrero-Muñoz, M.J., Lasagna-
Reeves, C.A., Gerson, J.E., Singh, G., Estes, D.M., Barrett, A.D.T., 
Dineley, K.T., Jackson, G.R., Kayed, R., (2014). Passive immunization 
with Tau oligomer monoclonal antibody reverses tauopathy phenotypes 
without affecting hyperphosphorylated neurofibrillary tangles. Journal of 
Neurosciences 34, 4260–4272. 
https://doi.org/10.1523/JNEUROSCI.3192-13.2014 
Cathala, L., Paupardin-Tritsch, D., (1999). Effect of catecholamines on the 
hyperpolarization-activated cationic Ih and the inwardly rectifying 
potassium I(Kir) currents in the rat substantia nigra pars compacta. 
European Journal of Neurosciences 11, 398–406. 
https://doi.org/10.1046/j.1460-9568.1999.00452.x 
Catterall, W.A., (2012). Voltage-gated sodium channels at 60: structure, 
function, and pathophysiology. Journal of Physiology 590, 2577–2589. 
https://doi.org/10.1113/jphysiol.2011.224204 
249 
Catterall, W.A., (1981). Localization of sodium channels in cultured neural 
cells. Journal of Neurosciences 1, 777–783. 
Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, 
R., Pezzoli, G., (2013). Diabetes and risk of Parkinson’s disease. 
Movement Disorders 28, 257–261. https://doi.org/10.1002/mds.25211 
Chai, X., Wu, S., Murray, T.K., Kinley, R., Cella, C.V., Sims, H., Buckner, N., 
Hanmer, J., Davies, P., O’Neill, M.J., Hutton, M.L., Citron, M., (2011). 
Passive Immunization with Anti-Tau Antibodies in Two Transgenic 
Models: REDUCTION OF TAU PATHOLOGY AND DELAY OF 
DISEASE PROGRESSION. Journal of Biological Chemistry 286, 
34457–34467. https://doi.org/10.1074/jbc.M111.229633 
Chang, E.H., Savage, M.J., Flood, D.G., Thomas, J.M., Levy, R.B., 
Mahadomrongkul, V., Shirao, T., Aoki, C., Huerta, P.T., (2006). AMPA 
receptor downscaling at the onset of Alzheimer’s disease pathology in 
double knockin mice. Proceedings of the National Academy of 
Sciences. 103, 3410–3415. https://doi.org/10.1073/pnas.0507313103 
Chaudhuri, K.R., Healy, D.G., Schapira, A.H.V., National Institute for Clinical 
Excellence, (2006). Non-motor symptoms of Parkinson’s disease: 
diagnosis and management. Lancet Neurology 5, 235–245. 
https://doi.org/10.1016/S1474-4422(06)70373-8 
Checkoway, H., Powers, K., Smith-Weller, T., Franklin, G.M., Longstreth, 
W.T., Swanson, P.D., (2002). Parkinson’s disease risks associated with 
cigarette smoking, alcohol consumption, and caffeine intake. American 
Journal of Epidemiology 155, 732–738. 
https://doi.org/10.1093/aje/155.8.732 
Chen, Y., Dolt, K.S., Kriek, M., Baker, T., Downey, P., Drummond, N.J., 
Canham, M.A., Natalwala, A., Rosser, S., Kunath, T., (2019). 
Engineering synucleinopathy-resistant human dopaminergic neurons 
by CRISPR-mediated deletion of the SNCA gene. European Journal of 
Neuroscience 49, 510–524. https://doi.org/10.1111/ejn.14286 
Chen, H., Huang, X., Guo, X., Mailman, R.B., Park, Y., Kamel, F., Umbach, 
D.M., Xu, Q., Hollenbeck, A., Schatzkin, A., Blair, A., (2010). Smoking 
duration, intensity, and risk of Parkinson disease. Neurology 74, 878–
884. https://doi.org/10.1212/WNL.0b013e3181d55f38 
Chen, J.F., Schwarzschild, M.A., (2020). Do caffeine and more selective 
adenosine A2A receptor antagonists protect against dopaminergic 
neurodegeneration in Parkinson’s disease? Parkinsonism Related  
Disorders 80, S45–S53. 
https://doi.org/10.1016/j.parkreldis.2020.10.024 
250 
Chen, Q., He, Y., Yang, K., (2005). Gene Therapy for Parkinson’s Disease: 
Progress and Challenges. Current Gene Therapy 5, 71–80. 
https://doi.org/10.2174/1566523052997505 
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N.K., 
Shin, Y.-K., (2013). Large αSynuclein oligomers inhibit neuronal 
SNARE-mediated vesicle docking. Proceedings of the National 
Academy of Sciences 110, 4087–4092. 
https://doi.org/10.1073/pnas.1218424110 
Chowdhury, S., Matsubara, T., Miyazaki, T., Ono, D., Fukatsu, N., Abe, M., 
Sakimura, K., Sudo, Y., Yamanaka, A., (2019). GABA neurons in the 
ventral tegmental area regulate non-rapid eye movement sleep in mice. 
eLife 8, e44928. https://doi.org/10.7554/eLife.44928 
Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, 
N.C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., 
Chen, H.-H., Beach, T.G., Lashley, T., Zetterberg, H., Blennow, K., 
Höglund, K., (2019). Novel tau fragments in cerebrospinal fluid: relation 
to tangle pathology and cognitive decline in Alzheimer’s disease. Acta 
Neuropathologica 137, 279–296. https://doi.org/10.1007/s00401-018-
1948-2 
Cieślak, M., Komoszyński, M., Wojtczak, A., (2008). Adenosine A(2A) 
receptors in Parkinson’s disease treatment. Purinergic Signal. 4, 305–
312. https://doi.org/10.1007/s11302-008-9100-8 
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., 
Vigo-Pelfrey, C., Lieberburg, I., Selkoe, D.J., (1992). Mutation of the 
beta-amyloid precursor protein in familial Alzheimer’s disease increases 
beta-protein production. Nature 360, 672–674. 
https://doi.org/10.1038/360672a0 
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., 
Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., 
Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, 
I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., 
Selkoe, D.J., (1997). Mutant presenilins of Alzheimer’s disease 
increase production of 42-residue amyloid beta-protein in both 
transfected cells and transgenic mice. Nature Medicine 3, 67–72. 
https://doi.org/10.1038/nm0197-67 
Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., 
Probst, A., Fraser, G., Stalder, A.K., Beibel, M., Staufenbiel, M., Jucker, 
M., Goedert, M., Tolnay, M., (2009). Transmission and spreading of 
tauopathy in transgenic mouse brain. Nature Cell Bioliogy 11, 909–913. 
https://doi.org/10.1038/ncb1901 
251 
Cleveland, D.W., Hwo, S.Y., Kirschner, M.W., (1977). Purification of tau, a 
microtubule-associated protein that induces assembly of microtubules 
from purified tubulin. Journal of Molecular Biology 116, 207–225. 
https://doi.org/10.1016/0022-2836(77)90213-3 
Condorelli, D.F., Trovato‐Salinaro, A., Mudò, G., Mirone, M.B., Belluardo, N., 
(2003). Cellular expression of connexins in the rat brain: neuronal 
localization, effects of kainate-induced seizures and expression in 
apoptotic neuronal cells. European Journal of Neuroscience 18, 1807–
1827. https://doi.org/10.1046/j.1460-9568.2003.02910.x 
Congdon, E.E., Gu, J., Sait, H.B.R., Sigurdsson, E.M., (2013). Antibody 
Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ 
Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein 
Clearance. Journal of Biological Chemistry 288, 35452–35465. 
https://doi.org/10.1074/jbc.M113.491001 
Congdon, E.E., Kim, S., Bonchak, J., Songrug, T., Matzavinos, A., Kuret, J., 
(2008). Nucleation-dependent tau filament formation: the importance of 
dimerization and an estimation of elementary rate constants. Journal of 
Biological Chemistry 283, 13806–13816. 
https://doi.org/10.1074/jbc.M800247200 
Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, 
P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A., 
(1993). Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer’s disease in late onset families. Science 261, 921–923. 
https://doi.org/10.1126/science.8346443 
Corrêa, S.A.L., Hunter, C.J., Palygin, O., Wauters, S.C., Martin, K.J., 
McKenzie, C., McKelvey, K., Morris, R.G.M., Pankratov, Y., Arthur, 
J.S.C., Frenguelli, B.G., (2012). MSK1 Regulates Homeostatic and 
Experience-Dependent Synaptic Plasticity. Journal of Neuroscience. 
32, 13039–13051. https://doi.org/10.1523/JNEUROSCI.0930-12.2012 
Cotzias, G.C., Papavasiliou, P.S., Gellene, R., (1969). Modification of 
Parkinsonism--chronic treatment with L-dopa. New England Journal of 
Medicine 280, 337–345. 
https://doi.org/10.1056/NEJM196902132800701 
Cotzias, G.C., Van Woert, M.H., Schiffer, L.M., (1967). Aromatic Amino Acids 
and Modification of Parkinsonism. New England Journal of Medicine 
276, 374–379. https://doi.org/10.1056/NEJM196702162760703 
Coune, P.G., Schneider, B.L., Aebischer, P., (2012). Parkinson’s disease: 
gene therapies. Cold Spring Harbor Perspectives in Medicine 2, 
a009431. https://doi.org/10.1101/cshperspect.a009431 
252 
Courte, J., Bousset, L., Boxberg, Y.V., Villard, C., Melki, R., Peyrin, J.-M., 
(2020). The expression level of alpha-synuclein in different neuronal 
populations is the primary determinant of its prion-like seeding. 
Scientific Reports 10, 4895. https://doi.org/10.1038/s41598-020-61757-
x 
Cowan, C.M., Chee, F., Shepherd, D., Mudher, A., (2010). Disruption of 
neuronal function by soluble hyperphosphorylated tau in a Drosophila 
model of tauopathy. Biochemical Society Transactions 38, 564–570. 
https://doi.org/10.1042/BST0380564 
Crimins, J.L., Rocher, A.B., Peters, A., Shultz, P., Lewis, J., Luebke, J.I., 
(2011). Homeostatic responses by surviving cortical pyramidal cells in 
neurodegenerative tauopathy. Acta Neuropathologica 122, 551–564. 
https://doi.org/10.1007/s00401-011-0877-0 
d’Abramo, C., Acker, C.M., Jimenez, H.T., Davies, P., (2013). Tau Passive 
Immunotherapy in Mutant P301L Mice: Antibody Affinity versus 
Specificity. PLOS ONE 8, e62402. 
https://doi.org/10.1371/journal.pone.0062402 
Dadak, S., Beall, C., Vlachaki Walker, J.M., Soutar, M.P.M., McCrimmon, R.J., 
Ashford, M.L.J., (2017). Oleate induces KATP channel-dependent 
hyperpolarization in mouse hypothalamic glucose-excited neurons 
without altering cellular energy charge. Neuroscience 346, 29–42. 
https://doi.org/10.1016/j.neuroscience.2016.12.053 
Dahan, A., Nieuwenhuijs, D., Teppema, L., (2007). Plasticity of Central 
Chemoreceptors: Effect of Bilateral Carotid Body Resection on Central 
CO2 Sensitivity. PLOS Medicine 4, e239. 
https://doi.org/10.1371/journal.pmed.0040239 
Dale, N., (2008). Dynamic ATP signalling and neural development. Journal of 
Physiology 586, 2429–2436. 
https://doi.org/10.1113/jphysiol.2008.152207 
D’Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., 
Diamantini, A., De Zio, D., Carrara, P., Battistini, L., Moreno, S., Bacci, 
A., Ammassari-Teule, M., Marie, H., Cecconi, F., (2011). Caspase-3 
triggers early synaptic dysfunction in a mouse model of Alzheimer’s 
disease. Nature Neurosciences 14, 69–76. 
https://doi.org/10.1038/nn.2709 
Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., (1999). The substantia nigra 
of the human brain: II. Patterns of loss of dopamine-containing neurons 
in Parkinson’s disease. Brain 122, 1437–1448. 
https://doi.org/10.1093/brain/122.8.1437 
253 
Danzer, K.M., Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, 
L., Vanderburg, C.R., McLean, P.J., (2012). Exosomal cell-to-cell 
transmission of alpha synuclein oligomers. Molecular 
Neurodegeneration 7, 42. https://doi.org/10.1186/1750-1326-7-42 
Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I., Vitek, M.P., 
(2001). Inhibition of neuronal maturation in primary hippocampal 
neurons from tau deficient mice. Journal of Cell Science 114, 1179–
1187. 
de Lau, L.M.L., Bornebroek, M., Witteman, J.C.M., Hofman, A., Koudstaal, 
P.J., Breteler, M.M.B., (2005). Dietary fatty acids and the risk of 
Parkinson disease: the Rotterdam study. Neurology 64, 2040–2045. 
https://doi.org/10.1212/01.WNL.0000166038.67153.9F 
de Lau, L.M.L., Breteler, M.M.B., (2006). Epidemiology of Parkinson’s disease. 
Lancet Neurology 5, 525–535. https://doi.org/10.1016/S1474-
4422(06)70471-9 
de Lera Ruiz, M., Kraus, R.L., (2015). Voltage-Gated Sodium Channels: 
Structure, Function, Pharmacology, and Clinical Indications. Journal of 
Medicinal Chemistry 58, 7093–7118. 
https://doi.org/10.1021/jm501981g 
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., 
Annaert, W., Von Figura, K., Van Leuven, F., (1998). Deficiency of 
presenilin-1 inhibits the normal cleavage of amyloid precursor protein. 
Nature 391, 387–390. https://doi.org/10.1038/34910 
de Wolf, E., van de Wiel, J., Cook, J., Dale, N., (2016). Altered CO2 sensitivity 
of connexin26 mutant hemichannels in vitro. Physiological Reports 4. 
https://doi.org/10.14814/phy2.13038 
de Wolf, E., Cook, J., Dale, N., (2017). Evolutionary adaptation of the 
sensitivity of connexin26 hemichannels to CO 2. Proceedings of the 
Royal Society Biological Sciences 284, 20162723. 
https://doi.org/10.1098/rspb.2016.2723 
Debanne, D., Boudkkazi, S., Campanac, E., Cudmore, R.H., Giraud, P., 
Fronzaroli-Molinieres, L., Carlier, E., Caillard, O., (2008). Paired-
recordings from synaptically coupled cortical and hippocampal neurons 
in acute and cultured brain slices. Nature Protocols 3, 1559–1568. 
https://doi.org/10.1038/nprot.2008.147 
Decker, J.M., Krüger, L., Sydow, A., Zhao, S., Frotscher, M., Mandelkow, E., 
Mandelkow, E.-M., (2015). Pro-aggregant Tau impairs mossy fiber 
plasticity due to structural changes and Ca++ dysregulation. Acta 
Neuropathologica Communications 3. https://doi.org/10.1186/s40478-
015-0193-3 
254 
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., 
Singleton, A., Olanow, C.W., Merchant, K.M., Bezard, E., Petsko, G.A., 
Meissner, W.G., (2015). Targeting αSynuclein for treatment of 
Parkinson’s disease: mechanistic and therapeutic considerations. 
Lancet Neurology 14, 855–866. https://doi.org/10.1016/S1474-
4422(15)00006-X 
Del Tredici, K., Rüb, U., De Vos, R.A.I., Bohl, J.R.E., Braak, H., (2002). Where 
does parkinson disease pathology begin in the brain? Journal of 
Neuropathology and Experimental Neurology 61, 413–426. 
https://doi.org/10.1093/jnen/61.5.413 
DeLong, M.R., Wichmann, T., (2007). Circuits and circuit disorders of the basal 
ganglia. Archives of Neurology 64, 20–24. 
https://doi.org/10.1001/archneur.64.1.20 
Deng, W., Aimone, J.B., Gage, F.H., (2010). New neurons and new memories: 
how does adult hippocampal neurogenesis affect learning and 
memory? Nature Reviews Neuroscience 11, 339–350. 
https://doi.org/10.1038/nrn2822 
Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., 
Lees, A.J., Jenner, P., Marsden, C.D., (1991). Alterations in the levels 
of iron, ferritin and other trace metals in Parkinson’s disease and other 
neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 
4), 1953–1975. https://doi.org/10.1093/brain/114.4.1953 
Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., Marsden, 
C.D., (1989). Increased nigral iron content and alterations in other metal 
ions occurring in brain in Parkinson’s disease. Journal of 
Neurochemistry 52, 1830–1836. https://doi.org/10.1111/j.1471-
4159.1989.tb07264.x 
Dhuriya, Y.K., Sharma, D., (2020). Neuronal Plasticity: Neuronal Organization 
is Associated with Neurological Disorders. Journal of Molecular 
Neuroscience. 70, 1684– 1701. https://doi.org/10.1007/s12031-020-
01555-2 
Dickson, D.W., Kouri, N., Murray, M.E., Josephs, K.A., (2011). Neuropathology 
of frontotemporal lobar degeneration-tau (FTLD-tau). Journal of 
Molecular Neurosciences 45, 384–389. https://doi.org/10.1007/s12031-
011-9589-0 
Dickson, D.W., Ruan, D., Crystal, H., Mark, M.H., Davies, P., Kress, Y., Yen, 
S.H., (1991). Hippocampal degeneration differentiates diffuse Lewy 
body disease (DLBD) from Alzheimer’s disease: light and electron 
microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. 
Neurology 41, 1402–1409. https://doi.org/10.1212/wnl.41.9.1402 
255 
Diógenes, M.J., Dias, R.B., Rombo, D.M., Miranda, H.V., Maiolino, F., 
Guerreiro, P., Näsström, T., Franquelim, H.G., Oliveira, L.M.A., 
Castanho, M.A.R.B., Lannfelt, L., Bergström, J., Ingelsson, M., Quintas, 
A., Sebastião, A.M., Lopes, L.V., Outeiro, T.F., (2012). Extracellular 
Alpha-Synuclein Oligomers Modulate Synaptic Transmission and 
Impair LTP Via NMDA-Receptor Activation. Journal of Neuroscience. 
32, 11750–11762. https://doi.org/10.1523/JNEUROSCI.0234-12.2012 
Divac, I., (1975). Magnocellular nuclei of the basal forebrain project to 
neocortex, brain stem, and olfactory bulb. Review of some functional 
correlates. Brain Research 93, 385–398. https://doi.org/10.1016/0006-
8993(75)90178-X 
Diwakar, S., Magistretti, J., Goldfarb, M., Naldi, G., D’Angelo, E., (2009). 
Axonal Na+ Channels Ensure Fast Spike Activation and Back-
Propagation in Cerebellar Granule Cells. Journal of Neurophysiology 
101, 519–532. https://doi.org/10.1152/jn.90382.2008 
Dufour, M.A., Woodhouse, A., Amendola, J., Goaillard, J.-M., (2014). Non-
linear developmental trajectory of electrical phenotype in rat substantia 
nigra pars compacta dopaminergic neurons. eLife 3, e04059. 
https://doi.org/10.7554/eLife.04059 
Dufour, M.A., Woodhouse, A., Amendola, J., Goaillard, J.-M., (2014). Non-
linear developmental trajectory of electrical phenotype in rat substantia 
nigra pars compacta dopaminergic neurons. eLife 3, e04059. 
https://doi.org/10.7554/eLife.04059 
Eban-Rothschild, A., Rothschild, G., Giardino, W.J., Jones, J.R., de Lecea, L., 
(2016). VTA dopaminergic neurons regulate ethologically relevant 
sleep-wake behaviors. Nature Neurosciences 19, 1356–1366. 
https://doi.org/10.1038/nn.4377 
Eftekharzadeh, B., Daigle, J.G., Kapinos, L.E., Coyne, A., Schiantarelli, J., 
Carlomagno, Y., Cook, C., Miller, S.J., Dujardin, S., Amaral, A.S., 
Grima, J.C., Bennett, R.E., Tepper, K., DeTure, M., Vanderburg, C.R., 
Corjuc, B.T., DeVos, S.L., Gonzalez, J.A., Chew, J., Vidensky, S., 
Gage, F.H., Mertens, J., Troncoso, J., Mandelkow, E., Salvatella, X., 
Lim, R.Y.H., Petrucelli, L., Wegmann, S., Rothstein, J.D., Hyman, B.T., 
(2018). Tau Protein Disrupts Nucleocytoplasmic Transport in 
Alzheimer’s Disease. Neuron 99, 925-940.e7. 
https://doi.org/10.1016/j.neuron.2018.07.039 
Eldridge, F.L., Kiley, J.P., Millhorn, D.E., (1985). Respiratory responses to 
medullary hydrogen ion changes in cats: different effects of respiratory 
and metabolic acidoses. The Journal of Physiology 358, 285–297. 
https://doi.org/10.1113/jphysiol.1985.sp015551 
256 
Emborg, M.E., Carbon, M., Holden, J.E., During, M.J., Ma, Y., Tang, C., 
Moirano, J., Fitzsimons, H., Roitberg, B.Z., Tuccar, E., Roberts, A., 
Kaplitt, M.G., Eidelberg, D., (2007). Subthalamic Glutamic Acid 
Decarboxylase Gene Therapy: Changes in Motor Function and Cortical 
Metabolism. J. Cereb. Blood Flow Metab. 27, 501–509. 
https://doi.org/10.1038/sj.jcbfm.9600364 
Eriksen, N., Stark, A.K., Pakkenberg, B., (2009). Age and Parkinson’s disease-
related neuronal death in the substantia nigra pars compacta. Journal 
of Neural Transmission 203–213. https://doi.org/10.1007/978-3-211-
92660-4_16 
Eshel, N., Bukwich, M., Rao, V., Hemmelder, V., Tian, J., Uchida, N., (2015). 
Arithmetic and local circuitry underlying dopamine prediction errors. 
Nature 525, 243–246. https://doi.org/10.1038/nature14855 
Evans, L.D., Wassmer, T., Fraser, G., Smith, J., Perkinton, M., Billinton, A., 
Livesey, F.J., (2018). Extracellular Monomeric and Aggregated Tau 
Efficiently Enter Human Neurons through Overlapping but Distinct 
Pathways. Cell Reports 22, 3612–3624. 
https://doi.org/10.1016/j.celrep.2018.03.021 
Fá, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M.A., 
Li Puma, D.D., Chatterjee, I., Li, J., Saeed, F., Berman, H.L., Ripoli, C., 
Gulisano, W., Gonzalez, J., Tian, H., Costa, J.A., Lopez, P., Davidowitz, 
E., Yu, W.H., Haroutunian, V., Brown, L.M., Palmeri, A., Sigurdsson, 
E.M., Duff, K.E., Teich, A.F., Honig, L.S., Sierks, M., Moe, J.G., 
D’Adamio, L., Grassi, C., Kanaan, N.M., Fraser, P.E., Arancio, O., 
(2016). Extracellular Tau Oligomers Produce An Immediate Impairment 
of LTP and Memory. Scientific Reports 6, 19393. 
https://doi.org/10.1038/srep19393 
Fagan, A.M., Xiong, C., Jasielec, M.S., Bateman, R.J., Goate, A.M., 
Benzinger, T.L.S., Ghetti, B., Martins, R.N., Masters, C.L., Mayeux, R., 
Ringman, J.M., Rossor, M.N., Salloway, S., Schofield, P.R., Sperling, 
R.A., Marcus, D., Cairns, N.J., Buckles, V.D., Ladenson, J.H., Morris, 
J.C., Holtzman, D.M., Dominantly Inherited Alzheimer Network, (2014). 
Longitudinal change in CSF biomarkers in autosomal-dominant 
Alzheimer’s disease. Science Translational Medicine 6, 226ra30. 
https://doi.org/10.1126/scitranslmed.3007901 
Fahn,. Elton, (2003). The Unified Parkinson’s Disease Rating Scale (UPDRS): 
Status and recommendations. Movement Disorders. 18, 738–750. 
https://doi.org/10.1002/mds.10473 
Fan, Y., Winanto, Ng, S.-Y., (2020). Replacing what is lost: a new era of stem 
cell therapy for Parkinson’s disease. Translational Neurodegeneration 
9, 2. https://doi.org/10.1186/s40035-019-0180-x 
257 
Faraci, F.M., Fedde, M.R., (1986). Regional circulatory responses to 
hypocapnia and hypercapnia in bar-headed geese. American Journal 
of Physiology. 250,  R499-504. 
https://doi.org/10.1152/ajpregu.1986.250.3.R499 
Ferreira, D.G., Temido-Ferreira, M., Vicente Miranda, H., Batalha, V.L., 
Coelho, J.E., Szegö, É.M., Marques-Morgado, I., Vaz, S.H., Rhee, J.S., 
Schmitz, M., Zerr, I., Lopes, L.V., Outeiro, T.F., (2017). α-synuclein 
interacts with PrP C to induce cognitive impairment through mGluR5 
and NMDAR2B. Nature Neuroscience 20, 1569–1579. 
https://doi.org/10.1038/nn.4648 
Fifel, K., Meijer, J.H., Deboer, T., (2018). Circadian and Homeostatic 
Modulation of Multi-Unit Activity in Midbrain Dopaminergic Structures. 
Scientific Reports 8, 7765. https://doi.org/10.1038/s41598-018-25770-
5 
Filosa, J., Dean, J., Putnam, R., (2002). Role of intracellular and extracellular 
pH in the chemosensitive response of rat Locus coeruleus neurones. 
The Journal of physiology 541, 493–509. 
https://doi.org/10.1113/jphysiol.2001.014142 
Fortin, S.M., Cone, J.J., Ng‐Evans, S., McCutcheon, J.E., Roitman, M.F., 
(2015). Sampling Phasic Dopamine Signaling with Fast-Scan Cyclic 
Voltammetry in Awake, Behaving Rats. Current Protocols in 
Neuroscience 70, 7.25.1-7.25.20. 
https://doi.org/10.1002/0471142301.ns0725s70 
Fourcaud, N., Brunel, N., (2002). Dynamics of the firing probability of noisy 
integrate-and-fire neurons. Neural Computation 14, 2057–2110. 
https://doi.org/10.1162/089976602320264015 
Fourcaud-Trocmé, N., Hansel, D., Vreeswijk, C. van, Brunel, N., (2003). How 
Spike Generation Mechanisms Determine the Neuronal Response to 
Fluctuating Inputs. Journal of Neuroscience. 23, 11628–11640. 
https://doi.org/10.1523/JNEUROSCI.23-37-11628.2003 
Fozzard, H.A., Sheets, M.F., Hanck, D., (2011). The Sodium Channel as a 
Target for Local Anesthetic Drugs. Frontiers in Pharmacology 2. 
https://doi.org/10.3389/fphar.2011.00068 
Frandemiche, M.L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., 
Lanté, F., Buisson, A., (2014). Activity-dependent tau protein 
translocation to excitatory synapse is disrupted by exposure to amyloid-
beta oligomers. The Journal of Neuroscience 34, 6084–6097. 
https://doi.org/10.1523/JNEUROSCI.4261-13.2014 
Freed, C.R., Breeze, R.E., Rosenberg, N.L., Schneck, S.A., Kriek, E., Qi, J.X., 
Lone, T., Zhang, Y.B., Snyder, J.A., Wells, T.H., (1992). Survival of 
258 
implanted fetal dopamine cells and neurologic improvement 12 to 46 
months after transplantation for Parkinson’s disease. New England 
Journal of Medicine 327, 1549–1555. 
https://doi.org/10.1056/NEJM199211263272202 
Friedhoff, P., von Bergen, M., Mandelkow, E.M., Davies, P., Mandelkow, E., 
(1998). A nucleated assembly mechanism of Alzheimer paired helical 
filaments. Proceedings of the National Academy of Sciences 95, 
15712–15717. https://doi.org/10.1073/pnas.95.26.15712 
Fujio, K., Sato, M., Uemura, T., Sato, T., Sato-Harada, R., Harada, A., (2007). 
14-3-3 proteins and protein phosphatases are not reduced in tau-
deficient mice. Neuroreport 18, 1049–1052. 
https://doi.org/10.1097/WNR.0b013e32818b2a0b 
Galvan, A., Wichmann, T., (2008). Pathophysiology of Parkinsonism. Clinical 
Neurophysiology 119, 1459–1474. 
https://doi.org/10.1016/j.clinph.2008.03.017 
Garrido, J.J., Giraud, P., Carlier, E., Fernandes, F., Moussif, A., Fache, M.-P., 
Debanne, D., Dargent, B., (2003). A targeting motif involved in sodium 
channel clustering at the axonal initial segment. Science 300, 2091–
2094. https://doi.org/10.1126/science.1085167 
George, C.H., Kendall, J.M., Evans, W.H., (1999). Intracellular trafficking 
pathways in the assembly of connexins into gap junctions. Journal of 
Biological Chemistry 274, 8678–8685. 
https://doi.org/10.1074/jbc.274.13.8678 
Ghasemi, A., Zahediasl, S., (2012). Normality Tests for Statistical Analysis: A 
Guide for Non-Statisticians. International Journal of Endocrinology and  
Metabolism 10, 486–489.  https://doi.org/10.5812/ijem.3505 
Gibb, W.R., Lees, A.J., (1991). Anatomy, pigmentation, ventral and dorsal 
subpopulations of the substantia nigra, and differential cell death in 
Parkinson’s disease. Journal of Neurology, Neurosurgery, and 
Psychiatry 54, 388–396. https://doi.org/10.1136/jnnp.54.5.388 
Gibbons, G.S., Lee, V.M.Y., Trojanowski, J.Q., (2019). Mechanisms of Cell-to-
Cell Transmission of Pathological Tau: A Review. JAMA Neurology 76, 
101–108. https://doi.org/10.1001/jamaneurol.2018.2505 
Goedert, M., Jakes, R., (2005). Mutations causing neurodegenerative 
tauopathies. Biochimica et Biophysica Acta 1739, 240–250. 
https://doi.org/10.1016/j.bbadis.2004.08.007 
Goedert, M., Spillantini, M.G., Potier, M.C., Ulrich, J., Crowther, R.A., (1989). 
Cloning and sequencing of the cDNA encoding an isoform of 
microtubule-associated protein tau containing four tandem repeats: 
259 
differential expression of tau protein mRNAs in human brain. EMBO 
Journal 8, 393–399. 
Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E., Klug, A., (1988). 
Cloning and sequencing of the cDNA encoding a core protein of the 
paired helical filament of Alzheimer disease: identification as the 
microtubule-associated protein tau. Proceedings of the National 
Academy of Sciences 85, 4051–4055. 
https://doi.org/10.1073/pnas.85.11.4051 
Gómez-Ramos, A., Díaz-Hernández, M., Rubio, A., Díaz-Hernández, J.I., 
Miras-Portugal, M.T., Avila, J., (2009). Characteristics and 
consequences of muscarinic receptor activation by tau protein. 
European Neuropsychopharmacology 19, 708–717. 
https://doi.org/10.1016/j.euroneuro.2009.04.006 
Goodenough, D.A., Goliger, J.A., Paul, D.L., (1996). Connexins, connexons, 
and intercellular communication. Annual Reviews Biochemistry 65, 
475–502.  https://doi.org/10.1146/annurev.bi.65.070196.002355 
Gorell, J.M., Johnson, C.C., Rybicki, B.A., Peterson, E.L., Kortsha, G.X., 
Brown, G.G., Richardson, R.J., (1997). Occupational exposures to 
metals as risk factors for Parkinson’s disease. Neurology 48, 650–658. 
https://doi.org/10.1212/wnl.48.3.650 
Gourine, A.V., Kasymov, V., Marina, N., Tang, F., Figueiredo, M.F., Lane, S., 
Teschemacher, A.G., Spyer, K.M., Deisseroth, K., Kasparov, S., (2010). 
Astrocytes Control Breathing Through pH-Dependent Release of ATP. 
Science 329, 571–575. https://doi.org/10.1126/science.1190721 
Gourine, A.V., Llaudet, E., Dale, N., Spyer, K.M., (2005). ATP is a mediator of 
chemosensory transduction in the central nervous system. Nature 436, 
108–111. https://doi.org/10.1038/nature03690 
Grace, A.A., Bunney, B.S., (1983). Intracellular and extracellular 
electrophysiology of nigral dopaminergic neurons—3. Evidence for 
electrotonic coupling. Neuroscience 10, 333–348. 
https://doi.org/10.1016/0306-4522(83)90137-9 
Grace, A.A., Onn, S.P., (1989). Morphology and electrophysiological 
properties of immunocytochemically identified rat dopamine neurons 
recorded in vitro. Journal of Neuroscience 9, 3463–3481. 
Grosso, G., Godos, J., Galvano, F., Giovannucci, E.L., (2017). Coffee, 
Caffeine, and Health Outcomes: An Umbrella Review. Annual Reviews 
Nutrition  37, 131–156. https://doi.org/10.1146/annurev-nutr-
071816-064941 
260 
Grover, L., Kim, E., Cooke, J. and Holmes, W., (2009). LTP in hippocampal 
area  CA1 is induced by burst stimulation over a broad frequency range 
centered around delta. Learning & Memory, 16(1), pp.69-81. 
Guan, Y., Ye, J.-H., (2010). Ethanol blocks long-term potentiation of 
GABAergic synapses in the ventral tegmental area involving mu-opioid 
receptors. Neuropsychopharmacology 35, 1841–1849. 
https://doi.org/10.1038/npp.2010.51 
Guo, J.L., Lee, V.M.-Y., (2011). Seeding of normal Tau by pathological Tau 
conformers drives pathogenesis of Alzheimer-like tangles. The Journal 
of Biological Chemistry 286, 15317–15331. 
https://doi.org/10.1074/jbc.M110.209296 
Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., 
Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., 
(1992). Amyloid beta-peptide is produced by cultured cells during 
normal metabolism. Nature 359, 322–325. 
https://doi.org/10.1038/359322a0 
Haaxma, C.A., Bloem, B.R., Borm, G.F., Oyen, W.J.G., Leenders, K.L., 
Eshuis, S., Booij, J., Dluzen, D.E., Horstink, M.W.I.M., (2007). Gender 
differences in Parkinson’s disease. Journal of Neurology, 
Neurosurgery, and Psychiatry 78, 819–824. 
https://doi.org/10.1136/jnnp.2006.103788 
Haehner, A., Hummel, T., Hummel, C., Sommer, U., Junghanns, S., 
Reichmann, H., (2007). Olfactory loss may be a first sign of idiopathic 
Parkinson’s disease. Movement Disorders 22, 839–842. 
https://doi.org/10.1002/mds.21413 
Haller, M., Mironov, S.L., Karschin, A., Richter, D.W., (2001). Dynamic 
activation of K(ATP) channels in rhythmically active neurons. Journal of 
Physiology 537, 69–81. https://doi.org/10.1111/j.1469-
7793.2001.0069k.x 
Hamill, O.P., Marty, A., Neher, E., Sakmann, B., Sigworth, F.J., (1981). 
Improved patch-clamp techniques for high-resolution current recording 
from cells and cell-free membrane patches. Pflügers Archive 391, 85–
100. https://doi.org/10.1007/BF00656997 
Hammond, C., Bergman, H., Brown, P., (2007). Pathological synchronization 
in Parkinson’s disease: networks, models, and treatments. Trends in 
Neurosciences 30, 357–364. https://doi.org/10.1016/j.tins.2007.05.004 
Hampel, H., Blennow, K., Shaw, L.M., Hoessler, Y.C., Zetterberg, H., 
Trojanowski, J.Q., (2010). Total and phosphorylated tau protein as 
biological markers of Alzheimer’s disease. Experimental Gerontology 
45, 30–40. https://doi.org/10.1016/j.exger.2009.10.010 
261 
Han, S.-S., Jiao, Q., Bi, M.-X., Du, X.-X., Jiang, H., (2018). The expression of 
KATP channel subunits in alpha-synuclein-transfected MES23.5 cells. 
Annals of Translational Medicine 6. 
https://doi.org/10.21037/atm.2018.04.24 
Hanger, D.P., Byers, H.L., Wray, S., Leung, K.-Y., Saxton, M.J., Seereeram, 
A., Reynolds, C.H., Ward, M.A., Anderton, B.H., (2007). Novel 
phosphorylation sites in tau from Alzheimer brain support a role for 
casein kinase 1 in disease pathogenesis. The Journal of Biological 
Chemistry 282, 23645–23654. https://doi.org/10.1074/jbc.M703269200 
Hantikainen, E., Lagerros, Y.T., Ye, W., Serafini, M., Adami, H.-O., Bellocco, 
R., Bonn, S., (2021). Dietary Antioxidants and the Risk of Parkinson 
Disease: The Swedish National March Cohort. Neurology 96, e895–
e903.  https://doi.org/10.1212/WNL.0000000000011373 
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., Minthon, 
L., (2006). Association between CSF biomarkers and incipient 
Alzheimer’s disease in patients with mild cognitive impairment: a follow-
up study. Lancet Neurology 5, 228–234. https://doi.org/10.1016/S1474-
4422(06)70355-6 
Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., Sato-
Yoshitake, R., Takei, Y., Noda, T., Hirokawa, N., (1994). Altered 
microtubule organization in small-calibre axons of mice lacking tau 
protein. Nature 369, 488–491. https://doi.org/10.1038/369488a0 
Harris, K.D., Mrsic-Flogel, T.D., (2013). Cortical connectivity and sensory 
coding. Nature 503, 51–58. https://doi.org/10.1038/nature12654 
Harris, N.C., Constanti, A., (1995). Mechanism of block by ZD 7288 of the 
hyperpolarization-activated inward rectifying current in guinea pig 
substantia nigra neurons in vitro. Journal of Neurophysiology 74, 2366–
2378. https://doi.org/10.1152/jn.1995.74.6.2366 
Harrison, P.M., Badel, L., Wall, M.J., Richardson, M.J.E., (2015). 
Experimentally Verified Parameter Sets for Modelling Heterogeneous 
Neocortical Pyramidal-Cell Populations. PLoS Computational Biology 
11, e1004165. https://doi.org/10.1371/journal.pcbi.1004165 
Hartline, D.K., Castelfranco, A.M., (2003). Simulations of Voltage Clamping 
Poorly Space-Clamped Voltage-Dependent Conductances in a Uniform 
Cylindrical Neurite. Journal of Computational Neuroscience 14, 253–
269. https://doi.org/10.1023/A:1023208926805 
Hatch, R.J., Wei, Y., Xia, D., Götz, J., (2017). Hyperphosphorylated tau causes 
reduced hippocampal CA1 excitability by relocating the axon initial 
segment. Acta Neuropathologica 133, 717–730. 
https://doi.org/10.1007/s00401-017-1674-1 
262 
He, Z., McBride, J.D., Xu, H., Changolkar, L., Kim, S.-J., Zhang, B., 
Narasimhan, S., Gibbons, G.S., Guo, J.L., Kozak, M., Schellenberg, 
G.D., Trojanowski, J.Q., Lee, V.M.-Y., (2020). Transmission of 
tauopathy strains is independent of their isoform composition. Nature 
Communications 11, 7. https://doi.org/10.1038/s41467-019-13787-x 
Herantis Pharma, (2020). Herantis - Herantis Pharma Plc announces topline 
results of Phase 1-2 CDNF trial. Herantis. URL 
https://herantis.com/press_releases/herantis-pharma-plc-announces-
topline-results-of-phase-1-2-cdnf-trial/ (accessed 1.25.21). 
Hernán, M.A., Chen, H., Schwarzschild, M.A., Ascherio, A., (2003). Alcohol 
consumption and the incidence of Parkinson’s disease. Annals of 
Neurology 54, 170–175. https://doi.org/10.1002/ana.10611 
Hernán, M.A., Takkouche, B., Caamaño-Isorna, F., Gestal-Otero, J.J., (2002). 
A meta-analysis of coffee drinking, cigarette smoking, and the risk of 
Parkinson’s disease. Annals of Neurology 52, 276–284. 
https://doi.org/10.1002/ana.10277 
Hill, E., Dale, N., Wall, M.J., (2020a). Moderate Changes in CO2 Modulate the 
Firing of Neurons in the VTA and Substantia Nigra. iScience 23, 
101343. https://doi.org/10.1016/j.isci.2020.101343 
Hill, E., Dale, N., Wall, M.J., (2020b). Detecting CO2-Sensitive Hemichannels 
in Neurons in Acute Brain Slices. STAR Protocols 1, 100139. 
https://doi.org/10.1016/j.xpro.2020.100139 
Hill, E., Gowers, R., Richardson, M.J.E., Wall, M.J., (2021). αSynuclein 
Aggregates Increase the Conductance of Substantia Nigra Dopamine 
Neurons, an Effect Partly Reversed by the KATP Channel Inhibitor 
Glibenclamide. eNeuro 8. https://doi.org/10.1523/ENEURO.0330-
20.2020 
Hill, E., Karikari, T.K., Moffat, K.G., Richardson, M.J.E., Wall, M.J., (2019). 
Introduction of Tau Oligomers into Cortical Neurons Alters Action 
Potential Dynamics and Disrupts Synaptic Transmission and Plasticity. 
eNeuro 6, doi.org/10.1523/ENEURO.0166-19.2019 
Hindle, J.V., (2010). Ageing, neurodegeneration and Parkinson’s disease. Age 
Ageing 39, 156–161. https://doi.org/10.1093/ageing/afp223 
Hirokawa, N., Shiomura, Y., Okabe, S., (1988). Tau proteins: the molecular 
structure and mode of binding on microtubules. Journal of Cell Biology 
107, 1449–1459. https://doi.org/10.1083/jcb.107.4.1449 
Hisahara, S., Shimohama, S., (2011). Dopamine Receptors and Parkinson’s 
Disease. International Journal of Medicinal Chemistry. 
https://doi.org/10.1155/2011/403039 
263 
Hiyama, T.Y., Noda, M., (2016). Sodium sensing in the subfornical organ and 
body-fluid homeostasis. Neuroscience Research 113, 1–11. 
https://doi.org/10.1016/j.neures.2016.07.007 
Hodges, J.L., Lehmann, E.L., (1956). The Efficiency of Some Nonparametric 
Competitors of the t-Test. The Annals of Mathematical Statistics. 27, 
324–335.  https://doi.org/10.1214/aoms/1177728261 
Hodgkin, A.L., Huxley, A.F., (1952). A quantitative description of membrane 
current and its application to conduction and excitation in nerve. Journal 
of Physiology 117, 500–544. 
Holly, E.N., Miczek, K.A., (2016). Ventral tegmental area dopamine revisited: 
effects of acute and repeated stress. Psychopharmacology 233, 163–
186. https://doi.org/10.1007/s00213-015-4151-3 
Hong, C.T., Chan, L., Bai, C.-H., (2020). The Effect of Caffeine on the Risk 
and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients 12. 
https://doi.org/10.3390/nu12061860 
Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., 
Pitstick, R., Carlson, G.A., Lanier, L.M., Yuan, L.-L., Ashe, K.H., Liao, 
D., (2010). Tau mislocalization to dendritic spines mediates synaptic 
dysfunction independently of neurodegeneration. Neuron 68, 1067–
1081. https://doi.org/10.1016/j.neuron.2010.11.030 
Horowitz, P.M., LaPointe, N., Guillozet-Bongaarts, A.L., Berry, R.W., Binder, 
L.I., (2006). N-terminal fragments of tau inhibit full-length tau 
polymerization in vitro. Biochemistry 45, 12859–12866. 
https://doi.org/10.1021/bi061325g 
Hosford, P.S., Mosienko, V., Kishi, K., Jurisic, G., Seuwen, K., Kinzel, B., 
Ludwig, M.G., Wells, J.A., Christie, I.N., Koolen, L., Abdala, A.P., Liu, 
B.H., Gourine, A.V., Teschemacher, A.G., Kasparov, S., (2018). CNS 
distribution, signalling properties and central effects of G-protein 
coupled receptor 4. Neuropharmacology 138, 381–392. 
https://doi.org/10.1016/j.neuropharm.2018.06.007 
Hossain, W.A., Antic, S.D., Yang, Y., Rasband, M.N., Morest, D.K., (2005). 
Where is the spike generator of the cochlear nerve? Voltage-gated 
sodium channels in the mouse cochlea. Journal of Neuroscience 25, 
6857–6868. https://doi.org/10.1523/JNEUROSCI.0123-05.2005 
Huang, Y., (2006). Molecular and cellular mechanisms of apolipoprotein E4 
neurotoxicity and potential therapeutic strategies. Current Opinions in 
Drug Discovery and Development 9, 627–641. 
Huang, Z.-L., Qu, W.-M., Eguchi, N., Chen, J.-F., Schwarzschild, M.A., 
Fredholm, B.B., Urade, Y., Hayaishi, O., (2005). Adenosine A2A, but 
264 
not A1, receptors mediate the arousal effect of caffeine. Nature 
Neuroscience  8, 858–859. https://doi.org/10.1038/nn1491 
Huckstepp, R.T.R., Bihi, R.I., Eason, R., Spyer, K.M., Dicke, N., Willecke, K., 
Marina, N., Gourine, A.V., Dale, N., (2010a). Connexin hemichannel-
mediated CO2-dependent release of ATP in the medulla oblongata 
contributes to central respiratory chemosensitivity. The Journal of 
Physiology 588, 3901–3920. 
https://doi.org/10.1113/jphysiol.2010.192088 
Huckstepp, R.T.R., Eason, R., Sachdev, A., Dale, N., (2010b). CO2-dependent 
opening of connexin 26 and related β connexins. The Journal of 
Physiology 588, 3921–3931. 
https://doi.org/10.1113/jphysiol.2010.192096 
Huff, J., (2015). The Airyscan detector from ZEISS: confocal imaging with 
improved signal-to-noise ratio and super-resolution. Nature Methods 
12, i–ii. https://doi.org/10.1038/nmeth.f.388 
Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., Lee, V.M.-Y., 
(2013). Synthetic tau fibrils mediate transmission of neurofibrillary 
tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. 
Journal of Neuroscience 33, 1024–1037. 
https://doi.org/10.1523/JNEUROSCI.2642-12.2013 
Inagaki, N., Gonoi, T., Clement, J.P., Namba, N., Inazawa, J., Gonzalez, G., 
Aguilar-Bryan, L., Seino, S., Bryan, J., (1995). Reconstitution of IKATP: 
an inward rectifier subunit plus the sulfonylurea receptor. Science 270, 
1166–1170. https://doi.org/10.1126/science.270.5239.1166 
Ishizuka, N., Cowan, W.M., Amaral, D.G., (1995). A quantitative analysis of 
the  dendritic organization of pyramidal cells in the rat hippocampus. 
Journal of  Computational Neurology 362, 17–45. 
https://doi.org/10.1002/cne.903620103  
Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., Eersel, J. van, Wölfing, 
H., Chieng, B.C., Christie, M.J., Napier, I.A., Eckert, A., Staufenbiel, M., 
Hardeman, E., Götz, J., (2010). Dendritic Function of Tau Mediates 
Amyloid-β Toxicity in Alzheimer’s Disease Mouse Models. Cell 142, 
387–397. https://doi.org/10.1016/j.cell.2010.06.036 
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, 
A., Saitoh, T., (1995). The precursor protein of non-A beta component 
of Alzheimer’s disease amyloid is a presynaptic protein of the central 
nervous system. Neuron 14, 467–475. https://doi.org/10.1016/0896-
6273(95)90302-x 
Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., 
Aisen, P.S., Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., 
265 
Lesnick, T.G., Pankratz, V.S., Donohue, M.C., Trojanowski, J.Q., 
(2013). Tracking pathophysiological processes in Alzheimer’s disease: 
an updated hypothetical model of dynamic biomarkers. Lancet 
Neurology 12, 207–216. https://doi.org/10.1016/S1474-
4422(12)70291-0 
Jack, C.R., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, 
M.W., Petersen, R.C., Trojanowski, J.Q., (2010). Hypothetical model of 
dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet 
Neurology 9, 119. https://doi.org/10.1016/S1474-4422(09)70299-6 
Jack, C.R., Petersen, R.C., Xu, Y.C., O’Brien, P.C., Smith, G.E., Ivnik, R.J., 
Boeve, B.F., Waring, S.C., Tangalos, E.G., Kokmen, E., (1999). 
Prediction of AD with MRI-based hippocampal volume in mild cognitive 
impairment. Neurology 52, 1397–1403. 
https://doi.org/10.1212/wnl.52.7.1397 
Jakes, R., Spillantini, M.G., Goedert, M., (1994). Identification of two distinct 
synucleins from human brain. FEBS Letters 345, 27–32. 
https://doi.org/10.1016/0014-5793(94)00395-5 
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T.G., Serrano, 
G.E., Chai, X., Proctor, N.K., Eichenlaub, U., Zetterberg, H., Blennow, 
K., Reiman, E.M., Stomrud, E., Dage, J.L., Hansson, O., (2020). 
Plasma P-tau181 in Alzheimer’s disease: relationship to other 
biomarkers, differential diagnosis, neuropathology and longitudinal 
progression to Alzheimer’s dementia. Nature Medicine 26, 379–386. 
https://doi.org/10.1038/s41591-020-0755-1 
Janson, A.M., Fuxe, K., Goldstein, M., (1992). Differential effects of acute and 
chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) induced degeneration of nigrostriatal dopamine 
neurons in the black mouse. Clinical Investigation Journal.  70, 232–
238.  https://doi.org/10.1007/BF00184656 
Jiang, C., Haddad, G.G., (1997). Modulation of K+ channels by intracellular 
ATP in human neocortical neurons. Journal of Neurophysiology 77, 93–
102. https://doi.org/10.1152/jn.1997.77.1.93 
Johnson, S.W., North, R.A., (1992). Two types of neurone in the rat ventral 
tegmental area and their synaptic inputs. Journal of Physiology 450, 
455–468. https://doi.org/10.1113/jphysiol.1992.sp019136 
Jouanne, M., Rault, S., Voisin-Chiret, A.-S., (2017). Tau protein aggregation 
in Alzheimer’s disease: An attractive target for the development of novel 
therapeutic agents. European Journal of Medicinal Chemistry 139, 153–
167. https://doi.org/10.1016/j.ejmech.2017.07.070 
266 
Jurado, S., (2018). AMPA Receptor Trafficking in Natural and Pathological 
Aging. Frontiers in Molecular Neuroscience 10. 
https://doi.org/10.3389/fnmol.2017.00446 
Kachroo, A., Schwarzschild, M.A., (2012). Adenosine A2A receptor gene 
disruption protects in an α-synuclein model of Parkinson’s disease. 
Annals of Neurology. 71, 278–282. https://doi.org/10.1002/ana.22630 
Kajiwara, R., Wouterlood, F.G., Sah, A., Boekel, A.J., Baks-te Bulte, L.T.G., 
Witter, M.P., (2008). Convergence of entorhinal and CA3 inputs onto 
pyramidal neurons and interneurons in hippocampal area CA1--an 
anatomical study in the rat. Hippocampus 18, 266–280. 
https://doi.org/10.1002/hipo.20385 
Kanaan, N.M., Morfini, G.A., LaPointe, N.E., Pigino, G.F., Patterson, K.R., 
Song, Y., Andreadis, A., Fu, Y., Brady, S.T., Binder, L.I., (2011). 
Pathogenic forms of tau inhibit kinesin-dependent axonal transport 
through a mechanism involving activation of axonal 
phosphotransferases. Journal of Neuroscience 31, 9858–9868. 
https://doi.org/10.1523/JNEUROSCI.0560-11.2011 
Karikari, T.K., (2017). Distinct conformations, aggregation, and neuronal 
internalisation of different tau strains. (PhD Thesis). University of 
Warwick. 
Karikari, T.K., Nagel, D.A., Grainger, A., Clarke-Bland, C., Crowe, J., Hill, E.J., 
Moffat, K.G., (2019a). Distinct Conformations, Aggregation and Cellular 
Internalization of Different Tau Strains. Frontiers in Cellular 
Neuroscience 13. https://doi.org/10.3389/fncel.2019.00296 
Karikari, T.K., Nagel, D.A., Grainger, A., Clarke-Bland, C., Hill, E.J., Moffat, 
K.G., (2019b). Preparation of stable tau oligomers for cellular and 
biochemical studies. Analytical Biochemistry 566, 67–74. 
https://doi.org/10.1016/j.ab.2018.10.013 
Karikari, Thomas K, Pascoal, T.A., Ashton, N.J., Janelidze, S., Benedet, A.L., 
Rodriguez, J.L., Chamoun, M., Savard, M., Kang, M.S., Therriault, J., 
Schöll, M., Massarweh, G., Soucy, J.-P., Höglund, K., Brinkmalm, G., 
Mattsson, N., Palmqvist, S., Gauthier, S., Stomrud, E., Zetterberg, H., 
Hansson, O., Rosa-Neto, P., Blennow, K., (2020). Blood 
phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a 
diagnostic performance and prediction modelling study using data from 
four prospective cohorts. The Lancet Neurology 19, 422–433. 
https://doi.org/10.1016/S1474-4422(20)30071-5 
Karikari, Thomas K., Thomas, R., Moffat, K.G., (2020). The C291R Tau Variant 
Forms Different Types of Protofibrils. Frontiers in Molecular 
Neuroscience 13. https://doi.org/10.3389/fnmol.2020.00039 
267 
Karikari, T.K., Turner, A., Stass, R., Lee, L.C.Y., Wilson, B., Nagel, D.A., Hill, 
E.J., Moffat, K.G., (2017). Expression and purification of tau protein and 
its frontotemporal dementia variants using a cleavable histidine tag. 
Protein Expression and Purification 130, 44–54. 
https://doi.org/10.1016/j.pep.2016.09.009 
Kasper, E.M., Larkman, A.U., Lübke, J., Blakemore, C., (1994). Pyramidal 
neurons in layer 5 of the rat visual cortex. II. Development of 
electrophysiological properties. Journal of Comparative Neurology 339, 
475–494. https://doi.org/10.1002/cne.903390403 
Kaufmann, T.J., Harrison, P.M., Richardson, M.J.E., Pinheiro, T.J.T., Wall, 
M.J., (2016). Intracellular soluble αSynuclein oligomers reduce 
pyramidal cell excitability. Journal of Physiology 594, 2751–2772. 
https://doi.org/10.1113/JP271968 
Keeler, J.F., Pretsell, D.O., Robbins, T.W., (2014). Functional implications of 
dopamine D1 vs. D2 receptors: A “prepare and select” model of the 
striatal direct vs. indirect pathways. Neuroscience 282, 156–175. 
https://doi.org/10.1016/j.neuroscience.2014.07.021 
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, 
M., Widner, H., Rehncrona, S., Brundin, P., Björklund, A., Lindvall, O., 
Limousin, P., Quinn, N., Foltynie, T., (2014). Long-term clinical outcome 
of fetal cell transplantation for Parkinson disease: two case reports. 
JAMA Neurology 71, 83–87. doi.org/10.1001/jamaneurol.2013.4749 
Kehr, W., (1974). A method for the isolation and determination of 3-
methoxytyramine in brain tissue. Naunyn-Schmiedeberg’s Naunyn-
Schmiedeberg's Archives of Pharmacology 284, 149–158. 
https://doi.org/10.1007/BF00501119 
Kerr, M.I., Wall, M.J., Richardson, M.J.E., (2013). Adenosine A1 receptor 
activation mediates the developmental shift at layer 5 pyramidal cell 
synapses and is a determinant of mature synaptic strength. Journal of 
Physiology 591, 3371–3380. doi.org/10.1113/jphysiol.2012.244392 
Kim, J.-I., Ganesan, S., Luo, S.X., Wu, Y.-W., Park, E., Huang, E.J., Chen, L., 
Ding, J.B., (2015). Aldehyde dehydrogenase 1a1 mediates a GABA 
synthesis pathway in midbrain dopaminergic neurons. Science 350, 
102–106. https://doi.org/10.1126/science.aac4690 
Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J., Lundblad, M., 
Lindvall, O., Parmar, M., (2012). Generation of regionally specified 
neural progenitors and functional neurons from human embryonic stem 
cells under defined conditions. Cell Reports 1, 703–714. 
https://doi.org/10.1016/j.celrep.2012.04.009 
268 
Klein, C., Westenberger, A., (2012). Genetics of Parkinson’s disease. Cold 
Spring Harbor Perspectives in Medicine 2, a008888. 
https://doi.org/10.1101/cshperspect.a008888 
Knierim, J.J., (2015). The hippocampus. Current Biology. 25, R1116–R1121. 
https://doi.org/10.1016/j.cub.2015.10.049 
Kole, M.H.P., Ilschner, S.U., Kampa, B.M., Williams, S.R., Ruben, P.C., Stuart, 
G.J., (2008). Action potential generation requires a high sodium channel 
density in the axon initial segment. Nature Neuroscience 11, 178–186. 
https://doi.org/10.1038/nn2040 
Kontis, K.J., Rounaghi, A., Goldin, A.L., (1997). Sodium Channel Activation 
Gating Is Affected by Substitutions of Voltage Sensor Positive Charges 
in All Four Domains. The Journal of General Physiology 110, 391–401. 
Kontsekova, E., Zilka, N., Kovacech, B., Novak, P., Novak, M., (2014). First-
in-man tau vaccine targeting structural determinants essential for 
pathological tau–tau interaction reduces tau oligomerisation and 
neurofibrillary degeneration in an Alzheimer’s disease model. 
Alzheimer's Research & Therapy 6, 44. https://doi.org/10.1186/alzrt278 
Köpke, E., Tung, Y.C., Shaikh, S., Alonso, A.C., Iqbal, K., Grundke-Iqbal, I., 
(1993). Microtubule-associated protein tau. Abnormal phosphorylation 
of a non-paired helical filament pool in Alzheimer disease. Journal of 
Biological Chemistry 268, 24374–24384. 
https://doi.org/10.1016/S0021-9258(20)80536-5 
Koval, M., Molina, S.A., Burt, J.M., (2014). Mix and match: investigating 
heteromeric and heterotypic gap junction channels in model systems 
and native tissues. FEBS Letters 588, 1193–1204. 
https://doi.org/10.1016/j.febslet.2014.02.025 
Kozloski, J., Hamzei-Sichani, F., Yuste, R., (2001). Stereotyped position of 
local synaptic targets in neocortex. Science 293, 868–872. 
https://doi.org/10.1126/science.293.5531.868 
Krashia, P., Martini, A., Nobili, A., Aversa, D., D’Amelio, M., Berretta, N., 
Guatteo, E., Mercuri, N.B., (2017). On the properties of identified 
dopaminergic neurons in the mouse substantia nigra and ventral 
tegmental area. The European Journal of Neuroscience 45, 92–105. 
https://doi.org/10.1111/ejn.13364 
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-
Reid, L., Auyeung, G., Antonacci, C., Buch, A., Yang, L., Beal, M.F., 
Surmeier, D.J., Kordower, J.H., Tabar, V., Studer, L., (2011). Dopamine 
neurons derived from human ES cells efficiently engraft in animal 
models of Parkinson’s disease. Nature 480, 547–551. 
https://doi.org/10.1038/nature10648 
269 
Kumar, S., Tepper, K., Kaniyappan, S., Biernat, J., Wegmann, S., Mandelkow, 
E.-M., Müller, D.J., Mandelkow, E., (2014). Stages and Conformations 
of the Tau Repeat Domain during Aggregation and Its Effect on 
Neuronal Toxicity. The Journal of Biological Chemistry 289, 20318–
20332. https://doi.org/10.1074/jbc.M114.554725 
Kumar, S.T., Donzelli, S., Chiki, A., Syed, M.M.K., Lashuel, H.A., (2020). A 
simple, versatile and robust centrifugation-based filtration protocol for 
the isolation and quantification of αSynuclein monomers, oligomers and 
fibrils: Towards improving experimental reproducibility in αSynuclein 
research. Journal of Neurochemistry 153, 103–119. 
https://doi.org/10.1111/jnc.14955 
Kumar, M.J., Andersen, J.K., (2004). Perspectives on MAO-B in aging and 
neurological disease: where do we go from here? Molecular 
Neurobiology 30,  77–89. https://doi.org/10.1385/MN:30:1:077 
Kumar, N.M., Gilula, N.B., (1996). The gap junction communication channel. 
Cell 84, 381–388. https://doi.org/10.1016/s0092-8674(00)81282-9 
Lacey, M.G., Mercuri, N.B., North, R.A., (1989). Two cell types in rat substantia 
nigra zona compacta distinguished by membrane properties and the 
actions of dopamine and opioids. Journal of Neuroscience 9, 1233–
1241. 
Lacey, M.G., Mercuri, N.B., North, R.A., (1987). Dopamine acts on D2 
receptors to increase potassium conductance in neurones of the rat 
substantia nigra zona compacta. Journal of Physiology 392, 397–416. 
https://doi.org/10.1113/jphysiol.1987.sp016787 
Lai, B.C.L., Marion, S.A., Teschke, K., Tsui, J.K.C., (2002). Occupational and 
environmental risk factors for Parkinson’s disease. Parkinsonism 
Related Disorders 8, 297–309. https://doi.org/10.1016/s1353-
8020(01)00054-2 
Lammel, S., Lim, B.K., Malenka, R.C., (2014). Reward and aversion in a 
heterogeneous midbrain dopamine system. Neuropharmacology 76. 
https://doi.org/10.1016/j.neuropharm.2013.03.019 
Lanciego, J.L., Luquin, N., Obeso, J.A., (2012). Functional Neuroanatomy of 
the Basal Ganglia. Cold Spring Harbour Perspectives in Medicine 2. 
https://doi.org/10.1101/cshperspect.a009621 
Lapointe, N.E., Horowitz, P.M., Guillozet-Bongaarts, A.L., Silva, A., Andreadis, 
A., Binder, L.I., (2009). Tau 6D and 6P isoforms inhibit polymerization 
of full-length tau in vitro. Biochemistry 48, 12290–12297. 
https://doi.org/10.1021/bi901304u 
Largo-Barrientos, P., Apóstolo, N., Creemers, E., Callaerts-Vegh, Z., Swerts, 
J., Davies, C., McInnes, J., Wierda, K., Strooper, B.D., Spires-Jones, 
270 
T., Wit, J. de, Uytterhoeven, V., Verstreken, P., (2021). Lowering 
Synaptogyrin-3 expression rescues Tau-induced memory defects and 
synaptic loss in the presence of microglial activation. Neuron 0. 
https://doi.org/10.1016/j.neuron.2020.12.016 
Larson, J., Munkácsy, E., (2015). Theta-Burst LTP. Brain Research 1621, 38–
50. https://doi.org/10.1016/j.brainres.2014.10.034 
Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Guerrero-Muoz, M.J., 
Jackson, G.R., Kayed, R., (2010). Preparation and characterization of 
neurotoxic tau oligomers. Biochemistry 49, 10039–10041. 
https://doi.org/10.1021/bi1016233 
Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Sarmiento, J., 
Troncoso, J., Jackson, G.R., Kayed, R., (2012). Identification of 
oligomers at early stages of tau aggregation in Alzheimer’s disease. 
FASEB Journal 26, 1946–1959. https://doi.org/10.1096/fj.11-199851 
Lasagna-Reeves, C.A., Sengupta, U., Castillo-Carranza, D., Gerson, J.E., 
Guerrero-Munoz, M., Troncoso, J.C., Jackson, G.R., Kayed, R., (2014). 
The formation of tau pore-like structures is prevalent and cell specific: 
possible implications for the disease phenotypes. Acta 
Neuropathologica Communications 2. https://doi.org/10.1186/2051-
5960-2-56 
Lashuel, H.A., Overk, C.R., Oueslati, A., Masliah, E., (2013). The many faces 
of αSynuclein: from structure and toxicity to therapeutic target. Nature 
Reviews Neuroscience 14, 38–48. https://doi.org/10.1038/nrn3406 
Lavezzi, A.M., Mehboob, R., Alfonsi, G., Ferrero, S., (2020). Substantia Nigra 
Abnormalities Provide New Insight on the Neural Mechanisms 
Underlying the Sleep-Arousal Phase Dysfunctions in Sudden Infant 
Death Syndrome. ASN NEURO 12. 
https://doi.org/10.1177/1759091420962695 
Lee, V.M., Goedert, M., Trojanowski, J.Q., (2001). Neurodegenerative 
tauopathies. Annual Review of Neuroscience 24, 1121–1159. 
https://doi.org/10.1146/annurev.neuro.24.1.1121 
Lee, Y.-S., Silva, A.J., (2009). The molecular and cellular biology of enhanced 
cognition. Nature Reviews Neuroscience 10, 126–140. 
https://doi.org/10.1038/nrn2572 
Lemay, S., Chouinard, S., Blanchet, P., Masson, H., Soland, V., Beuter, A., 
Bédard, M.-A., (2004). Lack of efficacy of a nicotine transdermal 
treatment on motor and cognitive deficits in Parkinson’s disease. Prog. 
Neuropsychopharmacol. Biological Psychiatry 28, 31–39. 
https://doi.org/10.1016/S0278-5846(03)00172-6 
271 
Lesage, S., Brice, A., (2009). Parkinson’s disease: from monogenic forms to 
genetic susceptibility factors. Human Molecular Genetics 18, R48–R59. 
https://doi.org/10.1093/hmg/ddp012 
Levin, B.E., Dunn-Meynell, A.A., Routh, V.H., (1999). Brain glucose sensing 
and body energy homeostasis: role in obesity and diabetes. American 
Journal of   Physiology 276, R1223-1231. 
https://doi.org/10.1152/ajpregu.1999.276.5.R1223 
Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, 
S.H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, 
M., McGowan, E., (2001). Enhanced neurofibrillary degeneration in 
transgenic mice expressing mutant tau and APP. Science 293, 1487–
1491. https://doi.org/10.1126/science.1058189 
LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., 
Eskandar, E.N., Kostyk, S.K., Thomas, K., Sarkar, A., Siddiqui, M.S., 
Tatter, S.B., Schwalb, J.M., Poston, K.L., Henderson, J.M., Kurlan, 
R.M., Richard, I.H., Meter, L.V., Sapan, C.V., During, M.J., Kaplitt, M.G., 
Feigin, A., (2011). AAV2-GAD gene therapy for advanced Parkinson’s 
disease: a double-blind, sham-surgery controlled, randomised trial. The 
Lancet Neurology 10, 309–319. https://doi.org/10.1016/S1474-
4422(11)70039-4 
Li, W., Englund, E., Widner, H., Mattsson, B., Westen, D. van, Lätt, J., 
Rehncrona, S., Brundin, P., Björklund, A., Lindvall, O., Li, J.-Y., (2016). 
Extensive graft-derived dopaminergic innervation is maintained 24 
years after transplantation in the degenerating parkinsonian brain. 
Proceedings of the National Academy of Sciences 113, 6544–6549. 
https://doi.org/10.1073/pnas.1605245113 
Li, Y., Li, C.-Y., Xi, W., Jin, S., Wu, Z.-H., Jiang, P., Dong, P., He, X.-B., Xu, 
F.-Q., Duan, S., Zhou, Y.-D., Li, X.-M., (2019). Rostral and Caudal 
Ventral Tegmental Area GABAergic Inputs to Different Dorsal Raphe 
Neurons Participate in Opioid Dependence. Neuron 101, 748-761.e5. 
https://doi.org/10.1016/j.neuron.2018.12.012 
Li, F.-J., Ji, H.-F., Shen, L., (2012). A Meta-Analysis of Tea Drinking and Risk 
of Parkinson’s Disease. Scientific World Journal 2012, e923464. 
https://doi.org/10.1100/2012/923464 
Li, X., Li, W., Liu, G., Shen, X., Tang, Y., (2015). Association between cigarette 
smoking and Parkinson’s disease: A meta-analysis. Archives of 
Gerontology and Geriatrics 61, 510–516. 
https://doi.org/10.1016/j.archger.2015.08.004 
Light, P.E., French, R.J., (1994). Glibenclamide selectively blocks ATP-
sensitive K+ channels reconstituted from skeletal muscle. European 
272 
Journal of Pharmacology 259, 219–222. https://doi.org/10.1016/0014-
2999(94)90647-5 
Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, 
R., Leenders, K.L., Sawle, G., Rothwell, J.C., Marsden, C.D., (1990). 
Grafts of fetal dopamine neurons survive and improve motor function in 
Parkinson’s disease. Science 247, 574–577. 
https://doi.org/10.1126/science.2105529 
Liss, B., Bruns, R., Roeper, J., (1999). Alternative sulfonylurea receptor 
expression defines metabolic sensitivity of K-ATP channels in 
dopaminergic midbrain neurons. EMBO Journal 18, 833–846. 
https://doi.org/10.1093/emboj/18.4.833 
Liss, B., Roeper, J., (2001). ATP-Sensitive Potassium Channels in 
Dopaminergic Neurons: Transducers of Mitochondrial Dysfunction. 
Physiology 16, 214–217. 
https://doi.org/10.1152/physiologyonline.2001.16.5.214 
Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., Roeper, J., (2005). K-
ATP channels promote the differential degeneration of dopaminergic 
midbrain neurons. Nature Neuroscience 8, 1742–1751. 
https://doi.org/10.1038/nn1570 
Loeschcke, H.H., (1982). Central chemosensitivity and the reaction theory. 
The Journal of Physiology 332, 1–24. 
https://doi.org/10.1113/jphysiol.1982.sp014397 
London, M., Häusser, M., (2005). Dendritic computation. Annual Review of 
Neuroscience 28, 503–532. 
doi.org/10.1146/annurev.neuro.28.061604.135703 
Loomis, P.A., Howard, T.H., Castleberry, R.P., Binder, L.I., (1990). 
Identification of nuclear tau isoforms in human neuroblastoma cells. 
Proceedings of the National Academy of Sciences 87, 8422–8426. 
https://doi.org/10.1073/pnas.87.21.8422 
López-Gambero, A.J., Martínez, F., Salazar, K., Cifuentes, M., Nualart, F., 
(2019). Brain Glucose-Sensing Mechanism and Energy Homeostasis. 
Mol. Neurobiol. 56, 769–796. https://doi.org/10.1007/s12035-018-1099-
4 
Lorincz, A., Nusser, Z., (2010). Molecular Identity of Dendritic Voltage-Gated 
Sodium Channels. Science 328, 906–909. 
https://doi.org/10.1126/science.1187958 
Lu, L., Fu, D., Li, H., Liu, A., Li, J., Zheng, G., (2014). Diabetes and Risk of 
Parkinson’s Disease: An Updated Meta-Analysis of Case-Control 
Studies. PLOS ONE 9, e85781. 
https://doi.org/10.1371/journal.pone.0085781 
273 
Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., 
Kurth, J.H., Rydel, R.E., Rogers, J., (1999). Soluble amyloid beta 
peptide concentration as a predictor of synaptic change in Alzheimer’s 
disease. The American Journal of Pathology 155, 853–862. 
https://doi.org/10.1016/s0002-9440(10)65184-x 
Luk, K.C., Song, C., O’Brien, P., Stieber, A., Branch, J.R., Brunden, K.R., 
Trojanowski, J.Q., Lee, V.M.-Y., (2009). Exogenous αSynuclein fibrils 
seed the formation of Lewy body-like intracellular inclusions in cultured 
cells. PNAS 106, 20051–20056. 
https://doi.org/10.1073/pnas.0908005106 
Luna, E., Decker, S.C., Riddle, D.M., Caputo, A., Zhang, B., Cole, T., Caswell, 
C., Xie, S.X., Lee, V.M.Y., Luk, K.C., (2018). Differential αSynuclein 
expression contributes to selective vulnerability of hippocampal neuron 
subpopulations to fibril-induced toxicity. Acta Neuropathologica 135, 
855–875. https://doi.org/10.1007/s00401-018-1829-8 
Luo, J., Kaplitt, M.G., Fitzsimons, H.L., Zuzga, D.S., Liu, Y., Oshinsky, M.L., 
During, M.J., (2002). Subthalamic GAD gene therapy in a Parkinson’s 
disease rat model. Science 298, 425–429. 
https://doi.org/10.1126/science.1074549 
Luo, Y., Batalao, A., Zhou, H., Zhu, L., (1997). Mammalian two-hybrid system: 
a complementary approach to the yeast two-hybrid system. 
Biotechniques 22, 350–352. https://doi.org/10.2144/97222pf02 
Lüscher, C., Malenka, R.C., (2012). NMDA Receptor-Dependent Long-Term 
Potentiation and Long-Term Depression (LTP/LTD). Cold Spring 
Harbour  Perspect. Biol. 4. 
https://doi.org/10.1101/cshperspect.a005710 
Luth, E.S., Stavrovskaya, I.G., Bartels, T., Kristal, B.S., Selkoe, D.J., (2014). 
Soluble, Prefibrillar αSynuclein Oligomers Promote Complex I-
dependent, Ca2+-induced Mitochondrial Dysfunction. The Journal of 
Biological Chemistry 289, 21490–21507. 
https://doi.org/10.1074/jbc.M113.545749 
Ma, C., Liu, Y., Neumann, S., Gao, X., (2017). Nicotine from cigarette smoking 
and diet and Parkinson disease: a review. Translational 
Neurodegeneration 6.  https://doi.org/10.1186/s40035-017-0090-8 
Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., Takashima, A., 
(2006). Increased levels of granular tau oligomers: an early sign of brain 
aging and Alzheimer’s disease. Neuroscience Research 54, 197–201. 
https://doi.org/10.1016/j.neures.2005.11.009 
Magnani, E., Fan, J., Gasparini, L., Golding, M., Williams, M., Schiavo, G., 
Goedert, M., Amos, L.A., Spillantini, M.G., (2007). Interaction of tau 
274 
protein with the dynactin complex. EMBO Journal 26, 4546–4554. 
https://doi.org/10.1038/sj.emboj.7601878 
Mair, W., Muntel, J., Tepper, K., Tang, S., Biernat, J., Seeley, W.W., Kosik, 
K.S., Mandelkow, E., Steen, H., Steen, J.A., (2016). FLEXITau: 
Quantifying Post-translational Modifications of Tau Protein in Vitro and 
in Human Disease. Analytical chemistry 88, 3704–3714. 
https://doi.org/10.1021/acs.analchem.5b04509 
Malenka, R.C., Bear, M.F., (2004). LTP and LTD: An Embarrassment of 
Riches. Neuron 44, 5–21. https://doi.org/10.1016/j.neuron.2004.09.012 
Marcantoni, A., Raymond, E.F., Carbone, E., Marie, H., (2014). Firing 
properties of entorhinal cortex neurons and early alterations in an 
Alzheimer’s disease transgenic model. Pflugers Archives 466, 1437–
1450. https://doi.org/10.1007/s00424-013-1368-z 
Markram, H., Lübke, J., Frotscher, M., Roth, A., Sakmann, B., (1997). 
Physiology and anatomy of synaptic connections between thick tufted 
pyramidal neurones in the developing rat neocortex. Journal of 
Physiology 500, 409–440. 
Markram, H., Muller, E., Ramaswamy, S., Reimann, M.W., Abdellah, M., 
Sanchez, C.A., Ailamaki, A., Alonso-Nanclares, L., Antille, N., Arsever, 
S., Kahou, G.A.A., Berger, T.K., Bilgili, A., Buncic, N., Chalimourda, A., 
Chindemi, G., Courcol, J.-D., Delalondre, F., Delattre, V., Druckmann, 
S., Dumusc, R., Dynes, J., Eilemann, S., Gal, E., Gevaert, M.E., 
Ghobril, J.-P., Gidon, A., Graham, J.W., Gupta, A., Haenel, V., Hay, E., 
Heinis, T., Hernando, J.B., Hines, M., Kanari, L., Keller, D., Kenyon, J., 
Khazen, G., Kim, Y., King, J.G., Kisvarday, Z., Kumbhar, P., Lasserre, 
S., Le Bé, J.-V., Magalhães, B.R.C., Merchán-Pérez, A., Meystre, J., 
Morrice, B.R., Muller, J., Muñoz-Céspedes, A., Muralidhar, S., 
Muthurasa, K., Nachbaur, D., Newton, T.H., Nolte, M., Ovcharenko, A., 
Palacios, J., Pastor, L., Perin, R., Ranjan, R., Riachi, I., Rodríguez, J.-
R., Riquelme, J.L., Rössert, C., Sfyrakis, K., Shi, Y., Shillcock, J.C., 
Silberberg, G., Silva, R., Tauheed, F., Telefont, M., Toledo-Rodriguez, 
M., Tränkler, T., Van Geit, W., Díaz, J.V., Walker, R., Wang, Y., 
Zaninetta, S.M., DeFelipe, J., Hill, S.L., Segev, I., Schürmann, F., 
(2015). Reconstruction and Simulation of Neocortical Microcircuitry. 
Cell 163, 456–492. https://doi.org/10.1016/j.cell.2015.09.029 
Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., 
Beyreuther, K., (1985). Amyloid plaque core protein in Alzheimer 
disease and Down syndrome. Proceedings of the National Academy of 
Sciences 82, 4245–4249. https://doi.org/10.1073/pnas.82.12.4245 
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P.S., Andreasson, U., 
Stomrud, E., Palmqvist, S., Baker, D., Hehir, C.A.T., Jeromin, A., 
275 
Hanlon, D., Song, L., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., 
Hansson, O., Blennow, K., (2016). Plasma tau in Alzheimer disease. 
Neurology 87, 1827–1835. doi.org/10.1212/WNL.0000000000003246 
Mayer, M.L., Westbrook, G.L., (1983). A voltage-clamp analysis of inward 
(anomalous) rectification in mouse spinal sensory ganglion neurones. 
Journal of Physiology 340, 19–45. 
https://doi.org/10.1113/jphysiol.1983.sp014747 
Mayeux, R., (2003). EPIDEMIOLOGY OFNEURODEGENERATION. Annual 
Review of Neuroscience, 26(1), pp.81-104. 
Mayeux, R., (2003). Epidemiology of neurodegeneration. Annual Reviews 
Neuroscience 26, 81–104. 
https://doi.org/10.1146/annurev.neuro.26.043002.094919 
Mccutcheon, J.E., Ebner, S.R., Loriaux, A.L., Roitman, M.F., (2012). Encoding 
of Aversion by Dopamine and the Nucleus Accumbens. Frontiers in 
Neuroscience. 6. https://doi.org/10.3389/fnins.2012.00137 
McInnes, J., Wierda, K., Snellinx, A., Bounti, L., Wang, Y.-C., Stancu, I.-C., 
Apóstolo, N., Gevaert, K., Dewachter, I., Spires-Jones, T.L., De 
Strooper, B., De Wit, J., Zhou, L., Verstreken, P., (2018). Synaptogyrin-
3 Mediates Presynaptic Dysfunction Induced by Tau. Neuron 97, 823-
835.e8. https://doi.org/10.1016/j.neuron.2018.01.022 
McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., 
Beyreuther, K., Bush, A.I., Masters, C.L., (1999). Soluble pool of Abeta 
amyloid as a determinant of severity of neurodegeneration in 
Alzheimer’s disease. Annals of Neurology 46, 860–866. 
https://doi.org/10.1002/1531-8249(199912)46:6<860::aid-
ana8>3.0.co;2-m 
Meigh, L., Cook, D., Zhang, J., Dale, N., (2015). Rational design of new NO 
and redox sensitivity into connexin26 hemichannels. Open Biology 5, 
140208. https://doi.org/10.1098/rsob.140208 
Meigh, L., Greenhalgh, S.A., Rodgers, T.L., Cann, M.J., Roper, D.I., Dale, N., 
(2013). CO2 directly modulates connexin 26 by formation of carbamate 
bridges between subunits. eLife 2, e01213. 
https://doi.org/10.7554/eLife.01213 
Meigh, L., Hussain, N., Mulkey, D.K., Dale, N., (2014). Connexin26 
hemichannels with a mutation that causes KID syndrome in humans 
lack sensitivity to CO2. eLife 3, e04249. 
https://doi.org/10.7554/eLife.04249 
Mercuri, N.B., Saiardi, A., Bonci, A., Picetti, R., Calabresi, P., Bernardi, G., 
Borrelli, E., (1997). Loss of autoreceptor function in dopaminergic 
276 
neurons from dopamine D2 receptor deficient mice. Neuroscience 79, 
323–327. https://doi.org/10.1016/s0306-4522(97)00135-8 
Michel, C.H., Kumar, S., Pinotsi, D., Tunnacliffe, A., St. George-Hyslop, P., 
Mandelkow, E., Mandelkow, E.-M., Kaminski, C.F., Kaminski Schierle, 
G.S., (2014). Extracellular Monomeric Tau Protein Is Sufficient to 
Initiate the Spread of Tau Protein Pathology. The Journal of Biological 
Chemistry 289, 956–967. https://doi.org/10.1074/jbc.M113.515445 
Mielke, M.M., Syrjanen, J.A., Blennow, K., Zetterberg, H., Vemuri, P., Skoog, 
I., Machulda, M.M., Kremers, W.K., Knopman, D.S., Jack, C., Petersen, 
R.C., Kern, S., (2019). Plasma and CSF neurofilament light: Relation to 
longitudinal neuroimaging and cognitive measures. Neurology 93, 
e252–e260. https://doi.org/10.1212/WNL.0000000000007767 
Milescu, L.S., Bean, B.P., Smith, J.C., (2010). Isolation of somatic Na+ 
currents by selective inactivation of axonal channels with a voltage pre-
pulse. Journal of Neuroscience 30, 7740–7748. 
https://doi.org/10.1523/JNEUROSCI.6136-09.2010 
Miller, E.C., Teravskis, P.J., Dummer, B.W., Zhao, X., Huganir, R.L., Liao, D., 
(2014). Tau phosphorylation and tau mislocalization mediate soluble Aβ 
oligomer-induced AMPA glutamate receptor signaling deficits. 
European Journal of Neuroscience 39, 1214–1224. 
https://doi.org/10.1111/ejn.12507 
Mirbaha, H., Chen, D., Morazova, O.A., Ruff, K.M., Sharma, A.M., Liu, X., 
Goodarzi, M., Pappu, R.V., Colby, D.W., Mirzaei, H., Joachimiak, L.A., 
Diamond, M.I., (2018). Inert and seed-competent tau monomers 
suggest structural origins of aggregation. Elife 7. 
https://doi.org/10.7554/eLife.36584 
Mironov, S.L., (2015). αSynuclein forms non-selective cation channels and 
stimulates ATP-sensitive potassium channels in hippocampal neurons. 
Journal of Physiology 593, 145–159. 
https://doi.org/10.1113/jphysiol.2014.280974 
Mitsuoka, T., Kaseda, Y., Yamashita, H., Kohriyama, T., Kawakami, H., 
Nakamura, S., Yamamura, Y., (2002). Effects of nicotine chewing gum 
on UPDRS score and P300 in early-onset parkinsonism. Hiroshima 
Journal of Medical Sciences 51, 33–39. 
Mondragón-Rodríguez, S., Salas-Gallardo, A., González-Pereyra, P., Macías, 
M., Ordaz, B., Peña-Ortega, F., Aguilar-Vázquez, A., Orta-Salazar, E., 
Díaz-Cintra, S., Perry, G., Williams, S., (2018). Phosphorylation of Tau 
protein correlates with changes in hippocampal theta oscillations and 
reduces hippocampal excitability in Alzheimer’s model. Journal of 
277 
Biological Chemistry 293, 8462–8472. 
https://doi.org/10.1074/jbc.RA117.001187 
Moore, A.R., Zhou, W.-L., Sirois, C.L., Belinsky, G.S., Zecevic, N., Antic, S.D., 
(2014). Connexin hemichannels contribute to spontaneous electrical 
activity in the human fetal cortex. Proceedings of the National Academy 
of Sciences 111, E3919-3928. doi.org/10.1073/pnas.1405253111 
Morales, M., Margolis, E.B., (2017). Ventral tegmental area: cellular 
heterogeneity, connectivity, and behaviour. Nature Reviews 
Neuroscience 18, 73–85. https://doi.org/10.1038/nrn.2016.165 
Morales, M., Root, D.H., (2014). Glutamate neurons within the midbrain 
dopamine regions. Neuroscience 282, 60–68. 
https://doi.org/10.1016/j.neuroscience.2014.05.032 
Morgan, D.G., Finch, C.E., (1988). Dopaminergic changes in the basal ganglia. 
A generalized phenomenon of aging in mammals. Annals of the New 
York Academy of Sciences 515, 145–160. 
https://doi.org/10.1111/j.1749-6632.1988.tb32978.x 
Morgan, C.J., (2017). Use of proper statistical techniques for research studies 
with small samples. American Journal of Physiology - Lung Cellular and 
Molecular Physiology 313, L873– L877. 
https://doi.org/10.1152/ajplung.00238.2017 
Mountcastle, V.B., (1998). Perceptual Neuroscience: The Cerebral Cortex. 
Harvard University Press. 
Mountcastle, V.B., (1957). Modality and topographic properties of single 
neurons of cat’s somatic sensory cortex. Journal of Neurophysiology 
20, 408–434. https://doi.org/10.1152/jn.1957.20.4.408 
Mukrasch, M.D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., 
Griesinger, C., Mandelkow, E., Zweckstetter, M., (2009). Structural 
polymorphism of 441-residue tau at single residue resolution. PLoS 
Biology 7, e34. https://doi.org/10.1371/journal.pbio.1000034 
Mullane, K., Williams, M., (2020). Alzheimer’s disease beyond amyloid: Can 
the repetitive failures of amyloid-targeted therapeutics inform future 
approaches to dementia drug discovery? Biochemical Pharmacology 
177, 113945. https://doi.org/10.1016/j.bcp.2020.113945 
Müller, M.L.T.M., Bohnen, N.I., (2013). Cholinergic Dysfunction in Parkinson’s 
Disease. Current Neurology and Neuroscience Reports 13, 377. 
https://doi.org/10.1007/s11910-013-0377-9 
Munoz, D.G., Fujioka, S., (2018). Caffeine and Parkinson disease: A possible 
diagnostic and pathogenic breakthrough. Neurology 90, 205–206. 
https://doi.org/10.1212/WNL.0000000000004898 
278 
Muñoz, P., Huenchuguala, S., Paris, I., Segura-Aguilar, J., (2012). Dopamine 
oxidation and autophagy. Parkinson's Disease, 920953. 
https://doi.org/10.1155/2012/920953 
Murphy, D.D., Rueter, S.M., Trojanowski, J.Q., Lee, V.M., (2000). Synucleins 
are developmentally expressed, and alpha-synuclein regulates the size 
of the presynaptic vesicular pool in primary hippocampal neurons. 
Journal of Neuroscience 20, 3214–3220. 
Nabavi, S., Fox, R., Proulx, C.D., Lin, J.Y., Tsien, R.Y., Malinow, R., (2014). 
Engineering a memory with LTD and LTP. Nature 511, 348–352. 
https://doi.org/10.1038/nature13294 
Nagy, J.I., Lynn, B.D., Tress, O., Willecke, K., Rash, J.E., (2011). Connexin26 
expression in brain parenchymal cells demonstrated by targeted 
connexin ablation in transgenic mice. European Journal of 
Neuroscience 34, 263–271. https://doi.org/10.1111/j.1460-
9568.2011.07741.x 
Nagatsu, T., Sawada, M., (2006). Molecular mechanism of the relation of 
monoamine oxidase B and its inhibitors to Parkinson’s disease: 
possible implications of glial cells. Journal of Neural Transmission 
Suppl. 53–65. https://doi.org/10.1007/978-3-211-33328-0_7 
Nagy, J.I., Ionescu, A.V., Lynn, B.D., Rash, J.E., (2003). Connexin29 and 
Connexin32 at Oligodendrocyte and Astrocyte Gap Junctions and in 
Myelin of the Mouse Central Nervous System. Journal of Computational 
Neurology 464, 356–370. https://doi.org/10.1002/cne.10797 
Narasimhan, S., Guo, J.L., Changolkar, L., Stieber, A., McBride, J.D., Silva, 
L.V., He, Z., Zhang, B., Gathagan, R.J., Trojanowski, J.Q., Lee, V.M.Y., 
(2017). Pathological Tau Strains from Human Brains Recapitulate the 
Diversity of Tauopathies in Nontransgenic Mouse Brain. Journal of 
Neuroscience 37, 11406–11423. doi.org/10.1523/JNEUROSCI.1230-
17.2017 
Näslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., 
Buxbaum, J.D., (2000). Correlation between elevated levels of amyloid 
beta-peptide in the brain and cognitive decline. JAMA 283, 1571–1577. 
https://doi.org/10.1001/jama.283.12.1571 
Nattie, E., (1999). CO2, brainstem chemoreceptors and breathing. Progress in 
Neurobiology 59, 299–331. https://doi.org/10.1016/S0301-
0082(99)00008-8 
Navarro, M., Rodriquez de Fonseca, F., Alvarez, E., Chowen, J.A., Zueco, 
J.A., Gomez, R., Eng, J., Blázquez, E., (1996). Colocalization of 
glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-
2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role 
279 
of GLP-1 receptor agonists as an inhibitory signal for food and water 
intake. Journal of Neurochemistry 67, 1982–1991. 
https://doi.org/10.1046/j.1471- 4159.1996.67051982.x 
Neher, E., Sakmann, B., (1976). Single-channel currents recorded from 
membrane of denervated frog muscle fibres. Nature 260, 799–802. 
https://doi.org/10.1038/260799a0 
Nelson, P.T., Abner, E.L., Schmitt, F.A., Kryscio, R.J., Jicha, G.A., Santacruz, 
K., Smith, C.D., Patel, E., Markesbery, W.R., (2009). Brains with medial 
temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are 
a diagnostic dilemma but may have pathogenetic aspects distinct from 
Alzheimer disease. Journal of Neuropathology and Experimental 
Neurology 68, 774–784. doi.org/10.1097/NEN.0b013e3181aacbe9 
Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., 
Castellani, R.J., Crain, B.J., Davies, P., Del Tredici, K., Duyckaerts, C., 
Frosch, M.P., Haroutunian, V., Hof, P.R., Hulette, C.M., Hyman, B.T., 
Iwatsubo, T., Jellinger, K.A., Jicha, G.A., Kövari, E., Kukull, W.A., 
Leverenz, J.B., Love, S., Mackenzie, I.R., Mann, D.M., Masliah, E., 
McKee, A.C., Montine, T.J., Morris, J.C., Schneider, J.A., Sonnen, J.A., 
Thal, D.R., Trojanowski, J.Q., Troncoso, J.C., Wisniewski, T., Woltjer, 
R.L., Beach, T.G., (2012). Correlation of Alzheimer Disease 
Neuropathologic Changes With Cognitive Status: A Review of the 
Literature. Journal of neuropathology and experimental neurology 71, 
362–381. https://doi.org/10.1097/NEN.0b013e31825018f7 
Neuhoff, H., Neu, A., Liss, B., Roeper, J., (2002). Ih Channels Contribute to 
the Different Functional Properties of Identified Dopaminergic 
Subpopulations in the Midbrain. Journal of Neuroscience. 22, 1290–
1302. https://doi.org/10.1523/JNEUROSCI.22-04-01290.2002 
Neves, G., Cooke, S.F., Bliss, T.V.P., (2008). Synaptic plasticity, memory and 
the hippocampus: a neural network approach to causality. Nature 
Reviews Neuroscience 9, 65–75. https://doi.org/10.1038/nrn2303. 
Neves, G., Cooke, S.F., Bliss, T.V.P., (2008). Synaptic plasticity, memory and 
the hippocampus: a neural network approach to causality. Nature 
Reviews Neuroscience. 9, 65–75. https://doi.org/10.1038/nrn2303 
Niccoli, T., Partridge, L., (2012). Ageing as a risk factor for disease. Current 
Biology 22, R741-752. https://doi.org/10.1016/j.cub.2012.07.024 
Niehaus, J.L., Murali, M., Kauer, J.A., (2010). Drugs of abuse and stress impair 
LTP at inhibitory synapses in the ventral tegmental area. European 
Journal of Neuroscience 32, 108–117. https://doi.org/10.1111/j.1460-
9568.2010.07256.x 
280 
Nielsen, S.S., Gallagher, L.G., Lundin, J.I., Longstreth, W.T., Smith-Weller, T., 
Franklin, G.M., Swanson, P.D., Checkoway, H., (2012). Environmental 
tobacco smoke and Parkinson disease. Movement Disorders. 27, 293–
297.  https://doi.org/10.1002/mds.24012 
Nijjar, S., Maddison, D., Meigh, L., Wolf, E. de, Rodgers, T., Cann, M.J., Dale, 
N., (2021). Opposing modulation of Cx26 gap junctions and 
hemichannels by CO2. The Journal of Physiology 599, 103–118. 
https://doi.org/10.1113/JP280747 
Nugent, F.S., Niehaus, J.L., Kauer, J.A., (2009). PKG and PKA signaling in 
LTP at GABAergic synapses. Neuropsychopharmacology 34, 1829–
1842. https://doi.org/10.1038/npp.2009.5 
Nugent, F.S., Penick, E.C., Kauer, J.A., (2007). Opioids block long-term 
potentiation of inhibitory synapses. Nature 446, 1086–1090. 
https://doi.org/10.1038/nature05726 
Ogiwara, I., Miyamoto, H., Morita, N., Atapour, N., Mazaki, E., Inoue, I., 
Takeuchi, T., Itohara, S., Yanagawa, Y., Obata, K., Furuichi, T., 
Hensch, T.K., Yamakawa, K., (2007). Nav1.1 localizes to axons of 
parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic 
seizures in mice carrying an Scn1a gene mutation. Journal of 
Neuroscience 27, 5903–5914. doi.org/10.1523/JNEUROSCI.5270-
06.2007 
Ondrejcak, T., Klyubin, I., Corbett, G.T., Fraser, G., Hong, W., Mably, A.J., 
Gardener, M., Hammersley, J., Perkinton, M.S., Billinton, A., Walsh, 
D.M., Rowan, M.J., (2018). Cellular Prion Protein Mediates the 
Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo. 
Journal of Neuroscience 38, 10595–10606. 
https://doi.org/10.1523/JNEUROSCI.1700-18.2018 
Oomura, Y., Kimura, K., Ooyama, H., Maeno, T., Iki, M., Kuniyoshi, M., (1964). 
RECIPROCAL ACTIVITIES OF THE VENTROMEDIAL AND LATERAL 
HYPOTHALAMIC AREAS OF CATS. Science 143, 484–485. 
https://doi.org/10.1126/science.143.3605.484 
Oomura, Y., Ono, T., Ooyama, H., Wayner, M.J., (1969). Glucose and 
osmosensitive neurones of the rat hypothalamus. Nature 222, 282–284. 
https://doi.org/10.1038/222282a0 
O’Reilly, E.J., McCullough, M.L., Chao, A., Henley, S.J., Calle, E.E., Thun, 
M.J., Ascherio, A., (2005). Smokeless tobacco use and the risk of 
Parkinson’s disease mortality. Journal of Movement Disorders
20, 1383–1384. https://doi.org/10.1002/mds.20587 
Osborne, J.L., Mitchell, G.S., (1978). Intrapulmonary and systemic CO2-
chemoreceptor interaction in the control of avian respiration. 
281 
Respiration Physiology 33, 349–357. https://doi.org/10.1016/0034-
5687(78)90061-0 
Osborne, J.L., Mitchell, G.S., Powell, F., (1977). Ventilatory responses to CO2 
in the chicken: intrapulmonary and systemic chemoreceptors. 
Respiration Physiology.  30, 369–382. https://doi.org/10.1016/0034-
5687(77)90042-1 
O’Shea, A., Cohen, R.A., Porges, E.C., Nissim, N.R., Woods, A.J., (2016). 
Cognitive Aging and the Hippocampus in Older Adults. Frontiers in 
Aging Neuroscience 8, 298. https://doi.org/10.3389/fnagi.2016.00298 
Osorio, N., Alcaraz, G., Padilla, F., Couraud, F., Delmas, P., Crest, M., (2005). 
Differential targeting and functional specialization of sodium channels 
in cultured cerebellar granule cells. The Journal of Physiology 569, 
801–816. https://doi.org/10.1113/jphysiol.2005.097022 
Owens, R.L., Malhotra, A., (2010). Sleep-disordered breathing and COPD: the 
overlap syndrome. Respiratory Care 55, 1333–1344; discussion 1344-
1346. 
Palfi, S., Gurruchaga, J.M., Lepetit, H., Howard, K., Ralph, G.S., Mason, S., 
Gouello, G., Domenech, P., Buttery, P.C., Hantraye, P., Tuckwell, N.J., 
Barker, R.A., Mitrophanous, K.A., (2018). Long-Term Follow-Up of a 
Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for 
Parkinson’s Disease. Human Gene Therapy Clinical Development 29, 
148–155. https://doi.org/10.1089/humc.2018.081 
Palfi, S., Gurruchaga, J.M., Ralph, G.S., Lepetit, H., Lavisse, S., Buttery, P.C., 
Watts, C., Miskin, J., Kelleher, M., Deeley, S., Iwamuro, H., Lefaucheur, 
J.P., Thiriez, C., Fenelon, G., Lucas, C., Brugières, P., Gabriel, I., 
Abhay, K., Drouot, X., Tani, N., Kas, A., Ghaleh, B., Le Corvoisier, P., 
Dolphin, P., Breen, D.P., Mason, S., Guzman, N.V., Mazarakis, N.D., 
Radcliffe, P.A., Harrop, R., Kingsman, S.M., Rascol, O., Naylor, S., 
Barker, R.A., Hantraye, P., Remy, P., Cesaro, P., Mitrophanous, K.A., 
(2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-
based gene therapy for Parkinson’s disease: a dose escalation, open-
label, phase 1/2 trial. Lancet 383, 1138–1146. 
https://doi.org/10.1016/S0140-6736(13)61939-X 
Parain, K., Marchand, V., Dumery, B., Hirsch, E., (2001). Nicotine, but not 
cotinine, partially protects dopaminergic neurons against MPTP-
induced degeneration in mice. Brain Research 890, 347–350. 
https://doi.org/10.1016/s0006-8993(00)03198-x 
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., 
Mollenhauer, B., Blennow, K., Calabresi, P., (2019). CSF and blood 
282 
biomarkers for Parkinson’s disease. Lancet Neurology 18, 573–586. 
https://doi.org/10.1016/S1474-4422(19)30024-9 
Patel, J.C., Witkovsky, P., Coetzee, W.A., Rice, M.E., (2011). Subsecond 
regulation of striatal dopamine release by pre-synaptic KATP channels. 
Journal of Neurochemistry 118, 721–736. 
https://doi.org/10.1111/j.1471-4159.2011.07358.x 
Patel, S., Sharma, S., (2021). Respiratory Acidosis, in: StatPearls. StatPearls 
Publishing, Treasure Island (FL). 
Patino, G.A., Isom, L.L., (2010). Electrophysiology and beyond: Multiple roles 
of Na+ channel β subunits in development and disease. Neuroscience 
Letters, Proteomics of Voltage-Gated Ion Channels 486, 53–59. 
https://doi.org/10.1016/j.neulet.2010.06.050 
Patriarchi, T., Cho, J.R., Merten, K., Howe, M.W., Marley, A., Xiong, W.-H., 
Folk, R.W., Broussard, G.J., Liang, R., Jang, M.J., Zhong, H., Dombeck, 
D., von Zastrow, M., Nimmerjahn, A., Gradinaru, V., Williams, J.T., Tian, 
L., (2018). Ultrafast neuronal imaging of dopamine dynamics with 
designed genetically encoded sensors. Science 360. 
https://doi.org/10.1126/science.aat4422 
Paulus, W., Jellinger, K., (1991). The neuropathologic basis of different clinical 
subgroups of Parkinson’s disease. Journal of Neuropathology and 
Experimental Neurology 50, 743–755. 
https://doi.org/10.1097/00005072-199111000-00006 
Pearson, R.A., Dale, N., Llaudet, E., Mobbs, P., (2005). ATP released via gap 
junction hemichannels from the pigment epithelium regulates neural 
retinal progenitor proliferation. Neuron 46, 731–744. 
https://doi.org/10.1016/j.neuron.2005.04.024 
Pedersen, M.E.F., Fatemian, M., Robbins, P.A., (1999). Identification of fast 
and slow ventilatory responses to carbon dioxide under hypoxic and 
hyperoxic conditions in humans. Journal of Physiology 521, 273–287. 
https://doi.org/10.1111/j.1469-7793.1999.00273.x 
Petersen, R.C., (2004). Mild cognitive impairment as a diagnostic entity. 
Journal of Internal Medicine 256, 183–194. 
https://doi.org/10.1111/j.1365-2796.2004.01388.x 
Pickett, E.K., Henstridge, C.M., Allison, E., Pitstick, R., Pooler, A., Wegmann, 
S., Carlson, G., Hyman, B.T., Spires-Jones, T.L., (2017). Spread of tau 
down neural circuits precedes synapse and neuronal loss in the 
rTgTauEC mouse model of early Alzheimer’s disease. Synapse 71. 
https://doi.org/10.1002/syn.21965 
283 
Pierce, J.E., Péron, J., (2020). The basal ganglia and the cerebellum in human 
emotion. Social Cognitive and Affective Neuroscience. 15, 599–613. 
https://doi.org/10.1093/scan/nsaa076 
Pir, G.J., Choudhary, B., Kaniyappan, S., Chandupatla, R.R., Mandelkow, E., 
Mandelkow, E.-M., Wang, Y., (2019). Suppressing Tau Aggregation 
and Toxicity by an Anti-Aggregant Tau Fragment. Molecular 
Neurobiology 56, 3751–3767. https://doi.org/10.1007/s12035-018-
1326-z 
Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, 
J., Schrag, A.-E., Lang, A.E., (2017). Parkinson disease. Nature 
Reviews Disease Primers 3, 1–21. 
https://doi.org/10.1038/nrdp.2017.13 
Polinski, N.K., Volpicelli-Daley, L.A., Sortwell, C.E., Luk, K.C., Cremades, N., 
Gottler, L.M., Froula, J., Duffy, M.F., Lee, V.M.Y., Martinez, T.N., Dave, 
K.D., (2018). Best Practices for Generating and Using Alpha-Synuclein 
Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents. Journal 
of Parkinson's Disease 8, 303–322. https://doi.org/10.3233/JPD-
171248 
Polydoro, M., Acker, C.M., Duff, K., Castillo, P.E., Davies, P., (2009). Age-
dependent impairment of cognitive and synaptic function in the htau 
mouse model of tau pathology. Journal of Neuroscience 29, 10741–
10749. https://doi.org/10.1523/JNEUROSCI.1065-09.2009 
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, 
A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., 
Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., 
Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., 
Nussbaum, R.L., (1997). Mutation in the alpha-synuclein gene identified 
in families with Parkinson’s disease. Science 276, 2045–2047. 
https://doi.org/10.1126/science.276.5321.2045 
Pooler, A.M., Phillips, E.C., Lau, D.H.W., Noble, W., Hanger, D.P., (2013). 
Physiological release of endogenous tau is stimulated by neuronal 
activity. EMBO Reports 14, 389–394. 
https://doi.org/10.1038/embor.2013.15 
Popoli, P., Pèzzola, A., Scotti de Carolis, A., (1994). Modulation of striatal 
adenosine A1 and A2 receptors induces rotational behaviour in 
response to dopaminergic stimulation in intact rats. European Journal 
of Pharmacology 257, 21–25. https://doi.org/10.1016/0014-
2999(94)90689-0 
Privitera, L., Morè, L., Cooper, D.D., Richardson, P., Tsogka, M., Hebenstreit, 
D., Arthur, J.S.C., Frenguelli, B.G., (2020). Experience Recruits MSK1 
284 
to Expand the Dynamic Range of Synapses and Enhance Cognition. 
Journal of Neuroscience 40, 4644–4660. 
https://doi.org/10.1523/JNEUROSCI.2765-19.2020 
Puangmalai, N., Bhatt, N., Montalbano, M., Sengupta, U., Gaikwad, S., 
Ventura, F., McAllen, S., Ellsworth, A., Garcia, S., Kayed, R., (2020). 
Internalization mechanisms of brain-derived tau oligomers from patients 
with Alzheimer’s disease, progressive supranuclear palsy and dementia 
with Lewy bodies. Cell Death & Disease 11, 314. 
https://doi.org/10.1038/s41419-020-2503-3 
Puopolo, M., Raviola, E., Bean, B.P., (2007). Roles of Subthreshold Calcium 
Current and Sodium Current in Spontaneous Firing of Mouse Midbrain 
Dopamine Neurons. Journal of Neuroscience. 27, 645–656. 
https://doi.org/10.1523/JNEUROSCI.4341-06.2007 
Puthongkham, P., Venton, B.J., (2020). Recent advances in fast-scan cyclic 
voltammetry. Analyst 145, 1087–1102. 
https://doi.org/10.1039/C9AN01925A 
Putnam, R., (2001). CO2chemotransduction in central neurons: role of 
intracellular pH (pHi) and extracellular pH (pHo). Respiratory Research 
2, 6.4. https://doi.org/10.1186/rr122 
Puzzo, D., Piacentini, R., Fá, M., Gulisano, W., Li Puma, D.D., Staniszewski, 
A., Zhang, H., Tropea, M.R., Cocco, S., Palmeri, A., Fraser, P., 
D’Adamio, L., Grassi, C., Arancio, O., (2017). LTP and memory 
impairment caused by extracellular Aβ and Tau oligomers is APP-
dependent. eLife 6. https://doi.org/10.7554/eLife.26991 
Qiang, L., Sun, X., Austin, T.O., Muralidharan, H., Jean, D.C., Liu, M., Yu, W., 
Baas, P.W., (2018). Tau Does Not Stabilize Axonal Microtubules but 
Rather Enables Them to Have Long Labile Domains. Current Biology 
28, 2181-2189.e4. https://doi.org/10.1016/j.cub.2018.05.045 
Qui, F., Hu, W., Yang, Z., (2014). Enhancement of GABA-activated currents 
by arginine vasopressin in rat dorsal root ganglion neurons. Sheng Li 
Xue Bao 66, 647–657. 
Quik, M., Perez, X.A., Bordia, T., (2012). Nicotine as a potential 
neuroprotective agent for Parkinson’s disease. Movement Disorders 
27, 947–957. https://doi.org/10.1002/mds.25028 
Quik, M., Huang, L.Z., Parameswaran, N., Bordia, T., Campos, C., Perez, X.A., 
(2009). Multiple roles for nicotine in Parkinson’s disease. Biochem. 
Pharmacol. 78, 677–685. https://doi.org/10.1016/j.bcp.2009.05.003 
Quik, M., Mallela, A., Chin, M., McIntosh, J.M., Perez, X.A., Bordia, T., (2013a). 
Nicotine-mediated improvement in L-dopa-induced dyskinesias in 
MPTP-lesioned monkeys is dependent on dopamine nerve terminal 
285 
function. Neurobiology of Disease 50, 30–41. 
https://doi.org/10.1016/j.nbd.2012.09.006 
Quik, M., Mallela, A., Ly, J., Zhang, D., (2013b). Nicotine reduces established 
levodopa-induced dyskinesias in a monkey model of Parkinson’s 
disease. Journal of Movement Disorders. 28, 1398–1406. 
https://doi.org/10.1002/mds.25594 
Quik, M., Perez, X.A., Bordia, T., (2012). Nicotine as a potential 
neuroprotective agent for Parkinson’s disease. Journal of Movement 
Disorders. 27, 947–957. https://doi.org/10.1002/mds.25028 
Rademakers, R., Neumann, M., Mackenzie, I.R., (2012). Advances in 
understanding the molecular basis of frontotemporal dementia. Nature  
Reviews Neurology 8, 423–434. 
https://doi.org/10.1038/nrneurol.2012.117 
Rall, W., Segev, I., (1985). Space-Clamp Problems When Voltage Clamping 
Branched Neurons With Intracellular Microelectrodes, in: Smith, T.G., 
Lecar, H., Redman, S.J., Gage, P.W. (Eds.), Voltage and Patch 
Clamping with Microelectrodes. Springer, New York, NY, pp. 191–215. 
https://doi.org/10.1007/978-1-4614-7601-6_9 
Ramaswamy, S., Courcol, J.-D., Abdellah, M., Adaszewski, S.R., Antille, N., 
Arsever, S., Atenekeng, G., Bilgili, A., Brukau, Y., Chalimourda, A., 
Chindemi, G., Delalondre, F., Dumusc, R., Eilemann, S., Gevaert, M.E., 
Gleeson, P., Graham, J.W., Hernando, J.B., Kanari, L., Katkov, Y., 
Keller, D., King, J.G., Ranjan, R., Reimann, M.W., Rössert, C., Shi, Y., 
Shillcock, J.C., Telefont, M., Van Geit, W., Villafranca Diaz, J., Walker, 
R., Wang, Y., Zaninetta, S.M., DeFelipe, J., Hill, S.L., Muller, J., Segev, 
I., Schürmann, F., Muller, E.B., Markram, H., (2015). The neocortical 
microcircuit collaboration portal: a resource for rat somatosensory 
cortex. Frontiers in Neural Circuits 9. 
https://doi.org/10.3389/fncir.2015.00044 
Ramón y Cajal, S., (1911). Histologie du système nerveux de l’homme & des 
vertébrés., Ed. française rev. & mise à jour par l’auteur, tr. de l’espagnol 
par L. Azoulay. ed. Maloine, Paris : 
https://doi.org/10.5962/bhl.title.48637 
Ran, I., Laplante, I., Lacaille, J.-C., (2012). CREB-Dependent Transcriptional 
Control and Quantal Changes in Persistent Long-Term Potentiation in 
Hippocampal Interneurons. Journal of Neuroscience. 32, 6335–6350. 
https://doi.org/10.1523/JNEUROSCI.5463-11.2012 
Raux, G., Guyant-Maréchal, L., Martin, C., Bou, J., Penet, C., Brice, A., 
Hannequin, D., Frebourg, T., Campion, D., (2005). Molecular diagnosis 
of autosomal dominant early onset Alzheimer’s disease: an 
286 
update. Journal of Medical Genetics. 42, 793–795. 
https://doi.org/10.1136/jmg.2005.033456 
Regan, P., Piers, T., Yi, J.-H., Kim, D.-H., Huh, S., Park, S.J., Ryu, J.H., 
Whitcomb, D.J., Cho, K., (2015). Tau phosphorylation at serine 396 
residue is required for hippocampal LTD. Journal of Neuroscience 35, 
4804–4812. https://doi.org/10.1523/JNEUROSCI.2842-14.2015 
Ren, X., Chen, J.-F., (2020). Caffeine and Parkinson’s Disease: Multiple 
Benefits and Emerging Mechanisms. Frontiers in Neuroscience. 14. 
https://doi.org/10.3389/fnins.2020.602697 
Ren, Y., Sahara, N., Giasson, B., Lewis, J., (2015). Chapter 55 - Tauopathy 
Mouse Models, in: LeDoux, M.S. (Ed.), Movement Disorders (Second 
Edition). Academic Press, Boston, pp. 849–855. 
https://doi.org/10.1016/B978-0-12-405195-9.00055-X 
Reyes, A., Sakmann, B., (1999). Developmental Switch in the Short-Term 
Modification of Unitary EPSPs Evoked in Layer 2/3 and Layer 5 
Pyramidal Neurons of Rat Neocortex. Journal of Neuroscience. 19, 
3827–3835. https://doi.org/10.1523/JNEUROSCI.19-10-03827.1999 
Reyskens, K.M.S.E., Arthur, J.S.C., (2016). Emerging Roles of the Mitogen 
and Stress Activated Kinases MSK1 and MSK2. Frontiers in Cell and 
Developmental Biology 4. https://doi.org/10.3389/fcell.2016.00056 
Richards, C.D., Shiroyama, T., Kitai, S.T., (1997). Electrophysiological and 
immunocytochemical characterization of GABA and dopamine neurons 
in the substantia nigra of the rat. Neuroscience 80, 545–557. 
https://doi.org/10.1016/s0306-4522(97)00093-6 
Richardson, M.J.E., Silberberg, G., (2008a). Measurement and analysis of 
postsynaptic potentials using a novel voltage-deconvolution method. 
Journal of Neurophysiology 99, 1020–1031. 
https://doi.org/10.1152/jn.00942.2007 
Richardson, M.J.E., Silberberg, G., (2008b). Measurement and analysis of 
postsynaptic potentials using a novel voltage-deconvolution method. 
Journal of Neurophysiology 99, 1020–1031. 
https://doi.org/10.1152/jn.00942.2007 
Riederer, P., Konradi, C., Schay, V., Kienzl, E., Birkmayer, G., Danielczyk, W., 
Sofic, E., Youdim, M.B., (1987). Localization of MAO-A and MAO-B in 
human brain: a step in understanding the therapeutic action of L-
deprenyl. Advances in neurology. 45, 111–118. 
Ripoll, C., Lederer, W.J., Nichols, C.G., (1993). On the mechanism of inhibition 
of KATP channels by glibenclamide in rat ventricular myocytes. Journal 
of Cardiovascular Electrophysiology 4, 38–47. 
https://doi.org/10.1111/j.1540-8167.1993.tb01210.x 
287 
Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., 
Gerstein, H., Yu, G.-Q., Mucke, L., (2007). Reducing endogenous tau 
ameliorates amyloid beta-induced deficits in an Alzheimer’s disease 
mouse model. Science 316, 750–754. 
https://doi.org/10.1126/science.1141736 
Roberts, H.L., Brown, D.R., (2015). Seeking a Mechanism for the Toxicity of 
Oligomeric αSynuclein. Biomolecules 5, 282–305. 
https://doi.org/10.3390/biom5020282 
Robinson, J.E., Coughlin, G.M., Hori, A.M., Cho, J.R., Mackey, E.D., Turan, 
Z., Patriarchi, T., Tian, L., Gradinaru, V., (2019). Optical dopamine 
monitoring with dLight1 reveals mesolimbic phenotypes in a mouse 
model of neurofibromatosis type 1. eLife 8, e48983. 
https://doi.org/10.7554/eLife.48983 
Rocher, A.B., Crimins, J.L., Amatrudo, J.M., Kinson, M.S., Todd-Brown, M.A., 
Lewis, J., Luebke, J.I., (2010). Structural and functional changes in tau 
mutant mice neurons are not linked to the presence of NFTs. 
Experimental Neurology 223, 385–393. 
https://doi.org/10.1016/j.expneurol.2009.07.029 
Romand, S., Wang, Y., Toledo-Rodriguez, M., Markram, H., (2011). 
Morphological Development of Thick-Tufted Layer V Pyramidal Cells in 
the Rat Somatosensory Cortex. Frontiers in Neuroanatomy 5. 
https://doi.org/10.3389/fnana.2011.00005 
Root, D.H., Estrin, D.J., Morales, M., (2018). Aversion or Salience Signaling 
by Ventral Tegmental Area Glutamate Neurons. iScience 2, 51–62. 
https://doi.org/10.1016/j.isci.2018.03.008 
Röper, J., Ashcroft, F.M., (1995). Metabolic inhibition and low internal ATP 
activate K-ATP channels in rat dopaminergic substantia nigra neurones. 
Pflugers Archives 430, 44–54. https://doi.org/10.1007/BF00373838 
Ross, G.W., Petrovitch, H., Abbott, R.D., Tanner, C.M., Popper, J., Masaki, K., 
Launer, L., White, L.R., (2008). Association of olfactory dysfunction with 
risk for future Parkinson’s disease. Annals of Neurology 63, 167–173. 
https://doi.org/10.1002/ana.21291 
Rostami, J., Holmqvist, S., Lindström, V., Sigvardson, J., Westermark, G.T., 
Ingelsson, M., Bergström, J., Roybon, L., Erlandsson, A., (2017). 
Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling 
Nanotubes. Journal of Neuroscience 37, 11835–11853. 
https://doi.org/10.1523/JNEUROSCI.0983-17.2017 
Roth, R.H., (1984). CNS Dopamine Autoreceptors: Distribution, 
Pharmacology, and Functional Annals of the New York Academy of 
Sciences 430, 27–53. doi.org/10.1111/j.1749-6632.1984.tb14497.x 
288 
Royeck, M., Horstmann, M.-T., Remy, S., Reitze, M., Yaari, Y., Beck, H., 
(2008). Role of Axonal NaV1.6 Sodium Channels in Action Potential 
Initiation of CA1 Pyramidal Neurons. Journal of Neurophysiology 100, 
2361–2380. https://doi.org/10.1152/jn.90332.2008 
Rudinskiy, N., Hawkes, J.M., Wegmann, S., Kuchibhotla, K.V., Muzikansky, 
A., Betensky, R.A., Spires-Jones, T.L., Hyman, B.T., (2014). Tau 
pathology does not affect experience-driven single-neuron and 
network-wide Arc/Arg3.1 response. Acta Neuropathologica 
Communications 2. https://doi.org/10.1186/2051-5960-2-63 
Ryan, T.J., Roy, D.S., Pignatelli, M., Arons, A., Tonegawa, S., (2015). Memory. 
Engram cells retain memory under retrograde amnesia. Science 348, 
1007–1013. https://doi.org/10.1126/science.aaa5542 
Sakura, H., Ammälä, C., Smith, P.A., Gribble, F.M., Ashcroft, F.M., (1995). 
Cloning and functional expression of the cDNA encoding a novel ATP-
sensitive potassium channel subunit expressed in pancreatic beta-cells, 
brain, heart and skeletal muscle. FEBS Letters. 377, 338–344. 
https://doi.org/10.1016/0014-5793(95)01369-5 
Samii, A., Nutt, J.G., Ransom, B.R., (2004). Parkinson’s disease. Lancet 363, 
1783–1793. https://doi.org/10.1016/S0140-6736(04)16305-8 
Santos, S.F., de Oliveira, H.L., Yamada, E.S., Neves, B.C., Pereira, A., (2019). 
The Gut and Parkinson’s Disease—A Bidirectional Pathway. Frontiers 
in Neurology 10. https://doi.org/10.3389/fneur.2019.00574 
Schapira, A.H.V., Emre, M., Jenner, P., Poewe, W., (2009). Levodopa in the 
treatment of Parkinson’s disease. European Journal of Neurology 16, 
982–989. https://doi.org/10.1111/j.1468-1331.2009.02697.x 
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, 
T.D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., 
Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., 
Wasco, W., Lannfelt, L., Selkoe, D., Younkin, S., (1996). Secreted 
amyloid beta-protein similar to that in the senile plaques of Alzheimer’s 
disease is increased in vivo by the presenilin 1 and 2 and APP 
mutations linked to familial Alzheimer’s disease. Nature Medicine 2, 
864–870.  https://doi.org/10.1038/nm0896-864 
Schernhammer, E., Hansen, J., Rugbjerg, K., Wermuth, L., Ritz, B., (2011). 
Diabetes and the Risk of Developing Parkinson’s Disease in Denmark. 
Diabetes Care 34, 1102–1108. https://doi.org/10.2337/dc10-1333 
Schiemann, J., Schlaudraff, F., Klose, V., Bingmer, M., Seino, S., Magill, P.J., 
Zaghloul, K.A., Schneider, G., Liss, B., Roeper, J., (2012). K-ATP 
channels in dopamine substantia nigra neurons control bursting and 
289 
novelty-induced exploration. Nature Neuroscience 15, 1272–1280. 
https://doi.org/10.1038/nn.3185 
Shimizu, H., Watanabe, E., Hiyama, T.Y., Nagakura, A., Fujikawa, A., Okado, 
H., Yanagawa, Y., Obata, K., Noda, M., (2007). Glial Nax Channels 
Control Lactate Signaling to Neurons for Brain [Na+] Sensing. Neuron 
54, 59–72. https://doi.org/10.1016/j.neuron.2007.03.014 
Schoch, K.M., DeVos, S.L., Miller, R.L., Chun, S.J., Norrbom, M., Wozniak, 
D.F., Dawson, H.N., Bennett, C.F., Rigo, F., Miller, T.M., (2016). 
Increased 4R-Tau Induces Pathological Changes in a Human-Tau 
Mouse Model. Neuron 90, 941–947. 
https://doi.org/10.1016/j.neuron.2016.04.042 
Schwanstecher, M., Sieverding, C., Dörschner, H., Gross, I., Aguilar-Bryan, L., 
Schwanstecher, C., Bryan, J., (1998). Potassium channel openers 
require ATP to bind to and act through sulfonylurea receptors. EMBO 
Journal 17, 5529–5535. https://doi.org/10.1093/emboj/17.19.5529 
Scoville, W.B., Milner, B., (1957). LOSS OF RECENT MEMORY AFTER 
BILATERAL HIPPOCAMPAL LESIONS. Journal of Neurology, 
Neurosurgery, and Psychiatry 20, 11–21. 
Seino, S., (1999). ATP-sensitive potassium channels: a model of 
heteromultimeric potassium channel/receptor assemblies. Annual 
Review of Physiology 61, 337–362. 
https://doi.org/10.1146/annurev.physiol.61.1.337 
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, 
S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., 
Wolfert, R., Selkoe, D., Lieberburg, I., Schenk, D., (1992). Isolation and 
quantification of soluble Alzheimer’s β-peptide from biological fluids. 
Nature 359, 325–327. https://doi.org/10.1038/359325a0 
Shammas, S.L., Garcia, G.A., Kumar, S., Kjaergaard, M., Horrocks, M.H., 
Shivji, N., Mandelkow, Eva, Knowles, T.P.J., Mandelkow, Eckhard, 
Klenerman, D., (2015). A mechanistic model of tau amyloid aggregation 
based on direct observation of oligomers. Nature Communications 6. 
https://doi.org/10.1038/ncomms8025 
Shams, H., (1985). Differential effects of CO2 and H+ as central stimuli of 
respiration in the cat. Journal of Applied Physiology 58, 357–364. 
https://doi.org/10.1152/jappl.1985.58.2.357 
Shoji, M., Golde, T.E., Ghiso, J., Cheung, T.T., Estus, S., Shaffer, L.M., Cai, 
X.D., McKay, D.M., Tintner, R., Frangione, B., (1992). Production of the 
Alzheimer amyloid beta protein by normal proteolytic processing. 
Science 258, 126–129. https://doi.org/10.1126/science.1439760 
290 
Shrivastava, A.N., Redeker, V., Pieri, L., Bousset, L., Renner, M., Madiona, K., 
Mailhes‐Hamon, C., Coens, A., Buée, L., Hantraye, P., Triller, A., Melki, 
R., (2019). Clustering of Tau fibrils impairs the synaptic composition of 
α3‐Na+/K+‐ATPase and AMPA receptors. EMBO Journal 38. 
https://doi.org/10.15252/embj.201899871 
Shulman, L.M., (2007). Gender differences in Parkinson’s disease. Gender 
Medicine 4, 8–18. https://doi.org/10.1016/s1550-8579(07)80003-9 
Sian, J., Youdim, M.B.H., Riederer, P., Gerlach, M., (1999). MPTP-Induced 
Parkinsonian Syndrome, in: Basic Neurochemistry: Molecular, Cellular 
and Medical Aspects. 6th Edition. Lippincott-Raven, Philadelphia. 
Sigurdsson, E.M., (2018). Tau Immunotherapies for Alzheimer’s Disease and 
Related Tauopathies: Progress and Potential Pitfalls. Journal of 
Alzheimer’s Disease 64, S555–S565. https://doi.org/10.3233/JAD-
179937 
Silberberg, G., Gupta, A., Markram, H., (2002). Stereotypy in neocortical 
microcircuits. Trends in Neuroscience 25, 227–230. 
https://doi.org/10.1016/s0166-2236(02)02151-3 
Silva, M.C., Cheng, C., Mair, W., Almeida, S., Fong, H., Biswas, M.H.U., 
Zhang, Z., Huang, Y., Temple, S., Coppola, G., Geschwind, D.H., 
Karydas, A., Miller, B.L., Kosik, K.S., Gao, F.-B., Steen, J.A., Haggarty, 
S.J., (2016). Human iPSC-Derived Neuronal Model of Tau-A152T 
Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of 
Neuronal Vulnerability. Stem Cell Reports 7, 325–340. 
https://doi.org/10.1016/j.stemcr.2016.08.001 
Silva, N.L., Bunney, B.S., (1988). Intracellular studies of dopamine neurons in 
vitro: pacemakers modulated by dopamine. European Journal of 
Pharmacology 149, 307–315. https://doi.org/10.1016/0014-
2999(88)90661-9 
Simmons, D.V., Petko, A.K., Paladini, C.A., (2017). Differential expression of 
long-term potentiation among identified inhibitory inputs to dopamine 
neurons. Journal of Neurophysiology 118, 1998–2008. 
https://doi.org/10.1152/jn.00270.2017 
Skrabana, R., Skrabanova, M., Csokova, N., Sevcik, J., Novak, M., (2006) 
 Intrinsically disordered tau protein in Alzheimer's tangles: a  
 coincidence or a rule? Bratislavske Lekarske Listy 107(9-10):354-358 
Smith, Y., Wichmann, T., Factor, S.A., DeLong, M.R., (2012). Parkinson’s 
Disease Therapeutics: New Developments and Challenges Since the 
Introduction of Levodopa. Neuropsychopharmacology 37, 213–246. 
https://doi.org/10.1038/npp.2011.212 
291 
Sokolow, S., Henkins, K.M., Bilousova, T., Gonzalez, B., Vinters, H.V., Miller, 
C.A., Cornwell, L., Poon, W.W., Gylys, K.H., (2015). Pre-synaptic C-
terminal truncated tau is released from cortical synapses in Alzheimer’s 
disease. Journal of Neurochemistry 133, 368–379. 
https://doi.org/10.1111/jnc.12991 
Soldner, F., Laganière, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, 
R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S., Zhang, L., 
Guschin, D., Fong, L.K., Vu, B.J., Meng, X., Urnov, F.D., Rebar, E.J., 
Gregory, P.D., Zhang, H.S., Jaenisch, R., (2011). Generation of 
isogenic pluripotent stem cells differing exclusively at two early onset 
Parkinson point mutations. Cell 146, 318–331. 
https://doi.org/10.1016/j.cell.2011.06.019 
Sommer, U., Hummel, T., Cormann, K., Mueller, A., Frasnelli, J., Kropp, J., 
Reichmann, H., (2004). Detection of presymptomatic Parkinson’s 
disease: Combining smell tests, transcranial sonography, and SPECT. 
Movement Disorders 19, 1196–1202. 
https://doi.org/10.1002/mds.20141 
Song, C., Deng, P., Que, L., (2018). Rapid multiplexed detection of beta-
amyloid and total-tau as biomarkers for Alzheimer’s disease in 
cerebrospinal fluid. Nanomedicine 14, 1845–1852. 
https://doi.org/10.1016/j.nano.2018.05.013 
Sonsalla, P.K., Wong, L.-Y., Harris, S.L., Richardson, J.R., Khobahy, I., Li, W., 
Gadad, B.S., German, D.C., (2012). Delayed caffeine treatment 
prevents nigral dopamine neuron loss in a progressive rat model of 
Parkinson’s disease. Experimental Neurology. 234, 482–487. 
https://doi.org/10.1016/j.expneurol.2012.01.022 
Soto, C., (1999). Plaque busters: strategies to inhibit amyloid formation in 
Alzheimer’s disease. Molecular Medicine Today 5, 343–350. 
https://doi.org/10.1016/S1357-4310(99)01508-7 
Spillantini, M., Schmidt, M., Lee, V., Trojanowski, J., Jakes, R. and Goedert, 
M., (1997). α-Synuclein in Lewy bodies. Nature, 388(6645), pp.839-
840. 
Spires, T.L., Orne, J.D., SantaCruz, K., Pitstick, R., Carlson, G.A., Ashe, K.H., 
Hyman, B.T., (2006). Region-specific dissociation of neuronal loss and 
neurofibrillary pathology in a mouse model of tauopathy. The American 
Journal of Pathology 168, 1598–1607. 
https://doi.org/10.2353/ajpath.2006.050840 
Spruston, N., (2008). Pyramidal neurons: dendritic structure and synaptic 
integration. Nature Reviews Neuroscience 9, 206–221. 
https://doi.org/10.1038/nrn2286 
292 
Spruston, N., Jaffe, D.B., Williams, S.H., Johnston, D., (1993). Voltage- and 
space-clamp errors associated with the measurement of 
electrotonically remote synaptic events. Journal of Neurophysiology 70, 
781–802. https://doi.org/10.1152/jn.1993.70.2.781 
Squire, L.R., (2009). Memory and Brain Systems: 1969–2009. Journal of 
Neuroscience 29, 12711–12716. doi.org/10.1523/JNEUROSCI.3575-
09.2009 
Squire, L.R., Genzel, L., Wixted, J.T., Morris, R.G., (2015). Memory 
Consolidation. Cold Spring Harbor Perspectives in Biology 7. 
https://doi.org/10.1101/cshperspect.a021766 
Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Mandelkow, E.-M., (2002). 
Tau blocks traffic of organelles, neurofilaments, and APP vesicles in 
neurons and enhances oxidative stress. Journal of Cell Biology 156, 
1051–1063. https://doi.org/10.1083/jcb.200108057 
Stamford, J.A., (1990). Fast cyclic voltammetry: Measuring transmitter release 
in ‘real time.’ Journal of Neuroscience Methods 34, 67–72. 
https://doi.org/10.1016/0165-0270(90)90043-F 
Stanford, I.M., Lacey, M.G., (1995). Regulation of a potassium conductance in 
rat midbrain dopamine neurons by intracellular adenosine triphosphate 
(ATP) and the sulfonylureas tolbutamide and glibenclamide. Journal of 
Neuroscience 15, 4651–4657. 
Stoothoff, W.H., Johnson, G.V.W., (2005). Tau phosphorylation: physiological 
and pathological consequences. Biochimica Et Biophysica Acta 1739, 
280–297. https://doi.org/10.1016/j.bbadis.2004.06.017 
Storm, J.F., (1987). Action potential repolarization and a fast after-
hyperpolarization in rat hippocampal pyramidal cells. The Journal of 
Physiology 385, 733–759. doi.org/10.1113/jphysiol.1987.sp016517 
Stout, C.E., Costantin, J.L., Naus, C.C.G., Charles, A.C., (2002). Intercellular 
calcium signaling in astrocytes via ATP release through connexin 
hemichannels. The Journal of Biological Chemistry 277, 10482–10488. 
https://doi.org/10.1074/jbc.M109902200 
Strang, K.H., Golde, T.E., Giasson, B.I., (2019). MAPT mutations, tauopathy, 
and mechanisms of neurodegeneration. Laboratory Investigation. 99, 
912–928.  https://doi.org/10.1038/s41374-019-0197-x 
Stuart, G., Schiller, J., Sakmann, B., (1997). Action potential initiation and 
propagation in rat neocortical pyramidal neurons. The Journal of 
Physiology 505, 617–632. https://doi.org/10.1111/j.1469-
7793.1997.617ba.x 
293 
Stuber, G.D., Britt, J.P., Bonci, A., (2012). Optogenetic Modulation of Neural 
Circuits that Underlie Reward Seeking. Biological Psychiatry 71, 1061–
1067. https://doi.org/10.1016/j.biopsych.2011.11.010 
Sugiyama, H., Hainfellner, J.A., Yoshimura, M., Budka, H., (1994.) Neocortical 
changes in Parkinson’s disease, revisited. Clinical Neuropathology 13, 
55–59. 
Sullivan, L.M., Weinberg, J., Keaney, J.F., (2016). Common Statistical Pitfalls 
in Basic Science Research. J. Am. Heart Assoc. Cardiovascular and 
cerebrovascular diseases. 5. https://doi.org/10.1161/JAHA.116.004142 
Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., 
Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., Colin, M., 
Bonnefoy, E., Buée, L., Galas, M.-C., (2011). Nuclear tau, a key player 
in neuronal DNA protection. The Journal of Biological Chemistry 286, 
4566–4575. https://doi.org/10.1074/jbc.M110.199976 
Sun, Y., Tang, W., Chang, Q., Wang, Y., Kong, W., Lin, X., (2009). Connexin30 
null and conditional connexin26 null mice display distinct pattern and 
time course of cellular degeneration in the cochlea. The Journal of 
Comparative Neurology 516, 569–579. 
https://doi.org/10.1002/cne.22117 
Suzuki, M., Kimura, T., (2017). Microtubule-associated tau contributes to intra-
dendritic trafficking of AMPA receptors in multiple ways. Neuroscience 
Letters 653, 276–282. https://doi.org/10.1016/j.neulet.2017.05.056 
Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, L., Eckman, C., Golde, 
T.E., Younkin, S.G., (1994). An increased percentage of long amyloid 
beta protein secreted by familial amyloid beta protein precursor (beta 
APP717) mutants. Science 264, 1336–1340. 
https://doi.org/10.1126/science.8191290 
Swope, D., (2004). Rapid treatment of "wearing off" in Parkinson's disease. 
Neurology, 62(Issue 6, Supplement 4), pp.S27-S31. 
Tai, H.-C., Wang, B.Y., Serrano-Pozo, A., Frosch, M.P., Spires-Jones, T.L., 
Hyman, B.T., (2014). Frequent and symmetric deposition of misfolded 
tau oligomers within presynaptic and postsynaptic terminals in 
Alzheimer’s disease. Acta Neuropathologica Communications 2, 146. 
https://doi.org/10.1186/s40478-014-0146-2 
Tai, L.-H., Lee, A.M., Benavidez, N., Bonci, A., Wilbrecht, L., (2012). Transient 
stimulation of distinct subpopulations of striatal neurons mimics 
changes in action value. Nature Neuroscience 15, 1281–1289. 
https://doi.org/10.1038/nn.3188 
Takata, Y., Oishi, Y., Zhou, X.-Z., Hasegawa, E., Takahashi, K., Cherasse, Y., 
Sakurai, T., Lazarus, M., (2018). Sleep and Wakefulness Are Controlled 
294 
by Ventral Medial Midbrain/Pons GABAergic Neurons in Mice. Journal 
of Neuroscience 38, 10080–10092. 
https://doi.org/10.1523/JNEUROSCI.0598-18.2018 
Takigawa, T., Alzheimer, C., (1999). G protein-activated inwardly rectifying K+ 
(GIRK) currents in dendrites of rat neocortical pyramidal cells. Journal 
of Physiology 517 (Pt 2), 385–390. https://doi.org/10.1111/j.1469-
7793.1999.0385t.x 
Tamagnini, F., Walsh, D.A., Brown, J.T., Bondulich, M.K., Hanger, D.P., 
Randall, A.D., (2017). Hippocampal neurophysiology is modified by a 
disease-associated C-terminal fragment of tau protein. Neurobiology of 
Aging 60, 44–56. https://doi.org/10.1016/j.neurobiolaging.2017.07.005 
Tan, K.R., Yvon, C., Turiault, M., Mirzabekov, J.J., Doehner, J., Labouèbe, G., 
Deisseroth, K., Tye, K.M., Lüscher, C., (2012). GABA neurons of the 
VTA drive conditioned place aversion. Neuron 73, 1173–1183. 
https://doi.org/10.1016/j.neuron.2012.02.015 
Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., 
Ichikawa, M., Yamaguchi, H., Takashima, A., (2002). 
Neurodegeneration with tau accumulation in a transgenic mouse 
expressing V337M human tau. Journal of Neuroscience 22, 133–141. 
Tatebayashi, Y., Miyasaka, T., Chui, D.-H., Akagi, T., Mishima, K., Iwasaki, K., 
Fujiwara, M., Tanemura, K., Murayama, M., Ishiguro, K., Planel, E., 
Sato, S., Hashikawa, T., Takashima, A., (2002). Tau filament formation 
and associative memory deficit in aged mice expressing mutant 
(R406W) human tau. Proceedings of the National Academy of Sciences 
99, 13896–13901. https://doi.org/10.1073/pnas.202205599 
Taylor, C.J., Peacock, S., Chaudhry, A.N., Bradley, J.A., Bolton, E.M., (2012). 
Generating an iPSC bank for HLA-matched tissue transplantation 
based on known donor and recipient HLA types. Cell Stem Cell 11, 147–
152. https://doi.org/10.1016/j.stem.2012.07.014 
Teich, A.F., Nicholls, R.E., Puzzo, D., Fiorito, J., Purgatorio, R., Fa’, M., 
Arancio, O., (2015). Synaptic therapy in Alzheimer’s disease: a CREB-
centric approach. Neurotherapeutics 12, 29–41. 
https://doi.org/10.1007/s13311-014-0327-5 
Teravskis, P.J., Covelo, A., Miller, E.C., Singh, B., Martell-Martínez, H.A., 
Benneyworth, M.A., Gallardo, C., Oxnard, B.R., Araque, A., Lee, M.K., 
Liao, D., (2018). A53T Mutant Alpha-Synuclein Induces Tau-Dependent 
Postsynaptic Impairment Independently of Neurodegenerative 
Changes. Journal of Neuroscience. 38, 9754–9767. 
https://doi.org/10.1523/JNEUROSCI.0344-18.2018 
295 
Thakur, P., Luk, K., Roeper, J., (2019). Selective K-ATP channel-dependent 
loss of pacemaking in vulnerable nigrostriatal dopamine neurons by 
αSynuclein aggregates. bioRxiv 842344. 
https://doi.org/10.1101/842344 
Thal, D.R., Rüb, U., Orantes, M., Braak, H., (2002). Phases of A beta-
deposition in the human brain and its relevance for the development of 
AD. Neurology 58, 1791–1800. https://doi.org/10.1212/wnl.58.12.1791 
Thies, E., Mandelkow, E.-M., (2007). Missorting of tau in neurons causes 
degeneration of synapses that can be rescued by the kinase 
MARK2/Par-1. Journal of Neuroscience 27, 2896–2907. 
https://doi.org/10.1523/JNEUROSCI.4674-06.2007 
Thijssen, E.H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., 
Bourakova, V., Cobigo, Y., Heuer, H., Spina, S., VandeVrede, L., Chai, 
X., Proctor, N.K., Airey, D.C., Shcherbinin, S., Duggan Evans, C., Sims, 
J.R., Zetterberg, H., Blennow, K., Karydas, A.M., Teunissen, C.E., 
Kramer, J.H., Grinberg, L.T., Seeley, W.W., Rosen, H., Boeve, B.F., 
Miller, B.L., Rabinovici, G.D., Dage, J.L., Rojas, J.C., Boxer, A.L., 
(2020). Diagnostic value of plasma phosphorylated tau181 in 
Alzheimer’s disease and frontotemporal lobar degeneration. Nature 
Medicine 26, 387–397. https://doi.org/10.1038/s41591-020-0762-2 
Toombs, J., Zetterberg, H., (2020). In the blood: biomarkers for amyloid 
pathology and neurodegeneration in Alzheimer’s disease. Brain 
Communications 2. https://doi.org/10.1093/braincomms/fcaa054 
Tovar, K.R., Maher, B.J., Westbrook, G.L., (2009). Direct actions of 
carbenoxolone on synaptic transmission and neuronal membrane 
properties. Journal of Neurophysiology 102, 974–978. 
https://doi.org/10.1152/jn.00060.2009 
Tracy, T.E., Gan, L., (2018). Tau-mediated synaptic and neuronal dysfunction 
in neurodegenerative disease. Current Opinion in Neurobiology 51, 
134–138. https://doi.org/10.1016/j.conb.2018.04.027 
Trapp, S., Aller, M.I., Wisden, W., Gourine, A.V., (2008). A Role for TASK-1 
(KCNK3) Channels in the Chemosensory Control of Breathing. Journal 
of Neuroscience 28, 8844–8850. doi.org/10.1523/JNEUROSCI.1810-
08.2008 
Trapp, S., Ashcroft, F., (1997). A Metabolic Sensor in Action: News From the 
ATP-Sensitive K+-Channel. Physiology 12, 255–263. 
https://doi.org/10.1152/physiologyonline.1997.12.6.255 
Tritsch, N.X., Ding, J.B., Sabatini, B.L., (2012). Dopaminergic neurons inhibit 
striatal output via non-canonical release of GABA. Nature 490, 262–
266. https://doi.org/10.1038/nature11466 
296 
Tucker, K.L., Meyer, M., Barde, Y.A., (2001). Neurotrophins are required for 
nerve growth during development. Nature Neuroscience 4, 29–37. 
https://doi.org/10.1038/82868 
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, 
D.A., Kondo, J., Ihara, Y., Saitoh, T., (1993). Molecular cloning of cDNA 
encoding an unrecognized component of amyloid in Alzheimer disease. 
Proceedings of the National Academy of Sciences 90, 11282–11286. 
Uehara, T., Choong, C.-J., Nakamori, M., Hayakawa, H., Nishiyama, K., 
Kasahara, Y., Baba, K., Nagata, T., Yokota, T., Tsuda, H., Obika, S., 
Mochizuki, H., (2019). Amido-bridged nucleic acid (AmNA)-modified 
antisense oligonucleotides targeting αSynuclein as a novel therapy for 
Parkinson’s disease. Scientific reports 9, 7567. 
https://doi.org/10.1038/s41598-019-43772-9 
Usenovic, M., Niroomand, S., Drolet, R.E., Yao, L., Gaspar, R.C., Hatcher, 
N.G., Schachter, J., Renger, J.J., Parmentier-Batteur, S., (2015). 
Internalized Tau Oligomers Cause Neurodegeneration by Inducing 
Accumulation of Pathogenic Tau in Human Neurons Derived from 
Induced Pluripotent Stem Cells. Journal of Neuroscience 35, 14234–
14250. https://doi.org/10.1523/JNEUROSCI.1523-15.2015 
van de Wiel, J., Meigh, L., Bhandare, A., Cook, J., Nijjar, S., Huckstepp, R., 
Dale, N., (2020). Connexin26 mediates CO2-dependent regulation of 
breathing via glial cells of the medulla oblongata. Communications 
Biology 3, 521. https://doi.org/10.1038/s42003-020-01248-x 
Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, 
A., Bloch, D.A., Nelson, L.M., (2003). Incidence of Parkinson’s disease: 
variation by age, gender, and race/ethnicity. American Journal of 
Epidemiology 157, 1015–1022. https://doi.org/10.1093/aje/kwg068 
Van Hook, M.J., Thoreson, W.B., (2014). Whole-Cell Patch-Clamp Recording, 
in: Xiong, H., Gendelman, H.E. (Eds.), Current Laboratory Methods in 
Neuroscience Research, Springer Protocols Handbooks. Springer, 
New York, NY, pp. 353–367. https://doi.org/10.1007/978-1-4614-8794-
4_25 
Van Thienen, R., Hespel, P., (2016). Enhanced muscular oxygen extraction in 
athletes exaggerates hypoxemia during exercise in hypoxia. Journal of 
Applied Physiology 120, 351–361. 
https://doi.org/10.1152/japplphysiol.00210.2015 
Van Wart, A., Matthews, G., (2006). Impaired firing and cell-specific 
compensation in neurons lacking nav1.6 sodium channels. Journal of 
Neuroscience 26, 7172–7180. doi.org/10.1523/JNEUROSCI.1101-
06.2006 
297 
Van Wart, A., Trimmer, J.S., Matthews, G., (2007). Polarized distribution of ion 
channels within microdomains of the axon initial segment. The Journal 
of Comparative Neurology 500, 339–352. 
https://doi.org/10.1002/cne.21173 
van Zessen, R., Phillips, J.L., Budygin, E.A., Stuber, G.D., (2012). Activation 
of VTA GABA neurons disrupts reward consumption. Neuron 73, 1184–
1194. https://doi.org/10.1016/j.neuron.2012.02.016 
Vandecasteele, M., Deniau, J.-M., Glowinski, J., Venance, L., (2007). 
Electrical synapses in basal ganglia. Reviews in the Neurosciences 18, 
15–35. https://doi.org/10.1515/revneuro.2007.18.1.15 
Vandecasteele, M., Glowinski, J., Venance, L., (2006). Connexin mRNA 
expression in single dopaminergic neurons of substantia nigra pars 
compacta. Neuroscience Research 56, 419–426. 
https://doi.org/10.1016/j.neures.2006.08.013 
Vandecasteele, M., Glowinski, J., Venance, L., (2005). Electrical Synapses 
between Dopaminergic Neurons of the Substantia Nigra Pars 
Compacta. Journal of Neuroscience 25, 291–298. 
https://doi.org/10.1523/JNEUROSCI.4167-04.2005 
Villafane, G., Cesaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Le 
Houezec, J., Macquin-Mavier, I., Maison, P., (2007). Chronic high dose 
transdermal nicotine in Parkinson’s disease: an open trial. European 
Journal of Neurology. 14, 1313–1316. https://doi.org/10.1111/j.1468-
1331.2007.01949.x 
Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, 
O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, 
C.C., Masters, C.L., (2013). Amyloid β deposition, neurodegeneration, 
and cognitive decline in sporadic Alzheimer’s disease: a prospective 
cohort study. The Lancet Neurology 12, 357–367. 
https://doi.org/10.1016/S1474-4422(13)70044-9 
Wahlqvist, M.L., Lee, M.-S., Hsu, C.-C., Chuang, S.-Y., Lee, J.-T., Tsai, H.-N., 
(2012). Metformin-inclusive sulfonylurea therapy reduces the risk of 
Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese 
population cohort. Parkinsonism & Related Disorders 18, 753–758. 
https://doi.org/10.1016/j.parkreldis.2012.03.010 
Wall, M.J., Collins, D.R., Chery, S.L., Allen, Z.D., Pastuzyn, E.D., George, A.J., 
Nikolova, V.D., Moy, S.S., Philpot, B.D., Shepherd, J.D., Müller, J., 
Ehlers, M.D., Mabb, A.M., Corrêa, S.A.L., (2018). The Temporal 
Dynamics of Arc Expression Regulate Cognitive Flexibility. Neuron 98, 
1124-1132.e7. https://doi.org/10.1016/j.neuron.2018.05.012 
298 
Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., 
Rowan, M.J., Selkoe, D.J., (2002). Naturally secreted oligomers of 
amyloid beta protein potently inhibit hippocampal long-term potentiation 
in vivo. Nature 416, 535–539. https://doi.org/10.1038/416535a 
Walsh, D.M., Selkoe, D.J., (2016). A critical appraisal of the pathogenic protein 
spread hypothesis of neurodegeneration. Nature Reviews 
Neuroscience 17, 251–260. https://doi.org/10.1038/nrn.2016.13 
Wang, G.J., Volkow, N.D., Fowler, J.S., Cervany, P., Hitzemann, R.J., Pappas, 
N.R., Wong, C.T., Felder, C., (1999). Regional brain metabolic 
activation during craving elicited by recall of previous drug experiences. 
Life Sciences 64, 775–784. https://doi.org/10.1016/s0024-
3205(98)00619-5 
Wang, F., Shi, Y., Lu, L., Liu, L., Cai, Y., Zheng, H., Liu, X., Yan, F., Zou, C., 
Sun, C., Shi, J., Lu, S., Chen, Y., (2012). Targeted Delivery of GDNF 
through the Blood–Brain Barrier by MRI-Guided Focused Ultrasound. 
PLOS ONE 7, e52925. https://doi.org/10.1371/journal.pone.0052925 
Wang, J., Ou, S.-W., Wang, Y.-J., (2017). Distribution and function of voltage-
gated sodium channels in the nervous system. Channels 11, 534–554. 
https://doi.org/10.1080/19336950.2017.1380758 
Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I., Iqbal, K., (2013). Abnormal 
hyperphosphorylation of tau: sites, regulation, and molecular 
mechanism of neurofibrillary degeneration. Journal of Alzheimer's 
disease 33 Suppl 1, S123-139. https://doi.org/10.3233/JAD-2012-
129031 
Wang, S., Benamer, N., Zanella, S., Kumar, N.N., Shi, Y., Bévengut, M., 
Penton, D., Guyenet, P.G., Lesage, F., Gestreau, C., Barhanin, J., 
Bayliss, D.A., (2013). TASK-2 Channels Contribute to pH Sensitivity of 
Retrotrapezoid Nucleus Chemoreceptor Neurons. Journal of 
Neuroscience. 33, 16033–16044. doi.org/10.1523/JNEUROSCI.2451-
13.2013 
Wang, Y., Mandelkow, E., (2016). Tau in physiology and pathology. Nature 
Reviews Neuroscience 17, 5–21. https://doi.org/10.1038/nrn.2015.1 
Watanabe, E., Hiyama, T.Y., Shimizu, H., Kodama, R., Hayashi, N., Miyata, 
S., Yanagawa, Y., Obata, K., Noda, M., (2006). Sodium-level-sensitive 
sodium channel Nax is expressed in glial laminate processes in the 
sensory circumventricular organs. American Journal of Physiology - 
Regulatory, Integrative and Comparative Physiology 290, R568–R576. 
https://doi.org/10.1152/ajpregu.00618.2005 
Waung, M.W., Pfeiffer, B.E., Nosyreva, E.D., Ronesi, J.A., Huber, K.M., 
(2008). Rapid translation of Arc/Arg3.1 selectively mediates mGluR-
299 
dependent LTD through persistent increases in AMPAR endocytosis 
rate. Neuron 59, 84–97. https://doi.org/10.1016/j.neuron.2008.05.014 
Weber, P.A., Chang, H.-C., Spaeth, K.E., Nitsche, J.M., Nicholson, B.J., 
(2004). The Permeability of Gap Junction Channels to Probes of 
Different Size Is Dependent on Connexin Composition and Permeant-
Pore Affinities. Biophysical Journal 87, 958–973. 
https://doi.org/10.1529/biophysj.103.036350 
Wegmann, S., Nicholls, S., Takeda, S., Fan, Z., Hyman, B.T., (2016). 
Formation, release, and internalization of stable tau oligomers in cells. 
Journal of Neurochemistry 139, 1163–1174. doi.org/10.1111/jnc.13866 
Weissman, T.A., Riquelme, P.A., Ivic, L., Flint, A.C., Kriegstein, A.R., (2004). 
Calcium waves propagate through radial glial cells and modulate 
proliferation in the developing neocortex. Neuron 43, 647–661. 
https://doi.org/10.1016/j.neuron.2004.08.015 
White, J.A., Sekar, N.S., Kay, A.R., (1995). Errors in persistent inward currents 
generated by space-clamp errors: a modeling study. Journal of 
Neurophysiology 73, 2369–2377. doi.org/10.1152/jn.1995.73.6.2369 
Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, 
J., Cronin, D., Schroers, C., Barua, N.U., Longpre, L., Barclay, C.L., 
Boiko, C., Johnson, G.A., Fibiger, H.C., Harrison, R., Lewis, O., 
Pritchard, G., Howell, M., Irving, C., Johnson, D., Kinch, S., Marshall, 
C., Lawrence, A.D., Blinder, S., Sossi, V., Stoessl, A.J., Skinner, P., 
Mohr, E., Gill, S.S., (2019). Randomized trial of intermittent 
intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s 
disease. Brain 142, 512–525. https://doi.org/10.1093/brain/awz023 
Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., 
Björklund, A., Lindvall, O., Langston, J.W., (1992). Bilateral Fetal 
Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 
1-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine (MPTP). New England 
Journal of Medicine 327, 1556–1563. 
https://doi.org/10.1056/NEJM199211263272203 
Willecke, K., Eiberger, J., Degen, J., Eckardt, D., Romualdi, A., Güldenagel, 
M., Deutsch, U., Söhl, G., (2002). Structural and functional  diversity 
of connexin genes in the mouse and human genome. Biological 
Chemistry 383, 725–737. https://doi.org/10.1515/BC.2002.076 
Wilson, D.F., Pastuszko, A., DiGiacomo, J.E., Pawlowski, M., Schneiderman, 
R., Delivoria-Papadopoulos, M., (1991). Effect of hyperventilation on 
oxygenation of the brain cortex of newborn piglets. Journal of Applied 
Physiology  Bethesda Md 1985 70, 2691–2696. 
https://doi.org/10.1152/jappl.1991.70.6.2691 
300 
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.-O., 
Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., 
Blennow, K., Leon, M.D., DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, 
C., Hardy, J., Jack, C., Jorm, A., Ritchie, K., Duijn, C.V., Visser, P., 
Petersen, R.C., (2004). Mild cognitive impairment – beyond 
controversies, towards a consensus: report of the International Working 
Group on Mild Cognitive Impairment. Journal of Internal Medicine 256, 
240–246. https://doi.org/10.1111/j.1365-2796.2004.01380.x 
Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., 
Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, 
A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, 
F.H., Riek, R., (2011). In vivo demonstration that αSynuclein oligomers 
are toxic. Proceedings of the National Academy of Sciences 108, 4194–
4199. https://doi.org/10.1073/pnas.1100976108 
Wischik, C.M., Harrington, C.R., Storey, J.M.D., (2014). Tau-aggregation 
inhibitor therapy for Alzheimer’s disease. Biochemical Pharmacology 
88, 529–539. https://doi.org/10.1016/j.bcp.2013.12.008 
Wittmann, C.W., Wszolek, M.F., Shulman, J.M., Salvaterra, P.M., Lewis, J., 
Hutton, M., Feany, M.B., (2001). Tauopathy in Drosophila: 
neurodegeneration without neurofibrillary tangles. Science 293, 711–
714. https://doi.org/10.1126/science.1062382 
Wolf, M.E., Roth, R.H., (1990). Autoreceptor Regulation of Dopamine 
Synthesis. Annals of the New York Academy of Sciences 604, 323–
343. https://doi.org/10.1111/j.1749-6632.1990.tb32003.x 
Wykes, R., Kalmbach, A., Eliava, M., Waters, J., (2012). Changes in the 
physiology of CA1 hippocampal pyramidal neurons in pre-plaque 
CRND8 mice. Neurobiology of Aging 33, 1609–1623. 
https://doi.org/10.1016/j.neurobiolaging.2011.05.001 
Xu, K., Xu, Y.-H., Chen, J.-F., Schwarzschild, M.A., (2002). Caffeine’s 
neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
toxicity shows no tolerance to chronic caffeine administration in mice. 
Neuroscience Letters. 322, 13–16. https://doi.org/10.1016/S0304-
3940(02)00069-1 
Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E., Hoehn, M.M., (1969). 
Treatment of parkinsonism with levodopa. Archives of Neurology 21, 
343–354. https://doi.org/10.1001/archneur.1969.00480160015001 
Yamada, K., Holth, J.K., Liao, F., Stewart, F.R., Mahan, T.E., Jiang, H., Cirrito, 
J.R., Patel, T.K., Hochgräfe, K., Mandelkow, E.-M., Holtzman, D.M., 
(2014). Neuronal activity regulates extracellular tau in vivo. The Journal 
301 
of Experimental Medicine 211, 387–393. 
https://doi.org/10.1084/jem.20131685 
Yamamoto-Sasaki, M., Ozawa, H., Saito, T., Rösler, M., Riederer, P., (1999). 
Impaired phosphorylation of cyclic AMP response element binding 
protein in the hippocampus of dementia of the Alzheimer type. Brain 
Research 824, 300–303. https://doi.org/10.1016/s0006-
8993(99)01220-2 
Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., 
Diamond, M.I., Holtzman, D.M., (2015). Anti-tau antibody reduces 
insoluble tau and decreases brain atrophy. Annals of Clinical and 
Translational Neurology 2, 278–288. https://doi.org/10.1002/acn3.176 
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., 
Wozniak, D.F., Diamond, M.I., Holtzman, D.M., (2013). Anti-Tau 
Antibodies that Block Tau Aggregate Seeding In Vitro Markedly 
Decrease Pathology and Improve Cognition In Vivo. Neuron 80, 402–
414. https://doi.org/10.1016/j.neuron.2013.07.046 
Yin, Y., Gao, D., Wang, Y., Wang, Z.-H., Wang, X., Ye, J., Wu, D., Fang, L., 
Pi, G., Yang, Y., Wang, X.-C., Lu, C., Ye, K., Wang, J.-Z., (2016). Tau 
accumulation induces synaptic impairment and memory deficit by 
calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. 
Proceedings of the National Academy of Sciences 113, E3773-3781. 
https://doi.org/10.1073/pnas.1604519113 
Yoo, J.H., Zell, V., Gutierrez-Reed, N., Wu, J., Ressler, R., Shenasa, M.A., 
Johnson, A.B., Fife, K.H., Faget, L., Hnasko, T.S., (2016). Ventral 
tegmental area glutamate neurons co-release GABA and promote 
positive reinforcement. Nature Communications 7, 13697. 
https://doi.org/10.1038/ncomms13697 
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T.C., 
Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M.-Y., (2007). 
Synapse loss and microglial activation precede tangles in a P301S 
tauopathy mouse model. Neuron 53, 337–351. 
https://doi.org/10.1016/j.neuron.2007.01.010 
Yu, X., Ba, W., Zhao, G., Ma, Y., Harding, E.C., Yin, L., Wang, D., Li, H., 
Zhang, P., Shi, Y., Yustos, R., Vyssotski, A.L., Dong, H., Franks, N.P., 
Wisden, W., (2020). Dysfunction of ventral tegmental area GABA 
neurons causes mania-like behavior. Molecular Psychiatry 1–16. 
https://doi.org/10.1038/s41380-020-0810-9 
Yu, X., Li, W., Ma, Y., Tossell, K., Harris, J.J., Harding, E.C., Ba, W., Miracca, 
G., Wang, D., Li, L., Guo, J., Chen, M., Li, Y., Yustos, R., Vyssotski, 
A.L., Burdakov, D., Yang, Q., Dong, H., Franks, N.P., Wisden, W., 
302 
(2019). GABA and glutamate neurons in the VTA regulate sleep and 
wakefulness. Nature Neuroscience 22, 106–119. 
https://doi.org/10.1038/s41593-018-0288-9 
Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., 
Mandelkow, E.-M., (2013). Amyloid-β oligomers induce synaptic 
damage via Tau-dependent microtubule severing by TTLL6 and 
spastin. EMBO Journal 32, 2920–2937. 
https://doi.org/10.1038/emboj.2013.207 
Zetterberg, H., (2019). Blood-based biomarkers for Alzheimer’s disease—An 
update. Journal of Neuroscience Methods, Methods and Models in 
Alzheimer’s Disease Research 319, 2–6. 
https://doi.org/10.1016/j.jneumeth.2018.10.025 
Zetterberg, H., Bendlin, B.B., (2021). Biomarkers for Alzheimer’s disease-
preparing for a new era of disease-modifying therapies. Molecular 
Psychiatry 26, 296–308. https://doi.org/10.1038/s41380-020-0721-9 
Zetterberg, H., Burnham, S.C., (2019). Blood-based molecular biomarkers for 
Alzheimer’s disease. Molecular Brain 12, 26. 
https://doi.org/10.1186/s13041-019-0448-1 
Zhang, J., Xia, J., Xiong, H., (2014). Techniques for Extracellular Recordings, 
in: Xiong, H., Gendelman, H.E. (Eds.), Current Laboratory Methods in 
Neuroscience Research, Springer Protocols Handbooks. Springer, 
New York, NY, pp. 325–345. https://doi.org/10.1007/978-1-4614-8794-
4_23 
Zhang, S.M., Hernán, M.A., Chen, H., Spiegelman, D., Willett, W.C., Ascherio, 
A., (2002). Intakes of vitamins E and C, carotenoids, vitamin 
supplements, and PD risk. Neurology 59, 1161–1169. 
https://doi.org/10.1212/01.wnl.0000028688.75881.12 
Zhang, D., Bordia, T., McGregor, M., McIntosh, J.M., Decker, M.W., Quik, M., 
(2014a). ABT-089 and ABT-894 reduce levodopa-induced dyskinesias 
in a monkey model of Parkinson’s disease. Journal of Movement 
Disorders. 29, 508–517. https://doi.org/10.1002/mds.25817 
Zhang, D., McGregor, M., Decker, M.W., Quik, M., (2014b). The α7 nicotinic 
receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in 
parkinsonian monkeys. Journal of Pharmacology and Experimental 
Therapeutics 351, 25–32.  https://doi.org/10.1124/jpet.114.216283 
Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A.G., Jackson, R.J., 
Wang, Y.-C., Swerts, J., Beyens, J., Miskiewicz, K., Vilain, S., 
Dewachter, I., Moechars, D., De Strooper, B., Spires-Jones, T.L., De 
Wit, J., Verstreken, P., (2017). Tau association with synaptic vesicles 
303 
causes presynaptic dysfunction. Nature Communications 8, 15295. 
https://doi.org/10.1038/ncomms15295 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., 
Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., 
Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F., 
Müller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., Wszolek, 
Z.K., Gasser, T., (2004). Mutations in LRRK2 cause autosomal-




8. App endix 
8.1 Materials 
Drug/ pharmacological agent Company Catalog 
Number
Acrylamide/bisacrylamide (30 % 
solution) 
Sigma Aldrich A3574 
Ammonium persulfate (APS) Sigma Aldrich A3678 
BamHI Fisher ER0051 
Bicinchoninic Acid (BCA)  G Biosciences 786-570 
Bovine Serum Albumin (BSA) Sigma Aldrich A7906 
Carbenoxolone disodium salt Sigma Aldrich C4790 
Chelating sepharose resin GE Healthcare 17-0575-01 
CutSmart Buffer New England 
Biolabs 
B7204S 
D-Glucose  Fisher 0500/53 
DHPG ((RS)-3,5-DHPG) Tocris/ Biotechne 0342/1 
Dopamine Hydrochloride Sigma Aldrich H8502 
DTT (1,4-Dithiothreitol) Sigma Aldrich 10197777001 
EcoRI Invitrogen IVGN0116 
EGTA Sigma Aldrich A102X 
HEPES Sigma Aldrich H4034 
Imidazole Sigma Aldrich I2399 
IPTG (Isopropyl β-D-
thiogalactoside) 
Sigma Aldrich I6758 
KCl Fisher 4280/53 
KH2PO4 Fisher 4800/53 
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L-689,560 Tocris/ Biotechne 0742 
Met5[enkephalin] Merck M6638 
MgATP Sigma Aldrich A3377 
MgSO4 Fisher 1050/53 
Milk powder Marvel, Uk NA 
Monarch plasmid miniprep kit New England 
Biolabs 
T1010 
N, N, N’, N’-
tetramethylethylenediamine 
(TEMED) 
Sigma Aldrich T-7024 
NaCl Fisher 3160/65 
NaGTP Merck G8877 
NaHCO3 Fisher 4240/60 
NaOAc Fisher 2120/53 
NiCl2 Sigma Aldrich 339350 
Phosphocreatine Sigma Aldrich 1001244549 
Picrotoxin Sigma Aldrich P1675 
Potassium Gluconate Sigma Aldrich 299-27-4 
Protease Inhibitor tablets Thermofisher 
Scientific 
A32963 
Site directed mutagenesis kit (Q5) New England 
Biolabs 
E0554S 
SOC medium Sigma Aldrich S1797 




Sigma Aldrich C4706 
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Triton x100 Fisher  9002-93-1 
Tween 20 Sigma Aldrich 1379 
ZD 7288 Hello-Bio HB1152 
Primary antibodies 









T22 oligomeric tau 
Antibody 
Merck  ABN454 1:1000 
Polyclonal rabbit anti-
human tau. Epitope: C 
terminus of 2N4R tau 
Dako A0024 1:5000 
Sheep polyclonal Anti-
Tyrosine hydroxylase 








Abcam ab4674 1:1000 
Rabbit polyclonal anti-
GAD65 + GAD67 
Abcam ab49832 1:1000 
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Secondary antibodies 
Secondary Antibody Company Catalog 
Number
Alexa Fluor 594-conjugated 
AffiniPure Goat anti-mouse IgG + 
IgM (H + L) 1:400
Jackson Immuno 115-585-044 
Rabbit Anti-mouse (IgG (H+L), 
horseradish peroxidase 1:1000
Thermofisher 61-6520 
Goat anti-rabbit IgG Thermo Scientific 31460
Goat Anti-rabbit 1:1000 488 Invitrogen A11008
Alexa Fluor 594 Donkey anti-rabbit 
1:250
Invitrogen A-21207 
Alexa Fluor 594 Donkey anti-sheep 
1:250
Invitrogen A11016 





Donkey anti-mouse 594 Invitrogen A21203
Donkey anti-sheep 488 Invitrogen A-11015
Fluorescent dyes and imaging  
Antibody Company Catalog Number
Alexa Fluor 488 C5-maleimide Molecular Probes A10254 
Alexa Fluor 488 Hydrazide (12.5 
mM stock in distilled water, stored 
at -20 degrees)
Thermofisher A10436 
Clarity Western ECL Substrate BioRad 1705060
Alexa Fluor 594 Hydrazide (12.5 
mM stock in distilled water, stored 
at -20 degrees)
Thermofisher 10072752 
(6)-Carboxy-fluorescein (CBF) Novabiochem 8.51082.001
Vectashield mounting medium Vector 
Laboratories
H-5000 
InstantBlue Protein Stain Expedeon ISB1L
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Consumables  
Product Company Catalog 
Number
Slide-A-Lyzer Mini Dialysis devices 
(10K) MWCO 
Thermo Scientific 69570 
Formvar/carbon coated 300 – 
mesh copper grids 
Agar Scientific 162 
ECL Nitrocellulose membrane Amersham 
Biosciences 
10600002 





8.2 Tau DNA and protein sequences 







































































8.3 Production of tau truncations  
I spent three months working towards producing CFRAG tau (see methods for 
full details). I used the full length wild-type plasmid and performed site directed 
mutagenesis (NEB Q5 Kit) to remove amino acids 1-123. I left the initial 
methionine in place for structural integrity. Following mutagenesis, samples 
were transformed into competent cells and grown LB + ampicillin plates. 
Plamsid DNA was recovered using a Monarch Miniprep kit and a DNA double 
digest with BamHI and EcoRI performed to look for successful mutagenesis 
using gel electrophoresis (Figure 8.1). Undigested full-length samples should 
give a 1.4kb fragment and successful mutagenesis should give a 1.1kb 
fragment. 
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Figure 8.1: DNA gel electrophoresis following double restriction digest to look 
for successful site directed mutagenesis clones. 
The gel confirms that 12 out of the 18 samples were successfully digested. Sample 7 
was discarded as it appeared to have two bands. Samples U8 and U10 represent the 
undigested sample controls that were run to ensure validity of results. Ladders 
(middle) were used for comparison of band sizes.  
Samples that had successfully been mutated were sent for sanger sequencing 
(Eurofins) to confirm the correct mutation, to confirm that they are in the correct 
frame and that the cysteine residue mutations had been maintained during the 
mutagenesis. These samples (that were confirmed to have correct sequences) 
were then transformed into competent cells and grown on LB + ampicillin 
plates overnight, picked and transferred directly into LB + ampicillin and 
allowed to grow overnight. The next morning samples began the expression 
and purification protocol as for FL tau (see Methods). I used hand cast SDS 
page gels (Fig 8.2 A, B) to look for the presence of protein for the two 
preparations. The only protein expected to be present is tau and therefore I 
was expecting one band. However, there were lots of other contaminating 
bands. This could be because the gradient of the column had not worked as it 
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should, and other contaminants had not been washed thoroughly before the 
eluted protein. I therefore pooled the middle fractions with the highest protein 
content from the samples in gel A (Fig 8.2A; black box) and re-ran the 
purification column, with extra wash steps of buffer A and B to ensure that any 
product that is not tightly bound to the column (tau: due to its his tag) should 
have been washed through before buffer C was used to elute the protein. This 
did reduce the prominence of the extra bands (Fig 8.2C) and the samples on 
the right hand side (Fig 8.2C; orange box) are fairly pure. I therefore ran a 
western blot to confirm whether it was tau (using the Ht7 monoclonal tau 
antibody; Fig 8.2D). This confirmed that the preparations are positive for tau, 
the contamination is still too prominent to isolate the tau.  
Figure 8.2: SDS-page gels confirm that the purification stage has been 
unsuccessful due to the presence of lots of additional contamination bands.  
SDS-page gels to confirm the purity of the tau truncation preparations. There is a lot 
of contamination within both of the preparations (A and B), as displayed by additional 
bands. (C) Another run of purification with increased wash steps reduced the 
contamination but was unable to fully isolate the tau as was confirmed by western blot 
analysis (D).  
Due to time constraints this preparation was abandoned, and I sourced a 
collaboration with a group from the University of Gothenburg who specialise in 
tau biochemistry to produce this mutant for me.
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8.4 Comparison of P7-10 and P17-21 neuronal function 
Given that connexin 26 expression was reported to be developmentally 
regulated. In chapter 6, I tested this using two groups of mice. P7-10 pups, 
where I expected it to be expressed and P17-21 juvenile mice, where I 
expected the expression to be gone based on previously published data 
(Vandecasteele et al 2006). This comparison between age groups could be 
complicated by the developmental changes to electrophysiological properties, 
which are known to occur over this period. Therefore firstly, I compared the 
normal input resistance and resting membrane potential measurements from 
SNpc DNs of the two age groups (Figure 8.3). 
Figure 8.3: Comparison of the baseline electrophysiological parameters of P7-
10 and P17-21 SNpc dopaminergic neurons. 
Input resistance measurements both at ‘steady state’ (A) and at ‘before the sag’ (B) 
were decreased as the pups aged. This is in line with previously published work 
(Dufour et al, 2014). We saw no difference in the stability of recordings and there was 
no change to resting membrane potential (C).
There was no significant difference in input resistance (pre-sag) between the 
two age groups of mice (P7-10, Rin = 380 ± 28.16 MΩ, P17-21, Rin = 290 ± 
22.45 MΩ, p = 0.307). There was also no significant difference in the resting 
membrane potential (P7-10, RMP = -59.3 ± 1.33 mV, P17-21, RMP = -60 ± 
2.08 mV, p = 0.835) or the size of the sag response, measured between the 
peak hyperpolarisation and steady state after IH has activated (P7-10: 22.6 ± 
2.25 mV, P17-21 20.1 ± 2.3 mV, p = 0.454). These results are consistent with 
expected values for these age groups of mice as reported in (Dufour et al., 
2014).  
